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Cardiovascular Disease
Although considerable improvements in diagnosis, therapeutic interventions and prog-
nostification of patients with cardiovascular disease have been made over the last several 
decades, cardiovascular disease remains one of the foremost challenges of public health 
these days.1-3
Based upon National Health Surveys, the World Health Organization (WHO) has reported 
that cardiovascular disease affects approximately 17.3 million individuals worldwide, with 
an estimated 7.3 million people who are suffering from ischemic heart disease.3 The WHO 
has stated that 4.6 million Europeans have been diagnosed with cardiovascular disease, 
including 2.2 million individuals with ischemic heart disease across European countries.3 
Even though the age-adjusted incidence of cardiovascular disease may appear constant over 
the last couple of years, its prevalence is expected to grow considerably in the upcoming 
years as the population ages over time due to further improvements in early diagnosis, 
treatment options along with advances in risk stratification of patients with cardiovascular 
disease. Additionally, the world-wide under-recognition and under-treatment of individuals 
with risk factors for atherosclerosis will lead to an even further increase in cardiovascular 
disease, predominantly ischemic heart disease.2
At present, cardiac imaging has contributed significantly to the currently applied 
diagnostic, therapeutic and prognostic algorithms for patients with cardiovascular disease. 
Among available cardiac imaging techniques, computed tomography (CT) has emerged as 
one of most potent cardiac imaging techniques for non-invasive evaluation of coronary 
atherosclerosis. However, despite the presence of highly advanced image acquisition tech-
niques for cardiac CT, the evaluation of coronary artery disease (CAD) is usually based on 
a rather simple dichotomous visual approach. Based upon visual analysis of cardiac CT 
images, coronary lesions with ≥50% luminal narrowing are usually defined as lesions with 
significant coronary stenosis.
Accordingly, the use of automated quantitative algorithms for post-processing of cardiac 
CT images may help to improve diagnosis of coronary atherosclerosis by cardiac CT (Part 
I). A detailed assessment of coronary atherosclerosis on cardiac CT can be used to guide 
patient referral for percutaneous coronary intervention or coronary artery bypass grafting 
surgery.
Beyond advances in diagnosis of cardiovascular disease, cardiac imaging has also been 
used to improve the selection of patients who will benefit from specific therapeutic inter-
ventions. Cardiac imaging has been applied to guide clinicians in the selection of heart 
failure patients for cardiac resynchronization therapy (CRT). Even though several cardiac 
imaging techniques are already available in clinical practice, the selection of heart failure 
patients who will gain benefit from dedicated cardiac device therapies remains difficult.
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Phase analysis on gated myocardial perfusion single photon emission computed tomog-
raphy (SPECT) (GMPS) provides potential important information in patients with heart failure 
referred for CRT. Novel insights in GMPS with phase analysis may further improve the selec-
tion of heart failure patients who will benefit from CRT (Part II).
Finally, cardiac imaging can be used to risk stratify patients with cardiovascular disease 
for future adverse events. Although significant improvements in prognostification of patients 
with cardiovascular disease have been made in recent years, appropriate selection of patients 
at risk for adverse cardiac events remains a main challenge these days. Recent developments 
in sympathetic nerve imaging with 123-iodine metaiodobenzylguanidine (123-I MIBG) 
imaging may be used to improve risk stratification of patients with cardiovascular disease 
(Part III).
Dedicated Automated Quantitative Computed 
Tomography in Patients with Coronary Artery 
Disease (Part I)
The presence of coronary artery disease can be detected by direct anatomic assessment 
of coronary atherosclerosis and luminal narrowing using cardiac CT, which has emerged 
as a potent non-invasive imaging technique since it provides excellent image quality and 
high diagnostic accuracy for visualization of CAD when compared to invasive coronary 
angiography.4-6
Although invasive coronary angiography is primarily restricted to luminography, cardiac 
CT offers the ability for a comprehensive evaluation of CAD by assessment of location, 
extent and severity as well as composition of atherosclerotic lesions, rather than the degree 
of coronary artery stenosis alone.6 A complete analysis of coronary atherosclerosis may 
provide important information to identify patients at risk for adverse cardiovascular events7, 
and importantly, may be used to guide future therapeutic interventions such as percutaneous 
coronary intervention or coronary artery bypass grafting surgery. Despite the rapid develop-
ments in CT acquisition technology, cardiac CT angiography images are most commonly 
post-processed and evaluated by an expert CT reader using a rather simple visual and 
dichotomous approach, in which ≥50% luminal narrowing is usually defined as a significant 
coronary stenosis.
In this perspective, the introduction of new dedicated algorithms for automated quanti-
fication of coronary atherosclerosis (Figure 1) may further improve diagnostic accuracy of 
cardiac CT, and interestingly, may lead to a more time-efficient post-processing of cardiac 
CT images. Moreover, even though the number of cardiac CT scans with ambiguous or 
inconclusive results has become considerably smaller with the introduction of modern CT 
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scanners and image acquisition protocols, the use of dedicated post-processing techniques 
may result in a further decrease in the number of inconclusive or misinterpreted cardiac CT 
scans.
Additionally, one should acknowledge that cardiac CT is still hampered by reduced posi-
tive predictive values due to image artifacts along with a tendency to overestimate coronary 
stenosis in calcified lesions.5, 6, 8 Visual analysis of heavily calcified lesions can lead to 
(severe) overestimation of luminal narrowing due to blooming artifacts, which in turn, results 
in false-positive findings on invasive coronary angiography. Accordingly, the development 
of novel automated quantitative approaches for cardiac CT has gained increasingly interest 
over the recent years.
Current preliminary data for quantitative CT have been derived from semi-manual or 
manually-assisted cardiac CT approaches, rather than automated dedicated algorithms 
for quantification of coronary atherosclerosis.9-14 As compared to intravascular ultrasound 
(IVUS), these quantitative approaches were limited by substantial variability and large 
limits of agreement.9-14 The use of sophisticated automated post-processing algorithms 
for quantification of coronary atherosclerosis may lead to improved diagnostic accuracy 
and reproducibility of cardiac CT. Such quantitative information can be used to improve 
diagnosis of coronary atherosclerosis, and for this reason, may improve the patient referral 
for percutaneous coronary intervention or coronary artery bypass grafting surgery.
Figure 1. Schematic illustration of consecutive processing steps involved in automated 
quantification using dedicated quantitative post-processing software for cardiac computed 
tomography (CT).
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Myocardial Perfusion SPECT for Selection of 
Heart Failure Patients Referred for Cardiac 
Resynchronization Therapy (Part II)
Within the last 10 to 15 years, multiple randomized controlled trials have clearly demon-
strated the benefits of biventricular pacing on morbidity and mortality rates in patients with 
moderate-to-severe heart failure who remain symptomatic despite optimal pharmacological 
treatment.15, 16 Based on several landmark trials15-19, international guidelines have recom-
mended CRT with a class I indication in patients with symptomatic drug-refractory systolic 
heart failure New York Heart Association (NYHA) functional class III and IV, ventricular 
dyssynchrony (prolonged QRS duration ≥120 ms), reduced LV ejection fraction (LVEF) ≤35% 
and sinus rhythm.20, 21
Although considerable improvements in heart failure symptoms, exercise capacity, mitral 
regurgitation and LV dimensions have been observed in heart failure patients receiving 
CRT17-19, 21-24, a consistent proportion of patients who meet the current selection criteria for 
CRT fail to respond to CRT.24, 25
As a consequence, numerous clinical studies have been conducted that were designed to 
improve current selection of patients referred to CRT by identification of potential determi-
nants for response to CRT.24-28 Among the multiple pathophysiologic mechanisms involved 
in heart failure, the presence of LV systolic dyssynchrony has been identified as one of the 
major determinants of CRT response.29, 30  It has been shown that LV systolic dyssynchrony 
can affect biomechanics and performance of the LV considerably.31
At present, many cardiac imaging techniques have been applied in clinical practice to 
assess the presence and extent of LV systolic dyssynchrony in heart failure patients, wherein 
echocardiographic techniques such as 2D echocardiography with tissue Doppler imag-
ing (TDI) have been used most widely for detection of LV systolic dyssynchrony.29, 30 At 
present however, no consensus exists on the echocardiographic definition of LV systolic 
dyssynchrony, an issue which can be addressed by nuclear imaging techniques since phase 
analysis on GMPS allows assessment of mechanical dyssynchrony using an automated and 
reproducible post-processing algorithm.
Moreover, non-synchrony issues such as location, extent and severity of scar tissue have 
been identified as (important) determinants affecting the likelihood of response to CRT.25, 
32-34 Additionally, the relation between LV lead position and site of latest mechanical activa-
tion has been shown to play an important role in prediction of CRT response.35 Accordingly, 
SPECT may be of interest, since it provides information on cardiac dyssynchrony (by phase 
analysis of gated SPECT data) along with assessment of presence, location and extent of scar 
tissue.
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As indicated in Figure 2, phase analysis is performed on standard GMPS short-axis images 
and involves several processing steps. A histogram is generated that provides information 
on LV systolic (dys) synchrony for the entire ventricle. A total of 5 quantitative parameters 
for LV systolic dyssynchrony can be derived from the phase histogram, including histo-
gram bandwidth (HBW), phase standard deviation (SD), histogram kurtosis, skewness and 
peakedness. HBW (including 95% of the phase angles) and phase SD (SD of the phase 
distribution) have been validated against echocardiographic techniques for assessment of LV 
systolic dyssynchrony.36, 37 Along with LV systolic dyssynchrony, phase analysis can be used 
for assessment of LV diastolic dyssynchrony by detection of changes in myocardial counts 
during the diastolic phase of the LV. Additionally, phase analysis on GMPS can be used to 
Figure 2: Phase analysis on gated myocardial perfusion single photon emission computed 
tomography (SPECT) (GMPS) allows integrated assessment of left ventricular (LV) systolic 
dyssynchrony, myocardial infarction and site of latest mechanical activation. Phase analysis is 
performed on standard GMPS reconstructed short-axis images and involves several processing 
steps: (1) detection of maximal counts in 3D for each temporal frame, (2) count-based wall-
thickening curves are created from regional count changes during the R-R cycle, (3) approximation 
of separate sample points into a continuous curve using first Fourier Harmonic function (middle, 
left panel). As indicated below, the phase polar map (bottom, left panel) shows a considerable 
phase delay (bright region) at the anterior and apical segments of the LV. Subsequently, the phase 
histogram (bottom, mid panel) shows the degree of systolic dyssynchrony or synchrony for the 
entire LV, in which histogram bandwidth (HBW) and phase standard deviation (SD) are the most 
commonly used indicators of LV (dys) synchrony.
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identify the site of latest mechanical activation (and whether this region is viable) which may 
help in selecting the optimal LV lead position. Thus, GMPS with phase analysis is a potent 
cardiac imaging technique that provides important information in patients with heart failure 
referred for CRT. In part II, the role of phase analysis on GMPS for selection of heart failure 
patients for CRT will be addressed.
Cardiac Sympathetic Nerve Scintigraphy 
with 123-I Metaiodobenzylguanidine for Risk 
Stratification of Patients with Cardiovascular 
Disease (Part III)
Among patients with cardiovascular disease, the clinical syndrome of heart failure is a com-
mon pathophysiologic disorder, with an estimated prevalence of approximately 5.3 million 
individuals in the United States.38 The risk for newly diagnosed heart failure is considerably 
high in the western population, with a life-time risk of 1 out of 5 in patients aged 40 years. 
Importantly, heart failure patients are suffering from a serious pathophysiologic condition as 
20% of patients will die within the first year after the beginning of heart failure.38 Moreover, 
heart failure patients also exhibit a considerably high long-term mortality rate, with an 
estimated 5-year mortality rate of 59% in men and 45% in women.39
Even though considerable advances in risk stratification of patients with heart failure 
have been made in recent years, identification of heart failure patients who will suffer from 
serious adverse events remains a difficult issue.
The cardiac sympathetic nervous system may serve as an important determinant for 
risk stratification in heart failure as it is directly involved in preservation of cardiovascular 
homeostasis by regulation of heart frequency, electrical conduction and cardiac contrac-
tility.40 A chronic dysfunctional cardiac sympathetic nervous system exerts pleiotropic 
detrimental effects on the structural and functional integrity of the myocardium, including 
stimulation of cardiomyocyte hypertrophy, fibroblast and smooth muscle cell proliferation, 
which altogether contribute to a worse cardiovascular outcome.41, 42 As a consequence, 
the cardiac sympathetic nervous system can been used for risk stratification of patients with 
cardiovascular disease, most commonly in the setting of chronic heart failure.41-45
Although plasma norepinephrine levels and the rate of norepinephrine spillover can be 
used as determinants for identification of patients at risk for adverse cardiovascular out-
come41, 42, a direct assessment of cardiac sympathetic innervation by nuclear imaging may 
represent a more sensitive marker for risk stratification of patients with heart failure.45
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Among nuclear imaging techniques, SPECT can be used for mapping the cardiac sym-
pathetic nervous system as it provides enough sensitivity to assess distinct aspects of the 
cardiac neurotransmission itself, including norepinephrine uptake at the presynaptic site 
(sympathetic innervation) as well as binding of norepinephrine at the post-synaptic site.46-48 
Moreover, the rate in which radionuclide SPECT tracers are washed out of the myocardium 
provides information on the degree of sympathetic activity within the heart.
The norepinephrine analogue metaiodobenzylguanidine labeled to iodine-123 (123-I 
MIBG) has been used most commonly as a SPECT radionuclide tracer for assessment of 
cardiac sympathetic innervation (Figure 3).44, 45 Thus far, a large number of studies have 
demonstrated the predictive value of cardiac 123-I MIBG imaging in patients with heart 
failure.44, 45, 49 Agostini et al.50 evaluated whether 123-I MIBG scintigraphy allowed risk 
stratification of 290 heart failure patients. Patients with adverse events (n=67) showed 
significantly lower cardiac 123-I MIBG uptake on late planar imaging (as expressed as 
the heart-to-mediastinum (H/M) ratio) when compared to patient without adverse events 
(n=223) (p<0.001). Moreover, both H/M ratio (on late planar 123-I MIBG scintigraphy) and 
LVEF were significant predictors for adverse cardiac events. More recently, the prospective 
multicenter AdreView Myocardial Imaging for Risk Evaluation in Heart Failure (ADMIRE-HF) 
study has evaluated the predictive value of cardiac neuronal status as derived from cardiac 
123-I MIBG scintigraphy in 961 patients with NYHA functional class II or III. Heart failure 
patients with a late H/M ratio of <1.60 experienced significantly more adverse events than 
heart failure patients with a late H/M ratio of ≥1.60 (p<0.001).45
Figure 3. 123-iodine metaiodobenzylguanidine (123-I MIBG) for assessment of cardiac sympathetic 
innervation using planar imaging (panel A) and single photon emission computed tomography 
(SPECT) (panel B). Planar imaging is used for assessment of global sympathetic innervation patterns 
by calculation of the heart-to-mediastinum (H/M) ratio, in which the mean counts per pixel within 
the heart (H) is divided by the mean counts per pixel within the upper mediastinum (M). Regional 
defects in sympathetic innervation of the myocardium can be assessed using SPECT, as depicted in 
panel B.
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Beyond prediction of cardiac death or worsening heart failure, some studies have also 
postulated the use of cardiac 123-I MIBG scintigraphy for identification of patients at risk 
for adverse arrhythmogenic events, including lethal ventricular arrhythmias and sudden 
cardiac death.44, 45 It has been shown that parasympathetic stimulation of the ventricles 
exerts anti-fibrillatory effects on the myocardium, while ventricular sympathetic activation 
emerged to have a pro-arrhythmogenic effect on the myocardium.51 Moreover, activation of 
the cardiac sympathetic nervous system contributes to cardiac arrhythmogenesis as regions 
with abnormalities in cardiac sympathetic innervation may show a denervation supersensi-
tivity response to circulating catecholamines with an enhanced automaticity of cardiomyo-
cytes and a reduction of ventricular effective refraction period.51-53 Finally, co-existence of 
sympathetic denervated regions alongside regions with preserved sympathetic innervation 
may lead to inhomogeneous neuronal release of neurotransmitter norepinephrine, which 
subsequently, can cause considerable changes in action potential duration and configura-
tion with associated electrophysiologic heterogeneity of the myocardium.51-53
Accordingly, cardiac 123-I MIBG scintigraphy may provide important information to risk 
stratify patients with cardiovascular disease by assessment of cardiac sympathetic innerva-
tion and activation.
More specifically, cardiac 123-I MIBG scintigraphy may serve as a potent imaging tech-
nique for identification of patients at risk for future ventricular arrhythmia or sudden cardiac 
death, which potentially, could help to improve the current selection of patients indicated 
for implantable cardioverter-defibrillator (ICD) treatment (Part III).
Objective and Outline of the Thesis
Although cardiac imaging has already contributed significantly in the evaluation of patients 
with cardiovascular disease, novel insights into cardiac imaging techniques may further 
improve diagnostic and therapeutic algorithms as well as prognostification of patients with 
cardiovascular disease. More specifically, the current thesis describes the role of novel 
insights into cardiac imaging for diagnosis (Part I), treatment (Part II) and risk stratification 
(Part III) of patients with cardiovascular disease.
In part I, the value of automated quantitative CT for evaluation of coronary atheroscle-
rosis is described. Chapter 2 provides an overview of the currently available approaches for 
quantification of coronary atherosclerosis. Additionally, chapter 2 describes the potential 
role of quantitative CT to guide percutaneous coronary intervention procedures. In chapter 
3, the validation of a dedicated CT algorithm for automated quantification of coronary 
stenosis severity is discussed. Chapter 4 shows the feasibility of automated coronary plaque 
quantification using dedicated CT software in comparison with IVUS. At last, the feasibility 
of cardiac CT to assess diastolic function is described in chapter 5.
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In part II, the potentials of nuclear imaging with GMPS in heart failure patients referred 
for CRT are described. Chapter 6 reviews the role of phase analysis on GMPS for assessment 
of LV systolic dyssynchrony, myocardial infarction and viability. Chapter 7 describes the 
validation of a dedicated algorithm for phase analysis on GMPS in a direct comparison with 
echocardiography using TDI for assessment of LV systolic dyssynchrony. Chapter 8 evaluates 
the relation between the site of latest mechanical activation as derived from GMPS, LV lead 
position and response to CRT. In chapter 9, the feasibility of GMPS with phase analysis 
to assess LV diastolic dyssynchrony in a direct comparison with TDI is evaluated. Finally, 
chapter 10 evaluates the prediction of response to CRT by LV diastolic dyssynchrony as 
assessed from GMPS with phase analysis.
In part III, the role of cardiac sympathetic nerve imaging with 123-I MIBG for risk strati-
fication of patients with cardiovascular disease is described. Chapter 11 describes the value 
of cardiac 123-I MIBG scintigraphy for prognostification of patients with heart failure. The 
potentials of cardiac 123-I MIBG imaging for identification of patients at risk for ventricular 
arrhythmias are described in chapter 12. In chapter 13, the relation between contrast-
enhanced magnetic resonance imaging (MRI) and 123-I MIBG/perfusion scintigraphy for 
assessment of infarct size and infarct border zone, referred to as myocardium at risk for 
ventricular arrhythmias, is evaluated.
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Abstract
A comprehensive evaluation of coronary anatomy and atherosclerosis can be provided by 
multidetector row computed tomography (CT). Currently, several studies have used either 
manual or semi-automated algorithms for quantification of different plaque characteristics, 
in particular the degree of luminal narrowing. Although the feasibility of previously used 
quantitative algorithms has been demonstrated, further refinement of quantitative CT 
algorithms is currently indicated to allow a comprehensive yet fully automated analysis of 
plaque characteristics.
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Introduction
Multidetector row computed tomography (MDCT) allows non-invasive evaluation of coro-
nary artery disease (CAD) with excellent image quality and diagnostic accuracy as compared 
to invasive coronary angiography.1-3 In recent years, rapid technological advances have led 
to an enormous increase in the use of MDCT for non-invasive evaluation of patients with 
known or suspected coronary atherosclerosis.
One of the advantages of MDCT is the fact that it provides a detailed overview of coro-
nary anatomy (including the location of coronary ostia, coronary tree dominancy, tortuosity 
and coronary angulation) as well as comprehensive analysis of coronary stenosis (extent, 
distribution and location). Moreover, the technique is not restricted to luminography and 
additional important information on coronary plaques can be easily derived, including 
plaque morphology, degree of plaque remodeling, plaque burden and the longitudinal 
length of atherosclerotic lesions. Such an integrated analysis of coronary atherosclerotic 
disease may provide important information to risk stratify patients for potential forthcoming 
cardiovascular events, and while it can also be used to guide future therapeutic clinical 
interventions, including percutaneous coronary intervention.
At present, MDCT images are most commonly post-processed and evaluated by an 
experienced reader using a visual approach. However, the introduction of dedicated algo-
rithms for automated quantification of plaque characteristics may further improve diagnostic 
accuracy and reproducibility of MDCT. Moreover, automated quantitative approaches may 
reduce the amount of time required to evaluate MDCT images. Accordingly, the develop-
ment and validation of novel quantitative approaches for MDCT are increasingly attracting 
interest.
The current review will provide an overview of the currently available approaches for 
MDCT to quantify plaque characteristics, with particular focus on the quantification of ste-
nosis severity. Additionally, the review will discuss the potential role of quantitative MDCT 
analyses to guide percutaneous coronary intervention procedures.
Quantification of Coronary Artery Stenosis
Invasive coronary angiography is considered the golden standard for evaluation of stenosis 
severity in clinical cardiology.4 As compared to the standard of reference, MDCT has been 
shown in several studies, including large multicenter trials, to be an accurate technique for 
detection of significant coronary artery luminal narrowing (≥50% stenosis).1-3 However, 
despite these promising results, one of the major drawbacks of MDCT remains the fact that 
the degree of coronary stenosis is most often determined visually using a dichotomous scor-
ing system with 50% lumen diameter stenosis as a cutoff.3, 5 This binary approach restricts 
the amount of potential useful information that can be derived from MDCT with regard to 
stenosis severity. For clinical purposes, an accurate discrimination between low, intermediate 
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and high-grade stenotic coronary plaques is of importance. In recent years, a large number 
of studies have evaluated the performance of quantitative MDCT approaches to assess the 
degree of coronary stenosis in a direct comparison to invasive imaging techniques, includ-
ing invasive coronary angiography and gray-scale intravascular ultrasound (IVUS).5-10 An 
interesting study was performed by Leber et al.6 who have evaluated the accuracy of a 
manual quantification approach for assessment of the degree of lumen diameter stenosis 
as compared to invasive angiographic evaluation with quantitative coronary angiography 
(QCA) and gray-scale IVUS. Using MDCT images, the grade of stenosis was determined 
by dividing the minimal lumen diameter at the level of the stenosis through the lumen 
diameter at the adjacent non-diseased region. Quantitative measurements were performed 
in longitudinal multi-planar curved reconstructions in 2 projections similar as those used for 
QCA. In total, MDCT and invasive coronary angiography were performed in 55 consecutive 
patients with known or suspected coronary atherosclerosis, of whom 18 patients underwent 
a combined examination with gray-scale IVUS. Reliable quantitative analysis could be per-
formed in 825 coronary segments (using the 15-segment model). Overall, MDCT showed 
an only moderate correlation with QCA (r=0.54) and IVUS (r=0.61) for quantification of 
the degree of coronary stenosis. Importantly, sub-analysis showed that quantification was 
particularly challenging in distal coronary tree segments (segment 8 and 13) and marginal 
coronary branches (segment 12, 14 and 15). Additionally, coronary segments with heavily 
calcified lesions showed more often misclassifications when compared to coronary seg-
ments without severe calcified lesions. Moreover, it is important to note that the degree of 
luminal obstruction was significantly underestimated with MDCT as compared to gray-scale 
IVUS (41.1%±22.7% vs. 50.4%±14.0%, p<0.01). More recently, Cheng et al.11 sought to 
determine the relation between a visual multi-tiered grading system, semi-automated MDCT 
quantification of stenosis severity and QCA in 84 patients who had undergone invasive 
coronary angiography and MDCT. Only interpretable native coronary segments with a 
diameter stenosis of ≥25% were included. All non-stented coronary segments were evalu-
ated by 2 experienced and blinded MDCT readers who visually graded segments as follows: 
0 = 0%, 1 = 1 - 24%, 2 = 25 - 49%, 3 = 50 - 69%, 4 = 70 - 89%, 5 = 90 - 100%. All coronary 
segments were also quantified by a semi-automated approach using a manually determined 
proximal and distal reference region, representing an approximation of the normal coronary 
vessel tapering. The reference regions were used to determine luminal narrowing at the 
level of maximal diameter stenosis (lesion marker) on longitudinal images. Consecutively, 
the degree of coronary stenosis, as derived from visual and semi-automated MDCT analysis, 
was compared to QCA. In total, 278 coronary segments with ≥25% diameter stenosis were 
included. Overall, the multi-tiered visual scoring system showed good correlation to QCA 
(Kendall’s tau-b 0.76, weighted kappa 0.70, p <0.05). Of note, the semi-automated MDCT 
approach showed no improvement in diagnostic accuracy when compared to expert visual 
grading. One of the potential explanations for these findings may be the fact that the use of 
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semi-automated quantification was associated with large variability introduced by manual 
interference. The minimal luminal diameter, the proximal and distal reference points were 
assessed manually, as indicated in Figure 1, whereas a computed-assisted approach could 
have improved the accuracy of the quantitative measurements.
Recently, Joshi et al.10 have aimed to determine the performance of quantitative computer-
assisted MDCT analysis in 48 patients using gray-scale IVUS as the standard of reference. 
Quantitative coronary angiographic MDCT analysis was used to calculate percentage 
diameter stenosis on cross-sectional images. At first, semi-automated detection of coronary 
lumen centerline was performed with the use of vessel calipers, which could be manually 
adapted to ensure true coronary lumen detection. Consecutively, proximal and distal refer-
ence regions were defined by hand, after which the program automatically calculated mini-
mal lumen diameter and minimal lumen area as well as the degree of percentage diameter 
stenosis. In this study, a moderate correlation between MDCT and IVUS was found for mini-
mal lumen area (r2=0.41, p<0.01), whereas no correlation was found between MDCT and 
QCA for minimal lumen diameter (r2=0.01, p=0.57) or diameter stenosis (r2=0.02, p=0.31). 
For moderate to severe calcified lesions, MDCT showed no correlation for minimal lumen 
diameter (r2<0.01) and area (r2<0.01) as well as percentage diameter stenosis (r2=0.06) as 
compared to IVUS. However, for mildly calcified or non-calcified lesions, MDCT showed 
Figure 1. Quantification of stenosis severity on multidetector row computed tomography (MDCT). 
Diameter coronary stenosis can be manually determined by assessing the lumen diameter at the 
lesion site and proximal/distal reference sites using either axial slices (panel A) or cross-sectional 
images perpendicular to the centerline of the vessel (panel B). Similarly, area stenosis can be 
calculated by tracing lumen areas on the cross-sectional images (panel C).
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significantly improved correlations with IVUS for minimal lumen diameter (r2=0.40) and 
minimal lumen area (r2=0.68).
Currently, the majority of studies have used semi-manual MDCT approaches rather than 
dedicated automated segmentation algorithms to quantify stenosis severity. Recently, the 
feasibility of a novel dedicated algorithm for automated quantification of the degree of 
coronary stenosis was shown in a subset of 93 patients with known and suspected CAD.12 
In this study, performance of the novel quantitative algorithm was evaluated against QCA 
measurements in 282 coronary lesions. Quantitative analysis involved several automated 
processing steps, with less manual interference when compared to previous attempts to 
calculate the degree of stenosis (Figure 2). A 3D centerline of the region of interest (rang-
ing from proximal to distal marker) was obtained with the use of a fast vessel tracking 
algorithm, which consisted of: (1) pre-segmentation of the coronary vessel and (2) fastest 
path back-tracking from distal to the proximal point. The 3D centerline was used to gener-
ate a multi-planar reconstructed volume and 4 longitudinal cross-sections of the region of 
interest. Finally, coronary lumen borders were detected by a model guided minimum cost 
approach (MCA) and used to quantify the percentage diameter stenosis. The MCA used spa-
tial first-, and second-derivative gradient filters combined with knowledge of the expected 
intracoronary CT intensity to detect the contours. The study showed good correlations for 
quantification of percentage diameter stenosis on a vessel- (n=282, r=0.83, p<0.01) and 
patient basis (n=93, r=0.86, p<0.01), as shown in Figure 3. Importantly, MDCT scans were 
also visually scored using a binary scoring system with 50% diameter stenosis as a cutoff. An 
Figure 2. Illustration of automated quantification of stenosis severity on multidetector row 
computed tomography (MDCT). The automated process involved several consecutive processing 
steps: (A) Determination of proximal (red) and distal (green) reference markers on axial slices; 
(B) Automated generation of the lumen centerline ranging from the proximal to distal reference 
marker; (C) Automated detection of lumen contours in transversal and (D) longitudinal planes; (E) 
Quantification of stenosis severity was based on the interrelation between lumen diameter at the 
site of minimal lumen diameter (yellow line, panel E) and the corresponding reference diameter 
(oblique orange line, panel E). (E) The reference line was generated from proximal (green markers) 
and distal reference (red markers) regions. For this lesion (indicated by the blue markers, panel E), 
the maximal degree of stenosis was 39.0%. Corresponding invasive coronary angiography view 
was shown in panel F. Data based on reference 12.
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improved diagnostic accuracy (95% vs. 87%, p=0.08) and positive predictive value (100% 
vs. 78%, p<0.05) was found for assessment of significant lesions (≥50% diameter stenosis) 
using quantitative MDCT analysis as compared to visual analysis.
Despite these promising results, one has to take into consideration that the use of 
quantitative MDCT algorithms is currently only feasible in data sets with good or moderate 
image quality. In case of severe cardiac motion artifacts, decreased image/noise ratio or 
suboptimal contrast arrival, the consistency of quantitative analyses may be distorted, and if 
so, visual interpretation may be preferred in these data sets. Additionally, quantification of 
atherosclerotic lesions located at coronary bifurcations remains challenging. In such lesions, 
visual analysis to evaluate stenosis severity may be preferred, rather than automated quanti-
tative MDCT analysis. However, further improvement in quantitative MDCT algorithms may 
enhance the diagnostic accuracy of automated quantification and extend the analysis to 
more difficult cases. Moreover, rapid technological developments have led to considerable 
improvement in spatial and temporal resolution of the currently available MDCT scanners. 
Potentially, the introduction of new MDCT scanners as well as the continuous refinement of 
acquisition and post-processing protocols may even further improve diagnostic image qual-
ity of MDCT coronary angiography, resulting in an increased number of data sets suitable 
for automated MDCT quantification.
Quantitative Analysis of Coronary Plaque Characteristics
MDCT enables a comprehensive non-invasive evaluation of coronary atherosclerosis 
beyond the isolated detection of significant coronary artery stenosis. It provides information 
on location, extent and distribution of coronary atherosclerotic plaques as well as a wide 
variety of additional geometric plaque characteristics, including plaque volume, plaque 
A B
Figure 3. Automated quantification of diameter stenosis (%) using dedicated software (QAngioCT) 
showed good correlation with quantitative coronary angiography (QCA) on a vessel basis (panel 
A) (n=282, r=0.83, p<0.01) and patient-basis (panel B) (n=93, r=0.86, p<0.01). Data based on 
reference 12.
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length and the degree of remodeling (Figure 4). These variables may be valuable for risk 
stratification as well as for planning of therapeutic coronary interventions.13, 14
Currently, comprehensive evaluation of the presence and extent of coronary athero-
sclerosis is usually performed by visual analysis of MDCT images. However, one of the 
major limitations of visual MDCT analysis of plaque characteristics remains the fact that 
it is observer dependent and requires substantial reading experience. Accordingly, several 
attempts have been made that sought to determine the performance of automated or 
computed-based algorithms for quantification of plaque characteristics without extensive 
manual interference. The use of automated quantitative algorithms may potentially improve 
the robustness and reproducibility of MDCT analyses, and importantly, the combined 
post-processing and interpretation of MDCT data sets may become less time-consuming. 
Moreover, quantification of plaque characteristics (e.g. plaque volume) with an automated 
and robust approach becomes of special interest when using MDCT to assess progression of 
coronary atherosclerosis.
Figure 4. Multidetector row computed tomography (MDCT) provides a comprehensive overview 
of the coronary anatomy and coronary atherosclerosis. The location, extent and morphology of 
atherosclerotic plaques can be derived using multi-planar reconstructed volumes (panel A and 
B). Additionally, with the use of quantitative algorithms, detection of lumen (panel C) and outer 
vessel wall (panel D) contours can be performed based on image gradients and lumen center lines. 
Consecutively, the detected contours allow evaluation of stenosis severity, plaque burden, plaque 
length and the degree of remodeling.
Chapter 2 : Quantification of stenosis severity on cardiac CT
35
Plaque Morphology
In recent years, the non-invasive evaluation of plaque morphology and plaque configura-
tion gained increasingly interest in clinical cardiology, as these variables may be important 
predictors for plaque rupture and acute coronary events.13, 15 For this reason, several studies 
have sought to evaluate the potential of MDCT to quantify coronary plaque composition.16-18 
Schroeder et al.16 has evaluated the diagnostic accuracy of plaque composition analysis 
on MDCT using IVUS as the standard of reference. In total, 34 coronary plaques of 15 
patients with chronic stable anginal complaints were identified on both imaging modalities, 
including non-calcified (n=12), mixed (n=5) and calcified (n=17) atherosclerotic lesions. 
Differentiation of plaque composition was performed visually by an expert observer. For 
each plaque type, the mean attenuation (expressed in Hounsfield units (HU)) of 16 randomly 
selected locations within the intracoronary plaque (defined as >40% luminal narrowing) 
was measured using a dedicated post-processing software. On MDCT, the mean attenua-
tion was 14±26 HU for non-calcified lesions, whereas mixed and calcified lesions showed 
a mean attenuation of 91±21 HU and 419±194 HU, respectively. Moreover, the mean 
attenuation values on MDCT were significantly different for each IVUS-derived plaque type 
(p<0.05). More recently, Leber et al.18 performed a study that aimed to assess the accuracy 
of plaque type characterization on MDCT in 46 patients with an increased risk profile. For 
each coronary plaque, density measurements (HU) were performed at each 3-mm coronary 
section using axial slices. After a raster consisting of 1 mm2 boxes was placed for each 
3-mm section, density measurements were performed on 5 randomly selected locations. In 
this study, the mean attenuation values were 49±22 HU (hypo-echoic), 91±22 HU (hyper-
echoic) and 391±156 HU (calcified lesions). Accordingly, these studies have indicated that 
MDCT can be used to quantify different types of plaque morphology. However, it has also 
been demonstrated that further classification of plaque type using MDCT can be difficult. 
Using IVUS, Pohle et al.19 have demonstrated that mean MDCT density was significantly 
lower in lesions consisting mainly of fibrofatty tissue as compared to fibrotic lesions. Never-
theless, between individual lesions, substantial overlap in density values was noted. Similar 
findings were reported by Choi et al.20, evaluating 80 non-calcified plaques and compared 
findings to IVUS radiofrequency analysis (VH-IVUS). In addition, differences in acquisition 
characteristics, including flow rate and contrast agent, as well as patient characteristics such 
as cardiac output and body weight, may substantially influence individual measurements. 
Finally, one should also be aware of the restrictions in spatial resolution of MDCT. In calci-
fied lesions, the blooming effect of the calcium may result in overestimation of the extent of 
calcium and inaccurate classification of adjacent plaque areas. Vice versa, one has to take 
into consideration that plaques deemed to be entirely non-calcified on MDCT may contain 
small amounts of calcium.21
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Plaque Volume, Burden and Remodeling Index
A large number of studies have aimed to quantify plaque volume, burden and the degree 
of remodeling using semi-automated MDCT approaches.7, 9, 13, 22 Leber et al.7 sought to 
determine the accuracy of plaque volume measurements using MDCT as compared to 
invasive gray-scale IVUS in 20 patients. For both techniques, the total plaque volume was 
measured by adding the semi-automated detected plaque area per coronary section. The 
study showed a good correlation for plaque volume (r2=0.69, p<0.01) (Figure 5) between 
both imaging modalities, with a significant underestimation for mixed (47.7±87.5 mm3 vs. 
57.5±99.4 mm3, p<0.05) and non-calcified (59.8±76.6 mm3 vs. 67.7±67.9 mm3, p<0.05) 
plaques. Calcified lesions were slightly overestimated on MDCT when compared to IVUS 
(65.8±110.0 mm3 vs. 53.2±90.3 mm3, p=0.19). In addition, Bruining and colleagues9 have 
used an automated MDCT approach with limited manual interference to assess plaque vol-
ume using IVUS as the standard of reference. In 48 symptomatic patients, computed-assisted 
coronary plaque MDCT measurements were performed by 2 independent observers. After 
the regions of interest were matched for both techniques, they were extracted from the 3D 
data set with the use of semi-automated vessel extraction software (CURAD). Thereafter, 
for each region of interest, lumen borders were automatically detected on the basis of an 
edge-detection method using a dedicated filter (digital Deriche filter) which calculated the 
gradient of the images. Of note, the automated edge-detection method could only be used 
for detection of lumen borders, whereas the vessel wall borders were manually outlined. 
Using this approach, plaque volume was significantly overestimated on MDCT when com-
pared to IVUS (222±121 mm3 vs. 189±93 mm3, p<0.01). Importantly, for both readers, good 
correlations were found between MDCT and IVUS for plaque volume (r=0.74 and r=0.79). 
Similarly, Otsuka et al.22 have evaluated the accuracy of quantitative plaque volume MDCT 
BA
Figure 5. Semi-automated quantification of plaque volume as assessed with multidetector 
row computed tomography (MDCT) and intravascular ultrasound (IVUS). A. Plaque volume was 
systematically underestimated with MDCT as compared to IVUS as shown in the Bland-Altman 
Analysis (p<0.05). B. Good correlation was found for quantification of plaque volume between both 
techniques (r2=0.69, p<0.01). Data based on reference 7.
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measurements in 47 patients as compared to IVUS. After coronary-tree extraction was per-
formed, plaque volume and plaque burden were measured using manually-traced MDCT 
lumen and vessel wall contours (Figure 6). The study found good correlations for regional 
plaque burden (r=0.96, p<0.01) and plaque volume (r=0.98, p<0.01) between quantitative 
CT and IVUS. In addition, good reproducibility was observed as indicated by a Pearson’s 
correlation coefficient of 0.98 (p<0.001) and 0.91 (p<0.001), respectively, for intraobserver 
and interobserver correlation.
Coronary plaque remodeling has also been recognized as an important plaque char-
acteristic that has been linked to increased vulnerability.13, 15 With IVUS as the standard 
of reference, several studies have explored the potential of MDCT to assess coronary 
plaque remodeling.13, 23 Achenbach et al.23 evaluated the feasibility of MDCT to evaluate 
remodeling index in 44 patients with known atherosclerotic plaques. In this study, plaque 
remodeling was calculated by dividing the manually-traced cross-sectional vessel wall area 
at the level of maximal luminal narrowing by the cross-sectional vessel wall area at the 
proximal non-diseased reference region, as indicated in Figure 7. Interestingly, the study 
demonstrated that the degree of remodeling was significantly higher in patients with non-
stenotic lesions as compared to patients with stenotic lesions (1.3±0.2 vs. 1.0±0.2, p<0.01). 
Moreover, remodeling index as derived from MDCT showed good correlation with IVUS 
(r2=0.82, p<0.01).
Figure 6. Schematic illustration of plaque burden quantification as assessed with multidetector row 
computed tomography (MDCT). Coronary arteries were extracted using semi-automated vessel 
extraction software. For each coronary artery, lumen plaque interface (red lines) and the outer 
vessel wall border (green lines) were identified and manually delineated in at least 4 orthogonal 
L -mode views with rotational display of the extracted coronary artery (step 1 and 2). Further 
refinement of the contour tracing was performed by referring to the corresponding transversal 
images (step 3). Finally, plaque burden (blue line) was derived from the interrelation of vessel wall 
area (green line) and lumen area (red line). Reprinted with permission from reference 22.
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Future Challenges
A systematic evaluation of atherosclerotic lesions requires the detection of both lumen 
and outer vessel wall borders throughout the coronary tree. Although the feasibility for 
automated detection of luminal borders has been demonstrated12, the automated detection 
of outer vessel wall borders remains a challenge as it is usually hampered by subtle differ-
ences in image gradients, particularly in peripheral coronary segments. A fully automated 
approach for detection of outer vessel wall borders has not been validated yet for clinical 
practice. Accordingly, the feasibility to quantify plaque volume, burden and remodeling 
index have only been demonstrated using semi-automated vessel wall border detection.7, 9, 
13, 22 With the currently applied algorithms, extensive manual interference is still required to 
generate reliable outer vessel wall borders. Potentially, the introduction of advanced quan-
titative algorithms in combination with developments in scanner technology may further 
improve the consistency of vessel wall and reference contour detection, leading to improved 
quantification of plaque characteristics.
Quantitative Computed Tomography Angiography to Guide Percutaneous 
Coronary Interventions
Non-invasive evaluation of coronary atherosclerosis with the use of MDCT provides 
important information which can be used to guide percutaneous coronary interventions. 
MDCT provides integrated information on extent, location and distribution of coronary 
atherosclerosis, beyond the isolated assessment of coronary stenosis severity. More in-depth 
Figure 7. Quantitative approach for assessment of coronary plaque remodeling using multidetector 
row computed tomography (MDCT) (panel A) and IVUS (panel B). With MDCT, remodeling index 
was calculated using manually-traced outer vessel wall area at the site of maximal luminal 
narrowing (right panel) and non-diseased proximal reference region (left panel). A similar approach 
was used to calculate the degree of plaque remodeling on IVUS. For both imaging modalities, the 
degree of remodeling was calculated by dividing the vessel wall area at the level of the maximal 
stenosis by the proximal reference vessel wall area. Reprinted with permission from reference 23.
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pre-procedural evaluation of coronary plaques (stenosis severity, plaque location and 
length) may be valuable for procedural planning and may increase procedural success. For 
example, it has been recently demonstrated that depicting the degree of calcification and 
the length of an occluded segment on MDCT (which can be difficult on invasive coronary 
angiography but can be easily derived from MDCT) may predict the success of percutaneous 
treatment of chronic total coronary artery occlusions.24 Bifurcation lesions represent another 
challenge in interventional cardiology. One of the underlying mechanisms of the observed 
lower angiographic success rate of these lesions is the occurrence of coronary plaque shift-
ing or rupture, which may lead an occlusion of coronary side branches. Pre-interventional 
MDCT assessment of the coronary angulation and tortuosity as well as plaque location, 
severity and composition could potentially prevent difficult and high-risk percutaneous 
procedures.
Conclusions
MDCT provides a comprehensive evaluation of coronary anatomy and atherosclerosis. 
The majority of studies have used semi-automated algorithms to quantify a wide variety of 
plaque characteristics, predominantly focusing on the degree of luminal narrowing. Despite 
promising findings, further refinement of the quantitative MDCT algorithms is currently 
indicated. With the introduction of such improved quantitative post-processing algorithms, 
however, fully automated analysis of plaque characteristics may become feasible and may 
provide valuable information for the diagnosis and management of patients with CAD.
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Abstract
Background Limited information is available on quantification of coronary stenosis while 
previous attempts using semi-automated approaches were suboptimal. 
Objectives To demonstrate the feasibility of a novel dedicated algorithm for automated 
quantification of stenosis severity on multi-slice computed tomography (MSCT) in compari-
son to quantitative coronary angiography (QCA). 
Methods In patients who had undergone 64-slice MSCT and invasive coronary angiogra-
phy, the most severe lesion on QCA was quantified per coronary artery using quantitative 
computed tomography (QAngioCT) software. Additionally, visual grading of stenosis sever-
ity using a binary approach (50% stenosis as a cutoff) was performed. Diameter stenosis 
(percentage) was obtained from detected lumen contours at the minimal lumen area and 
corresponding reference diameter values obtained from an automatic trend analysis of the 
vessel areas within the artery.
Results One-hundred patients (53 men, 59.8±8.0 yrs) were evaluated and 282 (94%) ves-
sels were analyzed. Good correlations for diameter stenosis were observed for vessel-based 
(n=282, r=0.83, p<0.01) and patient-based (n=93, r=0.86, p<0.01) analyses. Mean differ-
ences between QAngioCT and QCA were -3.0±12.3% and -6.2±12.4%. Furthermore, good 
agreement was observed between QAngioCT and QCA for semi-quantitative assessment of 
diameter stenosis (accuracy of 95%). Diagnostic accuracy for assessment of ≥50% diameter 
stenosis was higher using QAngioCT as compared to visual analysis (95% vs. 87%, p=0.08). 
Moreover, a significantly higher positive predictive value was observed with QAngioCT 
when compared to visual analysis (100% vs. 78%, p<0.05). Although the visual approach 
showed a reduced diagnostic accuracy for data sets with moderate image quality, QAngioCT 
performed equally well in patients with moderate or good image quality. However, in data 
sets with good image quality, QAngioCT tended to have a reduced sensitivity as compared 
to visual analysis.
Conclusions Good correlations were found for quantification of stenosis severity between 
QAngioCT and QCA. QAngioCT showed an improved positive predictive value when 
compared to visual analysis.
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Introduction
Multi-slice computed tomography (MSCT) has emerged as a promising non-invasive modal-
ity to detect coronary artery disease (CAD).1-3 High diagnostic accuracy for detection of 
significant CAD as compared to invasive coronary angiography has been reported in studies 
using 64-MSCT.1-3 Moreover, high negative predictive values have been reported in studies 
using 64-slice MSCT and as a result MSCT is increasingly used in the evaluation of CAD.1-3
However, a major limitation of the technique remains the fact that at present stenosis 
severity on MSCT can only be assessed visually; most frequently a dichotomous score 
system with a cutoff value of 50% stenosis is used. A fully automated approach to quantify 
stenosis severity, similar to quantitative coronary angiography (QCA) would be preferred to 
further improve the diagnostic accuracy and reproducibility. However, such an automated 
quantitative approach is currently not available. In the majority of previous studies, attempts 
to quantify stenosis severity have used semi-manual approaches rather than dedicated 
automated segmentation algorithms. Unfortunately, these semi-manual approaches suffer 
from limited diagnostic accuracy and poor reproducibility, and as a result, results were 
suboptimal in the majority of studies.4-7
Recently, novel software has become available for automated quantification of stenosis 
severity which involves several automated processing steps with less manual interference as 
compared with previous attempts to quantify stenosis severity. Accordingly, this study aimed 
to demonstrate the feasibility of this novel dedicated algorithm for automated quantification 
of stenosis severity in comparison to QCA.
Methods
Study Population
The study population consisted of patients who underwent 64-slice MSCT and invasive 
coronary angiography sequentially, within 4 months. Patients were clinically referred for 
MSCT because of known or suspected CAD. Known CAD was defined as a history of myo-
cardial infarction, revascularization or evidence of CAD on previous diagnostic tests.
No adverse cardiac events or hospitalizations were documented between MSCT and 
invasive coronary angiography. Patients underwent comprehensive imaging as part of an 
ongoing study registry addressing the value of MSCT in relation to other imaging modalities. 
Referral for invasive coronary angiography was based on clinical presentation and/or imag-
ing results. Patients were excluded in case of atrial fibrillation, renal dysfunction (glomerular 
filtration rate <30 mL/min), documented iodine-containing contrast allergy and pregnancy. 
Risk factors for CAD were derived from existing patient medical record data.
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Conventional Invasive Coronary Angiography
Acquisition and Analysis
Conventional invasive coronary angiography was performed according to the standard 
protocols. QCA was performed offline by an independent and blinded observer, using a 
dedicated and validated software package (QAngioXA 7.1, Medis medical imaging systems, 
Leiden, the Netherlands). Coronary arteries were evaluated according to the 17-segment 
model as previously described8, and measurements were performed on a projection without 
superimposition of other coronary artery segments or cardiac structures as well as showing 
the stenosis in the tightest view. After catheter-based image calibration, side branches and 
coronary ostia were used as anatomical markers for accurate segment definition (17-segment 
model).8 Image calibration was performed in two end-diastolic frames with a catheter diam-
eter of 6F. Subsequently, the centerline was automatically defined followed by automated 
detection of lumen contours and calculation of luminal diameter function. From these data, 
the reference diameter function was derived and reference contours were reconstructed. The 
reference diameter function was obtained from a linear regression fit on the lumen diameter 
function. This regression fit approximates best the normal vessel tapering. Abnormal sec-
tions of a segment were excluded from the regression analysis by a user-interactive flagging 
procedure. At the site of minimal luminal diameter, the percentage diameter stenosis was 
calculated as: (1 – minimal luminal diameter / corresponding reference diameter) x 100%.9 




MSCT examinations were performed with a 64-slice CT scanner (Aquilion 64, Toshiba Medi-
cal Systems, Tokyo, Japan; General Electrics (GE) Lightspeed VR 64, Milwaukee, Wisconsin, 
USA). Patients with an elevated heart rate (≥65 beats/min) were administered metoprolol 50 
or 100 mg orally, if not contra-indicated. The contrast-enhanced helical scan was performed 
using a bolus of 95 to 130 mL of nonionic contrast medium (Iomeron 400; Bracco, Milan, 
Italy) followed by a bolus of saline flush (50 mL).
Prior to the helical scan, all patients underwent a non-enhanced electrocardiographic 
(ECG)-gated scan to assess the coronary calcium score. For the 64-slice GE Lightspeed 
system, the following parameters were used for the coronary calcium scan: 4 x 3.0 mm or 
2.5 mm, rotational time 350-500 ms, tube voltage 120 kV and tube current 200-250 mA. 
The following parameters were used for the helical scan: collimation of 64 x 0.625 mm, 
rotation time 350 ms, tube voltage 120 kV, and tube current 600 mA. Scan parameters 
for the Aquilion 64 CT scanner have been published previously.3 The ECG was obtained 
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simultaneously for retrospective gating of the raw data. Images were reconstructed with a 
slice thickness of 0.5 mm and a reconstruction interval of 0.3 mm, for the 64-slice Toshiba 
Aquilion system. For the 64-slice GE Lightspeed system, data were reconstructed at an effec-
tive slice thickness of 0.625 mm.
MSCT Examination
Coronary Artery Calcium Score
The non-helical scans performed with the Toshiba multislice Aquilion 64 system or the 
64-slice GE Lightspeed system were analyzed using dedicated offline software (Vitrea 2, Vital 
Images, Plymouth, Minnesota, USA or Advantage, GE Healthcare, Milwaukee, Wisconsin, 
USA, respectively). An overall Agatston score was calculated for each patient.10
Computed Tomography Coronary Angiography
The MSCT angiography examinations were evaluated by an independent and experienced 
observer who was blinded to quantitative data, as derived from QAngioCT and QCA. Coro-
nary arteries were divided into 17 segments according to the American Heart Association 
classification.8
The most severely diseased segment per coronary artery was evaluated for the presence 
of significant (≥50% diameter stenosis) or non-significant (<50% diameter stenosis) diameter 
stenosis with the use of axial images and curved multiplanar reconstructions in at least 2 
orthogonal planes.
Automated quantitative computed tomography angiography (QAngioCT) was performed 
by an independent observer, blinded to QCA data, using dedicated software (QAngioCT 1.1, 
Medis medical imaging systems, Leiden, the Netherlands). Using the 17-segment model8, 
quantitative measurements were performed on the most severely diseased segment for each 
coronary artery, as defined with QCA. A single coronary stenosis was assigned per coronary 
segment. To ensure that similar segments were analyzed with QCA and QAngioCT, accurate 
segment definition (defined with proximal and distal markers) was based on the 17-segment 
model. Side branches and coronary ostia were used as anatomical markers. Before auto-
matic quantification, image quality of coronary segments was classified using the following 
scale: 1 = good image quality, 2 = moderate image quality, 3 = poor image quality. Data sets 
with moderate image quality showed either motion artifacts or increased image noise. Data 
sets with poor image quality were non-diagnostic. In addition, atherosclerotic plaques were 
classified as non-calcified (lesions with lower density compared with contrast-enhanced 
lumen), mixed (lesions having elements of both non-calcified and calcified lesions) or calci-
fied (lesions with high density).
Consecutively, automated quantification of diameter stenosis was performed. A fast ves-
sel tracking algorithm was used to obtain the three dimensional centerline (ranging from 
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the proximal to distal marker) of the coronary artery. This vessel tracking step consists of: 
(1) a pre-segmentation of the vessel between the proximal and distal point; and (2) a fastest 
path back-tracking from distal to the proximal point through the center of the segmentation. 
Based on this centerline, a stretched multi planar reformatted (MPR) volume was created 
of the segment of interest. MPR volumes allowed analysis of curved coronary arteries as 
straight vessels. Next, four longitudinal cross-sections were extracted from the MPR volume 
at 45o degrees angular intervals. Subsequently, lumen borders in these four longitudinal 
images were detected by a model guided minimum cost approach (MCA).11 A compre-
hensive overview of the whole coronary segment of interest was provided by these four 
longitudinal images and corresponding longitudinal contours. Consecutively, the lumen 
border contours were detected in each transversal slice of the MPR volume using MCA with 
a circular lumen model. The MCA method uses a combination of spatial first-, and second-
derivative gradient filters in combination with knowledge of the expected CT intensity 
values in the arteries. Therefore, the MCA method is insensitive to differences in attenuation 
values between data sets. During this step, the intersection points of each transversal slice 
with the earlier obtained longitudinal contours were used to guide the contour detection in 
each particular slice. Based on the cross-sectional area of the obtained transversal contours 
a diameter function along the vessel course was derived using the formula for circular cross 
sections. Finally, from these data, the reference diameter function, minimal lumen diameter 
and the degree of stenosis were obtained similar to the QCA method (Figure 1). The minimal 
detectable diameter is approximately 0.25 mm with the currently used settings for coronary 
analyses in QAngioCT. This is the image resolution at which the CTA data set is re-sampled 
along the vessel within the stretched image. Automated quantitative processing steps were 
independent from the standard viewing settings (window level 1024, width 0). Only limited 
manual input was used to improve the automated processing steps. Corrections could be 
made in the longitudinal contour detection to improve contour detection in a limited num-
ber of transversal slices (less than 5 minutes per patient). If indicated, coronary flagging of 
particular segments was performed to improve the luminal reference line (less than 1 minute 
per patient).
Reproducibility of QAngioCT was evaluated by assessment of inter- and intraobserver 
variability. A second blinded observer performed QAngioCT measurements in 20 patients 
(58 interpretable vessels) who were randomly identified. To assess intraobserver variability 
measurements were performed twice by the same observer in a subset of 20 randomly 
selected patients (58 interpretable vessels).
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Statistical Analysis
Continuous data are presented as mean ± standard deviation, and categorical data are 
presented as absolute numbers or percentages. QAngioCT and QCA were compared on a 
vessel and patient basis using Pearson’s linear regression analysis. Segments with the most 
severe lesion per coronary vessel were included in de vessel-based analysis, whereas seg-
ments with the most severe lesion per patient were included in the patient-based analysis. 
Additionally, a segment-based analysis on a subset of 10 randomly selected patients was 
performed to evaluate the performance of QAngioCT in a wide range of stenosis and to 
avoid potential bias towards the most severe stenosis. For the segment-based analysis, each 
location of luminal narrowing per coronary segment was identified and analyzed using 
both quantitative approaches. Pearson’s linear regression analysis was used to compare 
Figure 1. Process of automated quantification of stenosis severity on 64-slice multi-slice computed 
tomography (MSCT). Automated quantification of stenosis severity on MSCT. Initially, accurate 
segment definition was performed using proximal and distal markers (Panel A and B). Automated 
contour detection was performed in longitudinal (Panel C) and transversal (Panel D) views. The 
longitudinal contours provide an initial approximation of the lumen border locations and are used 
to guide the automatic transversal contour detection. The right side of panel C shows the gradient 
image which is used to provide an intensity independent border description. Lumen quantification 
is only based on the transversal contours. Finally, in Panel E and F, quantification of stenosis was 
based on differences between reference line (red line) and contour area (yellow line). Reference 
line represented an estimate of normal tapering of the coronary artery. Diameter stenosis was 
35.0% on QAngioCT which corresponded with 41.5% on QCA.
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QAngioCT and QCA on a segment basis. Furthermore, separate analyses were performed for 
non-calcified, mixed and calcified lesions. When appropriate, wilcoxon signed-rank tests 
were used to compare percentage diameter stenosis as derived from QAngioCT and QCA. 
Limits of agreement between QAngioCT and QCA were calculated with Bland-Altman 
analyses showing the mean value of differences of each pair plotted against the average 
value of each pair. In addition, separate analyses were performed for non-calcified, mixed 
and calcified lesions.
Diagnostic accuracy for assessment of significant coronary artery stenosis (≥50% diam-
eter stenosis) was assessed for QAngioCT and visual analysis. Corresponding sensitivity, 
specificity, negative and positive predictive values were calculated. The 95% confidence 
intervals were calculated using the following formula: p±1.96 x standard error (SE) and the 
SE was estimated by √ [p (1 – p) / n]. Agreement between quantitative and visual analysis 
was evaluated using Cohen’s Kappa statistics, and k values were qualified as poor (<0.40), 
moderate (0.40-0.75) or good (>0.75) agreement. Inter- and intraobserver variability were 
determined with Bland-Altman analyses (GraphPad Prism software, version 5.01, GraphPad 
software Inc, San Diego, California, USA). Analyses were performed with statistical software 
(SPSS version 16.0, SPSS inc., Chicago, Illinois, USA). A p value <0.05 was considered 
statistically significant.
Results
Study Population and Baseline Results
One-hundred patients (53 men, 59.8±8.0 yrs) who underwent 64-slice MSCT and invasive 
coronary angiography were enrolled retrospectively. The mean duration between both 
examinations was 38.0±49.3 days. Baseline characteristics of the study population are 
listed in Table 1. Fifty patients underwent a 64-slice Toshiba Aquilion MSCT examination 
(Leiden University Medical Center, Leiden, the Netherlands) and 50 patients underwent a 
64-slice GE Lightspeed MSCT examination (Medical Center Haaglanden, the Hague, the 
Netherlands).
In total, 282 (94%) vessels were included in the vessel-based analysis. Eighteen (6%) 
vessels from 18 patients were excluded because of poor image quality, including motion 
artifacts on MSCT (n=7), reduced contrast arrival on MSCT (n=7) or the presence of a total 
occlusion (n=4). Good image quality was documented in 212 (71%) vessels, whereas mod-
erate image quality was documented in 70 (23%) vessels. Mean values of diameter stenosis 
and minimal lumen diameter for vessel-based analysis are shown in Table 2.
On a patient basis, 93 (93%) patients were included, whereas in 7 (7%) patients, the 
vessel with the most severe lesion was excluded because of poor image quality, including 
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motion artifacts (n=3) or total occlusion (n=4). Of the 93 patients, good image quality was 
observed in 62 (62%) patients and moderate image quality in 31 (31%) patients.
Table 1. Baseline characteristics of study population (n=100)
Men 53
Age (yrs) 59.8±8.0




Previous coronary angioplasty 4
Indications of CAD on previous tests 3
Clinical presentation prior to MSCT
Atypical angina pectoris 70







Positive family history 36
Data are presented as mean ± standard deviation or as number. CAD = coronary artery disease; MSCT 
= multislice computed tomography
Table 2. Diameter stenosis (%) and minimal lumen diameter (mm) derived from QAngioCT and 
QCA for all vessels (n=282), non-calcified (n=146), mixed (n=81) and calcified lesions (n=55)
QAngioCT QCA
Diameter stenosis (%)
All vessels 26.4±19.4 29.4±22.0*
Non-calcified lesions 16.8±11.9 20.1±15.3*
Mixed lesions 35.1±21.5 38.5±23.2*
Calcified lesions 39.2±19.0 40.9±24.4
Minimal lumen diameter (mm)
All vessels 2.4±0.8 2.2±1.0*
Non-calcified lesions 2.7±0.7 2.5±0.9*
Mixed lesions 2.1±0.9 1.9±1.1*
Calcified lesions 2.0±0.7 1.7±0.9*
Data are presented as mean ± standard deviation. QAngioCT = quantitative computed tomography 
angiography; QCA = quantitative coronary angiography. *p<0.05.
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Agreement between Visual Analysis and QCA
The agreement between visual analysis and QCA for semi-quantitative assessment of sig-
nificant coronary stenosis (using ≥50% diameter stenosis as a cutoff) was determined on a 
patient basis (Table 3). In total, 30 vessels were identified as significant stenosis on QCA, of 
which 25 vessels were also classified as having significant stenosis on visual analysis (sen-
sitivity 83%, 95% CI 70-97%). Of the 63 vessels which were classified as non-significant 
using QCA, visual analysis incorrectly classified 7 vessels as having a significant stenosis 
(specificity 89%, 95% CI 81-97%). The corresponding negative and positive predictive 
values were 92% (95% CI 85-99%) and 78% (95% CI 64-93%). The agreement between 
the visual analysis and QCA was 87% (95% CI 80-94%), with a k value of 0.71 using ≥50% 
diameter stenosis as a cutoff for significant lesions.
In addition, further analysis of the agreement between visual analysis and QCA was per-
formed in relation to image quality. In Table 4, corresponding sensitivity, specificity, negative 
and positive predictive values are provided.
Table 3. Diagnostic accuracy of QAngioCT and visual analysis for assessment of significant 
coronary artery stenosis (≥50% diameter stenosis) on a patient basis (n=93)
TN TP FN FP Se Sp NPV PPV Accuracy
Visual score 56 25 5 7 83 89 92 78 87
95% CI (70-97)  (81-97)  (85-99) (64-93) (80-94)
QAngioCT 63 25 5 0 83 100 93 100 95
95% CI (70-97) (87-99) (90-99)
CI = confidence interval; FN = false negative; FP = false positive; NPV = negative predictive value; 
PPV = positive predictive value; QAngioCT = quantitative computed tomography angiography; Se = 
sensitivity; Sp = specificity; TN = true negative; TP = true positive.
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Agreement between QAngioCT and QCA
Good correlations for diameter stenosis were observed between QAngioCT and QCA on a 
vessel basis (n=282, r=0.83, p<0.01) and a patient basis (n=93, r=0.86, p<0.01) (Figures 2 
and 3). Additionally, the segment-based analysis which provided information regarding the 
performance of QAngioCT in a wide range of percentage diameter stenosis showed a good 
correlation between QAngioCT and QCA for diameter stenosis (n=127, r=0.82, p<0.01).
In addition, limits of agreement between QAngioCT and QCA for assessment of diameter 
stenosis were assessed. On a vessel basis, mean value of differences ± standard deviation 
was -3.0±12.3% with 95% limits of agreement ranging from -27.1 to 21.0% (Figure 2), 
whereas on a patient basis mean value of differences ± standard deviation was -6.2±12.4% 
with 95% limits of agreement ranging from -30.5 to 18.1% (Figure 3). For the segment-based 
analysis, mean value of differences ± standard deviation was -0.1±8.2% with 95% limits of 
agreement ranging from -16.2 to 16.0%.
Evaluation of inter- and intraobserver variability revealed mean value of differences ± 
standard deviations of -1.4±7.4% and -1.9±7.2%.
The agreement between QAngioCT and QCA for assessment of significant (≥50% diam-
eter stenosis) or non-significant (<50% diameter stenosis) was calculated on a patient basis 
(Table 3). In 30 vessels a significant stenosis was identified on QCA, of which 25 vessels 
were classified similarly using QAngioCT (sensitivity 83%, 95% CI 70-97%). In 5 vessels a 
non-significant stenosis was identified with QAngioCT, whereas QCA showed a significant 
stenosis. Importantly, the majority of the lesions that were underestimated with QAngioCT 
showed <70% stenosis on QCA (n=4). Moreover, of the 63 non-significant lesions on QCA, 
Table 4. Diagnostic accuracy of QAngioCT and visual analysis for assessment of significant 
coronary artery stenosis (≥50% diameter stenosis) for data sets with good (n=62) or moderate 
(n=31) image quality.
TN TP FN FP Se Sp NPV PPV Accuracy
Visual analysis
Good quality 43 13 1 5 93 90 98 72 90
95% CI (79-100) (81-98)   (93-100) (52-93) (83-98)
Moderate quality 13 12 4 2 75 87 76 86 81
95% CI (54-96) (70-100) (56-97) (67-100) (67-95)
QAngioCT
Good quality 48 11 3 0 79 100 94 100 95
95% CI (57-100) (88-100) (90-100)
Moderate quality 15 14 2 0 88 100 88 100 94
95% CI (71-100) (73-100) (85-100)
CI = confidence interval; FN = false negative; FP = false positive; NPV = negative predictive value; 
PPV = positive predictive value; QAngioCT = quantitative computed tomography angiography; Se = 
sensitivity; Sp = specificity; TN = true negative; TP = true positive.
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63 lesions were also classified as non-significant using QAngioCT (specificity 100%). No 
lesions were overestimated on QAngioCT as compared to QCA, yielding an accuracy of 
95% (95% CI 90-99%) and a k value of 0.87. Using ≥50% diameter stenosis as a cutoff, cor-
responding negative and positive predictive values were 93% (95% CI 87-99%) and 100%.
Finally, further analysis of the agreement between QAngioCT and QCA was performed 
in relation to image quality (Table 4). QAngioCT performed equally well in patients with 
moderate or good image quality (diagnostic accuracy 94% vs. 95%, p=NS). However, as 
compared to visual analysis, QAngioCT tended to have a reduced sensitivity in data sets 
with good image quality. Corresponding sensitivity, specificity, negative and positive predic-
tive values are shown in Table 4.
Figure 2. Comparison between quantitative computed tomography angiography (QAngioCT) and 
quantitative coronary angiography (QCA) for assessment of diameter stenosis on a vessel basis.
Linear regression (left panel) and Bland-Altman (right panel) analyses for diameter stenosis on a vessel 
basis (n=282). QAngioCT and QCA showed good correlation and agreement for diameter stenosis.
Figure 3. Comparison between quantitative computed tomography angiography (QAngioCT) and 
quantitative coronary angiography (QCA) for assessment of diameter stenosis on a patient basis.
Linear regression (left panel) and Bland-Altman (right panel) analyses for diameter stenosis on a 
patients basis (n=93). QAngioCT and QCA showed good correlation and agreement for diameter 
stenosis.
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Influence of Plaque Composition
In addition, non-calcified (n=146), mixed (n=81) or calcified lesions (n=55) were analyzed 
separately. Mean diameter stenosis and minimal lumen diameter for different plaque types 
are shown in Table 2. A good correlation for non-calcified (n=146, r=0.79, p<0.01), mixed 
(n=81, r=0.80, p<0.01) and calcified (n=55, r=0.77, p<0.01) lesions was observed (Fig-
ures 4-6). For non-calcified lesions, mean value of differences ± standard deviation was 
-3.2±9.4% with 95% limits of agreement ranging from -21.6 to 15.1%. Furthermore, for 
mixed lesions, mean value of differences ± standard deviation was -3.5±14.2% with 95% 
limits of agreement ranging from -31.3 to 24.4%. Mean value of differences ± standard 
deviation for calcified lesions was -1.8±15.7% with 95% limits of agreement ranging from 
-32.5 to 29.0% (Figures 4-6).
Figure 4. Comparison between quantitative computed tomography angiography (QAngioCT) and 
quantitative coronary angiography (QCA) to assess diameter stenosis of segments with non-calci-
fied lesions.
Linear regression (left panel) and Bland-Altman (right panel) analyses of diameter stenosis of segments 
with non-calcified lesions (n=146). Good correlation and agreement were observed for assessment of 
diameter stenosis.
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Figure 5. Comparison between quantitative computed tomography angiography (QAngioCT) and 
quantitative coronary angiography (QCA) to assess diameter stenosis of segments with mixed 
lesions.
Linear regression (left panel) and Bland-Altman (right panel) analyses of diameter stenosis of segments 
with mixed lesions (n=81). Good correlation and agreement were observed for assessment of diameter 
stenosis.
Figure 6. Comparison between quantitative computed tomography angiography (QAngioCT) and 
quantitative coronary angiography (QCA) to assess diameter stenosis of segments with calcified 
lesions.
Linear regression (left panel) and Bland-Altman (right panel) analyses of diameter stenosis of segments 
with calcified lesions (n=55). Good correlation and agreement were observed for assessment of 
diameter stenosis.
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Discussion
The main findings of the study are as follows: novel automated dedicated QAngioCT 
software and QCA showed good correlations for quantification of stenosis severity on ves-
sel- and patient-based analysis. In addition, QAngioCT and QCA showed good agreement 
for semi-quantitative assessment of stenosis severity (accuracy of 95%, k value of 0.87). 
Moreover, a tendency towards improved diagnostic accuracy was observed with QAngioCT 
when compared to visual analysis of stenosis severity. Importantly, the positive predictive 
value was significantly higher with QAngioCT when compared to visual analysis for the 
assessment of significant coronary artery stenosis.
MSCT has appeared as a potent imaging technique for non-invasive evaluation of coro-
nary atherosclerosis. Most of the studies have used visual and, moreover, binary approaches 
(≥50% luminal narrowing based on visual assessment) to identify significant stenoses on 
MSCT. However, quantification of stenosis severity may be preferred in terms of diagnos-
tic accuracy and reproducibility. In addition, quantification of stenosis severity with an 
automated and robust approach may become particularly interesting when using MSCT to 
evaluate progression of coronary atherosclerosis.
At present however, limited evidence is available on quantification of stenosis severity on 
MSCT.5, 7, 13 Thus far, results of quantitative studies using a semi-automated CT approach for 
assessment of stenosis severity are lacking consistency. In addition, these semi-quantitative 
approaches resulted frequently in modest correlations between QCA and MSCT for the 
quantification of stenosis severity.5, 7 An important study was performed by Leber et al.5 who 
determined the diagnostic accuracy of 64-slice MSCT for quantification of stenosis severity 
in comparison to QCA. In 55 patients, 825 cardiac segments (15-segment model) could be 
visualized and analyzed using a semi-automated quantitative approach. Overall, moderate 
correlations were observed for stenosis severity between 64-slice MSCT and QCA (r=0.54). 
Also, stenosis severity as assessed with intravascular ultrasound (IVUS) was moderately 
correlated with 64-slice MSCT (r=0.61). Likewise, Raff and colleagues4 evaluated the diag-
nostic accuracy of a semi-automated quantitative CT approach in comparison to invasive 
quantitative analyses in 70 patients with suspected CAD. Quantitative MSCT showed high 
diagnostic accuracy for the assessment of significant stenosis as compared to QCA. Impor-
tantly, however, significant variability in stenosis severity was observed between QCA and 
quantitative MSCT. In particular, lesions of intermediate severity on QCA (30-70% diameter 
stenosis) showed high variability when compared to quantitative MSCT. Interestingly, Cheng 
et al.14 have recently showed that a multi-tiered visual grading system was more accurate as 
compared to semi-manual quantification of MSCT.
A potential explanation for the limited accuracy observed for these semi-manual quan-
tification approaches may be the large variation that is introduced due to manual interfer-
ence. For instance, in the study by Cheng et al.14, manual input was required to assess the 
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minimal luminal diameter at the site of stenosis (in addition to proximal and distal points). 
Furthermore, measurements were performed in a single longitudinal image. In the present 
study however, an automated quantification algorithm was used for assessment of diameter 
stenosis in which only limited manual input was used to guide the automated processing 
steps. Manual input was limited to accurate segment definition using proximal and distal 
markers. In this respect, Marquering et al.15 have demonstrated that deviations were mini-
mal in extracted centerlines when varying the position of placed proximal and distal mark-
ers. In addition, the manual corrections made in the longitudinal contour detection were 
only used to improve the detected transversal contours in a limited number of locations in 
the transversal slice. Accordingly, quantification of stenosis severity was performed by an 
automated dedicated approach consisting of several consecutive programmed processing 
steps. Nevertheless, small corrections could also be made to improve the luminal reference 
line by flagging particular coronary segments, similar as performed with QCA. Interestingly, 
this approach resulted in good correlations between QAngioCT and QCA for assessment of 
diameter stenosis on vessel- and patient-based analysis.
In the study by Bruining and colleagues16 an automated approach with limited manual 
interference was also used to determine its diagnostic accuracy and reproducibility. Quan-
titative CT analysis was performed in 48 symptomatic patients who underwent invasive 
coronary angiography and IVUS. Measurements were performed by two independent 
observers using a coronary artery extraction method with computed-assisted quantitative 
volumetric analysis. Both observers found good correlations between MSCT and IVUS for 
lumen (r=0.76 and r=0.95) and plaque volumes (r=0.74 and r=0.79).
Another important finding of the present study was that no influence of plaque type 
was observed and that the algorithm performed equally well in non-calcified, mixed and 
calcified lesions. In contrast, previous studies have reported that algorithms may quantify 
stenosis severity of non-calcified, mixed and calcified plaques with variable accuracy.6, 12, 
13 Overall, a tendency to underestimate stenosis severity of non-calcified lesions versus an 
overestimation of calcified lesions has been observed in many studies.6, 12 In a previous 
study by Leber and colleagues6, non-calcified and mixed plaque volumes were significantly 
underestimated on quantitative MSCT (59.8±76.6 mm3 vs. 67.7±67.9 mm3 and 47.7±87.5 
mm3 vs. 57.5±99.4 mm3, p<0.03) as compared to IVUS derived plaque volumes, whereas 
calcified plaques were systematically overestimated (65.8±110.0 mm3 vs. 53.2±90.3 mm3, 
p=0.19) on MSCT when compared to IVUS. In this study, a slight underestimation of stenosis 
severity using QAngioCT for non-calcified and mixed plaques was found. Also, for calcified 
lesions, although showing the lowest mean value of differences, a systematic underestima-
tion of stenosis severity was observed in comparison to QCA. In contrast, calcified lesions 
are usually overestimated with cardiac CT possibly due to the blooming effect of calcium. 
With the use of an automatic quantification algorithm however, the influence of blooming 
artifacts may be reduced, leading to a better estimate of stenosis severity.
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In this study, results of the Bland-Altman analysis revealed smaller limits of agreement 
for vessel-based and patient-based analysis, as compared to previously performed studies 
using semi-quantitative measurements of coronary stenosis.7, 13 These findings underline the 
feasibility of this novel automated quantitative algorithm to assess stenosis severity, although 
further improvements are needed.
Moreover, semi-quantitative assessment of the presence of significant coronary artery 
stenosis (≥50% diameter stenosis) revealed a good agreement (overall agreement of 95%). 
Only 5 lesions with ≥50% diameter stenosis on QCA were underestimated by QAngioCT; 
the majority of these significant lesions were not severe and showed <70% diameter stenosis 
on QCA. Importantly, the current study showed a tendency towards improved diagnostic 
accuracy for assessment of significant lesions with QAngioCT when compared to visual CT 
analysis (95% vs. 87%, p=0.08). In particular, a significantly improved positive predictive 
value was observed using QAngioCT when compared to visual analysis (100% vs. 78%, 
p<0.05).
In addition, the performance of QAngioCT and visual analysis was analyzed in data sets 
with different image quality. Although the visual approach showed a reduced diagnostic 
accuracy for data sets with moderate image quality, QAngioCT performed equally well in 
patients with moderate or good image quality. These findings demonstrate the feasibility of 
QAngioCT for evaluation of coronary artery stenosis in data sets with variable image quality. 
Only in data sets with good image quality, sensitivity tended to be lower with QAngioCT as 
compared to visual analysis.
Finally, the present study has demonstrated low inter- and intraobserver variability for 
automated quantification of stenosis severity. This is an important finding, since previous 
quantitative approaches were largely limited due to poor reproducibility.4-7, 13 Accordingly, 
the current study provides important information on the use of automated quantification 
of stenosis severity on MSCT. Still, more studies are needed to elucidate the precise role of 
automated quantification in clinical cardiology.
Limitations
The current study should be considered as a feasibility study, validating a novel approach 
for automated quantification of stenosis severity. Integration of other plaque characteristics 
(remodeling index, plaque burden, eccentricity and plaque length) would be preferred in 
evaluation of coronary atherosclerosis, however, the study was only designed to demon-
strate feasibility of the new approach. Further studies are needed to validate automated 
quantification of different plaque characteristics. In the present study, IVUS may have been 
a more reliable reference standard as compared to QCA as IVUS is considered to be a 
true tomographic atherosclerosis imaging technique. Indeed, MSCT may be more suited 
for the evaluation of atherosclerosis rather than stenosis. However, conventional coronary 
angiography represents the validated standard for detection of CAD in clinical cardiology. 
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Finally, in the current study the prevalence of significant CAD was relatively low and the 
performance of QAngioCT should be tested in more challenging populations with higher 
disease prevalence as well.
Conclusion
The novel automated QAngioCT approach and QCA showed good correlation for quan-
tification of stenosis severity on vessel and patient basis. Good agreement was observed 
for semi-quantitative assessment of significant coronary artery stenosis (≥50% diameter 
stenosis). The use of an automated quantification algorithm improves the positive predictive 
value of MSCT when compared to visual assessment of stenosis severity.
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Abstract
Aims Previous studies have only used semi-automated approaches for coronary plaque 
quantification on multi-detector row computed tomography (CT), while an automated quan-
titative approach using a dedicated registration algorithm is currently lacking. Accordingly, 
the study aimed to demonstrate the feasibility and accuracy of automated coronary plaque 
quantification on cardiac CT using dedicated software with a novel 3D coregistration algo-
rithm of CT and intravascular ultrasound (IVUS) datasets.
Methods Patients who had undergone CT and IVUS were enrolled. Automated lumen and 
vessel wall contour detection was performed for both imaging modalities. Dedicated auto-
mated quantitative software (QCT) with a unique registration algorithm was used to fuse a 
complete IVUS run with a CT angiography volume using true anatomical markers. At the 
level of the minimal lumen area (MLA), percentage lumen area stenosis, plaque burden and 
degree of remodeling were obtained on CT. Additionally, mean plaque burden was assessed 
for the whole coronary plaque. At the identical level within the coronary artery, the same 
variables were derived from IVUS.
Results Fifty-one patients (40 men, 58±11 yrs, 103 coronary arteries) with 146 lesions were 
evaluated. QCT and IVUS showed good correlation for MLA (n=146, r=0.75, p<0.001). 
At the level of the MLA, both techniques were well-correlated for lumen area stenosis 
(n=146, r=0.79, p<0.001) and plaque burden (n=146, r=0.70, p<0.001). Mean plaque 
burden (n=146, r=0.64, p<0.001) and remodeling index (n=146, r=0.56, p<0.001) showed 
significant correlations between QCT and IVUS.
Conclusion Automated quantification of coronary plaque on CT is feasible using dedicated 
quantitative software with a novel 3D registration algorithm.
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Introduction
Multi-detector row computed tomography (CT) permits non-invasive evaluation of coronary 
artery disease (CAD) with excellent image quality and diagnostic accuracy as compared to 
invasive coronary angiography.1-3 The degree of coronary luminal narrowing is commonly 
used to guide diagnosis and therapeutic interventions in clinical cardiology.3-5 However, 
cardiac CT is not restricted to coronary luminography as it provides additional information 
on the coronary atherosclerotic plaque itself, including plaque morphology, plaque burden 
and the degree of plaque remodeling. However, one of the current drawbacks of cardiac 
CT remains the fact that coronary plaque characteristics are most commonly evaluated by a 
visual approach, which is observer dependent and requires substantial reading experience.
Automated quantification of coronary plaque characteristics would be preferred to further 
improve the diagnostic accuracy, reproducibility and time-efficiency of cardiac CT. At pres-
ent however, the feasibility of automated quantification of coronary luminal narrowing using 
cardiac CT has only been demonstrated in a small number of studies.6, 7 Earlier attempts that 
aimed to measure other coronary plaque characteristics have used either manually-based 
or semi-automated techniques, rather than automated dedicated quantitative algorithms.8-10 
Moreover, in these previous studies, a visual approach was used to match coronary lesions 
on the different imaging techniques which may introduce inaccuracies.
Recently, dedicated automated quantitative computed tomography (QCT) software with a 
unique 3D registration algorithm has been developed to enable accurate matching of imag-
ing modalities along the longitudinal and transversal axis of coronary arteries. The novel 
3D registration algorithm allows fusion of cardiac imaging techniques using a slice-by-slice 
comparison of each location along the longitudinal and transversal axis of the coronary 
arteries and may improve detection and quantification of coronary plaques on cardiac CT 
when compared to previous quantitative CT studies using a visual approach.
At present, no study has evaluated the feasibility of automated coronary plaque quantifi-
cation on cardiac CT using an automated 3D registration algorithm of CT and intravascular 
ultrasound (IVUS) datasets. Accordingly, the current study aimed to demonstrate the feasi-
bility and accuracy of automated quantification of coronary plaque on cardiac CT using 
dedicated software with a novel 3D registration algorithm of CT and IVUS datasets.
Material and Methods
Patient Population and Study Protocol
The patient population consisted of patients who had undergone cardiac CT and conventional 
invasive coronary angiography with IVUS within a period of 4 months. Clinical data were 
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prospectively entered in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center). A total of 80 consecutive patients with known (n=32) or 
suspected (n=48) coronary atherosclerosis who were referred for cardiac CT were selected. 
From these 80 patients, 51 patients were referred within a period of 4 months for invasive 
coronary angiography with IVUS, because of patient’s clinical symptoms and/or imaging 
results to further evaluate the extent and severity of CAD. Accordingly, 29 patients who were 
not referred to invasive coronary angiography with IVUS (n=18) or did not undergo invasive 
coronary angiography along with IVUS (n=11) were excluded from further analyses. A flow 
chart of the patient inclusion is provided in Figure 1.
In each of the 51 patients, IVUS was performed in 1 to 3 coronary arteries during invasive 
coronary angiography. Of the 153 coronary arteries, IVUS was performed in 103 coronary 
arteries, whereas IVUS studies were not acquired in 50 coronary arteries due to vessel 
tortuosity (n=15), severe luminal narrowing (n=9), (subtotal) vessel occlusion (n=11) or time 
constraints (n=15).
Figure 1. Flow chart of the patient inclusion. A total of 80 patients referred for cardiac computed 
tomography (CT) because of known or suspected coronary artery disease (CAD) were selected, of 















No IVUS within 4 months
*IVUS examinations could not be performed in 50 coronary arteries due to vessel tortuosity (n=15), 
severe luminal narrowing (n=9), (subtotal) vessel occlusion (n=11) or time constraints (n=15).
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Conventional Invasive Coronary Angiography with Gray-Scale IVUS
Data Acquisition and Analysis
Invasive coronary angiography was performed according to the standard protocol.11 Vascu-
lar access was obtained via the femoral artery using the Seldinger technique with a 6 or 7F 
sheath. During invasive coronary angiography, IVUS examinations were performed in 103 
coronary arteries using a dedicated IVUS-console (Volcano Corporation, Rancho, Cordova, 
CA, USA). After administration of intracoronary nitrates, IVUS runs were acquired using a 20 
MHz, 2.9F phases-array IVUS catheter (Eagle Eye, Volcano Corporation, Rancho Cordova, 
CA, USA) which was positioned in the distal coronary segments. Consecutively, the IVUS 
catheter was pulled back towards the coronary ostium at a continuous speed of 0.5 mm/s 
using an automated pullback device. Images were acquired with a frame rate of 15 frames/s. 
Data sets were stored for offline post-processing analyses. Consecutively, lumen-intima and 
media-adventitia borders were obtained by dedicated post-processing software as described 
in the appendix.
Computed Tomography
Data Acquisition and Analysis
Cardiac CT was performed using either a 64-detector row helical scanner (Aquilion 64, 
Toshiba Medical Systems, Otawara, Japan) or a 320-detector row volumetric scanner 
(Aquilion ONE, Toshiba Medical Systems, Otawara, Japan). One hour prior to cardiac CT, 
all patients with an elevated heart rate (≥65 beats/min) were given metoprolol 50 or 100 mg 
orally, unless contra-indicated. Additionally, patients received sublingual nitroglycerine (0.4 
mg/dose, one dose per patient) directly before the CTA examination.
For the 64-detector and 320-detector row CT examination, patients underwent both a 
non-enhanced and contrast-enhanced scan. Prior to the contrast-enhanced helical scan, 
a non-enhanced electrocardiographic (ECG)-triggered scan was performed to assess the 
coronary calcium score. The non-enhanced and contrast-enhanced scans were performed 
as previously described.6, 12
Reconstructed images were transferred to a remote dedicated workstation with post-
processing software (Vitrea FX 1.0, Vital Images, Minnetonka, MN, USA). The non-enhanced 
scans were used to assess the total amount of coronary calcium according to the Agatston 
approach.13
CT angiography data sets were evaluated by an independent and experienced observer, 
who was blinded to the IVUS data. Prior to the automated quantitative analyses, image 
quality was evaluated using the following ordinal scale: (1) good image quality, (2) moderate 
image quality or (3) poor image quality. Data sets with good quality showed no motion arti-
facts and no image noise, whereas data sets were classified as moderate in case of motion 
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artifacts or increased image noise. Non-diagnostic scans were classified as data sets with 
poor image quality. Furthermore, coronary lesions were classified by an independent and 
blinded observer as either non-calcified (no coronary calcium) or calcium-containing (any 
presence of coronary calcium) lesions.
Automated quantitative computed tomography angiography (QCT)14 was performed by 
an independent observer who was blinded to IVUS data. A dedicated and extended version 
of the QAngioCT software (QAngioCT 1.1, Medis medical imaging systems, Leiden, the 
Netherlands) was used to perform quantitative CT analyses. On CT data sets, the dedicated 
software was able to detect both lumen and vessel wall contours which were used for 
automated quantitative measurements of coronary plaques, as depicted in Figure 2, upper 
panel. A detailed description of the lumen and vessel contour detection process is provided 
in the appendix.
Figure 2. Schematic illustration of automated quantification of coronary plaque on multi-detector 
row computed tomography (CT) (QCT) in a direct comparison to quantitative intravascular 
ultrasound (IVUS). QCT was based on several consecutive processing phases. After the 3-D 
centerline was generated from the CT data set using a fast vessel-tracking algorithm (panel I), 
automated lumen and vessel wall contour detection was performed for both imaging modalities 
(panel II). Consecutively, dedicated quantitative software with a unique registration algorithm was 
used to fuse a complete pullback series of IVUS images with a computed tomography angiography 
(CTA) volume using true anatomical markers (panel III). Finally, fusion-based quantification 
of atherosclerotic lesions was based on the lumen and vessel wall contours as well as the 
corresponding reference lines (estimate of normal tapering of the coronary artery), as shown 
in panel IV. At the level of the minimal lumen area (MLA) (yellow lines), lumen area, lumen area 
stenosis, plaque burden and remodeling index could be derived for both imaging techniques. 
Additionally, the mean plaque burden was derived for the whole coronary lesion, ranging from the 
proximal to distal lesion marker (blue markers).
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Registration and Fusion-based Quantification of Coronary Plaque
Dedicated quantitative software with a unique registration algorithm was developed for 
automated fusion of a complete pullback series of high-resolution IVUS images with CT 
angiography.15 The novel registration algorithm enabled an accurate matching of both imag-
ing modalities along the longitudinal and transversal axis of the coronary arteries. IVUS 
images were fused on the corresponding slices within the CT data using a two-step 3D 
fusion process. First, the stack of IVUS images was mapped onto the longitudinal CT image 
along the centerline of the vessel by locating corresponding anatomical landmarks. The ana-
tomical landmarks (side-branches, coronary ostia, calcified plaques, and overlapping veins) 
were located and marked within both imaging modalities. Second, the individual IVUS 
images were translated and rotated until they fit best onto the corresponding cross-sections 
of the CT image. The fitting procedure was based on the location of the center of the vessel 
in both images. In addition, the presence of anatomical landmarks (side-branches, calcified 
spots, and overlapping veins) in each image was used to identify the correct rotation of the 
IVUS image on top of the CT image. In between anatomical landmarks, IVUS images were 
aligned to the corresponding locations of the MPR volume of the CT data with the use of 
interpolation. For this reason, deviations within the motorized pullback speed of the IVUS 
catheter were corrected.
After both imaging modalities were aligned, fusion-based quantification of coronary 
lesions was performed using automated detected lumen and vessel wall contours as well as 
corresponding reference lines (Figure 2). In both modalities, the reference line represented 
an estimate of the normal proximal-to-distal tapering of the coronary artery. Reference lines 
were generated from proximal and distal non-diseased reference regions, in which the mean 
value of these regions was used to define a reference slope for both lumen and vessel wall 
contours. In the current study, proximal and distal reference regions were not positioned 
at coronary bifurcations. Importantly, the use of an average reference value results in a 
reduction of isolated discrepancies between sequential contours.
Per coronary lesion, fusion-based quantification was performed at the level of the mini-
mal lumen area (MLA) and for the whole lesion, ranging from the proximal to distal lesion 
marker. At first, the level of the MLA and lesion markers was automatically identified within 
the coronary artery using the detected lumen contours on CT. At the level of the MLA, 
plaque burden was calculated by the following equation: (vessel wall area – lumen area)/
vessel wall area x 100%. Using the same formula, the mean plaque burden was calculated 
for the whole coronary lesion. The percentage lumen area stenosis (%) was defined at the 
level of the MLA by: 1-(MLA/corresponding reference lumen area). In addition, at the level 
of the MLA, the degree of remodeling was calculated as reported previously.16 Positive 
remodeling was defined as a remodeling index ≥1.0.16
Both MLA and lesion markers were automatically set on the same level within the 
IVUS run using the dedicated registration algorithm (Figure 2 and 3). Consecutively, the 
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corresponding plaque variables on IVUS were automatically derived for each coronary 
lesion using the markers set at precisely the same level as used for cardiac CT.
Reproducibility of QCT for assessment of coronary plaque characteristics was evaluated 
in 10 randomly selected patients with 25 coronary lesions. To evaluate the reproducibility of 
QCT, automated lumen and vessel wall contour detection as well as plaque quantification 
were performed twice by the same observer. Quantification of coronary plaques was based 
on lesion as well as reference markers which were positioned at a similar level within the 
coronary artery in both CT data sets.
Statistical Analysis
Continuous data were expressed as mean ± standard deviation, and categorical data are 
presented as absolute numbers or percentages. Kolmogorov-Smirnov tests were used to 
evaluate the distribution of the data. When non-normally distributed, data were presented 
as medians and 25th and 75th percentiles. Comparison of both quantitative techniques was 
performed using Pearson’s linear regression analysis (or spearman’s rho correlation) and 
Bland-Altman analyses (GraphPad Prism software, version 5.01, GraphPad software Inc, San 
Diego, California, USA). The 95% confidence intervals for the correlations were calculated 
using Fisher z-transformation.
QCT and IVUS were compared on a lesion and vessel basis, in which lesion-based 
analysis was based on each coronary lesion, whereas vessel-based analysis was based on 
the most severe lesion per coronary vessel. Bland-Altman graphs showed the mean value of 
Figure 3. Dedicated quantitative software with a novel registration tool was used to merge a 
complete pullback IVUS run with a computed tomography angiography (CTA) volume. Fusion 
of both imaging modalities was based on the identification of true anatomical markers along 
the coronary artery. In this example, multi-detector row computed tomography (CT) (panel A) 
was aligned to the corresponding IVUS run (panel B) using a calcified spot (white arrow) and 
coronary side-branch (red arrow). Consecutively, the IVUS run (green color) was projected on 
the corresponding CT image (panel C). The IVUS overlay in panel C was color-coded in green to 
improve the visual appearance of the fusion process.
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differences of each pair plotted against the average value of each pair, in which IVUS was 
subtracted from the QCT measurements.
In addition, in the lesion-based analysis, comparisons between both quantitative tech-
niques were performed using generalized estimating equations in order to correct for the 
intra-patient correlation. The difference between QCT and IVUS was calculated for each 
quantitative parameter (MLA, lumen area stenosis, mean plaque burden, plaque burden at 
the MLA and remodeling index) and was entered as dependent variable. The 95% confi-
dence intervals for these analyses were calculated.
Furthermore, the accuracy of QCT for assessment of coronary plaque remodeling was 
assessed using a binary approach (using 1.0 as a cutoff) with IVUS as reference method. For 
this analysis, corresponding sensitivity, specificity, negative and positive predictive values 
were calculated. Additionally, the influence of image quality (good, moderate or poor) on 
the performance of QCT was determined using Pearson’s linear regression. Reproducibility 
of QCT was determined on a lesion basis (25 lesions) using intra-class correlation (ICC) 
analyses. Excellent agreement was defined as an ICC coefficient of >0.8. All p-values were 
two-sided and a p-value <0.05 was considered to indicate statistical significance. Statistical 




Baseline characteristics of the patient population are described in Table 1. Fifty-one patients 
(40 men, mean age 58.0±10.6 yrs) who had undergone cardiac CT and invasive coronary 
angiography with IVUS were enrolled. Patients had undergone either a 320-row volumetric 
(n=12) or a 64-row helical scan (n=39) to evaluate coronary atherosclerosis non-invasively. 
In the population consisting of 51 patients, IVUS studies were acquired in 103 coronary 
arteries in which a total of 146 non-stented coronary lesions were identified on both imag-
ing modalities. The mean heart rate during cardiac CT was 60.9±11.0 bpm. Only the MLA 
data as derived from QCT and IVUS were non-normally distributed.
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Minimal Lumen Area and Lumen Area Stenosis
On a lesion basis, good correlations were observed between QCT and IVUS for assessment 
of MLA (n=146, r=0.75, p<0.001) (95% CI 0.67-0.81) (Figure 4A) and lumen area stenosis 
(n=146, r=0.79, p<0.001) (95% CI 0.72-0.84) (Figure 5A). Lesions with a small MLA showed 
improved correlations between QCT and IVUS when compared to lesions with a large 
MLA. Similarly, vessel-based analysis showed good correlation between both quantitative 
techniques for assessment of MLA (n=103, r=0.73, p<0.001) (95% CI 0.63-0.81) and lumen 
area stenosis (n=103, r=0.82, p<0.001) (95% CI 0.75-0.88).
On a lesion basis, the mean bias between techniques for quantification of MLA was 
-3.0 mm2 with 95% limits of agreement ranging from -7.5 to 1.4 mm2 (Figure 4B). QCT 
significantly underestimated the MLA when compared to IVUS (3.6 mm2 [2.3 - 5.0] vs. 6.4 
mm2 [4.3 - 9.3]; 95% CI of the mean difference was -3.4 to -2.5; p<0.001).
On a lesion basis, the mean bias was 9.8% for lumen area stenosis with 95% limits of 
agreement ranging from -13.9% to 33.6% (Figure 5B). The lumen area stenosis was signifi-
cantly overestimated by QCT as compared to IVUS (44.4±19.6% vs. 34.6±17.8%; 95% CI 
of the mean difference 7.9 to 11.7; p<0.001).




Known CAD 11 (22)
Clinical presentation
Atypical anginal complaints 31 (61)
Typical anginal complaints 20 (39)
Cardiovascular risk factors
Diabetes 11 (22)
Systemic hypertension 32 (63)
Hypercholesterolemia 28 (55)
Current smoking 23 (45)
Obesity 8 (16)
Positive family history 15 (29)
Medication
Beta-blocker 27 (53)
Angiotensin converting enzyme / Angiotensin II blocker 18 (35)
Diuretic 13 (25)
Nitrate 11 (22)
Calcium antagonist 10 (20)
Data are presented as mean ± standard deviation or as number (percentage). CAD = coronary artery 
disease.
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Coronary Plaque Burden
Mean plaque burden (n=146, r=0.64, p<0.001) (95% CI 0.53-0.73) showed a good cor-
relation between QCT and IVUS on a lesion basis. On a vessel basis, QCT was correlated 
to IVUS for the assessment of mean plaque burden (n=103, r=0.62, p<0.001) (95% CI 
0.49-0.73). Bland-Altman analyses showed a mean bias for mean plaque burden of 12.3% 
with 95% limits of agreement ranging from -13.8 to 38.5%. Based on linear mixed models, 
the mean plaque burden was significantly overestimated with QCT as compared to IVUS 
(61.1±16.1% vs. 48.8±15.4%; 95% CI of the mean difference 14.8 - 19.6; p<0.001).
For plaque burden at the MLA, good correlations were found between QCT and IVUS 
on a lesion (n=146, r=0.70, p<0.001) (95% CI 0.61-0.77) and vessel (n=103, r=0.68, 
p<0.001) (95% CI 0.56-0.77) basis. For plaque burden at the MLA, Bland-Altman analyses 
Figure 4. Quantitative computed tomography (QCT) was compared to quantitative coronary 
ultrasound (IVUS) for assessment of minimal lumen area (MLA). Linear regression (panel A) and 
Bland-Altman analyses (panel B) for MLA on a lesion basis (n=146). The mean value of differences 
± standard deviation was -3.0±2.3 mm2 with 95% limits of agreement ranging from -7.5 to 1.4 
mm2.
Figure 5. Quantitative computed tomography (QCT) was compared to quantitative coronary 
ultrasound (IVUS) for assessment of percentage lumen area stenosis. Linear regression (panel A) 
and Bland-Altman analyses (panel B) for percentage lumen area stenosis on a lesion basis (n=146). 
The mean value of differences ± standard deviation was 9.8±12.1% with 95% limits of agreement 
ranging from -13.9 to 33.6%.
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showed mean bias of 17.2%, with 95% limits of agreement extending from -9.1 to 43.6%. 
Plaque burden at the MLA was significantly overestimated with QCT as compared to IVUS 
(69.4±17.7% vs. 52.1±16.8%; 95% CI of the mean difference 9.7 - 15.0; p<0.001) on a 
lesion basis.
Remodeling Index
On a lesion basis, a significant correlation was observed between QCT and IVUS for assess-
ment of remodeling index (n=146, r=0.56, p<0.001) (95% CI 0.44-0.66). Both quantitative 
approaches showed an improved correlation on a vessel basis (n=103, r=0.58, p<0.001) 
(95% CI 0.44-0.70). Bland-Altman analyses showed a mean bias of 0.05 with 95% limits of 
agreement ranging from -0.30 to 0.40. There was a trend towards overestimation of remodel-
ing index by QCT as compared to IVUS with linear regression mixed models (0.94±0.21 vs. 
0.90±0.14; 95% CI of the mean difference 0.01 - 0.08; p=0.005).
Additionally, the accuracy of QCT for assessment of coronary plaque remodeling was 
calculated using a binary approach on a vessel basis. In total, 20 coronary arteries showed 
positive remodeling on IVUS, of which 15 were classified similarly on QCT, yielding a 
sensitivity of 75% (95% CI 0.51-0.90). Of the 83 coronary vessels with negative plaque 
remodeling on IVUS, 66 were scored appropriately on QCT (specificity of 80%, 95% CI 
0.69-0.87). Furthermore, the negative and positive predictive values were 93% (95% CI 
0.85-0.97) and 47% (95% CI 0.31-0.64), respectively. Importantly, using IVUS as a refer-
ence method, the overall accuracy of QCT for assessment of plaque remodeling was modest 
(79%).
Influence of Image Quality on Automated Quantification
A sub-analysis was performed to evaluate the influence of image quality on the performance 
of QCT (Table 2). The image quality of CT data sets was classified as either good (n=49), 
moderate (n=63) or poor (n=34). For the MLA, good correlations between both quantitative 
approaches were observed for data sets with good (r=0.81, p<0.001) (95% CI 0.69-0.89) or 
moderate (r=0.75, p<0.001) (95% CI 0.62-0.84) quality, whereas they showed a moderate 
correlation for data sets with poor (r=0.68, p<0.001) (95% CI 0.44-0.83) quality. For the 
assessment of lumen area stenosis, QCT showed a slightly improved correlation with IVUS for 
data sets with good (r=0.84, p<0.001) (95% CI 0.73-0.91) and moderate (r=0.79, p<0.001) 
(95% CI 0.67-0.87) quality when compared to data sets with poor (r=0.78, p<0.001) (95% 
CI 0.60-0.89) image quality. Mean plaque burden showed a decreased correlation in data 
sets with suboptimal quality; good quality (r=0.70, p<0.001) (95% CI 0.52-0.82), moderate 
quality (r=0.65, p<0.001) (95% CI 0.48-0.77) and poor quality (r=0.60, p<0.001) (95% CI 
0.32-0.78). However, the influence of image quality for the assessment of plaque burden at 
the MLA was minimal; IVUS and QCT were well-correlated for data sets with good (r=0.70, 
p<0.001) (95% CI 0.52-0.82), moderate (r=0.71, p<0.001) (95% CI 0.56-0.81) or poor 
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(r=0.68, p<0.001) (95% CI 0.44-0.83) image quality. Additionally, image quality showed 
no effect on the assessment of plaque remodeling. Remodeling index showed significant 
but moderate correlations for data sets with good (r=0.42, p=0.002) (95% CI 0.16-0.63), 
moderate (r=0.62, p<0.001) (95% CI 0.44-0.75) and poor (r=0.55, p<0.001) (95% CI 0.26-
0.75) quality.
Influence of Coronary Calcium
Coronary lesions were classified as either non-calcified (lesions with no coronary calcium) 
or calcium-containing (any presence of coronary calcium) lesions. Of the 146 coronary 
lesions, 76 (52%) lesions were classified as calcium-containing lesions, whereas the remain-
ing 70 (48%) lesions were classified as non-calcified lesions. The correlation between QCT 
and IVUS was similar between non-calcified and calcium-containing lesions for assessment 
of MLA (r=0.70, 95% CI 0.56-0.80; r=0.73, 95% CI 0.60-0.82) and lumen area stenosis 
(r=0.77, 95% CI 0.65-0.85; r=0.75, 95% CI 0.63-0.83; both p<0.001).
Furthermore, as compared to IVUS, QCT showed a smaller underestimation of MLA 
in calcium-containing lesions than in non-calcified lesions, as reflected by mean value of 
differences of -2.9±2.2 mm2 and -3.1±2.3 mm2, respectively. In addition, the overestimation 
of lumen area stenosis on CT was higher in calcium-containing lesions than in non-calcified 
lesions (mean value of differences of 12.0±12.8% and 7.4±11.0%, respectively).
Accordingly, no substantial differences in coronary plaque quantification were observed 
between QCT and IVUS, except for a small overestimation of lumen area stenosis by QCT 
in calcium-containing lesions.
Table 2. Influence of image quality on automated quantification of coronary plaque characteristics 
using quantitative computed tomography (QCT) in a direct comparison with quantitative coronary 
ultrasound (IVUS). QCT and IVUS were compared on a lesion basis for data sets with good (n=49), 
moderate (n=63) or poor (n=34) image quality. For each comparison the corresponding Pearson’s 







MLA (mm2) 0.81 0.75 0.68
Lumen area stenosis (%) 0.84 0.79 0.78
Mean plaque burden (%) 0.70 0.65 0.60
Plaque burden MLA (%) 0.70 0.71 0.68
Remodeling index 0.42 0.62 0.55
MLA = minimal lumen area. All correlations showed a p<0.05.
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Reproducibility of Quantitative Computed Tomography
Reproducibility of QCT for coronary plaque quantification was evaluated in 10 randomly 
selected patients with 25 coronary lesions. On a lesion basis, QCT showed a good repro-
ducibility for assessment of MLA (ICC 0.91, 95% CI 0.78-0.96) and lumen area stenosis 
(ICC 0.86, 95% CI 0.37-0.95). Furthermore, on a lesion basis, QCT was reproducible for the 
assessment of mean plaque burden (ICC 0.88, 95% CI 0.74-0.95) as well as plaque burden 
at the MLA (ICC 0.92, 95% CI 0.78-0.96). Finally, the quantification of plaque remodeling 
showed good reproducibility with QCT, as reflected by an ICC of 0.84 (95% CI 0.63-0.93).
Discussion
The current study is the first study that has demonstrated the feasibility of automated quan-
tification of coronary plaque on cardiac CT using dedicated quantitative software with a 
novel 3D registration algorithm of CT and IVUS datasets.
Automated quantitative CT and IVUS were well-correlated for the assessment of MLA, 
lumen area stenosis and plaque burden on a vessel- and lesion basis. Coronary plaque 
remodeling showed a significant but moderate correlation between quantitative CT and 
IVUS on a vessel- and lesion basis. When using a binary approach, the accuracy of QCT for 
assessment of coronary plaque remodeling was fair. Finally, MLA was significantly under-
estimated by QCT when compared to IVUS, whereas lumen area stenosis was significantly 
overestimated by QCT in comparison with IVUS.
Non-invasive imaging of coronary atherosclerosis with the use of cardiac CT provides 
important information for patient diagnosis, evaluation of therapeutic options as well as 
for risk stratification of patients for potential adverse cardiovascular events.1-3 Rapid devel-
opments in CT technology have led to an improvement in image quality and diagnostic 
accuracy for detection of coronary atherosclerosis.1-3 Despite its advances, one of the 
current drawbacks of cardiac CT is the fact that evaluation of coronary atherosclerosis is 
most commonly based on a visual approach, which is observer dependent and requires 
substantial reading experience. A fully automated approach to quantify plaque character-
istics would be preferred to further improve the diagnostic accuracy and reproducibility 
of cardiac CT. Moreover, automated quantification could potentially decrease the amount 
of post-processing time required for cardiac CT. Accordingly, substantial effort has been 
invested in the development of quantitative strategies for CT.6-9, 17-19
Thus far, quantitative studies have used manually-based or semi-automated algorithms 
for detection of lumen and vessel wall contours, rather than dedicated automated algorithms 
for contour detection. Furthermore, previous studies were hampered since comparisons 
between cardiac imaging techniques were based on visual assessment of coronary plaques 
as well as manual fusion of imaging modalities. The current study is the first study that allows 
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comparison of cardiac CT and IVUS using a novel dedicated quantitative algorithm, which 
allows automated detection of both lumen and outer vessel wall from CT data sets fused 
with IVUS data along its longitudinal and transversal axis. Additionally, the currently applied 
novel 3D registration algorithm represents a unique fusion imaging technique as it allows 
comparison between cardiac imaging techniques using a slice-by-slice comparison of each 
location along the transversal axis of the coronary arteries in both CT and IVUS images. 
The novel 3D registration algorithm allows improved detection of various (anatomical) 
landmarks in both longitudinal and transversal axis of the coronary arteries, which are used 
to obtain an accurate fusion between imaging modalities, and as a consequence, improved 
quantification of coronary plaque. Accordingly, a detailed fusion-based imaging view is 
available, which permits a simultaneous quantification of the entire segmented coronary 
artery in both CT and IVUS.
At present, only a limited number of studies have aimed to quantify lumen area or lumen 
area stenosis using cardiac CT with variable results.8, 18, 20, 21 Leber et al.8 have evaluated the 
performance of cardiac CT for quantification of coronary lesions in 55 patients with stable 
CAD, of whom 18 patients underwent IVUS. Quantification of lumen area and lumen area 
stenosis was performed on cross sectional reconstructions derived from cardiac CT images. 
Even though lumen area showed a good correlation with IVUS (r=0.81, p<0.01), lumen 
area stenosis showed only a modest correlation between quantitative CT and IVUS (r=0.61, 
p<0.05). Another study from Joshi et al.18 has shown a modest correlation between IVUS 
and quantitative CT for assessment of lumen area (r2=0.41, p<0.05) in 48 patients with 67 
coronary lesions. Accordingly, previous investigations which aimed to quantify lumen area 
stenosis or lumen area on cardiac CT have shown a large variability. One of the potential 
explanations may be the fact that in these studies most often semi-manual approaches were 
used, rather than dedicated quantitative algorithms. Moreover, a visual approach to match 
coronary lesions identified on CT with IVUS was used, which may have led to an inaccurate 
alignment of coronary plaques on both imaging modalities. In the current study however, 
a novel registration algorithm was used permitting an accurate matching of lesions on both 
imaging modalities along the longitudinal and transversal axis of the coronary arteries. 
After both imaging modalities were aligned using true anatomical markers, fusion-based 
quantification showed a good correlation between CT and IVUS for MLA (r=0.75, p<0.001) 
and lumen area stenosis (r=0.79, p<0.001). Moreover, the quantification process itself was 
performed with the use of automated dedicated CT software, which represents a more robust 
approach for coronary plaque quantification as compared to manually-based or semi-
automated approaches. Furthermore, Bland-Altman analysis showed an underestimation of 
MLA (and overestimation of lumen area stenosis) as assessed with QCT when compared to 
IVUS. These findings may be related to the quantification of high-degree, heavily calcified 
lesions. In addition, QCT and IVUS showed a better correlation for lesions with a small MLA 
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than lesions with a large MLA. This could be explained by the calculation of lumen areas, in 
which small changes in radius can result in considerable changes in MLA for a large radius.
Beyond coronary luminography, cardiac CT provides information on plaque burden 
and the degree of plaque remodeling.3, 9 Previous studies have shown a good correlation 
between cardiac CT and IVUS for assessment of plaque volume. In these studies, the 
overall plaque volume was significantly underestimated with CT as compared to IVUS.9, 22 
Although the current study showed a good correlation for assessment of plaque burden with 
quantitative CT, a significant overestimation of plaque burden with cardiac CT was observed 
when compared to IVUS. The differences in study findings may be explained by the fact that 
the current population consisted of patients with advanced and heavily calcified lesions, 
which may have led to an overestimation of plaque burden with CT as compared to IVUS. 
In line with the current study, Bruining et al.19 have shown a significant overestimation of 
plaque volume with quantitative CT as compared to IVUS (222±121 mm3 vs.189±93 mm3, 
p<0.05). The study by Bruining et al.19 have used a quantitative CT approach with limited 
manual interference to assess plaque volume. In 48 patients with clinical symptoms of CAD, 
a semi-automated vessel extraction software was used to derive the region of interest, in 
which lumen contours were detected with an automated edge-detection method. However, 
it is important to note that Bruining et al.19 have used manually drawn vessel wall contours, 
rather than automated detected vessel wall contours. Furthermore, in the study by Bruining 
et al.19, the investigators were allowed to alter the window and level image settings during 
the quantification process, whereas the automated processing steps in the current study 
were independent from standard viewing settings. Accordingly, even though a significant 
overestimation of lumen area stenosis, mean plaque burden, plaque burden at the MLA 
and remodeling index on CT was observed, the present study showed that coronary plaque 
quantification using an automated approach was highly reproducible, as indicated by a 
high intra-class correlation value for assessment of MLA, lumen area stenosis, mean plaque 
burden, plaque burden at the MLA and remodeling index. This may represent an important 
advantage over previous quantification methods.9, 23
In addition, a sub-analysis was performed to determine the influence of image qual-
ity on the performance of automated quantitative CT. Although quantitative CT showed a 
slightly decreased performance in data sets with poor image quality for assessment of MLA 
and lumen area stenosis, no significant influence of image quality was observed for the 
quantification of plaque burden and remodeling index. Accordingly, these findings show 
the feasibility of automated quantification of coronary plaques in data sets with different 
image quality.
Finally, the study has evaluated the influence of coronary calcium on the accuracy of 
atherosclerotic plaque quantification using QCT. In line with previous observations21, the 
current study has shown that calcium-containing lesions showed a larger overestimation of 
lumen area stenosis when compared to non-calcified lesions. Although small differences 
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between non-calcified and calcium-containing lesions were observed, the current study has 
demonstrated that overall the QCT algorithm performed equally well in non-calcified and 
calcium-containing lesions.
Study Limitations and Clinical Perspectives
Some limitations need to be considered. In the current study, automated quantitative CT 
was only applied to non-stented coronary segments, whereas segments with coronary 
stents were excluded. Although a sub-analysis on stented segments would have provided 
additional information, the current study was only designed to demonstrate the feasibility of 
QCT for evaluation of coronary plaque. Moreover, IVUS was only performed in 103 (67%) 
coronary arteries as it could not be performed in 50 (33%) coronary arteries due to vessel 
tortuosity, severe luminal narrowing, (subtotal) vessel occlusion or severe time constraints.
In addition, even though both quantitative techniques showed good correlations for 
coronary plaque characteristics, a significant bias for quantitative plaque parameters was 
observed. However, the bias between both quantitative imaging modalities was consistent 
as indicated by a high intra-class correlation coefficient in the reproducibility analyses 
for assessment of MLA, lumen area stenosis, mean plaque burden, plaque burden at the 
MLA as well as remodeling index. Accordingly, the study showed the feasibility of QCT for 
automated coronary plaque quantification. Furthermore, the study showed only a moderate 
correlation between CT and IVUS for assessment of coronary plaque remodeling. However, 
when using a binary approach, the study showed a modest accuracy of QCT for assessment 
of plaque remodeling, indicating that quantitative CT allows assessment of coronary plaque 
remodeling. This is an important finding as outward remodeling of coronary lesions, which 
is commonly referred to as positive remodeling, represents one of the plaque characteristics 
that has been associated with an increased risk for plaque rupture and acute coronary 
syndromes.5, 24 Finally, although QCT was reproducible for assessment of coronary plaque 
parameters, reproducibility was only tested in a limited number of patients.
In addition, the influence of coronary calcium on the accuracy of QCT has been evalu-
ated in the current analysis. The study has demonstrated that QCT performed equally well in 
non-calcified and calcium-containing lesions when compared to IVUS. Although both tech-
niques can be used for assessment of coronary calcium, IVUS represents a more accurate 
technique due to its superior spatial and temporal resolution. However, despite these poten-
tials, IVUS studies are usually performed in only a limited number of patients (patients with 
a high likelihood of having a significant stenosis) due to the invasive nature of the technique. 
In contrast, cardiac CT allows non-invasive evaluation of plaque morphology in a wide 
variety of patients, predominantly patients with a low (or intermediate) pre-test likelihood of 
CAD and an early stage of CAD. One of limitations of cardiac CT remains its relatively low 
positive predictive value which may be caused by the overestimation of heavily calcified 
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lesions due to blooming artifacts. In the current study, the use of an automated quantitative 
algorithm may have resulted in only a small overestimation of calcium-containing lesions.
Conclusions
The current study demonstrated the feasibility of automated quantification of coronary plaque 
on cardiac CT using dedicated quantitative software with a novel 3D registration algorithm 
of CT and IVUS datasets. Both quantitative CT and IVUS showed good correlations for 
automated assessment of MLA, lumen area stenosis and plaque burden. Finally, even though 
QCT showed underestimation of MLA and overestimation of lumen area stenosis along with 
plaque burden, QCT was reproducible for quantification of MLA, lumen area stenosis, mean 
plaque burden, plaque burden at the MLA and remodeling index.
Appendix
IVUS
Lumen and Vessel Wall Contour Detection
Coronary plaque characteristics were evaluated on IVUS data sets by an independent and 
blinded observer using offline dedicated post-processing software (IVUS CMS 4.0, Medis 
Medical Imaging Systems, Leiden, the Netherlands). Along the full length of the IVUS run, 
lumen-intima and media-adventitia interface were identified in longitudinal and transver-
sal views by an automatic contour detection algorithm. A limited number of individual 
cross-sectional frames were manually adapted to optimize lumen and vessel wall contour 
detection. IVUS contour detection was performed independently from the contour detection 
derived from CT.
Computed Tomography
Lumen and Vessel Wall Contour Detection
On cardiac CT data sets, the dedicated software was able to detect both lumen and ves-
sel wall contours which were used for automated quantitative measurements of coronary 
plaques, as depicted in Figure 1, upper panel. At first, a fast vessel-tracking algorithm was 
used to obtain the 3-dimensional centerline (ranging from the proximal to distal marker) 
of each coronary artery. This vessel-tracking step consists of: (1) a pre-segmentation of the 
vessel between the proximal and distal point and (2) a fast path backtracking from distal 
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to the proximal point through the center of the segmentation. Based on this centerline, a 
stretched multi-planar reformatted (MPR) volume was created of the segment of interest. 
MPR volumes allow the analysis of curved coronary arteries as straight vessels. Next, four 
longitudinal cross-sections were extracted from the MPR volume at 45 degrees angular 
intervals. Subsequently, lumen borders in these four longitudinal images were detected by 
a model guided minimum cost approach (MCA). The MCA method uses a combination of 
spatial first-, and second-derivative gradient filters in combination with knowledge of the 
expected CT intensity values in the arteries. Therefore, the MCA method is not sensitive 
to differences in attenuation values between different data sets. The longitudinal detection 
allows a smooth interpolation between the proximal and distal sites of coronary bifurca-
tions. The MCA with a circular lumen model was used to detect the lumen border contours 
in each transversal slice of the MPR volume. In this step, the intersection points of each 
transversal slice with the earlier obtained longitudinal contours were used to guide the 
contour detection.
Additionally, the vessel wall borders were detected in these longitudinal images by a 
similar MCA with a different model. The applied model was based on several pre-defined 
constraints concerning the location of longitudinal vessel wall contours; contours were 
positioned outside the detected longitudinal lumen contours and the regions with high 
intensity values (e.g. calcified regions) were included according to a relative weighting 
scheme. Consecutively, transversal vessel wall contours were fitted on the transversal slices 
using the intersection of the longitudinal contours with each slice as attraction point. These 
automated processing steps were independent from the standard viewing settings (window 
level 1024, width 0).
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Abstract
Objectives This study aimed to demonstrate the feasibility of multidetector row computed 
tomography (CT) for assessment of diastolic function in comparison with 2-dimensional 
(2D) echocardiography using tissue Doppler imaging (TDI).
Background Diastolic left ventricular (LV) function plays an important role in patients with 
cardiovascular disease. Currently, 2D echocardiography using TDI has been used most com-
monly to evaluate diastolic LV function. Although the role of cardiac CT for evaluation of 
coronary atherosclerosis has been explored extensively, its feasibility to evaluate diastolic 
function has not been studied.
Methods Patients who had undergone 64-multidetector row CT and 2D echocardiography 
with TDI were enrolled. Diastolic function was evaluated using early (E) and late (A) trans-
mitral peak velocity (cm/s) and peak mitral septal tissue velocity (Ea) (cm/s). Peak transmitral 
velocity (cm/s) was calculated by dividing peak diastolic transmitral flow (mL/s) by the cor-
responding mitral valve area (cm2). Mitral septal tissue velocity was calculated from changes 
in LV length per cardiac phase. Subsequently, the estimation of LV filling pressures (E/Ea) was 
determined.
Results Seventy patients (46 men, mean age 55±11 years) who had undergone cardiac 
CT and 2D echocardiography with TDI were included. Good correlations were observed 
between cardiac CT and 2D echocardiography for assessment of E (r=0.73, p<0.01), E/A 
(r=0.87, p<0.01), Ea (r=0.82, p<0.01) and E/Ea (r=0.81, p<0.01). Moreover, a good diag-
nostic accuracy (79%) was found for detection of diastolic dysfunction using cardiac CT. 
Finally, the study showed a low intra- and interobserver variability for assessment of diastolic 
function on cardiac CT.
Conclusions Cardiac CT showed good correlations for transmitral velocity, mitral septal 
tissue velocity and the estimation of LV filling pressures when compared to 2D echocardiog-
raphy. Additionally, cardiac CT and 2D echocardiography were comparable for assessment 
of diastolic dysfunction. Accordingly, cardiac CT may provide information on diastolic 
dysfunction.
Chapter 5: Feasibility of diastolic function assessment with cardiac CT
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Introduction
Diastolic left ventricular (LV) function plays an important role in the evaluation of clinical 
symptoms, therapeutic options and prognosis in patients with cardiovascular disease.1, 
2 More specifically, it has been shown that diastolic dysfunction represents an important 
pathological condition in patients with coronary artery disease (CAD).3, 4
Currently, Doppler echocardiography is the most commonly used imaging technique 
for evaluation of diastolic function.5-10 For the evaluation of diastolic function, transmitral 
velocity has been used frequently as a non-invasive alternative to directly measured LV 
filling pressures.5, 7 However, it is important to note that several confounding factors may 
influence transmitral velocity and consequently transmitral velocity alone may not be the 
best marker for diastolic LV dysfunction.6, 7, 11 Combined assessment of early peak trans-
mitral velocity and early peak mitral septal tissue velocity may be more accurate for the 
evaluation of diastolic LV function, predominantly in patients with depressed or increased 
LV filling pressures.6, 10, 11
Cardiac computed tomography (CT) has emerged as a potent non-invasive imaging 
modality for the evaluation of coronary atherosclerosis.12, 13 In specific subsets of patients, 
multiphase CT may be indicated to ensure diagnostic image quality for visualization of the 
coronary arteries. Thus far, multiphase CT studies have been restricted to LV systolic function 
analysis14, and no information is available on the feasibility of cardiac CT to assess diastolic 
LV function. Accordingly, the present study aimed to evaluate the feasibility of cardiac CT 
for assessment of diastolic function in a direct comparison with 2D echocardiography using 
TDI.
Methods
Patient Population, Study Design
Seventy consecutive patients who had been referred for 64-CT imaging were retrospectively 
selected from our clinical registry. Cardiac CT was performed to evaluate known or estab-
lished CAD, and 2D echocardiography with TDI was performed to evaluate therapeutic 
options. Both examinations had been performed sequentially, in random order. Known CAD 
was defined as previous myocardial infarction, revascularization or evidence of CAD on 
previous diagnostic tests. Patients without evidence of CAD on previous diagnostic tests were 
suspected to have CAD (and therefore referred for CT angiography). Patients were derived 
from our ongoing clinical registry if they met the following selection criteria: (1) presence 
of multiphase cardiac CT (information acquired of the entire cardiac cycle), (2) availability 
of multiphase CT and 2D echocardiography with TDI within 3 months, (3) diagnostic image 
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quality of multiphase CT and 2D echocardiography with TDI, (4) sinus rhythm and (5) 
absence of valvulopathy (aortic or mitral valvulopathy, grade ≥I). Additionally, patients with 
unstable angina pectoris or acute coronary syndrome were excluded from further analysis. 
Our Institutional Review Board does not require its approval for retrospective technical 
analysis of clinically obtained data, as was the case in this study.
Cardiac CT - Data Acquisition and Analysis
Multidetector row CT (MDCT) was performed with a 64-slice CT scanner (Aquilion 64, 
Toshiba Medical Systems, Otawara, Japan). Prior to MDCT, patients were monitored for 
blood pressure and heart rate. Patients with a heart rate ≥65 beats/min were given meto-
prolol 50 or 100 mg orally, unless contra-indicated. Patients did not receive nitroglycerin 
before cardiac CT.
For the contrast-enhanced helical scan, collimation was 64x0.5 mm with a rotation time 
of 400 ms. Tube current and voltage were 350 mA and 120 kV. At an injection rate of 5 mL/
min, 95 to 130 mL of nonionic contrast medium (Iomeron 400; Bracco, Milan, Italy) was 
infused in the antecubital vein. After start of contrast infusion, recurrent low-dose examina-
tions were performed to monitor contrast arrival within the region of interest, placed in the 
descending aorta. The electrocardiogram (ECG) was registered simultaneously for retrospec-
tive gating of the data. The entire cardiac cycle was scanned without dose modulation. The 
ECG gated helical scan was automatically triggered once the predetermined threshold level 
of baseline +100 Hounsfield units was reached. After a preset delay of 2 seconds, scanning 
was performed during an inspiratory breath hold of 8 to 12 seconds.
Data were reconstructed with a slice thickness of 1 mm and a reconstruction interval of 
1 mm. With the use of half reconstruction algorithms, the actual temporal resolution was 
200 milliseconds. Segmented reconstruction algorithms yielded a temporal resolution of up 
to 50 milliseconds, depending on the actual imaging acquisition conditions (pitch, rotation 
time and heart rate). ECG-gated post processing software was used to reconstruct data in 
short-axis orientation. Images were reconstructed at 20 intervals (0% to 95% of the R-R 
interval) and transferred to a separate workstation with dedicated cardiac function analysis 
software (Mass V2008-EXP, LKEB, Leiden, the Netherlands).15 Contrast-enhanced scans 
were analyzed by an independent observer who was blinded to all other data. Significant 
coronary artery stenosis was defined as ≥50% luminal narrowing, whereas non-significant 
stenosis was defined as <50% luminal narrowing.
The evaluation of LV diastolic function was based on the assessment of transmitral veloc-
ity (15 minutes per patient) and mitral septal tissue velocity (5 minutes per patient). Accord-
ingly, the assessment of LV diastolic function was performed within 20 minutes per patient.
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Cardiac CT - Transmitral Velocity
Peak transmitral velocity (cm/s) was measured in early (E) and late (A) diastole. The peak 
value represents the highest mean value of the measurements obtained during early and late 
diastole. Late peak transmitral velocity (cm/s) was measured at atrial contraction. Transmitral 
velocity (cm/s) measurements were based on several processing steps (Figure 1). At first, LV 
volumes were calculated for 20 cardiac phases (each phase represented 5% of the cardiac 
cycle). For each phase, automatic contour detection was performed on 1 mm sliced recon-
structed short-axis images ranging from mitral valve annulus to the apex (Figure 1A, left 
panel). Manual corrections could be made to improve contour detection. Papillary muscles 
were regarded as part of the LV cavity and were included in the LV volume analyses.16 
Automatic contour detection was performed using dedicated in-house developed MASS 
research software package (Mass V2008-EXP, LKEB, Leiden, the Netherlands).15 Next, LV 
volumes were plotted in a volume versus time curve (Figure 1A, right upper curve). In addi-
tion, changes in LV volumes between two consecutive phases (first derivative) were derived 
and used to calculate the transmitral flow (mL/s) per phase (Figure 1A, right lower curve). 
Subsequently, the maximal transmitral flow (mL/s) in early and late diastole was derived 
using the transmitral flow versus time curve. To allow direct comparison with 2D echocar-
diography, the maximal transmitral flow (mL/s) in early and late diastole was divided by their 
corresponding mitral valve area (cm2) (which was measured during early and late diastole, 
as described below), yielding an early and late peak transmitral velocity (cm/s) and the E/A.
Cardiac CT - Mitral Septal Tissue Velocity
Myocardial tissue velocity (cm/s) was measured at the septal level of the mitral valve annulus 
attachment. Measurements of peak mitral septal tissue velocity (cm/s) during early diastole 
(Ea) are illustrated (Figure 1B). For 20 phases, LV length (mm) was calculated as the distance 
between two anatomical markers: (1) mitral septal annulus (MA) (the annular attachment 
of the septal mitral valve leaflet) and (2) cardiac apex (AP) (Figure 1B, left panel). Ana-
tomical markers were positioned at reconstructed 4-chamber views. Reconstruction of a 
4-chamber view was based on several reconstruction steps. At first, a 2-chamber view was 
reconstructed from axial slices, directing the image slice (cardiac axis) through the cardiac 
apex. Consecutively, a 4-chamber view was reconstructed by positioning the image slice at 
two-third of the mitral valve annulus (perpendicular to the interventricular septum) using the 
2-chamber view.
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The LV length (mm) per phase was plotted in a LV length versus time curve (Figure 1B, right 
upper panel). Changes in LV length between two consecutive phases were calculated and 
used to generate a velocity versus time curve (Figure 1B, right lower panel). In this curve, 
mitral septal tissue velocities were plotted against time. For each phase, mitral septal tissue 
velocity (cm/s) was computed using changes in LV length and heart rate. The maximal tissue 
velocity (cm/s) during early diastole represented early peak mitral septal tissue velocity (cm/s) 
(Ea). Measurements were performed using the MASS software.15 Finally, the estimation of LV 
filling pressures (E/Ea) was calculated by dividing early transmitral velocity (E) (cm/s) by the 
mitral septal tissue velocity (Ea) (cm/s).
Figure 1. Diastolic left ventricular (LV) function assessed with multidetector row computed 
tomography (CT).
A Transmitral flow. LV volumes (mL) were measured for 20 phases per cardiac cycle. LV volumes 
(mL) were measured using short-axis images by outlining endocardial contours in each phase. 
LV volumes (mL) were plotted in a volume versus time curve (right upper panel). These curves 
were used to define the diastole, ranging from end-systolic (ES) to end-diastolic (ED) phase. 
Consecutively, changes in LV volumes between two consecutive phases were plotted against 
time (transmitral flow versus time curve) (right lower curve). Subsequently, early and late peak 
transmitral flow (mL/s) were derived.
B Mitral septal tissue velocity. Anatomical markers were positioned at the mitral septal annulus 
(MA) and cardiac apex (AP). LV length (mm) (distance between anatomical markers) was calculated 
for each phase (left panel). LV length (mm) was plotted in a LV length versus time curve (right 
upper curve). Next, changes in LV length between two consecutive phases were calculated. Based 
on these numbers, mitral septal tissue velocities (cm/s) were calculated for each phase (velocity 
versus time curve, right lower panel). The early peak mitral septal tissue velocity (cm/s) (Ea) 
represented the maximal tissue velocity during early diastole.
C Mitral valve area. Measurements were performed at the most distal level of the mitral valve 
leaflets (smallest mitral valve area) using reconstructed images at peak early and late transmitral 
velocity. LV axis was positioned perpendicular to mid-mitral valve annulus on sagital and coronal 
views (left panel), yielding a 2-chamber view (panel 1). Consecutively, the 4-chamber view was 
reconstructed (panel 2) and mitral valve area was measured at the tip of the leaflets (panels 3 and 
4) on short-axis views. To allow direct comparison, transmitral velocity (cm/s) was calculated using 
the following formula: peak diastolic transmitral flow (mL/s) divided by the corresponding mitral 
valve area (cm2).
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Cardiac CT - Mitral Valve Area
Mitral valve area (cm2) was measured to enable direct comparison of volumetric indices 
derived from cardiac CT with velocity-based parameters as assessed with 2D echocardiogra-
phy. In Figure 1C, the processing steps involved in mitral valve area (cm2) measurements are 
illustrated. Images were reconstructed with a slice thickness of 0.5 mm and a reconstruction 
interval of 0.3 mm.
Mitral valve area (cm2) measurements were based on different steps: the LV axis was 
positioned perpendicular to mid-mitral valve annulus on sagital and coronal views, yielding 
a 2-chamber view (panel 1). Subsequently, a 4-chamber view (panel 2) was reconstructed 
and manual contour detection was performed at the most distal level of the mitral valve 
leaflets in short-axis views (panel 3 and 4). Measurements were performed during early 
and late peak transmitral flow (mL/s) using a dedicated workstation (Vitrea 2; Vital Images, 
Minnetonka, Minnesota, USA).
The mitral valve area (cm2) was calculated to enable direct comparison with 2D echocar-
diography. Transmitral velocity (cm/s) was calculated by the following formula: transmitral 
velocity = transmitral flow (mL/s) / corresponding mitral valve area (cm2) (Figure 1).
Intra- and Interobserver Reproducibility
Intra- and interobserver reproducibility for assessment of transmitral velocity was evalu-
ated in a subset of 15 patients who were randomly selected from the patient population. 
Transmitral velocity was measured twice by the same observer in these 15 patients. Sub-
sequently, transmitral velocity measurements were performed by a second independent 
observer in the same subset of patients. In addition, intra- and interobserver reproducibility 
for assessment of mitral septal tissue velocity was evaluated in another random sample of 
15 patients. Mitral septal tissue velocity was measured twice by the same observer in these 
patients according to the standardized protocol, as described above. Additionally, a second 
independent observer performed the mitral septal tissue velocity measurements in the same 
subset of patients.
Finally, the intra- and interobserver reproducibility of the mitral valve area measurements 
was evaluated in a subset of 20 patients who were randomly selected from the patient 
population. In these patients, the mitral valve area was measured twice by the same observer 
using the same processing steps, as described above. Furthermore, a second blinded observer 
performed the mitral valve measurements in the same subset of 20 patients.
Transthoracic 2D Echocardiography Using Tissue Doppler Imaging
Acquisition
Transthoracic 2D echocardiography was performed in left lateral decubitus position using 
a commercially available system (Vingmed Vivid-7, General Electric, Horten, Norway). 
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Standard parasternal (long- and short-axis) and apical views (2- and 4-chamber) were 
obtained. In addition, continuous-wave and pulsed-wave Doppler examinations were 
performed. From the 4-chamber view, TDI was obtained with color Doppler frame rates 
exceeding 115 frames/second, depending on the sector width of the range of interest. Alias-
ing velocities varied between 16 and 32 cm/s and resulted from pulse repetition frequen-
cies ranging from 500 Hz and 1 kHz. Echocardiographic analyses were performed by an 
independent and blinded observer.
2D Echocardiography - Transmitral Velocity
Transmitral velocity (cm/s) was recorded at the end of respiratory expiration (Figure 2, upper 
panel). Transmitral velocity (cm/s) measurements were performed using dedicated offline 
software (EchoPAC 7.0.0.; General Electric, Horten, Norway). Standard pulsed-wave Dop-
pler imaging was performed to assess early (E) and late (A) peak transmitral peak velocity 
(cm/s). Early and late peak transmitral velocity (cm/s) were used to calculate the E/A. Dop-
pler sample volume was placed at the tip of the mitral valve leaflets, on a 4-chamber view 
.17 Subsequently, early and late peak transmitral velocities (cm/s) were obtained in diastole.
2D Echocardiography - Mitral Septal Tissue Velocity
Early peak mitral septal tissue velocity (cm/s) (Ea) was assessed using color-coded TDI on a 
4-chamber view. Images were obtained in end-expiration in a patient in left lateral decubitus 
position. Doppler velocities (cm/s) were measured from the apical 4-chamber view using a 
6x6 mm sample volume positioned at the basal septal mitral valve annulus, as illustrated in 
Figure 2 (lower panel).17 Color-coded images from three consecutive heartbeats were ana-
lyzed using dedicated offline software (EchoPAC 7.0.0.; General Electric, Horten, Norway). 
Reliable tissue Doppler curves were obtained in 67 patients.
Detection of Diastolic Dysfunction
To evaluate the accuracy of cardiac CT to detect diastolic dysfunction, diastolic function 
was graded in four categories using the following criteria; normal diastolic function (≥1 E/A 
<2 and E/Ea ≤8), impaired relaxation pattern (diastolic dysfunction grade I) (E/A <1 and E/
Ea ≤8), pseudonormal pattern (diastolic dysfunction grade II) (≥1 E/A <2 and ≥9 E/Ea ≤12) 
and restrictive filling pattern (diastolic dysfunction grade III) (E/A ≥2 and E/Ea ≥13).18 Based 
on these criteria, the patient population was divided into two groups; patients with normal 
diastolic function and patients with diastolic dysfunction (including impaired LV relaxation, 
pseudonormal and restrictive LV filling pattern).
Statistical Analysis
Continuous data are presented as mean ± standard deviation, and categorical data are pre-
sented as absolute numbers or percentages. Kolmogorov-Smirnov tests were used to evaluate 
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Figure 2. Evaluation of diastolic function with 2-dimensional (2D) echocardiography using tissue 
Doppler imaging (TDI). 2D echocardiographic assessment of pulsed-wave Doppler of early (E) 
transmitral velocity (cm/s) (white arrow, panel A) and early diastolic peak mitral septal tissue 
velocity (cm/s) (Ea) (white arrow, panel B) at basal septal segment by TDI.
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the distribution of the data. All variables were normally distributed except for the estimation 
of LV filling pressures (E/Ea) on cardiac CT and 2D echocardiography with TDI. Data for E/Ea 
were presented as medians and 25th and 75th percentiles. When appropriate, paired t tests or 
Wilcoxon signed-rank tests were used to compare diastolic function parameters as derived 
from cardiac CT and 2D echocardiography with TDI.
Comparison of cardiac CT and 2D echocardiography with TDI was performed using Pear-
son’s linear regression analysis or spearman’s rho correlation. The 95% limits of agreement 
were calculated using Bland-Altman analysis that plotted the mean value of differences of 
each pair against the average value of similar pair of data. Cardiac CT was subtracted from 
2D echocardiography with TDI as the latter was considered the clinical standard. Reproduc-
ibility was evaluated by calculating the intraclass correlation coefficients (ICC) and an excel-
lent agreement was defined as an ICC >0.8. Diagnostic accuracy of cardiac CT for detection 
of diastolic dysfunction was assessed using a binary approach; normal diastolic function and 
diastolic dysfunction (including impaired LV relaxation, pseudonormal and restrictive LV 
filling pattern). Corresponding sensitivity and specificity values were calculated. For these 
values, the 95% confidence intervals (CI) were calculated using the following formula: 
p±1.96 x standard error (SE) and the SE was estimated by √ [p (1–p)/n]. Statistical analyses 
were performed with SPSS release 16.0 (SPSS Inc, Chicago, Illinois, USA). All tests p<0.05 
were considered statistically significant. Bland-Altman analyses were performed with dedi-




A total of 80 patients had undergone multiphase cardiac CT and 2D echocardiography with 
TDI within 3 months. Of these 80 patients, 10 patients were excluded due to the absence 
of sinus rhythm (n=2) or the presence of non-diagnostic image quality of either cardiac CT 
(n=7) or 2D echocardiography with TDI (n=1). Accordingly, a total of 70 patients (46 (66%) 
men, mean age 55±11 years) were included. Baseline characteristics of the patient popula-
tion are listed in Table 1. Cardiac CT and 2D echocardiography were performed within 3 
months, in which no acute coronary events or worsening of angina occurred. No changes 
in the use of medication occurred between both examinations. The mean duration between 
cardiac CT and 2D echocardiography was 34.1±25.0 days. Clinical referral for cardiac CT 
was based on suspected CAD in 58 patients and known CAD in 12 patients. Patients with 
known CAD included patients with previous myocardial infarction (n=10), percutaneous 
coronary intervention (n=7) and patients with indications of CAD on earlier diagnostic tests 
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Table 1. Baseline characteristics of study population (n=70)
Men 46 (66)
Age (yrs) 55±11
Suspected CAD 58 (83)
Known CAD 12 (17)
Significant coronary stenosis 21 (30)
Cardiovascular risk factors
Diabetes mellitus 35 (50)
Systemic hypertension 43 (61)
Hypercholesterolemia 40 (57)
Current smoking 11 (16)
Positive family history 27 (39)
Medication use
Beta-blockers 24 (34)





Heart rate (bpm) 58±10
LV end-systolic volume (mL) 70±50
LV end-diastolic volume (mL) 149±52
LV ejection fraction (%) 56±13
Data are presented as mean ± standard deviation or as number (%). ACE-I = angiotensin converting 
enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; LV = left ventricle; CT = 
computed tomography.
Table 2. Diastolic function parameters for cardiac CT and 2D echocardiography
Cardiac CT 2D echocardiography
Transmitral velocity
E (cm/s) 59.0±16.6 61.8±14.5*
A (cm/s) 56.2±17.4 64.8±18.2*
E/A 1.1±0.4 1.1±0.5*
Mitral septal tissue velocity
Ea (cm/s) 6.6±2.7 6.2±2.3*
E/Ea 8.8 (6.4-13.1) 9.7 (7.5-14.0)**
Data are presented as mean values ± standard deviation or as numbers. Data for E/Ea are presented 
as medians and corresponding 25th and 75th percentiles. 2D = 2-dimensional; CT = computed 
tomography. *Paired t-test showed a p-value <0.05. ** Wilcoxon signed-rank test showed a p-value 
<0.05.
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(n=3). Significant coronary artery stenosis (≥50% luminal narrowing) was reported in 21 
(30%) patients. In total, 31 (44%) patients received beta-blocking therapy prior to cardiac 
CT.
A B
Figure 3. Comparison between 2-dimensional (2D) echocardiography and multidetector row 
computed tomography (CT) for assessment of early maximal diastolic transmitral velocity (E). 
A. Good correlation was observed between both techniques. B. Bland-Altman analysis showing 
the difference of each pair plotted against the average value of same pair of values. Dotted lines 
represent 95% limits of agreement.
Figure 4. Comparison between 2-dimensional (2D) echocardiography and multidetector row 
computed tomography (CT) for E/A. A. Good correlation was observed between both techniques. 
B. Bland-Altman analysis showing the difference of each pair plotted against the average value of 
same pair of values. Dotted lines represent 95% limits of agreement.
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Transmitral Velocity
Transmitral flow versus time curves were obtained in all patients. Mean LV end-systolic 
and LV end-diastolic volumes were 70±50 mL and 149±52 mL on cardiac CT. Accord-
ingly, the mean LV ejection fraction was 56±13% (Table 1). Mean values for early and late 
peak transmitral velocity are shown in Table 2. The mean diastolic transmitral velocity was 
24.3±8.5 cm/s. Pearson’s correlation showed a good correlation for E (r=0.73, p<0.01) and 
E/A (r=0.87, p<0.01) (Figures 3A and 4A). Bland-Altman analysis for E showed a mean 
difference of 2.4±12.0 cm/s, with 95% limits of agreement ranging from -21.2 to 26.0 cm/s, 
whereas for E/A the mean value of difference was -0.1±0.2 with 95% limits of agreement 
ranging from -0.5 to 0.4 (Figures 3B and 4B).
A low intra- and interobserver variability was observed for assessment of early (ICC 0.97, 
95% CI 0.91-0.99 and ICC 0.93, 95% CI 0.78-0.97) and late (ICC 0.98, 95% CI 0.94-0.99 
and ICC 0.91, 95% CI 0.51-0.98) peak transmitral velocity. Moreover, the assessment of E/A 
showed a low intra- and interobserver variability (ICC 0.95, 95% CI 0.84-0.98 and ICC 0.95, 
95% CI 0.85-0.98)
Finally, the intra- and interobserver reproducibility of mitral valve area measurements 
was evaluated. In a subset of 15 patients, an excellent intra- and interobserver reproduc-
ibility was observed for assessment of mitral valve area (ICC 0.94, 95% CI 0.83-0.98 and 
ICC 0.92, 95% CI 0.80-0.97, respectively).
Figure 5. Comparison between 2-dimensional (2D) echocardiography and multidetector row 
computed tomography (CT) for assessment of early peak mitral septal tissue velocity (Ea). A. Good 
correlation was observed between both imaging techniques. B. Bland-Altman analysis showing 
the difference of each pair plotted against the average value of same pair of values. Dotted lines 
represent 95% limits of agreement.
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Mitral Septal Tissue Velocity
Velocity versus time curves were obtained for all patients. Mean values for Ea are shown in 
Table 2. In addition, the medians and corresponding 25th and 75th percentiles for E/Ea are 
shown in Table 2. A good correlation (r=0.82, p<0.01) (Figure 5A) for Ea was found. Bland-
Altman analysis showed a mean value of difference of -0.5±1.6 cm/s with 95% limits of 
agreement ranging from -3.6 to 2.5 cm/s (Figure 5B). In addition, good correlation (r=0.81, 
p<0.01, Figure 6A) was reported for E/Ea with a mean value of difference of 1.0±2.9 and 
95% limits of agreement ranging from -4.6 to 6.7 (Figure 6B).
An excellent intra- and interobserver reproducibility was observed for assessment of 
mitral septal tissue velocity (ICC 0.95, 95% CI 0.85-0.98 and ICC 0.89, 95% CI 0.69-0.96) 
and estimation of LV filling pressures (E/Ea) (ICC 0.96, 95% CI 0.87-0.99) and ICC 0.93, 95 
% CI 0.80-0.98).
Figure 6. Comparison between 2-dimensional (2D) echocardiography and multidetector row 
computed tomography (CT) for E/Ea. A. Good correlation for E/Ea was observed between both 
techniques. B. Bland-Altman analysis showing the difference of each pair plotted against the 
average value of same pair of values. Dotted lines represent 95% limits of agreement.
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Detection of Diastolic Dysfunction
The diagnostic accuracy of cardiac CT to detect diastolic dysfunction in comparison 
to 2D echocardiography with TDI was calculated.18 In total, 19 (27%) patients showed 
normal diastolic function, whereas 51 (73%) patients showed diastolic dysfunction using 
2D echocardiography. Of the patients with diastolic dysfunction on 2D echocardiography, 
40 patients were scored similarly using cardiac CT, yielding a sensitivity of 78% (95% CI 
67-89%). Normal diastolic function was found in 15 of the 19 patients using cardiac CT, 
yielding a specificity of 79% (95% CI 61-97%). Overall, diagnostic accuracy for assessment 
of diastolic dysfunction was 79% (95% CI 69-89%).
Discussion
This study demonstrated good correlations for transmitral velocity (E and E/A) and mitral 
septal tissue velocity (Ea). Additionally, combined assessment of transmitral and mitral septal 
tissue velocity (E/Ea) representing an estimation of LV filling pressures showed good cor-
relation between cardiac CT and 2D echocardiography with TDI. Finally, the study showed 
that cardiac CT and 2D echocardiography were comparable for assessment of diastolic 
dysfunction. Accordingly, cardiac CT may provide information on diastolic dysfunction.
The importance of diastolic function in patients with coronary atherosclerosis has been 
demonstrated in several studies.3, 4 A recent meta-analysis pooled 3396 patients with docu-
mented myocardial infarction from 12 prospective studies and demonstrated that patients 
with a restrictive LV filling pattern had a significantly higher mortality rate than patients with 
a non-restrictive LV filling pattern (28.7% vs. 11.3 %, p<0.01).3, 4 Although invasive mea-
surements of LV filling pressure are considered the most accurate approach for evaluation of 
diastolic LV function, they are not ideal for widespread application and follow-up examina-
tions. Consequently, several cardiac imaging techniques (particularly 2D echocardiography) 
have been used to assess transmitral velocity as a noninvasive alternative.5, 7 Even though 
complex interacting pathophysiologic mechanisms may underlie diastolic dysfunction, 
evaluation of diastolic LV function is most frequently based on transmitral velocity measure-
ments alone.5, 7, 11
Transmitral Velocity
Doppler echocardiography has been validated for the assessment of transmitral velocity as a 
noninvasive alternative of direct LV filling pressures.5 Additionally, Doppler echocardiogra-
phy has been compared to magnetic resonance imaging (MRI) for assessment of transmitral 
velocity.9, 10 The present study demonstrated that cardiac CT can be used for assessment 
of LV diastolic function as was indicated by good correlations between cardiac CT and 
Doppler echocardiography for early transmitral velocity (r=0.73, p<0.01) and E/A ratio 
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(r=0.87, p<0.01). In line with the study by Hartiala et al.9, a systematic underestimation of 
transmitral velocity was observed when compared to Doppler echocardiography (Table 2). 
One of the potential explanations of this underestimation could be related to the sampling 
rate of cardiac CT. As the data sets were sampled in 20 cardiac phases, each sampling 
took place in 5% steps of the RR interval. Accordingly, the sampling rate of cardiac CT 
was markedly lower as compared to 2D echocardiography, and this may resulted in an 
underestimation of transmitral velocity on CT as the peak transmitral velocity as derived 
from 2D echocardiography could be present in between 2 sampled cardiac phases. In both 
studies, correlations were not excellent for transmitral velocity and this may be related to 
other parameters that could influence transmitral velocity measurements, including filling 
pressures, degree of LV relaxation, myocardial elastic recoil and stiffness.7, 8 To overcome 
these limitations, additional measurements have been proposed, including the evaluation of 
pulmonary venous velocity, M-mode echocardiography flow velocity curves, and altering 
pre- and afterload conditions (Vasalva maneuver or nitroglycerin administration).19, 20 In 
the current study however, these measurements were not performed as this study was only 
performed to evaluate the feasibility of cardiac CT.
Additionally, it has been suggested to combine transmitral velocity and mitral septal 
tissue velocity measurements when evaluating diastolic heart function. Importantly, the 
combined assessment of transmitral velocity and mitral septal tissue velocity represents a 
better estimate of LV filling pressures as it is a normalization of LV filling gradient for filling 
LV volume.6, 10, 11
Mitral Septal Tissue Velocity
Ommen and colleagues6 have studied the clinical use of TDI for evaluation of diastolic LV 
function in 100 patients. Comparison between invasive LV filling pressures and combined 
assessment of early transmitral velocity and mitral septal tissue velocity showed improved 
correlation (r=0.64) as compared to transmitral velocity (r=0.59) or mitral septal tissue 
velocity (r=0.36) alone.6 In addition, MRI has been compared to TDI for assessment of tissue 
velocities.10 Paelinck et al.10 have used phase-contrast MRI and Doppler echocardiography 
to measure transmitral and mitral septal tissue velocities in 18 patients with hypertrophic 
cardiomyopathy. Importantly, combined assessment of early transmitral velocity and mitral 
septal tissue velocity (E/Ea) showed a good correlation between Doppler echocardiography 
and MRI (r=0.89, p<0.01). Moreover, invasive measurements were well correlated to E/Ea 
derived from Doppler echocardiography (r=0.85, p<0.01) and MRI (r=0.80, p<0.01). Like-
wise, the current study has reported good correlations for transmitral velocity (E/A, r=0.87, 
p<0.01) and E/Ea (r=0.81, p<0.01). Furthermore, both studies have shown that mitral septal 
tissue velocity was slightly overestimated when compared to 2D echocardiography with 
TDI. With tissue Doppler echocardiography, tissue velocities are quantified using changes 
in Doppler signal over time. Doppler patterns are only displayed for the region of interest 
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(sample volume), located at the basal septal mitral valve annulus. With cardiac CT however, 
tissue velocities are measured using a different region of interest; ranging from the basal 
septal mitral valve annulus to the apex. The different regions of interest may have caused a 
slight overestimation of tissue velocity using cardiac CT.
Diastolic Left Ventricular Function
Cardiac CT and 2D echocardiography with TDI were comparable for detection of diastolic 
dysfunction. This represents an important finding as the assessment of diastolic dysfunc-
tion provides important diagnostic, therapeutic and prognostic information in patients with 
cardiovascular disease, and more specifically, in patients with coronary atherosclerosis.1-4 
Additionally, it has been shown that patients with coronary atherosclerosis and normal 
LV systolic function may already exhibit diastolic dysfunction.21 Accordingly, additional 
post-processing for diastolic dysfunction may have the potential to enhance the clinical 
evaluation derived from cardiac CT, particularly in patients with evidence of coronary 
atherosclerosis but normal LV systolic function. Moreover, the feasibility of cardiac CT for 
assessment of diastolic function is of particular interest as the number of patients referred for 
noninvasive evaluation of known or suspected coronary atherosclerosis with cardiac CT has 
increased substantially over the recent years.
At present, prospective triggering techniques are commonly used in patients referred for 
cardiac CT, particularly for ruling out the presence of significant CAD in young patients. 
However, cardiac CT is also used in patients with advanced CAD or elderly patients for 
detailed characterization of coronary and cardiac anatomy. In these patients, multiphase 
CT images may still be acquired using retrospective ECG gating to ensure diagnostic image 
quality for coronary visualization. The additional information derived from this examination 
can be used for additional purposes, including the retrospective evaluation of systolic and, 
as demonstrated in the current manuscript, diastolic function. Accordingly, the informa-
tion that is needed for evaluation of diastolic function can be derived from conventional 
multiphase CT, without additional image acquisition or radiation dose.
Moreover, with the recent developments in acquisition and reconstruction algorithms, 
multiphase imaging may be performed at considerably lower radiation dose when com-
pared to the currently available imaging protocols.
Limitations
At first, the study represents a retrospective study, whereas a prospective study design would 
be more preferred. Secondly, transmitral velocity parameters were assessed with Doppler 
echocardiography and cardiac CT as a noninvasive alternative to directly measured LV filling 
pressures. Although direct measurements of LV filling pressures would have been preferred, 
they are not ideal for routine clinical examination. Furthermore, patients with valvular 
regurgitation were excluded. Severe valvular regurgitation may disturb accurate velocity 
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measurements, leading to an inaccurate diastolic LV function analysis. Future studies are 
needed to evaluate this potential confounding effect. Additionally, cardiac CT and 2D echo-
cardiography with TDI were performed within a period of maximal 3 months. However, to 
ensure optimal comparability between both examinations the study only included patients 
with stable hemodynamic conditions; patients with unstable angina pectoris or acute 
coronary syndromes were excluded. Also, in the current study, diastolic function indices 
were derived from multiphase CT data sets acquired without tube current modulation. To 
what extent tube modulation may influence the measurements of the mitral valve area and 
other diastolic function parameters needs to be addressed in additional studies. Finally, it is 
important to note that the effect of intravenous infusion of contrast media during cardiac CT 
angiography on diastolic function indices is currently unknown.22
Conclusions
Cardiac CT showed good correlations for transmitral velocity, mitral septal tissue veloc-
ity and estimation of LV filling pressures when compared to 2D echocardiography using 
TDI. Accordingly, cardiac CT may provide information on diastolic dysfunction in selected 
patients imaged by retrospectively ECG gated CT.
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Abstract
Cardiac resynchronization therapy (CRT) has become an integrated treatment option for 
patients with drug-refractory heart failure. Selection of patients for CRT is based on moderate 
to severe heart failure (New York Heart Association, NYHA functional class III-IV), depressed 
left ventricular (LV) systolic function ≤35% and prolonged QRS interval ≥120 ms. However, 
30-40% of selected patients do not exhibit improvement in heart failure symptoms or LV 
systolic performance.
Efforts have been made to improve patient selection criteria and several studies using 
echocardiography have demonstrated the significance of LV dyssynchrony for prediction 
of CRT response as an additional selection criterium. In addition, (location and extent of) 
viability and scar tissue are important for outcome after CRT. Nuclear imaging with ECG-
gated myocardial perfusion SPECT (GMPS) permits assessment of viability, scar tissue and 
LV dyssynchrony from 1 dataset. The potential value of GMPS in CRT patients is discussed 
in this review. In addition, the use of nuclear imaging (and particularly positron emission 
tomography, PET) for evaluation of changes in blood flow, metabolism and innervation after 
CRT is addressed.
Chapter 6: Role of nuclear imaging in CRT
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Introduction
Heart failure represents a major problem in the Western health care system. In the United 
States, heart failure affects 5.3 million patients and each year approximately 660,000 
patients are diagnosed with heart failure.1 Furthermore, (decompensated) heart failure is 
responsible for more than one million hospital admissions per year and direct and indirect 
costs accounted for $34.8 billion in 2008.1 Despite advanced treatment options for heart 
failure, the 5-year mortality rate still exceeds 50%.
In recent years, cardiac resynchronization therapy (CRT) has been integrated in the treat-
ment of patients with drug-refractory heart failure. The evidence for success of CRT in heart 
failure patients is mainly based on results of eight large clinical trials that have demonstrated 
beneficial effects of CRT on heart failure symptoms, quality of life, and exercise capacity.2-7 
In addition, a reduction in left ventricular (LV) volumes (indicating reverse remodeling) along 
with an improvement in LV ejection fraction (LVEF) and mitral regurgitation were observed 
in patients undergoing CRT.2-7 Besides clinical and echocardiographic end-points, two large 
clinical trials have demonstrated an improvement in survival with a reduction in morbidity 
in patients undergoing CRT as compared to patients on optimal medical therapy.8, 9
Current ACC/AHA/ESC guidelines recommend CRT in patients with advanced heart failure 
(NYHA class III or IV), prolonged QRS duration (≥120 ms), depressed LV systolic function 
(LVEF ≤35%) and sinus rhythm.10, 11 However, multiple clinical trials have demonstrated that 
a substantial group of patients (30-40%), who were selected according to current criteria 
on CRT, did not show significant improvement in heart failure symptoms or LV systolic 
performance.5, 12, 13 Hence, refinement of selection criteria is needed and several studies 
have emphasized the importance of cardiac dyssynchrony for response to CRT.13-15 Cardiac 
dyssynchrony includes atrioventricular dyssynchrony, interventricular dyssynchrony and 
intraventricular (LV) dyssynchrony, and most studies suggested that the latter may be most 
powerful for prediction of response to CRT.13, 14, 16 In this regard, QRS duration is of limited 
value for prediction of response to CRT, mainly since QRS duration reflects interventricular 
rather than intraventricular dyssynchrony.13, 14, 17, 18
At present, detection of LV dyssynchrony can be performed with several cardiac imaging 
techniques, including echocardiography13, 14, 19-21, magnetic resonance imaging22, 23 and 
nuclear imaging.24-30 The majority of clinical studies on LV dyssynchrony and the prediction 
of response to CRT used echocardiography.14, 16 These predominantly single-center studies 
have clearly demonstrated that LV dyssynchrony has additional value in selection of patients 
for CRT. Since all studies used different echocardiographic techniques and different criteria 
for LV dyssynchrony, it is currently unclear which are the precise cut-off values that could 
be used for prediction of CRT response. This issue has been addressed in the Predictors of 
Response to Cardiac Resynchronization Therapy (PROSPECT) trial, which was the first multi-
center prospective trial using echocardiography for identification of predictors of response 
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to CRT.31 The study has shown only a modest value of echocardiography to predict response 
to CRT, and an important problem posed the limited intra- and interobserver variability.32 
Another aspect that may have influenced the study results is the heterogeneous study 
population included. A substantial cohort of patients included had a LV ejection fraction 
>35% without severe LV dilatation. These patients were not able to demonstrate cardiac 
remodeling, one of major endpoints of the study. In addition, other issues could have con-
tributed to the disappointing results, including myocardial scar tissue, LV lead positioning 
and accessibility of the venous anatomy.
Accordingly, more sophisticated and reproducible imaging techniques are needed for 
assessment of LV dyssynchrony for selection of CRT candidates.
One of these techniques may be nuclear imaging. Particularly, ECG-gated myocardial 
perfusion SPECT (GMPS) has emerged as a reasonable technique to determine LV dyssyn-
chrony. Moreover, nuclear imaging is already used extensively in heart failure patients to 
detect LVEF, LV volumes, ischemia, viability and scar tissue. Accordingly, the addition of 
LV dyssynchrony to previously mentioned clinical data, provides heart failure clinicians 
tools to direct therapeutic strategy in the individual heart failure patient (medical therapy, 
revascularization or CRT). Beyond LV dyssynchrony, viability and scar tissue are particularly 
important in CRT patients, since the location and extent of scar tissue is also predictive of 
(non-) response to CRT.
In this review, the potential role of GMPS for prediction of response to CRT is addressed. 
Moreover, nuclear imaging (and particularly positron emission tomography, PET) is also 
important in the evaluation of changes in perfusion, metabolism and innervation after CRT, 
which is also discussed in this review.
Nuclear Imaging to Assess Left Ventricular Dyssynchrony
Several nuclear imaging techniques can be used for detection of cardiac dyssynchrony, 
including multi-gated equilibrium blood-pool scintigraphy24, 25, gated blood-pool SPECT26, 
27 and GMPS.28-30, 33, 34
Initially, gated blood-pool scintigraphy was used for assessment of the myocardial 
contraction pattern. In gated blood-pool imaging, labeled erythrocytes are used for generat-
ing count-based volume-time curves. Images are obtained from one left-anterior oblique 
view (LAO) in 16 to 64 frames per cardiac cycle and can be smoothed with spatial and 
temporal filtering in order to reduce noise.35 Subsequently, regions of interest (ROI) are 
drawn automatically or manually on the left and right ventricles respectively. For each pixel 
in the ROI, a time-activity curve is generated by approximation of discrete sample points 
into a continuous curve using the first Fourier Harmonic (FFH) function. The phase angle 
of the first FFH function corresponds to the timing of contraction at the particular region. 
The standard deviation (SD) of phase angles over the ventricle represents the intra-ventric-
ular dyssynchrony, and the difference between the means of the phase angles of the two 
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ventricles represents inter-ventricular dyssynchrony. The major limitation of this method is 
that determination of ROI from planar images is less accurate due to overlap of non-cardiac 
structures. Gated blood-pool SPECT, with the similar principles of phase analysis as gated 
blood-pool scintigraphy, allows assessment of inter- and intraventricular dyssynchrony in 3 
dimensions (3D).26, 27 The major limitation of this method is that it lacks standard processing 
procedures due to the complexity of generation time-activity curves from gated blood-pool 
SPECT images.
Recently, phase analysis of GMPS has attracted considerable attention. GMPS is fre-
quently applied in heart failure patients to evaluate for ischemia, viability and scar tissue to 
direct patient management (revascularization or medical therapy), and the current possibil-
ity to derive information on cardiac dyssynchrony from the same dataset has emerged as an 
appropriate alternative to assess cardiac dyssynchrony.28-30, 33, 34
The phase analysis of GMPS studies is based on the partial-volume effect in which 
changes in segmental maximal counts is proportional to cardiac wall thickening.36, 37 Phase 
analysis is performed on standard GMPS images without any additional acquisition. For 
each frame of the gated short-axis image, a 3D sampling algorithm is used to search for 
regional maximal counts. Next, a count-based wall-thickening curve is generated for each 
segment and then approximated using the FFH function. The phase angle of the FFH func-
tion represents the onset of mechanical activation of the region. Hetero- or homogeneity 
of the phase distribution over the entire LV represents LV dys- or synchrony. Peak phase 
(maximum of phase histogram), phase standard deviation (standard deviation (SD) of phase 
distribution), histogram bandwidth (bandwidth which includes 95% of phase angles), kur-
tosis (degree of peakedness of histogram) and skewness (symmetry of histogram) are used 
to quantify the phase distribution. In Figure 1, an example of a patient with a synchronous 
Figure 1A. Heart failure patient with minimal left ventricular (LV) dyssynchrony as evidenced by the 
homogeneous phase angle distribution (polar map, left panel) and a narrow phase histogram (right 
panel). This patient did not improve in symptoms or LV systolic function after 6 months of cardiac 
resynchronization therapy (CRT); particularly, LV ejection fraction did not improve (30% at baseline 
vs. 29% at follow-up).
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LV contraction pattern is illustrated in upper panel, whereas an example of a patient with 
extensive LV dyssynchrony is illustrated in the lower panel.
In general, GMPS studies are perceived with poor temporal resolution since data acquisi-
tion is based on 8 or 16 frames per cardiac cycle. However, phase analysis on GMPS is able 
to improve temporal resolution by replacing 8 or 16 discrete points into a continuous FFH 
curve.38 It has been shown that in clinical settings (≥10 counts per pixel) phase analysis 
using either first, second or third harmonics, phase analysis was able to detect phase differ-
ence of 5.6 degrees, reflecting 1/64 of the cardiac cycle.38 GMPS has been validated against 
echocardiography for assessment of LV dyssynchrony. Henneman and coworkers39 have 
published on the agreement between echocardiography with tissue Doppler imaging (TDI) 
and GMPS. Good correlations between LV dyssynchrony as measured by TDI and histogram 
bandwidth (r=0.89, P<0.0001) or phase SD (r=0.80, P<0.0001) as measured by phase 
analysis of GMPS were presented. Moreover, good correlations between LV dyssynchrony 
indices on 3D echocardiography and GMPS were recently reported. The systolic dyssyn-
chrony index (derived from real-time 3D echocardiography) correlated well with histogram 
bandwidth (r=0.76, P<0.0001) and phase SD (r=0.80, P<0.0001) as illustrated in Figure 2.20
Henneman and colleagues40 have evaluated 42 heart failure patients who underwent 
CRT with GMPS. After 6 months of CRT, a significant improvement in NYHA class, quality 
of life score and exercise capacity was noted. The authors demonstrated that LV dyssyn-
chrony derived from GMPS was related to CRT response. Particularly, histogram bandwidth 
(175±63 versus 117±51, P<0.05) and phase SD (56.3±19.9 versus 37.1±14.4, P<0.05) were 
significantly larger in responders as compared to non-responders to CRT. Receiver operat-
ing characteristic curve analysis revealed good predictive values for CRT response using 
histogram bandwidth (AUC 0.78) or phase SD (AUC 0.81) as markers of LV dyssynchrony 
(Figure 3). For histogram bandwidth, a cut-off value of 135° had a sensitivity and specificity 
Figure 1B. Heart failure patient with extensive left ventricular (LV) dyssynchrony as evidenced by 
heterogeneous phase distribution (polar map, left panel) and a broad phase histogram (right panel). 
This patient improved in symptoms and LV ejection fraction (from 28% to 40%) after 6 months of 
cardiac resynchronization therapy (CRT).
Chapter 6: Role of nuclear imaging in CRT
115
y = 0.0502x + 0.2921







0 50 100 150 200 250 300









Figure 2A. Comparison between left ventricular (LV) dyssynchrony derived from real-time 3 
dimensional echocardiography (RT3DE) and gated myocardial perfusion single photon emission 
computed tomography (SPECT) (GMPS). The systolic dyssynchrony index (SDI) from RT3DE 
correlated well with histogram bandwidth derived from GMPS. Reprinted with permission from 
reference 20.
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Figure 2B. Comparison between left ventricular (LV) dyssynchrony derived from real-time 3 
dimensional echocardiography (RT3DE) and gated myocardial perfusion single photon emission 
computed tomography (SPECT) (GMPS). Good correlation was observed between systolic 
dyssynchrony index (SDI) from RT3DE and phase standard deviation (SD) derived from GMPS. 
Reprinted with permission from reference 20.
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Figure 3A. Receiver operating characteristic curve analysis on histogram bandwidth demonstrated 
a good predictive value (AUC 0.78) for response to cardiac resynchronization therapy (CRT). A cut-
off value of 135° for histogram bandwidth showed a sensitivity and specificity of 70%. Reprinted 
with permission from reference 40.
Figure 3B. Receiver operating characteristic curve analysis on phase standard deviation (SD) 
showed a good predictive value (AUC 0.81) for response to cardiac resynchronization therapy 
(CRT). A cut-off value of 43° for phase SD yielded a sensitivity and specificity of 74%. Reprinted 
with permission from reference 40.
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of 70%; for phase SD, a threshold of 43° yielded a sensitivity and specificity of 74% for 
prediction of CRT response.
One important advantage of phase analysis of GMPS for assessment of LV dyssynchrony is 
that this method is largely automatic and has superior reproducibility to echocardiography. 
Trimble and colleagues33 have evaluated phase analysis of GMPS with 10 normal subjects 
and 10 patients with LV dysfunction and showed that intra-observer and inter-observer 
reproducibility of phase analysis of GMPS is very robust with correlation coefficients of 
1.00 and 0.99 respectively.
Nuclear Imaging to Assess Viability and Scar Tissue
It appears that viability and scar tissue are important for response to CRT. In particular, the 
presence of scar tissue in the region where the LV pacing lead is positioned is of importance. 
Bleeker et al.41 have demonstrated in an elegant study with contrast-enhanced magnetic 
resonance imaging that patients with scar tissue in the posterolateral region (where the 
LV lead was positioned in these patients) was associated with non-response to CRT41; the 
authors hypothesized that transmural scar tissue in the LV pacing region resulted in ineffec-
tive pacing prohibiting LV resynchronization. Another important issue in patients considered 
for CRT is identification of the region of latest activation for optimal LV lead positioning.42-44 
Recently, Ypenburg and colleagues44 have evaluated echocardiographic response to CRT in 
patients with LV lead positioned at the region of latest activation (concordant) and in patients 
with LV lead positioned at other regions than the area of latest activation (discordant). 
Patients with concordant LV lead positioning (n=153) showed significant reduction in LV 
end-systolic volume, whereas patients with discordant LV lead position (n=91) demonstrated 
no significant reduction in LV end-systolic volume.
In addition to the area of latest activation and its viability, the balance between the total 
extent of viable myocardium and scar tissue in the left ventricle is important.45-47 In 61 
patients with ischemic cardiomyopathy, Ypenburg and colleagues45 have shown that the 
extent of viable myocardium (assessed with F18-fluorodeoxyglucose, FDG) and SPECT) was 
directly related to improvement in LVEF (r=0.56, P<0.05) after 6 months of CRT, whereas the 
extent of scar tissue was inversely related to change in LVEF (r=-0.56, P<0.05) at 6 months 
follow-up. Also, responders to CRT had significantly more viable segments as compared 
to non-responders (12±3 vs. 7±3 viable segments respectively, P<0.01). Based on these 
data, receiver operating characteristic curve analysis was performed, and a cutoff value of 
11 viable segments was defined to predict CRT response with a sensitivity of 74% and a 
specificity of 87%.
Adelstein et al.48 have reported similar findings in 50 heart failure patients undergoing 
SPECT. Larger extent of scar tissue and the presence of scar tissue in the region where the LV 
pacing lead was positioned were inversely related to improvement in LVEF after CRT.
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Similar findings were reported with FDG PET in 39 patients with ischemic cardiomyopa-
thy undergoing CRT, confirming a direct relation between the extent of viable tissue and 
cardiac performance after CRT (r=0.64, P<0.001).49 The optimal threshold for prediction of 
hemodynamic response (improvement in cardiac index >15%) after LV pacing was defined 
at 3 viable segments, yielding a sensitivity of 72% with a specificity of 71% (AUC 0.80) to 
predict hemodynamic improvement after CRT.
Of note, these studies found different cutoff values for prediction of response to CRT. 
One of potential explanations for the observed discrepancy is the fact that different scoring 
models were used. In the study by Ypenburg and colleagues45, the 17-segment model was 
used for assessment of the number of viable and infarcted segments, whereas Van Campen 
et al.49 used a 13-segment model. Moreover, different definitions for response to CRT were 
used in these studies. Patients with an improvement in ≥1 NYHA class were considered 
responders to CRT in the study by Ypenburg et al.45, while Van Campen and colleagues49 
considered patients as responders to CRT in the presence of >15% improvement in cardiac 
index.
Nuclear Imaging to Evaluate CRT Effects on Blood Flow, Metabolism and 
Innervation
The effects of CRT on myocardial blood flow, metabolism and sympathetic innervation have 
been studied using nuclear imaging.50-61 To evaluate the beneficial effects of CRT, particu-
larly correction of LV dyssynchrony, the etiology of heart failure plays an important role as 
different mechanism may be involved. In this regard, two concepts are important, including 
cardiac dyssynchrony and cardiac dyssynnergy; cardiac dyssynchrony results from different 
timing of contraction between cardiac segments, whereas cardiac dyssynnergy refers to 
heterogeneous contractile capacity (contractile disparity) between cardiac segments with 
similar contraction timing. The former may play an important role in patients with congestive 
heart failure and left bundle branch block, whereas cardiac dyssynnergy may play a more 
evident role in ischemic heart failure patients. The effect of CRT in patients with cardiac 
dyssynchrony based on disparity in activation timing can be expected, however, the precise 
mechanisms of effects of CRT in patients with cardiac contractile disparity are less clear. 
Several studies on nuclear imaging have been performed to evaluate the beneficial effects of 
CRT on myocardial blood flow, oxidative metabolism, glucose utilization and sympathetic 
innervation. Particularly the effects of CRT on myocardial blood flow have been extensively 
studied with PET.50-57 Different studies demonstrated that global blood flow did not change 
after CRT.50-57 However, an inhomogeneous distribution of blood flow was observed in 
heart failure patients, with lower values in the septum as compared to the lateral wall. 
After CRT a more homogeneous distribution of blood flow was detected. Knaapen and 
coworkers54 have evaluated 14 heart failure patients who underwent CRT with O15-labeled 
water and PET. Myocardial blood flow was inhomogeneously distributed as reflected by a 
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baseline septal-to-lateral blood flow ratio of 0.77±0.27, which increased to 0.97±0.34 after 
3 months of CRT. Similarly, a heterogeneous distribution of glucose utilization was observed 
in heart failure patients, with lower glucose utilization in the septum as compared to the 
lateral wall.57, 58 Nowak and colleagues58 have used FDG PET in 15 patients with dilated 
cardiomyopathy and left bundle branch block configuration on the ECG, and demonstrated 
low FDG uptake in the septum as compared to the lateral wall (56±12% versus 89±6%, 
P<0.001). The septal-to-lateral FDG ratio improved significantly after CRT (0.62±0.12 versus 
0.91±0.26, P<0.001) indicating more homogeneous tracer uptake.
The effect of CRT on myocardial efficiency has been evaluated by Ukkonen and col-
leagues.59 The authors used C11-acetate with PET and showed an improvement in cardiac 
efficiency after CRT.
Finally, sympathetic innervation has been evaluated with 123-I-metaiodobenzylguanidine 
(MIBG) and SPECT in patients undergoing CRT, suggesting that patients with more preserved 
innervation had better response to CRT.60, 61 
Conclusions
In heart failure patients, nuclear imaging with GMPS can provide information on myocardial 
ischemia, viability and scar tissue; in addition, precise information on LV function and LV 
volumes can be derived. With current technology of phase analysis, assessment of LV dys-
synchrony is possible from the same dataset. It provides a comprehensive overview for 
the heart failure specialist, permitting therapeutic decision making. At present, large trials 
are needed to determine the precise role of GMPS for assessment of LV dyssynchrony and 
outcome after CRT.
Future Perspectives
Accurate prediction of response to CRT remains challenging. Different issues need to be 
concerned for appropriate patient selection for CRT, in particular the assessment of LV dys-
synchrony. Most frequently, echocardiography has been proposed to provide information on 
LV dyssynchrony, however the results from the PROSPECT trial are disappointing; a major 
issue was the reproducibility of echo analyses, with large inter- and intraobserver variability 
of dyssynchrony measurements. GMPS has the potential to provide objective, reproducible 
parameters on LV dyssynchrony. In clinical cardiology, many heart failure patients undergo 
nuclear imaging for assessment of myocardial perfusion state and simultaneous detection 
of mechanical dyssynchrony will add important information for therapeutic strategies. 
Although GMPS is promising, limited data are available on the use of GMPS for selection 
of CRT candidates and larger trials are needed to define to final role of GMPS in CRT. 
As a consequence, echocardiography remains the first choice for patient selection to CRT, 
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however, depending on upcoming studies GMPS may be incorporated in the clinical workup 
of patient selection for CRT.
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Introduction The significance of LV dyssynchrony for prediction of response to cardiac 
resynchronization therapy (CRT) has been demonstrated. Parameters reflecting LV dyssyn-
chrony (phase SD, histogram bandwidth) can be derived from gated myocardial perfusion 
SPECT (GMPS) using phase analysis. The feasibility of LV dyssynchrony assessment with 
phase analysis on GMPS using Quantitative Gated SPECT (QGS) software has not been 
demonstrated in patients undergoing CRT. The aim of the present study was to validate the 
QGS algorithm for phase analysis on GMPS in a direct comparison with echocardiography 
using tissue Doppler imaging (TDI) for LV dyssynchrony assessment. In addition, prediction 
of response to CRT using GMPS and phase analysis was evaluated.
Methods Patients (n=40) with severe heart failure (NYHA class III-IV), LV ejection fraction 
≤35%, QRS complex ≥120 ms were evaluated for LV dyssynchrony using GMPS and echo-
cardiography with TDI. At baseline and after 6 months of CRT, clinical status, LV volumes 
and LV ejection fraction were evaluated. Patients with functional improvement were classi-
fied as CRT responders.
Results Both histogram bandwidth (r=0.69, r2=0.48, SEE 25.4, p<0.01) and phase SD 
(r=0.65, r2=0.42, SEE 26.8, p<0.01) derived from GMPS correlated significantly with TDI 
for assessment of LV dyssynchrony. At baseline, CRT responders showed significantly larger 
histogram bandwidth as compared to non-responders (94±23° vs. 68±21°, p<0.01) and 
larger phase SD (26±6° vs. 18±5°, p<0.01). Receiver operating characteristic (ROC) curve 
analysis identified an optimal cutoff value of 72.5° for histogram bandwidth to predict CRT 
response, yielding a sensitivity of 83% with a specificity of 81%. Similar sensitivity and 
specificity were obtained at a cutoff value of 19.6° for phase SD.
Conclusions QGS phase analysis on GMPS was significantly correlated with TDI for assess-
ment of LV dyssynchrony. Moreover, a high accuracy for prediction of response to CRT was 
obtained using either histogram bandwidth or phase SD.
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Introduction
Cardiac resynchronization therapy (CRT) has become an established therapeutic option for 
patients with drug-refractory heart failure. Thus far, several clinical trials have been reported, 
which demonstrated the beneficial effect of CRT on heart failure symptoms, quality of life 
score, and exercise capacity.1, 2 In addition, CRT improved left ventricular ejection fraction 
(LVEF), reduced severity of mitral regurgitation and decreased LV volumes (reverse remodel-
ing).1, 2 Moreover, it has been demonstrated that CRT resulted in a superior survival with a 
reduction in heart failure hospitalization rate.3, 4
Although considerable benefit of CRT has been observed, one third of the patients meet-
ing the current selection criteria do not respond to CRT.5-8 Hence, attention has shifted 
towards improved patient selection for CRT.9, 10 Particularly, observational trials have shown 
the significance of LV dyssynchrony for prediction of response to CRT.6-8 LV dyssynchrony 
can be detected using different imaging modalities, including echocardiography with tissue 
Doppler imaging (TDI)6-8, or strain (rate) imaging11, magnetic resonance imaging (MRI)12 
or nuclear imaging with single photon emission computed tomography (SPECT).13-18 Par-
ticularly, phase analysis of gated myocardial perfusion SPECT (GMPS) has been evaluated 
recently for assessment of LV dyssynchrony.14-18 Recently, the Quantitative Gated SPECT 
(QGS) algorithm has been expanded to provide quantitative parameters for the assessment 
of LV (dys)synchrony, in addition to previously reported functional parameters.14, 18 With this 
algorithm, quantification of LV (dys)synchrony is based on phase calculations for each LV 
surface sampling point. The aim of the current study was to further validate the QGS modi-
fied algorithm for phase analysis on GMPS, in a direct comparison with echocardiography 
using TDI for the assessment of LV dyssynchrony. Moreover, outcome after 6 months of CRT 
was evaluated and related to baseline LV dyssynchrony on GMPS.
Materials and Methods
Study Population and Protocol
The study population consisted of 40 consecutive drug-refractory heart failure patients who 
were scheduled for implantation of a CRT device. Eligibility for CRT was based on advanced 
heart failure (New York Heart Association (NYHA) functional class III-IV), depressed systolic 
LV function (LVEF ≤35%), prolonged QRS duration (≥120 ms) and sinus rhythm. Patients 
with decompensated heart failure, recent myocardial infarction (<3 months) or previously 
implanted pacemaker were excluded.
Before CRT implantation, all patients underwent evaluation of clinical status, GMPS with 
99mtechnetium tetrofosmin and 2-dimensional (2D) echocardiography with TDI as part of 
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the clinical evaluation to determine therapeutic options. The clinical status was evaluated 
by assessment of NYHA functional class, exercise capacity (6-minute walk test) and quality 
of life score [using the Minnesota Quality-of-Life (QoL) Questionnaire].19
Six months after CRT implantation, assessment of clinical status and 2D echocardiog-
raphy with TDI were repeated. Patients with an improvement of 1 grade or more in NYHA 
class were classified as responders to CRT. Patients without improvement in NYHA class 
were considered non-responders; patients who died of progressive heart failure were also 
considered non-responders.
Gated Myocardial Perfusion SPECT: Data Acquisition
Resting ECG-gated GMPS with 99mtechnetium tetrofosmin (500 MBq, injected at rest) was 
performed with a triple-head SPECT camera system (GCA 9300/HG; Toshiba Corporation, 
Tokyo, Japan). High-resolution, low-energy collimators were used and a 20% window was 
centered around the 140-keV energy peak of 99mtechnetium tetrofosmin. Over a 360-degree 
circular orbit, 90 projections (step and shoot method, 35 s/projection, 64 x 64 matrix, total 
imaging time 23 min) were obtained in which data acquisition involved 16 frames per 
cardiac cycle. Data were reformatted into gated short-axis images by reconstruction with 
filtered back projection and reorientation. No attenuation correction was used. Data were 
displayed in polar map format and analyzed using a 17-segment model.20 Cardiac segments 
with <50% tracer uptake were considered as segments with a perfusion defect.
Phase Calculations
These reconstructed images were analyzed by a modified version of the QGS algorithm21 
that provides quantitative parameters for the assessment of LV dyssynchrony, in addition 
to previously described functional parameters.14 QGS operates by first computing a mid-
myocardial LV surface, then computing endo- and epicardial surfaces using count-profile 
as well as thickening information derived from myocardial mass conservation combined 
with count increases caused by partial volume effects. All surfaces are generated as two-
dimensional meshes in an ellipsoidal coordinate system with a fixed number of latitudinal 
and longitudinal samples.21 The current version of QGS uses 36 longitudinal and 28 latitu-
dinal samples, leading to a maximum of 1008 sampling points (usually fewer due to surface 
truncation by the valve plane). Subsequent phase calculations are performed using regional 
maximal counts obtained by searching between the endo- and epicardial surfaces, normally 
to the mid-myocardial surface, for each surface sampling point. A unidimensional array is 
created for each spatial sampling point containing the image counts at each interval. This 
array represents a time-varying, periodic function to which a cosine curve can be fitted. For 
the purposes of this analysis the constant component can be ignored, and therefore this 
process is equivalent to reducing the periodic function to its first Fourier harmonic (FFH), 
characterized by an amplitude and phase angle. Once the phase angle has been calculated 
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for each mid-myocardial surface point, a 2D median filter is applied to eliminate spurious 
variations. The window size of the filter (9 longitudinal samples out of 36, 7 latitudinal 
samples out of 28) was selected empirically. As phase measurements are essentially ill-
defined for signals that exhibit low temporal variations22, 5% of the samples for which the 
amplitude is lowest are eliminated.
(Dys)synchrony Parameters
Once phase information has been calculated for all sampling points, global and regional 
(dys)synchrony measures can be computed. For this study, a histogram was constructed from 
the phase values for the entire LV and phase standard deviation (SD) and bandwidth were 
calculated and examined as the global (dys)synchrony measures. Phase SD was calculated 
in the usual manner. Bandwidth was calculated to include 95% of histogram elements as 
previously reported by Chen et al.15 Timing values can be expressed in milliseconds (ms), 
angles in degrees (0o – 360o) or as a percentage of the average duration of the cardiac cycle 
(0% – 100%), the latter 2 being equivalent. While timing values expressed in milliseconds 
have been considered more clinically relevant with echocardiography, they are also directly 
dependent on the heart rate, potentially rendering comparison of studies acquired with 
different heart rates problematic.23 Hence, for this study all timing values are expressed in 
degrees.
2D Echocardiography
Transthoracic resting 2D echocardiography was performed with a commercially available 
system (Vivid Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA) with the 
patient in left lateral decubitus position. A 3.5 MHz transducer was used to obtain images 
at a depth of 16 cm in parasternal and apical views (standard long- and short-axis, 2- and 
4-chamber images). From apical 2- and 4-chamber images, LV end-systolic (LVESV) and LV 
end-diastolic (LVEDV) volumes along with LVEF were calculated using the biplane Simpson’s 
approach.24 In addition, TDI was performed to assess LV dyssynchrony. For TDI (triggered 
to the QRS complex) color Doppler frame rates exceeded 80 frames/s and pulse repeti-
tion frequencies varied between 500 Hz and 1 KHz, yielding aliasing velocities between 
16 cm/s and 32 cm/s. TDI images and conventional echo images were saved in cine-loop 
format and analyzed by 2 experienced observers blinded to the GMPS and clinical patient 
data. All analyses were performed using commercially available software (Echopac 6.0.1 
General Electric-Vingmed, Milwaukee, Wisconsin, USA). To determine LV dyssynchrony, the 
sample volume was placed in the basal portions of the septum and lateral wall; peak systolic 
velocities and time-to-peak systolic velocities were obtained and the delay in peak systolic 
velocity between the septum and the lateral wall was calculated as an indicator of LV dys-
synchrony.25 Reliable tissue Doppler curves for assessment of septal-to-lateral delay were 
obtained in 39 patients. The peak systolic velocity analysis was limited to the LV ejection 
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phase (marked by opening and closure of aortic valve). Inter- and intraobserver agreement 
for assessment of LV dyssynchrony were 90% and 96%, respectively.26 Substantial LV dys-
synchrony on TDI was defined as a delay in peak systolic velocity ≥65 ms between the basal 
septum and lateral wall.7
CRT Implantation
The LV pacing lead was inserted transvenously via the subclavian route as reported previ-
ously.25 A coronary sinus venogram was obtained during occlusion of the coronary sinus 
using a balloon catheter. The LV pacing lead was inserted in the coronary sinus with an 
8 Fr guiding catheter, and positioned as far as possible in the venous system, preferably 
in the (postero-) lateral vein. The right atrial and right ventricular leads were positioned 
conventionally. For each patient the atrio-ventricular interval was adjusted to maximize the 
mitral inflow duration using pulsed-wave Doppler echocardiography. No adjustments were 
made to the V-V interval during the first 6 months of CRT. CRT device and LV lead implanta-
tion were successful in all patients without major complications; all patients received a 
CRT-D device (Contak Renewal, Guidant, USA; InSync III, InSync Marquis or InSync Sentry, 
Medtronic Inc., USA; Atlas HF, St. Jude Medical, USA) and four types of pacemaker leads 
were used (Acuity 4554 or Easytrak 4517-4524, Guidant; Attain 4193-4194, Medtronic; 
Quicksite 1056T, St. Jude Medical).
Statistical Analysis
Continuous data are expressed as mean ± SD and categorical data are presented as percent-
ages (or numbers). When appropriate, 2-tailed paired or unpaired Student’s t test and the 
Chi-square test were used for numerical or categorical data.
Pearson’s correlation analysis was performed to evaluate the relation between histogram 
bandwidth and phase SD derived from GMPS and LV dyssynchrony derived from TDI. Next, 
univariate and multivariate analyses were performed to determine predictors of response to 
CRT. Receiver operating characteristic (ROC) curve analyses were performed to determine 
the optimal cutoff values of histogram bandwidth and phase SD to predict response to CRT. 
The highest sum of sensitivity and specificity was considered as the optimal cutoff value for 
prediction of response to CRT. For all analyses, a p-value <0.05 was considered statistically 
significant.




Baseline characteristics of the 40 patients (32 men, mean age 63±8 years) are summarized 
in Table 1. The etiology of heart failure was ischemic cardiomyopathy in 70% of patients 
and idiopathic dilated cardiomyopathy in 30%. Medication consisted of diuretics (90% of 
patients), ACE inhibitors (90% of patients) and beta-blockers (75% of patients) in maximum 
tolerated dosages. Prior to CRT implantation, the mean NYHA functional class was 3.1±0.4 
and the mean QoL score was 38±19. On the surface ECG, the mean QRS interval was 
156±34 ms and the 6-minute walking distance was 323±96 m. On 2D echocardiography, 
the mean LVESV was 193±79 ml, with a mean LVEDV of 252±84 ml and a mean LVEF of 
25±8%. Mean heart rate during GMPS was 68.6±12.9 beats/min, whereas mean heart rate 
during TDI was 68.5±13.2 beats/min (p=NS). The mean number of cardiac segments with a 
perfusion defect was 6±3.
LV Dyssynchrony: Gated Myocardial Perfusion SPECT versus Tissue 
Doppler Imaging
Phase analysis on GMPS yielded a mean histogram bandwidth of 84±26° (range 40° to 
152°) and a mean phase SD of 23±7° (range 12° to 41°). On TDI, the mean LV dyssynchrony 
was 53±35 ms (range 0 to 130 ms). Pearson’s correlation showed a significant correlation 
between LV dyssynchrony on TDI and histogram bandwidth on GMPS (r=0.69, r2=0.48, SEE 
25.4, n=39, p<0.01, Figure 1A). Also, a significant correlation between LV dyssynchrony on 
Table 1. Baseline characteristics of the study population (n=40)
Age (yrs) 63±8
Gender (M/F) 32/8
Etiology of heart failure
Ischemic cardiomyopathy 28 (70%)
Idiopathic dilated cardiomyopathy 12 (30%)
NYHA functional class 3.1±0.4
QoL score 38±19
6-min walking distance (m) 323±96




Cardiac segments with perfusion defect 6±3
Data are presented as mean ± standard deviation or as number (%). LVEDV = left ventricular end-
diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic 
volume; NYHA = New York Heart Association; QoL = quality of life.
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TDI and phase SD on GMPS was demonstrated (r=0.65, r2=0.42, SEE = 26.8, n=39, p<0.01, 
Figure 1B). Finally, pearson correlation showed a good correlation between histogram 
bandwidth and phase SD (r=0.95, r2=0.91, SEE 8.0, p<0.01).
Importantly, patients with LV dyssynchrony ≥65 ms on TDI (indicating substantial LV 
dyssynchrony) had significantly larger histogram bandwidth and phase SD as compared to 
patients with LV dyssynchrony <65 ms on TDI (Figure 2).
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Figure 1. Agreement between left ventricular (LV) dyssynchrony on tissue Doppler imaging (TDI) 
and histogram bandwidth (A) or phase standard deviation (SD) (B) derived from gated myocardial 
perfusion single photon emission computed tomography (SPECT). Significant correlation between 
LV dyssynchrony on TDI and histogram bandwidth or phase SD as assessed with gated myocardial 
perfusion SPECT was observed.



























Figure 2A. The histogram bandwidth was significantly larger in patients with substantial left 
ventricular (LV) dyssynchrony on tissue Doppler imaging (TDI) (defined as mechanical delay 
between the basal septum and lateral wall ≥65 ms) as compared to patients without LV 
dyssynchrony (delay <65 ms) on TDI (105±23 versus 71±17, p <0.05).
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Clinical Responders and Non-responders
At 6 months follow-up, 24 (60%) patients showed an improvement of 1 or more grades 
in NYHA functional class and were considered responders to CRT. Among the 16 (40%) 
non-responders, 5 patients died within 6 months of CRT due to progressive heart failure.
In Table 2, baseline clinical and imaging variables are summarized for responders and 
non-responders. Responders showed a significantly longer 6-minute walking distance and 
larger LVEDV. Furthermore, responders had significantly more LV dyssynchrony on TDI 
(Figure 3).
Concerning the GMPS data, responders showed significantly larger histogram bandwidth 
(94±23° vs. 68±21°, p<0.01) and phase SD (26±6° vs. 18±5°, p<0.01) as compared to non-
responders. Responders to CRT showed significantly lower number of cardiac segments with 
perfusion defects as compared to non-responders to CRT (5±2 vs. 8±2, p<0.01). Examples of 
GMPS data in patients with and without response to CRT are shown in Figure 4.


















Figure 2B. The phase standard deviation (SD) was significantly larger in patients with substantial 
left ventricular (LV) dyssynchrony on tissue Doppler imaging (TDI) (defined as mechanical 
delay between the basal septum and lateral wall ≥65 ms) as compared to patients without LV 
dyssynchrony (delay <65 ms) on TDI (28±6 versus 20±5, p<0.05).
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Age (yrs) 62±8 64±9 NS
Gender (M/F) 20/4 12/4 NS
Ischemic etiology 16 (67) 12 (75) NS
Clinical evaluation
NYHA class 3.0±0.2 3.2±0.5 NS
QoL score 34±17 45±20 NS
6-MWT (m) 354±81 272±99 0.01
QRS (ms) 162±35 146±31 NS
2D echocardiographic parameters
LVEDV (ml) 274±79 219±83 0.04
LVESV (ml) 211±75 167±78 NS
LVEF (%) 24±8 25±8 NS
LV dyssynchrony (ms) 62±37 40±26 0.04
Phase distribution
Bandwidth (°) 94±23 68±21 <0.01
Phase SD (°) 26±6 18±5 <0.01
Segments with perfusion defect 5±2 8±2 <0.01
Data are presented as mean ± standard deviation or as number (%). 2D = 2-dimensional; LVEDV = 
left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular 
end-systolic volume; 6-MWT = 6-minute walk test; NYHA = New York Heart Association; QoL = 

























Figure 3. The extent of left ventricular (LV) dyssynchrony on tissue Doppler imaging (TDI) at 
baseline was significantly larger in responders to cardiac resynchronization therapy (CRT) as 
compared to non-responders (62±37 ms versus 40±26 ms, p<0.05).
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Baseline and 6 months Follow-up Data
At 6 months follow-up, responders showed significant improvement in NYHA functional 
class, quality of life score and 6-minute walk distance, whereas non-responders did not 
show significant improvement in any of the clinical parameters (Table 3). Furthermore, only 
responders demonstrated a significant decrease in LVEDV and LVESV with a significant 
increase in LVEF at 6 months follow-up.
Univariate analysis was performed on clinical, echocardiographic and GMPS variables 
and demonstrated that 6-minute walk distance, LVEDV and LV dyssynchrony on TDI were 
Figure 4. A: Example of a patient without left ventricular (LV) dyssynchrony on gated myocardial 
perfusion SPECT (GMPS). Synchronous contraction pattern is reflected by a homogeneous phase 
angle distribution of the polar map (left) and the narrow highly-peaked histogram (right). At 6 
months follow-up, no improvement in NYHA functional class was observed and LV ejection fraction 
remained unchanged (32% at baseline versus 33% at 6 months follow-up). 
B: Example of a patient with extensive LV dyssynchrony on GMPS. LV dyssynchrony is indicated by 
the heterogeneous phase angle distribution of the polar map (left) and the wide histogram (right). 
At 6 months follow-up, NYHA functional class improved from 3 to 2, with an increase in LV ejection 
fraction from 21% to 33%.
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predictors of response to CRT at 6 months follow-up. In addition, histogram bandwidth and 
phase SD were predictive of CRT response at 6 months follow-up. Multivariate analysis 
showed that 6-minute walk distance and phase SD were the only independent predictors for 
response to CRT. ROC curve analysis was used to define the optimal threshold for prediction 
of response to CRT. For histogram bandwidth, optimal cutoff value was defined at 72.5° 
which yielded a sensitivity of 83% and a specificity of 81%; the area under the curve was 
0.83 (Figure 5A). For phase SD, optimal cutoff value was defined at 19.6° yielding a sensitiv-
ity of 83% and a specificity of 81%; the area under the curve was 0.85 (Figure 5B).
Table 3. Baseline and 6 months follow-up characteristics: responders versus non-responders
Baseline characteristics Responders (n=24) Non-responders (n=16) p-value
NYHA class
Baseline 3.0±0.2 3.2±0.5 NS
Follow-up 1.7±0.5* 3.2±0.5 <0.01
QoL score
Baseline 34.4±17.4 44.9±20.4 NS
Follow-up 21.6±19.2* 40.0±16.3 <0.05
6-MWT (m)
Baseline 353.9±80.9 272.2±99.4 <0.05
Follow-up 439.8±102.9* 326.8±108.6 <0.05
LVEDV (mL)
Baseline 274.4±79.2 219.3±82.8 <0.05
Follow-up 243.7±77.0* 180.7±56.5 <0.05
LVESV (mL)
Baseline 210.5±75.4 167.1±78.4 NS
Follow-up 166.8±76.8* 129.3±50.1 NS
LVEF (%)
Baseline 23.9±7.5 25.4±8.1 NS
Follow-up 33.8±12.7* 30.0±8.1 NS
LV dyssynchrony (ms)
Baseline 62.3±37.4 40.0±26.1 <0.05
Follow-up 40.4±32.5 33.2±31.6 NS
Data are presented as mean ± standard deviation or as absolute number (%). Abbreviations as in Table 
2. * p<0.05 follow-up versus baseline. 
Chapter 7: Quantitative gated SPECT-derived phase analysis on GMPS detects LV dyssynchrony and predicts response to CRT
139
































Figure 5. ROC curve analysis for histogram bandwidth (A) and phase standard deviation (SD) 
(B) for prediction of response to cardiac resynchronization therapy (CRT). ROC curve analysis for 
histogram bandwidth showed a good predictive value (AUC 0.83) for prediction of response to CRT. 
Optimal cutoff value was defined at 72.5° yielding a sensitivity of 83% with a specificity of 81%. 
For phase SD, ROC curve analysis demonstrated a good predictive value (AUC 0.85) for prediction 




The main observations are as follows: phase analysis on GMPS and echocardiography using 
TDI showed significant correlation for assessment of LV dyssynchrony. Moreover, both 
histogram bandwidth and phase SD derived from GMPS were predictive of CRT response 
at 6 months follow-up. For histogram bandwidth, an optimal cutoff value of 72.5° yielded a 
sensitivity of 83% with a specificity of 81% to predict response to CRT; for phase SD, a cutoff 
value of 19.6° yielded similar sensitivity and specificity.
LV Dyssynchrony Derived from GMPS
The current selection criteria for CRT have selected patients meeting the current American 
Heart Association/American college of Cardiology/European Society of Cardiology guide-
lines which recommend CRT in patients with NYHA class III or IV, LVEF ≤35%, and a 
prolonged QRS interval ≥120 ms.6-10
However, a substantial amount of the selected patients do not show response to CRT.2, 
5-8 As a consequence, efforts have been made to improve current selection criteria on CRT 
and previous studies have demonstrated that LV dyssynchrony is related to CRT response 
and may have additional value in the selection of potential candidates for CRT.6-8 One of 
the potential explanations of non-response in patients meeting contemporary guidelines is 
the fact that a wide QRS complex may reflect interventricular rather than intraventricular 
dyssynchrony.26
 To detect LV dyssynchrony a variety of imaging techniques can be used, including 
echocardiography using TDI6-8, or myocardial strain (rate) imaging11, magnetic resonance 
imaging12 and nuclear imaging using GMPS.14-18 Most studies on CRT have reported on 
echocardiographic methods to assess LV dyssynchrony; in particular echocardiography 
using TDI has been employed as a tool for assessment of LV dyssynchrony.6-8 Recently, the 
feasibility of phase analysis on GMPS for detection of LV dyssynchrony has been shown.27, 
28 This approach provides automatically quantitative parameters of LV dyssynchrony using 
count-based analysis and has been developed to extract amplitude and phase angle from 
changes in counts per region during the cardiac cycle.14-17 Amplitude of the phase curve 
indicates maximal systolic wall thickening, whereas phase angle is indicative of the begin-
ning of mechanical contraction per region, providing information on the degree of hetero- 
or homogeneity of the mechanical activation pattern within the ventricle. A histogram was 
constructed that represents the distribution of the phase angle for all sample points of the 
LV, providing quantitative parameters for LV dyssynchrony including histogram bandwidth 
(includes 95% of the elements of the phase histogram) and phase SD (SD of phase distribu-
tion).18
Various studies have shown that this approach can detect LV dyssynchrony in patients 
with heart failure and wide QRS complex.27, 28 Subsequent studies have shown the relation 
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between phase analysis on GMPS and echocardiographic techniques for assessment of LV 
dyssynchrony.29, 30 Henneman and colleagues29 have evaluated 75 heart failure patients 
with wide QRS complex in a head-to-head comparison between phase analysis on GMPS 
and 2D echocardiography using TDI. The authors have demonstrated that histogram band-
width and phase SD derived from GMPS related well with LV dyssynchrony derived from 
TDI. Marsan et al.30 have used real-time 3D echocardiography and also demonstrated good 
relation with phase analysis on GMPS for detection of LV dyssynchrony in 40 patients with 
heart failure. In the current study, GMPS data were processed with the QGS algorithm which 
was expanded to provide quantitative parameters for the assessment of LV dyssynchrony. 
It was shown that LV dyssynchrony derived from TDI related significantly with histogram 
bandwidth and phase SD obtained with the QGS algorithm.
GMPS for Prediction of Response to CRT
Many studies performed with echocardiography have shown that LV dyssynchrony is predic-
tive for response to CRT.6-8 Only 1 study has reported on the use of GMPS for prediction of 
response to CRT31; 42 patients with heart failure, NYHA class III-IV, LVEF <35%, QRS >120 
ms underwent GMPS before CRT implantation. In the patients, reflectors of LV dyssynchrony 
(phase SD and histogram bandwidth) were identified as predictors of response to CRT over 
a 6 months follow-up period. Particularly, a cutoff value of 43° for phase SD yielded a 
sensitivity and specificity of 74% for prediction of response to CRT; a cutoff value of 135° 
for histogram bandwidth had a sensitivity and specificity of 70%. In the current study, a 
different algorithm was used derived from the QGS program, for assessment of phase SD 
and histogram bandwidth. In line with previous work31, histogram bandwidth and phase SD 
were significantly larger in CRT responders as compared to non-responders (Table 2). When 
ROC curve analysis was applied, a cutoff value of 19.6° for phase SD yielded a sensitivity of 
83% with a specificity of 81% (with area under the curve 0.85) to predict response to CRT 
at 6 months follow-up. For histogram bandwidth a similar sensitivity and specificity were 
obtained at a cutoff value of 72.5° (with area under the curve 0.83). The accuracy to predict 
response to CRT in the current study is in line with earlier work using different software 
to analyze GMPS.31 The optimal cutoff values for phase SD and histogram bandwidth in 
the present study are not identical to the values obtained in the study by Henneman et 
al.31, and this may be related to differences in software packages or to differences in study 
populations. One of the major differences between these packages is the fact that QGS uses 
an ellipsoidal sampling system21, as opposed to the hybrid cylindrical-spherical coordinate 
system used by the Emory Cardiac Toolbox.32
In both the study by Henneman et al.31 and the current study, accuracy of GMPS to pre-
dict response to CRT was not perfect. In comparison to TDI, however, GMPS has advantages 
of providing global measurements and that the measurements are automatically derived. 
Given these advantages and the accuracy demonstrated by this and previous work, GMPS 
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may provide a reasonable alternative for clinical use to TDI in predicting CRT response. It is 
not realistic to expect a perfect accuracy for prediction of CRT response based solely on LV 
dyssynchrony. Indeed, recent work has indicated that other issues than LV dyssynchrony are 
important for response to CRT. Scar tissue has been identified as an important factor limiting 
the response to CRT.33, 34 It has been shown that the extent of scar tissue was inversely 
related to the response to CRT; also, patients with scar tissue in the region where the LV 
lead was positioned did not respond well to CRT and the extent (the total scar burden) of 
scar tissue have been shown to prevent response to CRT. It would therefore be preferred to 
not only assess the presence of LV dyssynchrony, but also the extent and location of scar 
tissue in the left ventricle. In this perspective, GMPS has the potential to provide both these 
parameters from the same dataset.
Finally, it has been shown that patients with the LV lead positioned outside the region of 
latest mechanical activation had less benefit from CRT, as compared to patients with the lead 
positioned in the area of latest activation.35 More recently, Ypenburg et al.36 have reported 
on the outcome of patients undergoing CRT with the LV lead positioned at or outside the 
region of latest mechanical activation and demonstrated that long-term survival was better 
when the LV pacing lead was positioned at the site of latest mechanical activation.
Limitations
The current study should be considered as a feasibility study, validating a new algorithm on 
phase analysis with QGS. As indicated above, patients with extensive scar tissue in the left 
ventricle benefit less from CRT. In addition, patients with the LV pacing lead located outside 
the region of latest mechanical activation will have a less favorable response to CRT. In the 
current study, only the number of cardiac segments with a perfusion defect was integrated, 
but to provide a meaningful analysis on all these issues, a much larger study population 
is needed. Whether integration of all this information will result in superior prediction of 
response to CRT needs further testing in future studies.
Conclusion
Phase analysis on GMPS using QGS software, correlated significantly with TDI for assess-
ment of LV dyssynchrony. In addition, both phase SD and histogram bandwidth were predic-
tive of response to CRT. Larger studies are needed to confirm these findings and to explore 
the relative clinical effectiveness of GMPS and TDI in prediction of response to TDI.
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Abstract
Purpose The current study aimed to evaluate the relation between the site of latest mechani-
cal activation as assessed with gated myocardial perfusion SPECT (GMPS), left ventricular 
(LV) lead position and response to cardiac resynchronization therapy (CRT).
Methods The patient population consisted of consecutive advanced heart failure patients 
currently indicated for CRT. Before implantation, 2D echocardiography and GMPS were 
performed. 2D echocardiography was performed to assess LV end-systolic volume (LVESV), 
LV end-diastolic volume (LVEDV) and LV ejection fraction (LVEF). The site of latest mechani-
cal activation was assessed by phase analysis on GMPS and related to LV lead position 
on fluoroscopy. Echocardiography was repeated after 6 months of CRT. CRT response was 
defined as >15% decrease in LVESV.
Results Ninety patients (72% men, 67±10 yrs) with advanced heart failure were enrolled. In 
52 (58%) patients, the LV lead was positioned at the site of latest mechanical activation (con-
cordant), whereas the LV lead was positioned outside the site of latest mechanical activation 
(discordant) in 38 (42%) patients. CRT response was significantly more often documented in 
patients with concordant LV lead position than in patients with discordant LV lead position 
(79% vs. 26%, p<0.01). After 6 months, patients with concordant LV lead position showed 
significant improvement in LVEF, LVESV and LVEDV (p<0.05), whereas patients with discor-
dant LV lead position showed no significant improvement in these variables.
Conclusions Patients with concordant LV lead position showed significant improvement 
in LV volumes and LV systolic function, whereas patients with discordant LV lead position 
showed no significant improvements.
Chapter 8: Optimal LV lead position assessed with phase analysis on GMPS
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Introduction
Cardiac resynchronization therapy (CRT) represents an established therapeutic option for 
patients with drug-refractory advanced heart failure and ventricular conduction delay.1, 2 
The merits of CRT have been demonstrated for morbidity and mortality in several random-
ized clinical trials which have currently included more than 4,000 patients diagnosed with 
moderate-to-severe heart failure.3-6 Even though promising results have been reported, 
individual response to CRT varies with up to one-third of the heart failure patients showing 
no success to CRT.5, 7
Different mechanisms play an important role in the response to CRT, such as pre-existent 
mechanical dyssynchrony, location and extent of scarred myocardium and the position 
of the left ventricular (LV) pacing lead.7, 8 The region of LV pacing and the area of latest 
mechanical activation, seem to be important factors in the prediction of outcome to CRT.9-14 
To date, the LV pacing lead is usually positioned in the lateral or posterolateral vein of the 
coronary sinus, since the largest hemodynamic response was observed when pacing the 
free lateral wall.9 However, recent studies have also demonstrated that the region of latest 
mechanical activation may vary significantly in patients eligible for CRT.10, 14-16 Previous 
studies using echocardiography have reported that patients with the LV lead positioned 
at the site of latest mechanical activation (concordant LV lead) showed superior response 
to CRT when compared to patients with the LV lead positioned outside the area of latest 
mechanical activation (discordant LV lead).10, 14-16
Phase analysis on gated myocardial perfusion single photon emission computed tomog-
raphy (SPECT) (GMPS) has been developed to evaluate the presence and extent of mechani-
cal dyssynchrony using an automatic and standardized approach.17, 18 Recent developments 
have resulted in an integrated evaluation of mechanical dyssynchrony, regional mechanical 
activation pattern and the site of latest mechanical activation using the same SPECT data 
set. Hence, GMPS with phase analysis may provide important information for assessment of 
optimal LV lead position in patients referred for CRT. Currently, no study has been performed 
evaluating the use of GMPS to assess the preferred LV lead position. Moreover, the relation 
between the site of latest mechanical activation as derived from GMPS, LV lead position and 
CRT response is unknown. Accordingly, the current study sought to evaluate the feasibility of 
GMPS to assess the preferred LV lead position. In addition, the study aimed to evaluate the 
relation between the site of latest mechanical activation, LV lead position and CRT response 
in patients with CRT.
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Materials and Methods
Patient Population and Protocol
Patients with advanced drug-refractory heart failure (New York Heart Association (NYHA) 
functional class III-IV), reduced LV systolic function (left ventricular ejection fraction (LVEF) 
≤35%), prolonged QRS interval (≥120 ms) and sinus rhythm were consecutively included 
for implantation of a CRT device.1, 2 Patients with decompensated heart failure, recent 
myocardial infarction (within 3 months of CRT device implantation) or who died during 
6-months follow-up were excluded. Ischemic cardiomyopathy was defined as the presence 
of ≥50% stenosis in one or more of the major epicardial coronary arteries and/or previous 
myocardial infarction or percutaneous coronary intervention.
Prior to CRT device implantation, resting GMPS with 99mtechnetium tetrofosmin and 
transthoracic 2D echocardiography were performed in all patients. Clinical status was 
evaluated by assessment of NYHA functional class. Resting myocardial perfusion imaging 
was performed to assess the presence and extent of myocardial infarction, whereas phase 
analyses of GMPS studies was used to assess the site of latest mechanical activation. Rest-
ing transthoracic 2D echocardiography was performed to measure LVEF and LV volumes. 
Additionally, speckle tracking radial strain analysis on 2D echocardiography was performed 
in a subset of 50 patients to validate the assessment of the site of latest mechanical activation 
as derived from GMPS.
After 6 months of CRT, assessment of clinical status and resting 2D transthoracic echo-
cardiography were repeated. Patients with a decrease of >15% in LV end-systolic volume 
(LVESV) were classified as responders to CRT, whereas patients with a <15% decrease in 
LVESV were classified as non-responders to CRT.19 Consecutively, the relation between 
the site of latest mechanical activation on GMPS, LV lead position and CRT response was 
evaluated.
Gated Myocardial Perfusion SPECT: Acquisition
GMPS with 99mtechnetium tetrofosmin (500 MBq, MYOVIEW, General Electric Healthcare, 
United Kingdom) was performed at rest using a triple-head SPECT camera system (GCA 
9300/HG; Toshiba Corporation, Tokyo, Japan) equipped with low-energy high-resolution 
collimators. A 20% window was used around the 140-KeV energy peak of 99mtechnetium 
tetrofosmin and 90 projections (step and shoot method, 35 s/projection, 64 x 64 matrix, 
total imaging time 23 minutes) were obtained over a 360° circular orbit. Acquisition 
involved 16 frames per cardiac cycle. Data were reconstructed by filtered back projec-
tion and reoriented into long- and short-axis projections perpendicular to the heart axis.20 
The short-axis slices were displayed in polar map format and they were normalized for 
maximal myocardial activity (100%). No attenuation correction was used in this study. Two 
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experienced observers who were blinded to other study data evaluated the SPECT studies. 
Cardiac segments with <50% tracer uptake were considered as segments with a perfusion 
defect. The extent of myocardial perfusion defects (<50% tracer uptake) was expressed as 
a percentage of the myocardium. Consecutively, reoriented gated short-axis images were 
submitted to the Emory Cardiac Toolbox (Emory University, Atlanta, Georgia, USA) for phase 
analysis processing. Phase analysis measurements were performed at the Emory University 
(blinded to echocardiographic and clinical data).
Phase Analysis
Phase analysis on GMPS was used to obtain the site of latest mechanical activation. Phase 
analysis of GMPS studies is based on the partial-volume effect wherein alterations in 
regional maximum counts are relative to myocardial wall thickening.21, 22 A 3D sampling 
algorithm is used to determine regional maximal counts per cardiac frame and is used to 
generate count-based wall thickening curves by approximation of first Fourier harmonics 
(FFH) function. The phase angle represents the onset of mechanical activation per segment. 
The distribution of phase angles within the LV can be displayed in polar map or histo-
gram format and provides quantitative parameters of global LV dyssynchrony; histogram 
bandwidth (includes 95% of the phase angles) and phase standard deviation (SD) (standard 
deviation of phase distribution).17, 18 In addition, phase analysis provides information on 
regional mechanical activation. For the current study, the area of latest mechanical activa-
tion was determined on GMPS studies using the 6-segment model (septal, anteroseptal, 
anterior, lateral, posterior and inferior).23 Regions of interests (ROI) corresponding to the 
6-segment model were automatically placed on the phase polar map as shown in Figure 1. 
Each ROI covered 45° and 6 short-axis slices starting from the middle slice toward the base. 
As the 3D sampling algorithm collected one sample for every 9°, each ROI contains 5 x 6 
= 30 samples. The mean phases of the 6 segments were calculated by averaging the phases 
of their 30 samples and then compared. The latest mechanically activated segment had the 
largest phase angles.
The intra- and interobserver reproducibility of phase analysis for assessment of the site of 
latest mechanical activation was determined in a subset of 30 patients, randomly selected 
from the patient population.
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Resting Transthoracic Echocardiography: Acquisition
Echocardiographic images were obtained with a commercially available system (Vivid 
Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA) in patients lying in left 
lateral decubitus position. With a 3.5 MHz transducer data acquisition was performed at a 
depth of 16 cm in the parasternal and apical views (standard long- and short-axis, 2- and 
4-chamber images). Conventional 2D images were obtained during breath hold and saved 
in cine-loop format from three consecutive beats for offline analysis (Echopac version 7.0.0, 
General Electric-Vingmed, Milwaukee, Wisconsin, USA). From apical 2- and 4-chamber 
views, LVESV and LV end-diastolic volume (LVEDV) along with LVEF were measured using 
the biplane Simpson’s approach.24 Semi-quantitative assessment of mitral regurgitation was 
performed from color-flow Doppler images using the apical 4-chamber views. The severity 
was scored according to the following scale: (1) mild jet (area/left atrial area <20%), (2) 
moderate (jet area/left atrial area 20-45%) and (3) severe (jet area/left atrial area >45%).25
In 50 patients, the site of latest mechanical activation was assessed using 2D speckle 
tracking radial strain analysis on baseline mid-ventricular short-axis images. Images were 
recorded at a frame rate of at least 30 frames/sec and time-frame curves were generated for 
6 cardiac segments (Echopac version 7.0.0, General Electric-Vingmed, Milwaukee, Wiscon-
sin, USA) similar as for GMPS studies. Finally, the time between QRS onset and peak radial 
strain of the cardiac segments was used to assess the site of latest mechanical activation.23
Figure 1 The site of latest mechanical activation was assessed on gated myocardial perfusion 
single photon emission computed tomography (SPECT) (GMPS) (panel B) and related to the left 
ventricular (LV) lead position on fluoroscopy (panel A).
A. Panel A shows an example of a patient with the LV lead positioned in the lateral cardiac region.
B. The region of latest mechanical activation was automatically calculated using phase analysis on 
GMPS. The region of latest mechanical activation was located on the phase polar map using the 
6-segment model.23
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CRT Implantation
All leads were placed via the subclavian route and the right atrial and ventricular lead were 
placed conventionally.26 With the use of a balloon catheter, a sinus venogram was obtained 
after occlusion of the coronary sinus. Subsequently, the LV pacing lead was inserted with an 
8 Fr guiding catheter in the coronary sinus, preferably in the lateral or posterolateral vein. 
The positioning of the LV pacing lead was performed by an electrophysiologist who was 
blinded to other data. The V-V interval was not adjusted during the first 6 months of CRT.
LV Lead Position and the Site of Latest Activation
LV lead positions were determined by an independent observer who was blinded to other 
data. The LV lead position was assessed on biplane fluoroscopy (which was obtained during 
implantation procedure) using the left anterior oblique (LAO 60˚) and right anterior oblique 
(RAO 30˚) view. For this analysis, LV pacing leads that were positioned in the basal or midre-
gion of the LV were included and LV leads positioned at the cardiac apex were excluded 
from further analysis. Using the 6-segment model23, the LV lead positions were scored as 
anterior, lateral, posterior or inferior. Subsequently, the LV lead positions were related to the 
area of latest activation (6-segment model) as assessed with GMPS using phase analysis.
The LV lead position was considered concordant if the LV lead was positioned at the area 
of latest activation, whereas the LV lead position was considered discordant if the LV lead 
was positioned outside the area of latest activation.
Intra- and interobserver reproducibility for assessment of LV lead position was evaluated 
in a randomly selected subset of 30 patients. To assess intraobserver reproducibility, the 
position of the LV lead on biplane fluoroscopy was assessed twice by the same observer. To 
assess interobserver reproducibility, a second blinded observer assessed the LV lead position 
on biplane fluoroscopy.
Statistical Analysis
Continuous data are presented as mean ± standard deviation and categorical data are pre-
sented as numbers and percentages. Differences in baseline characteristics between patients 
with concordant or discordant LV lead positions were studied with the unpaired Student’s t 
test (continuous data) and Chi-square or Fisher exact tests (categorical data). During follow-
up, changes in continuous data were studied using the paired Student’s t test for both study 
groups. Agreement between GMPS with phase analysis and 2D speckle tracking radial 
strain analysis for assessment of the site of latest mechanical activation was evaluated using 
Cohen’s Kappa statistics, and k values were qualified as poor (<0.40), moderate (0.40-0.75) 
or good (>0.75) agreement. In addition, Cohen’s Kappa statistics were used to evaluate intra- 
and interobserver reproducibility for assessment of the site of latest mechanical activation 
using phase analysis in a subset of 30 randomly selected patients. Similarly, Cohen’s Kappa 
statistics were used to evaluate the intra- and interobserver reproducibility for assessment 
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of the LV lead position on biplane fluoroscopy in 30 randomly selected patients. All tests 
were two-sided and for all analyses a p-value <0.05 was considered statistically significant. 




A total of 95 consecutive patients were derived from our ongoing clinical heart failure regis-
try, of which 50 patients were part of previous work. Five patients were excluded because of 
apical LV lead position (n=3) or cardiac death during 6-months follow-up (n=2). The baseline 
characteristics of 90 heart failure patients (72% men, mean age 67±10 yrs) are listed in Table 
1. The mean NYHA functional class was 3.0±0.4. Sixty-two (69%) patients were diagnosed 
with ischemic cardiomyopathy, whereas 28 (31%) patients had non-ischemic cardiomyopa-
thy. Patients showed reduced LV systolic function, with a mean LVEF of 26±8%. The extent 
of myocardial perfusion defect was 26±16% on average. Medication consisted of diuretics 
(90% of patients), angiotensin-converting enzyme (ACE) inhibitors or angiotensin (AT) II 
antagonists (88% of patients) and beta-blockers (69% of patients).
GMPS with Phase Analysis and LV Lead Position
The mean value of histogram bandwidth and phase SD was 139±77˚ and 41±21˚. The 
region of latest mechanical activation as assessed with GMPS was located in the posterior 
(42.2%), lateral (23.3%), inferior (13.3%), anterior (15.6%), anteroseptal (3%) or septal 
(2.3%) region. Furthermore, a good agreement was found between GMPS and 2D speckle 
tracking radial strain analysis for assessment of the site of latest mechanical activation (total 
agreement of 86%, k value=0.79). A good intraobserver (k=0.96, total agreement of 93%) 
and interobserver (k=0.92, total agreement of 87%) reproducibility of phase analysis was 
observed for assessment of the site of latest mechanical activation. CRT device and LV lead 
implantation were successful in all patients without major complications. The LV pacing 
lead was positioned in the lateral (44.4% of patients), posterior (50.0% of patients) or ante-
rior (5.6% of patients) region. A good intraobserver (k=0.82, total agreement of 90%) and 
interobserver (k=0.76, total agreement of 87%) reproducibility for assessment of LV lead 
position on fluoroscopy was observed. 
Fifty-two (58%) patients showed a concordant LV lead position and 38 (42%) patients 
showed a discordant LV lead position, as shown in Table 2. No significant differences were 
observed for demographic, clinical and echocardiographic variables between patients 
with concordant or discordant LV lead position. In addition, no difference was found for 
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histogram bandwidth and phase SD between both groups. Patients with concordant and 
discordant LV lead position showed no significant difference in perfusion defects located in 
the LV pacing region (13% vs. 26%, p=NS). Additionally, no difference was found between 
patients with concordant and discordant LV lead position in the extent of myocardial per-
fusion defects (22.9±14.1% vs. 29.3±18.1%, p=NS). The extent of myocardial perfusion 
defects was significantly smaller in patients with CRT response as compared to patients 
without CRT response (21.1±12.3% vs. 31.6±18.7%, p<0.05). Furthermore, the percent-
age CRT responders was significantly higher in patients with concordant LV lead position 
when compared to patients with discordant LV lead position (79% vs. 26%, p<0.01). Patient 
examples with a concordant and discordant LV lead position are shown in Figure 2. Of note, 
11 patients with concordant LV lead position showed no response to CRT after 6 months. In 
these patients, 7 patients showed severe perfusion defects at the region of LV pacing.
Table 1. Baseline characteristics of the patient population (n=90)
Age (yrs) 67±10
Male 65 (72)
Ischemic heart failure 62 (69)
NYHA functional class 3.0±0.4






Perfusion defect in LV pacing region 17 (19)
Extent of perfusion defect (%) 26±16
Histogram bandwidth (°) 139±77
Phase SD (°) 41±21
Medication
Diuretics 81 (90)




Data are presented as mean ± standard deviation or as number (%). 
NYHA = New York Heart Association; LVEDV = left ventricular end-diastolic volume; LVESV = left 
ventricular end-systolic volume; LVEF = left ventricular ejection fraction; GMPS = gated myocardial 
perfusion single photon emission computed tomography; SD = standard deviation; ACE = angiotensin-
converting enzyme; AT II = angiotensin II.
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Table 2. Baseline characteristics between patients with concordant and discordant LV lead 
positions
Baseline characteristics Concordant LV lead 
position (n=52)
Discordant LV lead 
position (n=38)
p-value
Age (yrs) 68±10 66±11 0.5
Gender (male) 37 (71) 28 (74) 0.8
Ischemic heart failure 38 (73) 24 (63) 0.4
NYHA functional class 3.0±0.4 3.0±0.4 1.0
QRS duration (ms) 168±35 153±33 0.1
LVEDV (mL) 214±67 213±62 1.0
LVESV (mL) 160±57 161±57 0.9
LVEF (%) 27±8 26±8 0.7
Mitral regurgitation (moderate/
severe)
19 (37) 19 (50) 0.2
Histogram bandwidth (°) 126±67 157±86 0.1
Phase SD (°) 38±20 45±21 0.1
Perfusion defect LV pacing region 7 (13) 10 (26) 0.2
Extent perfusion defect (%) 23±14 29±18 0.1
CRT response after 6 months 41 (79) 10 (26) <0.01
Data are presented as mean ± standard deviation or as number (%). 
NYHA = New York Heart Association; LVEDV = left ventricular end-diastolic volume; LVESV = left 
ventricular end-systolic volume; LVEF = left ventricular ejection fraction; SD = standard deviation; 
CRT = cardiac resynchronization therapy.
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Baseline and 6-months Follow-up
The total patient population showed a significant improvement in NYHA functional class 
from 3.0±0.4 to 2.5±0.7 (p<0.05). In addition, patients showed a significant improvement 
in echocardiographic variables, including LVESV (160±57 mL vs. 137±55 mL, p<0.05), 
LVEDV (214±64 mL vs. 197±64 mL, p<0.05) and LVEF (26±8% vs. 32±11%, p<0.05). After 
6 months of CRT, patients with a concordant LV lead position showed significant improve-
ment in LVESV (159±57 mL vs. 125±54 mL, p<0.05), LVEDV (214±67 mL vs. 188±62 mL, 
p<0.05) and LVEF (27±8% vs. 35±12%, p<0.05), as illustrated in Figure 3. Additionally, 
an improvement in NYHA functional class was observed in patients with a concordant LV 
lead position (3.0±0.4 vs. 2.3±0.7, p<0.05). However, patients with the LV lead positioned 
outside the region of latest mechanical activation (discordant LV lead position) showed no 
improvement in NYHA functional class (3.0±0.4 vs. 2.7±0.7, p=NS). In addition, LVESV 
Figure 2 Area of latest mechanical activation as assessed with phase analysis on gated myocardial 
perfusion single photon emission computed tomography (SPECT) (GMPS).
A. Example of a patient with the left ventricular (LV) lead positioned at the area of latest activation 
(concordant LV lead position). The area of latest activation was located in the lateral segment. The 
patient showed a significant improvement in LV end-systolic volume (LVESV) (139 mL vs. 86 mL) 
and LV ejection fraction (LVEF) (32% vs. 44%) after 6 months of cardiac resynchronization therapy 
(CRT).
B. Example of a patient with the LV lead positioned outside the area of latest activation (discordant 
LV lead position). The area of latest activation was located in the anterior segment, whereas the LV 
lead was positioned in the posterior segment. The patient showed no improvement in LVESV (124 
mL vs. 153 mL) and LVEF (27% vs. 22%) after 6 months of CRT.
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(161±57 mL vs. 153±53 mL, p=NS), LVEDV (213±62 mL vs. 210±65 mL, p=NS) and LVEF 
(26±8% vs. 28±9%, p=NS) showed no significant improvement after 6 months of CRT in 
patients with a discordant LV lead position, as depicted in Figure 3.
Discussion
The main findings of the current study can be summarized as follows: patients with con-
cordant LV lead position showed significant LV reverse remodeling and improvement in LV 
systolic function, whereas patients with discordant LV lead position showed no significant 
improvements. Accordingly, GMPS with phase analysis represents a feasible technique to 
identify the preferred LV lead position in patients referred for CRT.
Resynchronization therapy is based on the rationale to improve the intrinsic electrical 
ventricular conductance by pacing the ventricles in a synchronized manner.1, 2 To optimize 
synchronicity of the LV contraction, the LV pacing lead should be targeted at the region of 
latest mechanical activation.9-13 In this perspective, it is important to note that the region 
of latest mechanical activation may vary significantly in heart failure patients, with the pos-
terolateral region as the most common site of latest activation.10,14-16 The study by Becker 
et al.16, who sought to determine the effect of LV lead position on reverse remodeling and 
A B
Figure 3 Response to cardiac resynchronization therapy (CRT) in patients with concordant (n=52) 
and discordant (n=38) left ventricular (LV) lead positions. Baseline (white bars) and 6 months follow-
up (black bars) echocardiographic measurements are depicted below.
A. Patients with concordant LV lead position showed significant improvement in LV ejection 
fraction (LVEF) (27±8% vs. 35±12%, p<0.05), whereas patients with discordant LV lead position 
showed no significant improvement in LVEF (26±8% vs. 28±9%, p=NS).
B. Patients with concordant LV lead position showed significant improvement in LV end-systolic 
volume (LVESV) (159±57 mL vs. 125±54 mL, p<0.05), whereas patients with discordant LV lead 
position showed no significant improvement in LVESV (161±57 mL vs. 153±53 mL, p=NS).
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LV function as assessed with echocardiography, has shown that the site of latest mechanical 
activation differed significantly among 47 heart failure patients. The site of latest mechani-
cal activation was predominantly located in the posterolateral region of the ventricle (60% 
of patients). Likewise, the current study showed that the posterolateral cardiac segments 
represented the most common site of latest mechanical activation (66% of patients).
Additionally, the relation between LV lead position, the site of mechanical delay and 
CRT outcome has been evaluated in several studies.9-16 An important study was performed 
by Becker et al.16 who evaluated the efficacy of CRT in patients with optimal (n=28) or 
suboptimal (n=19) LV lead position. The position of the LV lead was considered optimal if 
the LV lead was concordant with the cardiac segment showing the latest mechanical con-
traction (≤1 segment between the LV pacing region and the segment with latest mechanical 
activation). Circumferential strain analysis on echocardiography was used to assess the 
site of delayed mechanical activation. After 10 months follow-up, patients with an optimal 
LV lead position showed a significantly larger decrease in LVESV and LVEDV as well as a 
significant improvement in LVEF, as compared to patients with suboptimal LV lead position 
(all, p<0.01).
Recently, Ypenburg et al.14 have evaluated 6-month echocardiograhic response to CRT 
as well as long-term outcome in patients with concordant (n=153) and discordant (n=91) 
LV lead position. Speckle tracking radial strain analysis on 2D echocardiography was used 
to determine the region of latest mechanical delay. After 6 months of CRT, patients with 
concordant LV lead position showed a significant decrease in LV volumes as well as a 
significant improvement in LVEF as compared to patients with discordant LV lead position 
(all, p<0.01). Importantly, a concordant LV lead position was an independent predictor of 
combined endpoint of hospitalization and all-cause mortality. Similarly, the current study 
has demonstrated that patients with concordant LV lead position showed superior improve-
ment in LVEF after 6 months of CRT (27±8% vs. 35±12%, p<0.05) when compared to 
patients with discordant LV lead position (26±8% vs. 28±9%, p=NS). Additionally, consider-
able reverse remodeling, as reflected by a significant decrease in LVESV and LVEDV, was 
observed in patients with the LV lead positioned at the site of latest activation as derived 
from GMPS with phase analysis. The findings demonstrate that CRT response is related to 
LV lead position and the region of latest mechanical contraction. More specifically, these 
observations support the hypothesis that resynchronization of the LV, induced by pacing at 
the region of latest mechanical activation, exerts positive effects on ventricular geometry 
and function.
Of interest, a small number of patients with the LV lead placed outside the region of latest 
activation responded positively to CRT. In these patients, the distance between the region 
of latest activation and the LV lead position (as reflected by the number of cardiac segments 
in between) was minimal (≤2 cardiac segments). As a consequence, the contraction pattern 
may have become less dyssynchronous in these patients. Additionally, 11 (21%) patients did 
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not show CRT response despite the fact that the LV lead was positioned at the latest activated 
area. This observation may be explained by the fact that extensive perfusion defects were 
located at or near the site of latest mechanical activation in this subset of patients. It has 
been demonstrated that the extent and location of scarred myocardium play an important 
role in CRT response.26-28 Bleeker et al.26 have performed an important study evaluating 
the effect of posterolateral scar tissue on CRT response in 40 consecutive advanced heart 
failure patients. The study has shown that patients with posterolateral scar tissue on mag-
netic resonance imaging showed a significantly lower response rate as compared to patients 
without posterolateral scar tissue (14% vs. 81%, p<0.05). Similarly, the current study has 
demonstrated that severe perfusion defects at or adjacent to the region of latest mechanical 
activation were associated with non-response to CRT. Patients with a concordant LV lead 
position but with severe perfusion defects at the region of LV pacing showed no response to 
CRT. Furthermore, the study has shown that the extent of myocardial perfusion defects was 
significantly smaller in patients with response to CRT as compared to patients without CRT 
response. Accordingly, location and extent of scarred myocardium play an important role in 
the likelihood of response to CRT.
At present, non-response to CRT has been associated with the absence of pre-existent 
mechanical dyssynchrony, location and extent of scarred myocardium (particularly at LV 
pacing region) and suboptimal LV lead position.7, 8, 26-28 For this reason, phase analysis 
on GMPS has gained increasingly interest for the evaluation of CRT patients as it allows 
an integrated evaluation of mechanical dyssynchrony, regional activation pattern and 
myocardial infarction.17, 18 More specifically, the presence of infarcted myocardium at or 
adjacent to the region of maximal mechanical delay can be evaluated using the SPECT data 
sets. Accordingly, phase analysis on GMPS represents a feasible technique to identify the 
preferred LV lead position.
At present, different non-invasive imaging techniques are available for the evaluation of 
patients referred for CRT, including echocardiography, magnetic resonance imaging as well 
as nuclear imaging. A comprehensive evaluation of CRT patients can be performed by each 
of these imaging techniques as they provide information on pre-existent LV mechanical 
dyssynchrony, presence and location of myocardial infarction as well as the site of latest 
mechanical activation. As they all provide useful information, the choice for one of these 
techniques is eventually determined by the local expertise and availability.
Some study limitations need to be acknowledged. First of all, the study findings are 
based on a relatively small number of patients who were referred for CRT. The current study 
however, represents only a feasibility study evaluating the role of phase analysis on GMPS 
for assessment of optimal LV lead position in advanced heart failure patients. The novelty of 
the present study relates to the evaluation of CRT response in patients with concordant and 
discordant LV lead position as assessed with phase analysis on GMPS. A second limitation 
is the fact that long-term effects of resynchronization therapy on mortality and/or morbidity 
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rates were not reported in the current study as the patient population was too small for 
long-term outcome analysis.
Conclusion
Patients with concordant LV lead position showed significant improvements in LV volumes 
and LV systolic function, whereas patients with discordant LV lead position showed no 
significant improvement in LV volumes and LV systolic function. Accordingly, phase analysis 
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Purpose The current study aimed to evaluate the feasibility of phase analysis on gated 
myocardial perfusion SPECT (GMPS) for assessment of left ventricular (LV) diastolic dys-
synchrony in a head-to-head comparison with tissue Doppler imaging (TDI).
Methods The patient population consisted of end-stage heart failure (HF) patients (New 
York Heart Association (NYHA) functional class III or IV) with reduced LV ejection fraction 
(LVEF) ≤35%. LV diastolic dyssynchrony was calculated using TDI as the maximal time delay 
between early peak diastolic velocities of 2 opposing LV walls (diastolic mechanical delay). 
Significant LV diastolic dyssynchrony was defined as a diastolic mechanical delay of >55 
ms on TDI. Furthermore, phase analysis on GMPS was performed to evaluate LV diastolic 
dyssynchrony; diastolic phase standard deviation (SD) and histogram bandwidth (HBW) 
were used as markers of LV diastolic dyssynchrony.
Results A total of 150 (114 men, mean age 66.0±10.4 yrs) patients with end-stage HF were 
enrolled. Both diastolic phase SD (r=0.81, p<0.01) and diastolic HBW (r=0.75, p<0.01) 
showed good correlations with LV diastolic dyssynchrony on TDI. Additionally, patients 
with LV diastolic dyssynchrony on TDI (>55 ms) showed significantly larger diastolic phase 
SD (68.1±13.4˚ vs. 40.7±14.0˚, p<0.01) and diastolic HBW (230.6±54.3˚ vs. 129.0±55.6˚, 
p<0.01) as compared to patients without LV diastolic dyssynchrony on TDI (≤55 ms). Finally, 
phase analysis on GMPS showed a good intra- and interobserver reproducibility for diastolic 
phase SD (ICC 0.97 and 0.88) and diastolic HBW (ICC 0.98 and 0.93).
Conclusions Phase analysis on GMPS showed good correlations with TDI for assessment of 
LV diastolic dyssynchrony.
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Introduction
Left ventricular (LV) systolic dyssynchrony is considered an important pathophysiologic 
condition in patients with heart failure (HF).1, 2 In addition, it has been shown that a dys-
synchronous relaxation pattern of the LV, which is commonly referred to as LV diastolic 
dyssynchrony, plays an important role in patients with HF.3-5 In these patients, LV diastolic 
dyssynchrony has been related to abnormalities in LV diastolic filling and LV filling rate, 
which may contribute to a further impairment of the hemodynamics of the failing heart.5 
Importantly, it has been recognized that LV diastolic dyssynchrony is a common pathophysi-
ologic condition in HF patients with an estimated prevalence of more than 50%.3, 6
At present, the majority of available studies have used echocardiography for the assess-
ment of LV diastolic dyssynchrony in patients with HF.3, 4, 6-8 Among the echocardiographic 
techniques, tissue Doppler imaging (TDI) has been used predominantly for the evaluation of 
diastolic relaxation patterns of the LV.6-8 Although TDI represents an accurate approach for 
the assessment of LV diastolic dyssynchrony, the post-processing of Doppler images requires 
special expertise and standardized protocols to optimize the interobserver variability.
Phase on gated myocardial perfusion single photon emission computed tomography 
(SPECT) (GMPS) has emerged as a practical technique for assessment of LV mechanical 
dyssynchrony as it automatically provides robust and reproducible indices of mechanical 
dyssynchrony.9, 10 Moreover, phase analysis can be performed on conventional GMPS 
studies without the use of additional image acquisitions. Although studies have shown that 
phase analysis on GMPS can be used for assessment of LV systolic dyssynchrony, its feasibil-
ity to assess LV diastolic dyssynchrony has not been demonstrated. Accordingly, the current 
study aimed to demonstrate the feasibility of phase analysis on GMPS for assessment of LV 
diastolic dyssynchrony in a head-to-head comparison with TDI.
Material and Methods
Patient Population and Protocol
The patient population consisted of end-stage HF patients (New York Heart Association 
(NYHA) functional class III or IV) with depressed LV ejection fraction (LVEF) ≤35%.  Patient 
data were prospectively collected in the departmental Cardiology Information System (EPD-
Vision®, Leiden University Medical Center (LUMC), Leiden, the Netherlands) and retrospec-
tively analyzed. All patients were treated according to the MISSION! - Heart Failure care 
track operational at the LUMC. All patients were stable on maximum tolerated doses of heart 
failure medications. Patients with recent myocardial infarction (within 3 months prior to 
GMPS), atrial fibrillation, decompensated HF or acute coronary syndrome were excluded. 
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Patients were diagnosed with ischemic cardiomyopathy in the presence of ≥50% stenosis 
in one or more of the major epicardial coronary arteries, previous myocardial infarction, 
percutaneous coronary intervention or coronary artery bypass grafting.
Resting GMPS and 2D echocardiography with TDI were performed as part of the clinical 
evaluation of HF patients to determine therapeutic options. A standard 12-lead electrocar-
diogram (ECG) was obtained prior to GMPS. GMPS and TDI were compared for assessment 
of LV diastolic dyssynchrony. TDI was considered the standard of reference for evaluation of 
LV diastolic dyssynchrony, which was calculated as the maximal time delay between early 
peak diastolic velocities of 2 opposing LV walls. As previously reported, a cutoff value of 
55 ms of diastolic mechanical delay on TDI was used as a marker of significant LV diastolic 
dyssynchrony.6
Phase analysis on GMPS was used to evaluate LV diastolic dyssynchrony and systolic dys-
synchrony. Both diastolic phase histogram bandwidth (HBW) and diastolic phase standard 
deviation (SD) as derived from the onset of mechanical relaxation (OMR) distribution were 
used as markers of LV diastolic dyssynchrony, whereas systolic HBW and systolic phase SD 
were used as markers of LV systolic dyssynchrony, as previously described.11 Consecutively, 
TDI and phase analysis on GMPS were compared for assessment of LV diastolic dyssyn-
chrony. Additionally, the extent of LV diastolic dyssynchrony on GMPS was evaluated in 
patients with (>55 ms) and without (≤55 ms) significant LV diastolic dyssynchrony on TDI. 
Finally, the relation between LV diastolic and systolic dyssynchrony as assessed with GMPS 
was evaluated.
Gated Myocardial Perfusion SPECT: Acquisition
Resting GMPS with 99mtechnetium tetrofosmin was performed on a triple-head SPECT 
camera (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan) equipped with low-energy 
high-resolution collimators. At rest, an average dose of 500 MBq of 99mtechnetium tetrofos-
min (MYOVIEW, General Electric Healthcare, UK) was administered intravenously. A 20% 
window was centered around the 140-KeV energy peak of 99mtechnetium tetrofosmin. A 
total of 90 projections (step and shoot method, 35 s/projection, 64 x 64 matrix, total imaging 
time 23 minutes) were obtained over a 360° circular orbit. ECG gating was applied on the 
cardiac cycle with 16 frames per cardiac cycle using a tolerance window of 50%.
Subsequently, the raw data were uploaded to the Emory Cardiac Toolbox (Emory Univer-
sity, Atlanta, Georgia, USA) for data reconstruction, reorientation and phase analysis pro-
cessing. All patient studies were reconstructed by ordered subsets expectation maximization 
(OSEM) with 3 iterations and 10 subsets. A Butterworth filter with a cutoff frequency of 0.35 
cycles/cm and a power of 10 was used to filter the gated images. The reconstructed images 
were thereafter reoriented manually with assistance of the automatic reorientation tool in 
the Emory Reconstruction Toolbox (Emory University, Atlanta, Georgia, USA) to generate 
gated short-axis images. The gated short-axis images were sampled for regional maximum 
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counts using the Emory Cardiac Toolbox (Emory University, Atlanta, Georgia, USA) and then 
submitted to the multi-harmonic phase analysis tool. Finally, phase analysis processing was 
performed blinded at Emory University.
Phase Analysis on GMPS
Phase analysis of GMPS studies was performed to derive LV diastolic and systolic dyssyn-
chrony. LV diastolic dyssynchrony was assessed using phase analysis which consisted of 
several consecutive processing steps, as illustrated in Figure 1. Initially, regional maximal 
count detection was performed in 3D for each temporal frame using the standard gated 
Figure 1 Schematic illustration of the processing steps involved in the assessment of diastolic 
dyssynchrony using phase analysis of gated myocardial perfusion single photon emission 
computed tomography (SPECT) (GMPS) studies. For each temporal frame, a regional maximal 
count detection was performed in 3D using the standard gated short-axis SPECT images. 
Consecutively, the third Fourier harmonic function was used to approximate the discrete sample 
points into a continuous wall-thickening curve. The wall-thickening curve provided a phase angle 
that represented the onset of mechanical relaxation (OMR) of the region (>600 regions for the 
entire left ventricle (LV)). The OMR phase angles of all LV regions were used to generate a phase 
distribution, which was displayed in a polar map and histogram. The phase histogram was used 
to obtain the LV diastolic dyssynchrony indices; diastolic phase standard deviation (SD) (SD of the 
OMR phase distribution) and diastolic histogram bandwidth (HBW) (the width of the band that 
includes 95% of the OMR phase angles).
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short-axis SPECT image. Phase analysis processing was based on the partial-volume effect 
wherein alterations in regional maximal counts are proportional to changes in regional 
myocardial wall thickening over the cardiac cycle.12, 13 This linear relationship was demon-
strated in a phantom study.13 Consecutively, the third Fourier harmonic function was used 
to approximate the discrete sample points into a continuous wall-thickening curve. For each 
region, the wall-thickening curve provided a phase angle that represented the OMR of the 
particular region. The OMR phase is the time point when the curves crossed the middle line 
from positive to negative. Once the OMR phase angles of all regions (>600 regions over the 
entire LV) were obtained, a phase distribution was generated that provided information on 
the degree of diastolic dyssynchrony for the entire LV. The phase distribution was displayed 
in a polar map and histogram as shown in Figure 1. The quantitative parameters for LV 
diastolic dyssynchrony were derived from the phase histogram; diastolic phase SD (SD of 
the OMR phase distribution) and diastolic HBW (the width of the band that includes 95% of 
the OMR phase angles), similar to as LV systolic dyssynchrony indices.11
Additionally, LV systolic dyssynchrony was evaluated measuring the systolic phase SD 
and systolic HBW.11 As previously described11, the onset of mechanical contraction per 
cardiac region was measured using count-based wall-thickening curves which were derived 
from alternations in myocardial counts during the cardiac cycle. Each myocardial segment 
yielded a phase angle representing the onset of mechanical contraction for that particular 
segment of the myocardium. Finally, the phase angles of the entire LV (exceeding 600 per 
LV) were plotted in a polar map and histogram, wherein the phase histogram was used to 
calculate systolic phase SD and systolic HBW as markers of LV systolic dyssynchrony.11
Furthermore, the intra- and interobserver reproducibility of phase analysis for assessment 
of diastolic phase SD and diastolic HBW was determined in a subset of 25 patients.
Transthoracic Echocardiography with Tissue Doppler Imaging
Transthoracic echocardiography was performed at rest in patients lying in left lateral 
decubitus position using a commercially available ultrasound device (M3S probe, Vivid 7, 
GE-Vingmed, Horten, Norway). With a 3.5 MHz transducer data acquisition was performed 
in the parasternal and apical views (standard long- and short-axis, 2-, 4-chamber and apical 
long-axis images). Conventional 2D images were obtained during breath hold and saved 
in cine-loop format from three consecutive beats for offline analysis (EchoPac 108.1.5, GE-
Vingmed, Horten, Norway). From apical 2- and 4-chamber views, LV end-systolic volume 
(LVESV) and LV end-diastolic volume (LVEDV) along with LVEF were measured using the 
biplane Simpson’s approach.14 Consecutively, color-coded TDI was performed to assess 
diastolic dyssynchrony of the LV, as shown in Figure 2. In each patient, color-coded TDI 
of the LV was obtained in the apical 2- and 4-chamber views during end-expiration. The 
sector size and depth were optimized for the highest possible frame rate (>115 frames/sec). 
Consecutively, a sample volume (12 x 6 mm) was positioned in the middle of the basal 
Chapter 9 : LV diastolic dyssynchrony assessed with phase analysis of GMPS: A comparison with TDI
173
Figure 2 Left ventricular (LV) diastolic dyssynchrony was assessed with color-coded tissue 
Doppler imaging (TDI). The time between the onset of the QRS complex and the peak early 
diastolic myocardial velocity (E’) of 4 different LV wall segments (anterior, lateral, inferior and 
septal) was obtained using color-coded TDI. LV dyssynchrony was calculated as the maximal time 
delay between peak early diastolic velocities of 2 opposing walls (diastolic mechanical delay). In 
this example, the diastolic mechanical delay was 70 ms between the septal and lateral LV wall 
(4-chamber view; upper panel) and 95 ms between the anterior and inferior LV wall (2-chamber 
view; lower panel).
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portion of the 4 different LV wall segments (anterior, lateral, inferior and septal) to obtain 
regional color-coded TDI velocity curves. For each region, the maximal diastolic delay was 
obtained measuring the time interval between the onset QRS complex and the peak early 
diastolic myocardial velocity (E’).7, 15 LV diastolic dyssynchrony was calculated as the time 
delay between peak early diastolic velocities of 2 opposing walls (diastolic mechanical 
delay). Significant LV diastolic dyssynchrony was defined as a diastolic mechanical delay 
of >55 ms.6 As previously reported6, the cutoff value of 55 ms was derived from the mean 
± 2 SD of the maximal diastolic delay in 38 control patients who had no history of cardio-
vascular disease. Post-processing of the TDI recordings was performed by two independent 
observers, who were blinded to the other clinical and phase analysis data.
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation as they were normally 
distributed when evaluated by Kolmogorov-Smirnov tests. Categorical data are presented as 
numbers or percentages. Phase analysis on GMPS and TDI were compared using Pearson’s 
linear regression analysis. Furthermore, patients were stratified into patients with and with-
out LV diastolic dyssynchrony using a cutoff value of 55 ms of diastolic mechanical delay on 
TDI.6 Phase SD and HBW were compared between patients with LV diastolic dyssynchrony 
(>55 ms) and without LV diastolic dyssynchrony (≤55 ms) on TDI using the Student’s t test. 
LV diastolic dyssynchrony and LV systolic dyssynchrony indices were compared using 
Pearson’s linear regression analyis. Intra- and interobserver reproducibility was evaluated 
by calculating the intraclass correlation coefficients (ICC). Excellent agreement was defined 
as an ICC of >0.8. Statistical analyses were performed with SPSS software package, version 
16.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Patient Population
A total of 150 end-stage HF patients (114 (76%) men, mean age 66.0±10.4 yrs) were included. 
Baseline characteristics of the patient population are listed in Table 1. One-hundred-one 
(67%) patients had ischemic cardiomyopathy, whereas 49 (33%) patients had non-ischemic 
cardiomyopathy. Patients showed a severely reduced LVEF (27±8%) on 2D echocardiogra-
phy. Medication consisted of diuretics (87% of patients), angiotensin-converting enzyme 
inhibitor (ACE-I) or angiotensin (AT) II antagonists (91% of patients) and beta-blockers (73% 
of patients).
Chapter 9 : LV diastolic dyssynchrony assessed with phase analysis of GMPS: A comparison with TDI
175
LV Diastolic Dyssynchrony
The mean values of LV diastolic dyssynchrony indices are shown in Table 2. The patient 
population showed a mean diastolic mechanical delay of 53.4±21.4 ms on TDI. Phase 
analysis on GMPS showed a mean diastolic phase SD of 53.3±19.4˚ and diastolic HBW 
of 175.7±74.7˚. Patient examples of a patient with and without extensive LV diastolic dys-
synchrony are provided in Figure 3.
Furthermore, phase analysis on GMPS showed a good correlation with TDI for assess-
ment of LV diastolic dyssynchrony; diastolic phase SD (r=0.81, p<0.01) and diastolic HBW 
(r=0.75, p<0.01) were well-correlated with LV diastolic dyssynchrony on TDI, as illustrated 
in Figure 4.
Table 1. Baseline characteristics of the patient population (n=150)
Age (yrs) 66±10
Male gender, n (%) 114 (76)
Ischemic cardiomyopathy 101 (67)
NYHA functional class III (%) 115 (77)
LVEF (%) 27±8
QRS duration (ms) 160±32
Cardiovascular risk factors, n (%)




Family history of CAD 58 (39)
Medication, n (%)
Diuretic 131 (87)
ACE-I / ATII antagonist 137 (91)
Beta-blocker 109 (73)
Statin 99 (66)
Data are presented as mean ± standard deviation or as number (%). 
ACE-I = angiotensin converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; 
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
Table 2. Left ventricular (LV) diastolic dyssynchrony indices of the patients (n=150)
Color-coded TDI
Diastolic mechanical delay (ms) 53.4±21.4
Phase analysis on GMPS
Diastolic phase SD (˚) 53.3±19.4
Diastolic HBW (˚) 175.7±74.7
GMPS = gated myocardial perfusion single photon emission computed tomography; HBW = 
histogram bandwidth; SD = standard deviation; TDI = tissue Doppler imaging.
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Figure 3 Diastolic left ventricular (LV) dyssynchrony as assessed with phase analysis on gated 
myocardial perfusion single photon emission computed tomography (SPECT) (GMPS) and 2D 
echocardiography with tissue Doppler imaging (TDI).
Left panel: Example of a patient with extensive LV diastolic dyssynchrony on GMPS (panel A) and 
TDI (panel B). Extensive LV diastolic dyssynchrony was reflected by a heterogeneous color-coded 
phase polar map and a broad phase histogram (panel A); diastolic phase standard deviation (SD) 
and diastolic histogram bandwidth (HBW) were respectively 90.6˚ and 312.0˚. Similarly, TDI showed 
extensive LV dyssynchrony with a diastolic mechanical delay of 60 ms (panel B).
Right panel: Example of a patient without LV diastolic dyssynchrony on GMPS (panel C) and TDI 
(panel D). Phase analysis on GMPS showed a homogeneous color-coded phase polar map and a 
narrow phase histogram (panel C); diastolic phase SD and diastolic HBW were respectively 14.2˚ 
and 46.0˚. In this patient, diastolic mechanical delay on TDI was 11 ms (panel D).
Figure 4 Phase analysis on gated myocardial perfusion single photon emission computed 
tomography (SPECT) (GMPS) was well-correlated to 2D echocardiography with tissue Doppler 
imaging (TDI) for assessment of left ventricular (LV) diastolic dyssynchrony. Diastolic phase 
standard deviation (SD) (panel A; r=0.81, p<0.01) and diastolic histogram bandwidth (HBW) (panel 
B; r=0.75, p<0.01) showed good correlations with LV diastolic dyssynchrony on TDI.
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Additionally, phase analysis on GMPS showed a good correlation with TDI for assessment 
of LV diastolic dyssynchrony in patients with non-ischemic cardiomyopathy as compared to 
patients with ischemic cardiomyopathy (diastolic phase SD; r=0.86 vs. r=0.78 and diastolic 
HBW; r=0.78 vs. r=0.73; p<0.01 for all analyses). Patients with ischemic cardiomyopa-
thy showed more extensive LV diastolic dyssynchrony, as reflected by diastolic phase SD 
(55.9±18.5˚ vs. 47.9±20.1˚, p=0.2) and diastolic HBW (185.0±72.5˚ vs. 156.6±76.3˚, 
p=0.4) than patients with non-ischemic cardiomyopathy.
In total, 69 (46%) patients showed LV diastolic dyssynchrony (diastolic mechanical 
delay >55 ms) on TDI, whereas 81 (54%) patients showed no LV diastolic dyssynchrony 
(diastolic mechanical delay ≤55 ms). Patients with LV diastolic dyssynchrony showed a 
significantly larger diastolic phase SD (68.1±13.4˚ vs. 40.7±14.0˚, p<0.01) and diastolic 
HBW (230.6±54.3˚ vs. 129.0±55.6˚, p<0.01) as compared to patients without LV diastolic 
dyssynchrony on TDI (Figure 5).
Finally, phase analysis on GMPS showed a good intra- and interobserver reproducibility 
for diastolic phase SD (ICC 0.97 and 0.88, respectively) and diastolic HBW (ICC 0.98 and 













Figure 5 The patient population was divided into patients with and without significant left 
ventricular (LV) diastolic dyssynchrony on tissue Doppler imaging (TDI) using a cutoff value of 55 
ms of diastolic mechanical delay.6 Gated myocardial perfusion single photon emission computed 
tomography (SPECT) (GMPS) with phase analysis was used to calculate diastolic phase standard 
deviation (SD) and diastolic histogram bandwidth (HBW), which were used as markers of LV 
diastolic dyssynchrony. Patients with significant LV diastolic dyssynchrony on TDI (>55 ms) (white 
bars) showed significantly higher values of diastolic phase SD (68.1±13.4˚ vs. 40.7±14.0˚, p<0.01) 
and diastolic HBW (230.6±54.3˚ vs. 129.0±55.6˚, p<0.01) as compared to patients without 
significant LV diastolic dyssynchrony on TDI (≤55 ms) (black bars).
GMPS (degrees)
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LV Diastolic Dyssynchrony and QRS Duration
QRS duration was not correlated to LV diastolic dyssynchrony as assessed with phase analy-
sis on GMPS or TDI. Diastolic phase SD (r=0.11, p=NS) and diastolic HBW (r=0.16, p=NS) 
showed no significant correlation with QRS duration. Similarly, LV diastolic dyssynchrony 
on TDI (r=0.12, p=NS) showed no significant correlation with QRS duration.
LV Diastolic Dyssynchrony and Systolic Dyssynchrony on GMPS
LV diastolic phase SD (r=0.91, p<0.01) and diastolic HBW (r=0.94, p<0.01) were well-
correlated with LV systolic SD and systolic HBW, respectively. In addition, LV diastolic 
phase SD showed a good correlation with LV systolic HBW (r=0.90, p<0.01). Finally, LV 
diastolic HBW and systolic phase SD (r=0.92, p<0.01) were well-correlated.
Discussion
The current study showed that phase analysis on GMPS was significantly correlated to 
TDI for assessment of LV diastolic dyssynchrony. Diastolic phase SD and diastolic HBW 
as derived from GMPS showed good correlations to diastolic mechanical delay on TDI. 
Accordingly, phase analysis on GMPS represents a feasible technique for evaluation of LV 
diastolic dyssynchrony in patients with HF.
Dyssynchrony of the LV contraction pattern, commonly referred to as LV systolic dys-
synchrony, is considered an important condition in patients with HF.1, 2 Previous studies 
have shown that patients with extensive LV systolic dyssynchrony are at risk for adverse 
cardiac events.1, 2 In addition, it has been suggested that LV diastolic dyssynchrony, which 
is a dyssynchronous relaxation pattern of the LV, plays an important role in patients with 
HF.3-5 In patients with HF, it is known that left bundle branch block can cause LV diastolic 
dyssynchrony and marked diastolic LV filling impairment by inducing a reduced diastolic 
filling rate, prolonged isovolumic contraction and relaxation times. As a consequence, LV 
diastolic dyssynchrony is related to abnormalities in diastolic filling pattern of the LV, which 
may further compromise the hemodynamic function of the failing heart.3, 4
At present, TDI echocardiography is a feasible method for evaluation of diastolic relax-
ation patterns of the LV.6-8 By measuring the time delays in peak diastolic velocities of LV 
segments diastolic dyssynchrony can be derived.6-8 Even though a detailed evaluation of 
LV diastolic dyssynchrony can be made with TDI, the post-processing of Doppler images 
remains observer dependent and requires substantial expertise.
Phase analysis on GMPS is another approach for evaluation of mechanical dyssyn-
chrony.16, 17 In recent years, phase analysis on GMPS has gained increasing interest as it 
provides robust and reproducible indices of mechanical dyssynchrony using an automated 
approach.9, 10 Moreover, GMPS with phase analysis provides integrated information on 
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mechanical dyssynchrony, regional mechanical activation pattern as well as myocardial 
perfusion using a single SPECT study. Thus far, several studies have shown its feasibility for 
assessment of LV systolic dyssynchrony in patients with HF.16, 17 Henneman et al.17 have 
shown that phase analysis on GMPS was well-correlated to 2D echocardiography with TDI 
for assessment of LV systolic dyssynchrony. Good correlations were found between systolic 
phase SD (r=0.80, p<0.05) or systolic HBW (r=0.89, p<0.01) and LV systolic dyssynchrony 
on TDI in 75 patients with moderate-to-severe HF. Additionally, phase analysis on GMPS 
has been compared with real-time 3-dimensional echocardiography (RT3DE) for assess-
ment of LV systolic dyssynchrony in 40 patients with severe HF.18 Both techniques showed 
a good agreement for LV systolic dyssynchrony; systolic phase SD (r=0.80, p<0.05) and 
systolic HBW (r=0.76, p<0.05) as derived from GMPS were well-correlated to LV systolic 
dyssynchrony on RT3DE. Although these studies have shown that phase analysis on GMPS 
can be used for assessment of LV systolic dyssynchrony, no study has currently evaluated 
its feasibility to assess LV diastolic dyssynchrony in patients with HF. The present study 
has shown the feasibility of phase analysis on GMPS for evaluation of LV diastolic dys-
synchrony, as reflected by good correlations between LV diastolic dyssynchrony indices on 
GMPS (phase SD and HBW) and LV diastolic dyssynchrony on TDI. Moreover, patients with 
LV diastolic dyssynchrony on TDI (diastolic mechanical delay >55 ms) showed significantly 
larger diastolic phase SD and diastolic HBW as compared to patients without LV diastolic 
dyssynchrony on TDI (diastolic mechanical delay ≤55 ms). Accordingly, phase analysis on 
GMPS represents a feasible technique for assessment of both LV diastolic and systolic dys-
synchrony in HF patients.
Furthermore, a sub-analysis was performed to evaluate whether phase analysis on GMPS 
could be used for assessment of LV diastolic dyssynchrony in patients with ischemic and 
non-ischemic cardiomyopathy. In the current study, the agreement between phase analysis 
on GMPS and TDI for measuring LV diastolic dyssynchrony was slightly reduced in patients 
with ischemic cardiomyopathy as compared to patients with non-ischemic cardiomyopathy. 
One of the potential explanations for this finding could be the fact that the presence of myo-
cardial scar tissue may have influenced the comparison between both techniques. In patients 
with ischemic cardiomyopathy, the presence of extensive scar tissue may have reduced the 
accuracy of TDI to assess LV diastolic dyssynchrony. Although the agreement between both 
techniques was slightly reduced in ischemic HF patients, the study demonstrated that phase 
analysis on GMPS can also be used for assessment of LV diastolic dyssynchrony in patients 
with ischemic cardiomyopathy. Finally, the current study has shown that LV diastolic dys-
synchrony was a common phenomenon in patients with HF. In the present study, 69 (46%) 
patients showed LV diastolic dyssynchrony defined as a diastolic mechanical delay of >55 
ms on TDI. Similarly, Schuster et al.3 have reported that diastolic dyssynchrony of the LV 
was prevalent in patients with HF; 58% of patients showed LV diastolic dyssynchrony on 
TDI. Furthermore, the current findings were in line with the study from Shanks et al.6 who 
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showed that LV diastolic dyssynchrony as assessed with TDI was present in nearly 52% of 
the patients with HF. Accordingly, phase analysis on GMPS allows detection of LV diastolic 
dyssynchrony.
LV Diastolic Dyssynchrony and QRS Duration
Several studies have shown that electrical dyssynchrony, as reflected by a prolonged QRS 
interval, is neither associated with systolic dyssynchrony nor diastolic dyssynchrony of the 
LV.3, 19, 20 Schuster et al.3 have shown that QRS duration was poorly correlated to LV systolic 
dyssynchrony and LV diastolic dyssynchrony in 108 patients with HF. Similar findings were 
reported by Wang et al.7 who revealed that LV diastolic dyssynchrony and QRS interval 
(r=0.36, p=0.03) were poorly correlated in 60 HF patients. In line with these studies, the 
present study showed that QRS duration was not correlated to LV diastolic dyssynchrony as 
assessed with phase analysis on GMPS or TDI.
Limitations
Although the study has demonstrated that phase analysis on GMPS could be used to assess 
LV diastolic dyssynchrony, some limitations need to be addressed. First, the current findings 
were based on a relatively small subset of patients, whereas a large cohort of HF patients 
would have been more preferred to evaluate the feasibility of phase analysis on GMPS for 
assessment of LV diastolic dyssynchrony. Secondly, even though the current evaluation has 
shown that phase analysis on GMPS was well-correlated with TDI for assessment of LV 
diastolic dyssynchrony, some variation was observed between both imaging techniques. 
This may be explained by the fact that GMPS with phase analysis allows evaluation of the 
time dispersion of mechanical phenomena (both diastolic relaxation and systolic contrac-
tion) in 3D, whereas TDI represents the time difference between 2 opposing walls. For this 
reason, 3D echocardiography (rather than 2D echocardiography with TDI) would be pre-
ferred to evaluate the feasibility of phase analysis on GMPS for assessment of LV diastolic 
dyssynchrony. At present however, TDI represents the most commonly used technique for 
the assessment of LV diastolic dyssynchrony. In addition, the implications of GMPS-derived 
LV diastolic dyssynchrony on response to cardiac resynchronization therapy (CRT) or the 
effects of CRT on LV diastolic mechanical relaxation were not evaluated. Additional studies 
are needed in order to establish the accuracy of GMPS-derived LV diastolic dyssynchrony 
to predict response to CRT or long-term outcome. 
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Conclusions
Phase analysis on GMPS showed a good correlation with TDI for assessment of LV diastolic 
dyssynchrony. Accordingly, phase analysis is a feasible technique for evaluation of LV dia-
stolic dyssynchrony in patients with HF.
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Background: Limited information is available about the role of LV diastolic dyssynchrony 
measured with gated myocardial perfusion single photon emission computed tomography 
(GMPS) to predict CRT response. Accordingly, the present evaluation explored whether LV 
diastolic dyssynchrony on GMPS predicts CRT response.
Methods: Heart failure (HF) patients with depressed LV systolic function (LV ejection fraction 
(LVEF) ≤35%) were included. Before CRT device implantation, patients underwent resting 
GMPS and real-time 3D echocardiography (RT3DE). GMPS was performed to evaluate myo-
cardial scar (<50% tracer uptake), whereas phase analysis on GMPS was used to assess LV 
systolic and diastolic dyssynchrony. Systolic histogram bandwidth (HBW) and systolic phase 
standard deviation (SD) were used as markers of LV systolic dyssynchrony, whereas diastolic 
HBW and diastolic phase SD were used as LV diastolic dyssynchrony indices. RT3DE was 
performed to measure LVEF and LV volumes. At 6 months after CRT, RT3DE was repeated 
and CRT response was defined as a reduction of ≥15% in LV end-systolic volume (LVESV).
Results: A total of 50 patients (36 men, mean age 66.5±9.9 yrs) were included. Thirty-six 
(72%) patients showed response to CRT, while 14 (28%) were non-responders. Multivariate 
analyses showed that LV systolic dyssynchrony, LV diastolic dyssynchrony and myocardial 
scar as assessed with GMPS were independent predictors of CRT response. Receiver operat-
ing characteristic curve analyses showed that diastolic HBW and diastolic phase SD were 
valuable predictors of response to CRT with an area under the curve of 0.79 and 0.80, 
respectively.
Conclusions: LV diastolic dyssynchrony together with LV systolic dyssynchrony and myocar-
dial scar assessed with GMPS are important determinants of CRT response.
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Introduction
Besides improvements in heart failure (HF) symptoms, left ventricular (LV) volumes and LV 
systolic function, cardiac resynchronization therapy (CRT) has been shown to considerably 
reduce mortality and morbidity rates in patients with moderate-to-severe HF and prolonged 
QRS duration.1, 2
Even though the benefits of CRT have been demonstrated in several studies, response 
to CRT may vary significantly among patients referred for CRT.3, 4 A significant proportion 
of these patients (approximately 30 to 40%) do not respond to CRT. The lack of response 
to CRT has been related to several factors such as the absence of pre-existent mechanical 
dyssynchrony or the presence of (extensive) myocardial scar tissue.5-7 Previous studies have 
indicated that pre-existent LV systolic dyssynchrony is associated with a high likelihood of 
response to CRT.5, 6
In addition, LV diastolic dyssynchrony may also be important in patients referred for 
CRT.8-10 Thus far, echocardiographic techniques have been commonly used for the assess-
ment of LV diastolic dyssynchrony in patients receiving CRT.10-13 Although echocardiography 
provides accurate measurements of LV diastolic dyssynchrony, it requires special expertise 
along with standardized image and post-processing protocols to achieve good interobserver 
reproducibility.
Gated myocardial perfusion single photon emission computed tomography (SPECT) 
(GMPS) with phase analysis is a comprehensive imaging technique that provides automatic 
and reproducible measures of LV mechanical dyssynchrony, including phase histogram 
bandwidth (HBW) and phase standard deviation (SD).14, 15 Although phase analysis on 
GMPS has been used to predict CRT response using LV systolic dyssynchrony16, limited 
information is available about the role of LV diastolic dyssynchrony assessment to predict 
response to CRT. Accordingly, the current study aimed to investigate whether LV diastolic 
dyssynchrony as derived from phase analysis on GMPS predicts response to CRT.
Methods
Patient Population and Data Collection
The patient population consisted of patients who were clinically referred for implantation 
of a CRT device because of drug-refractory HF, reduced LV systolic function (LV ejection 
fraction (LVEF) ≤35%) and sinus rhythm.1, 2 Patient data were prospectively collected in 
the departmental Cardiology Information System (EPD-Vision®, Leiden University Medical 
Center, Leiden, the Netherlands) and retrospectively analyzed. All patients were stable on 
maximum tolerated doses of medications. Patients with decompensated heart failure, recent 
188
myocardial infarction (within 3 months of CRT device implantation) or who died during 6 
months follow-up after CRT implantation were excluded. Ischemic cardiomyopathy was 
defined as a ≥50% stenosis in one or more of the major epicardial coronary arteries and/
or a history of myocardial infarction, percutaneous coronary intervention or coronary artery 
bypass grafting.
According to the institutional protocol, the clinical status was evaluated prior to CRT 
implantation, including New York Heart Association (NYHA) functional class, 6-minute walk 
test and quality of life score using the Minnesota Quality-of-Life Questionnaire.17 In addi-
tion, patients underwent resting GMPS as well as real-time 3D echocardiography (RT3DE). 
Resting GMPS was performed to evaluate the presence and extent of myocardial scar. Phase 
analysis on GMPS was used to assess LV systolic and diastolic dyssynchrony. Systolic HBW 
and systolic phase SD were used as markers of LV systolic dyssynchrony, whereas diastolic 
HBW and diastolic phase SD as derived from the diastolic phase distribution were used as 
LV diastolic dyssynchrony indices. RT3DE was performed to measure LVEF and LV volumes.
After 6 months of CRT, the evaluation of clinical status and RT3DE were repeated. As 
previously reported, a reduction of ≥15% in LV end-systolic volume (LVESV) at 6 months 
follow-up defined response to CRT.18 The value of baseline clinical, echocardiographic and 
GMPS variables for the prediction of response to CRT was evaluated.
Gated Myocardial Perfusion SPECT
Acquisition
GMPS with 99mtechnetium tetrofosmin was performed at rest using a triple-head SPECT 
camera (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan) which was equipped with low-
energy high-resolution collimators. An average dose of 500 MBq of 99mtechnetium tetrofos-
min (MYOVIEW, General Electric Healthcare, United Kingdom) was given intravenously per 
patient. Around the energy peak of 99mtechnetium tetrofosmin (140 KeV) a 20% window was 
centered. In total, 90 projections (step and shoot method, 35 s/projection, 64 x 64 matrix, 
total imaging time 23 minutes) were acquired over a 360° circular orbit. ECG gating was 
applied on the cardiac cycle with 16 frames per cardiac cycle using a tolerance window of 
50%.
Thereafter, the GMPS data sets were uploaded to the Emory Cardiac Toolbox (Emory 
University, Atlanta, Georgia, USA) for data reconstruction, reorientation and phase analysis 
processing. All data sets were reconstructed using ordered subsets expectation maximization 
(OSEM) with 3 iterations and 10 subsets. The gated images were filtered with a Butterworth 
filter with a cutoff frequency of 0.35 cycles/cm and a power of 10. Subsequently, the recon-
structed images were reoriented manually with the use of an automatic reorientation tool 
in the Emory Reconstruction Toolbox (Emory University, Atlanta, Georgia, USA) to generate 
gated short-axis images which were sampled for regional maximum counts using the Emory 
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Cardiac Toolbox (Emory University, Atlanta, Georgia, USA). These sampled data sets were 
then submitted to the multi-harmonic phase analysis tool for phase analysis processing that 
was performed blinded at Emory University.
Additionally, GMPS data sets were evaluated for the presence and extent of myocardial 
scar. Data sets were displayed in polar map format and normalized for maximal myocardial 
activity (100%). Myocardial scar was defined as myocardium with <50% tracer uptake. Sub-
sequently, the extent of myocardial scar was expressed as a percentage of the myocardium.
Phase Analysis on GMPS
Phase analysis on GMPS was used to assess LV systolic and diastolic dyssynchrony. First, 
LV systolic dyssynchrony was assessed using gated short-axis SPECT images, as previously 
described.16 In brief, the onset of mechanical contraction was detected per cardiac region 
using count-based wall thickening curves. These count-based wall-thickening curves were 
derived from changes in myocardial counts during the cardiac cycle. For each cardiac seg-
ment, the onset of mechanical contraction was reflected by a phase angle. After the phase 
angles were obtained for each cardiac segment within the LV (>600 regions over the entire 
LV), they were displayed in a polar map and phase histogram. Consecutively, the phase 
histogram was used to derive quantitative parameters of LV systolic dyssynchrony; systolic 
HBW (reflects 95% of the phase angles) and systolic phase SD (SD of the phase distribution) 
were used as markers of LV systolic dyssynchrony.
In addition, LV diastolic dyssynchrony was assessed using the same gated short-axis 
SPECT images. The assessment of LV diastolic dyssynchrony was based on several consecu-
tive processing steps (Figure 1). First, regional maximal count detection was performed on 
short-axis images in 3D for each temporal frame. Based on the partial volume effect19, 20, 
the variation of the regional maximal counts was proportional to changes in regional wall 
thickening over the cardiac cycle.20 Consecutively, the third Fourier harmonic function was 
used to approximate the discrete sample points into a continuous wall-thickening curve. For 
each region (>600 regions over the entire LV), a wall-thickening curve was generated that 
provided a phase angle which represented the onset of mechanical relaxation (OMR) of the 
particular region. The OMR phase is the time point when the curves crossed the middle line 
from positive to negative. Once the phase angles for the entire LV were obtained, a phase 
distribution was generated that provided information on the degree of diastolic dyssynchrony 
of the LV. A polar map and histogram were used to display the phase angle distribution of 
the LV. LV diastolic dyssynchrony indices were derived from the phase histogram; diastolic 
HBW (the histogram bandwidth including 95% of the OMR phase angles) and diastolic 




Patients underwent RT3DE with a commercially available system (iE33, Philips Medical 
Systems, Bothell, Washington, USA) equipped with an X3, fully sampled matrix transducer. 
Apical full-volume data sets were obtained combining, within 1 breath-hold, 7 real-time 
ECG-triggered subvolumes into a larger pyramidal volume (101 x 104 degrees). For this 
study, the frame rate varied between 20 to 35 frames/s. Post-processing of the digitally stored 
RT3DE data sets was performed off-line using a semi-automated contour tracing algorithm 
(Q-lab, version 7.0, Philips Medical Systems).
The apical 4-chamber and 2-chamber views as well as the parasternal short-axis views 
were automatically displayed during the post-processing of the RT3DE data set. Once the 
cardiac apex and mitral annulus were identified using 5 reference points in the end-diastolic 
and end-systolic frames, a pre-configured ellipse was fitted to the endocardial border for 
Figure 1. Diastolic mechanical dyssynchrony of the left ventricle (LV) can be assessed with phase 
analysis on gated myocardial perfusion single photon emission computed tomography (SPECT) 
(GMPS). At first, GMPS data sets were reoriented and reconstructed into gated short-axis images. 
A 3D regional maximal count detection was performed for each temporal time frame using 
reconstructed gated short-axis SPECT images. Subsequently, approximation of discrete sample 
points into a continuous wall-thickening curve was performed by the third Fourier harmonic 
function. These wall-thickening curves were generated for each cardiac region (>600 regions for 
the entire LV). Using the wall-thickening curve, a phase angle was derived which reflected the 
onset of mechanical relaxation (OMR) per cardiac region. All phase angles (>600 for entire LV) 
were plotted in a phase polar map or histogram. Finally, LV diastolic dyssynchrony indices were 
derived from the phase histogram; diastolic phase standard deviation (SD) (SD of the OMR phase 
distribution) and diastolic histogram bandwidth (HBW) (the width of the band that includes 95% of 
the OMR phase angles) were used as markers of LV diastolic dyssynchrony.
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each frame. Manual adaptations of the endocardial border could be performed to improve 
the endocardial border detection. Thereafter, the LV 3D model was automatically generated 
and used for the assessment of LVEF and LV volumes in each patient.21 RT3DE data sets 
were excluded from further analysis if they showed more than 2 LV segments that were not 
visualized or uninterpretable. RT3DE was performed at baseline and after 6 months of CRT. 
A decrease of ≥15% in LVESV at 6 months follow-up defined response to CRT.18
CRT Implantation
All leads were placed via the subclavian route and the right atrial and ventricular leads 
were positioned conventionally. Once a coronary sinus venogram was obtained using the 
balloon catheter, an 8 Fr guiding catheter was used to position the LV pacing lead as far as 
possible in the coronary venous system, preferably into the lateral or posterolateral vein. 
All LV leads were connected to a dual-chamber biventricular implantable cardiac device. 
Simultaneous biventricular pacing was applied in all patients and the interventricular delay 
was not systematically adjusted during the first 6 months. The optimal atrioventricular delay 
was set based on echocardiographic transmitral pulsed wave Doppler recordings.
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation and categorical data are 
presented as numbers or percentages. Kolmogorov-Smirnov tests were used to evaluate 
whether baseline variables were normally distributed. Changes in clinical, echocardio-
graphic and GMPS variables between baseline and 6 months follow-up were evaluated with 
paired Student t-tests or Wilcoxon signed-rank tests, as appropriate. Furthermore, differences 
in baseline variables between responders and non-responders to CRT were evaluated with 
unpaired Student t-tests and Mann-Whitney U-test, as appropriate (for continuous variables) 
and Chi-square or Fisher exact tests (for categorical variables).
Consecutively, univariate logistic regression models were constructed to identify signifi-
cant predictors of response to CRT. All variables that were significantly associated with CRT 
response at the p<0.05 level were included in the multivariate logistic regression model 
(using enter method). To avoid multi-collinearity different predictive models were created in 
order to identify significant independent determinants of response to CRT.
Finally, the optimal cutoff values of diastolic HBW and diastolic phase SD for prediction 
of CRT response were defined using receiver operating characteristic (ROC) curve analyses. 
Using the ROC curves, the area under the curve (AUC) was calculated for both diastolic 
HBW and diastolic phase SD. The optimal cutoff value was defined as the value that yielded 
the maximal sum of sensitivity and specificity. Statistical analyses were performed with SPSS 





From an ongoing registry of HF patients treated with CRT, 63 consecutive HF patients who 
had undergone GMPS prior to CRT implantation were evaluated.22 Of these 63 patients, 13 
patients were excluded as they did not undergo RT3DE at 6 months follow-up. Accordingly, 
a total of 50 patients (36 males, mean age 66.5±9.9 yrs) were included in the current analy-
sis. The baseline characteristics of these patients are shown in Table 1. Thirty (60%) patients 
had ischemic cardiomyopathy, and 20 (40%) patients had non-ischemic cardiomyopathy. In 
total, 43 (86%) patients were in NYHA functional class III, whereas the remaining 7 (14%) 
patients were in NYHA functional class IV. RT3DE showed a mean LVEF of 27.7±5.8%. 
Patients were treated with optimal HF medication, consisting of diuretics (86%), angiotensin 
converting enzyme-inhibitors (ACE-I) (90%) and beta-blockers (72%).
Furthermore, GMPS with phase analysis showed a mean systolic HBW and systolic 
phase SD of 160.9±73.1˚ and 47.7±18.6˚, respectively. In addition, mean diastolic HBW 
Table 1. Baseline characteristics of the patient population (n=50)
Age (yrs) 66.5±9.9
Male gender 36 (72)
Ischemic cardiomyopathy 30 (60)
Clinical evaluation
     NYHA functional class III/IV 43/7
     Quality-of-life score 26.1±15.4
     6-minute walk test (m) 358.6±105.9
     QRS duration (ms) 164.0±25.5
Real-time 3D echocardiography
     LVEDV (mL) 206.8±48.4
     LVESV (mL) 150.5±42.4
     LVEF (%) 27.7±5.8 
GMPS variables
     Myocardial scar (%) 26.1±14.9
     LV systolic dyssynchrony
     HBW (˚) 160.9±73.1
     Phase SD (˚) 47.7±18.6
     LV diastolic dyssynchrony
     HBW (˚) 183.3±74.2
     Phase SD (˚) 56.3±19.8 
Data are presented as mean ± standard deviation or as number (%). GMPS = gated myocardial 
perfusion single photon emission computed tomography; HBW = histogram bandwidth; LVEDV = left 
ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular 
end-systolic volume; NYHA = New York Heart Association; SD = standard deviation.
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and diastolic phase SD were 183.3±74.2˚ and 56.3±19.8˚. The extent of myocardial scar on 
GMPS was on average 26.1±14.9%.
Baseline versus 6 months Follow-up
After 6 months of CRT, 30 (60%) patients showed an improvement of 1 NYHA functional class 
and 12 (24%) patients showed an improvement of 2 NYHA functional classes at 6 months 
follow-up. In addition, a marked increase in 6-minute walk distance (from 352.9±108.4 m 
to 380.1±107.7 m, p<0.01) as well as a significant reduction in quality-of-life score (from 
25.5±15.0 to 17.4±14.1, p<0.01) were observed. At 6 months follow-up, patients showed 
a significant improvement in LVEDV (206.8±48.4 mL vs. 183.8±52.8 mL, p<0.01), LVESV 
(150.5±42.4 mL vs. 119.9±44.6 mL, p<0.01) and LVEF (27.7±5.8% vs. 35.6±7.5%, p<0.01).
After 6 months of CRT, 36 (72%) patients were classified as responders to CRT (reduction 
of ≥15% in LVESV at 6 months of CRT), whereas the remaining 14 (28%) patients were 
classified as non-responders to CRT.
Among responders to CRT, 23 (64%) patients showed an improvement of at least 1 
NYHA functional class at 6 months follow-up (baseline vs. follow-up, p<0.05). In addition, 
CRT responders showed a significant improvement in quality-of-life score (25.3±15.5 vs. 
17.8±14.8, p<0.01) and 6-minute walk distance (376.4±98.6 m vs. 409.0±87.3 m, p<0.01) 
at 6 months of follow-up. Finally, in these patients, a significant improvement in LVEDV 
(206.6±46.6 mL vs. 175.9±44.9 mL, p<0.01), LVESV (150.1±40.3 mL vs. 108.8±31.6 mL, 
p<0.01) and LVEF (27.8±5.3% vs. 38.4±6.3%, p<0.01) was observed at 6 months post-CRT.
Even though non-responders to CRT showed an improvement in NYHA functional 
class (baseline vs. follow-up, p=0.002) and quality-of-life score (25.8±14.2 vs. 16.3±12.7, 
p=0.009), no improvements were observed in 6-minute walk distance (298.2±114.6 m 
vs. 312.8±123.9 m, p=0.3), LVEDV (207.4±54.7 mL vs. 204.1±66.8 mL, p=0.2), LVESV 
(151.7±48.8 mL vs. 148.5±60.0 mL, p=0.2), and LVEF (27.6±7.1% vs. 28.6±6.0%. p=0.5).
Baseline Characteristics: Responders versus Non-Responders to CRT
Baseline characteristics of responders and non-responders to CRT are shown in Table 2. 
No significant differences were observed for clinical and echocardiographic variables 
between responders and non-responders to CRT. However, responders to CRT showed a 
significantly larger systolic HBW (180.8±66.1˚ vs. 109.6±66.9˚, p<0.01) and systolic phase 
SD (53.2±15.8˚ vs. 33.5±18.1˚, p<0.01) than non-responders to CRT.
Importantly, diastolic HBW (205.3±64.0˚ vs. 126.9±70.5˚, p<0.01) and diastolic phase 
SD (62.1±16.5˚ vs. 41.2±20.3˚, p<0.01) were also significantly higher in responders to CRT 
as compared to non-responders to CRT (Figure 2). Examples of a patient with and without 
extensive LV diastolic dyssynchrony are provided in Figure 3.
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Table 2. Baseline characteristics in patients with and without response to cardiac resynchronization 
therapy (CRT)





Age (yrs) 65.8±10.5 68.4±8.2 0.3
Male gender 26 (72) 10 (71) 1.0
Ischemic cardiomyopathy 21 (58) 10 (71) 0.7
Clinical evaluation
     NYHA functional class III/IV 29/7 14/0 0.07
     Quality-of-life score 26.3±16.2 25.5±13.6 0.9
     6-minute walk test (m) 378.7±95.2 310.5±118.5 0.05
     QRS duration (ms) 165.4±25.7 160.4±25.5 0.4
Real-time 3D echocardiography
     LVEDV (mL) 206.6±46.6 207.4±54.7 0.8
     LVESV (mL) 150.1±40.3 151.7±48.8 0.6
     LVEF (%) 27.7±5.3 27.5±7.1 0.9
GMPS variables
     Myocardial scar (%) 24.3±13.3 30.8±17.9 0.2
     LV systolic dyssynchrony
     HBW (˚) 180.8±66.1 109.6±66.9 0.001
     Phase SD (˚) 53.2±15.8 33.5±18.1 0.001
     LV diastolic dyssynchrony
     HBW (˚) 205.3±64.0 126.9±70.5 0.002
     Phase SD (˚) 62.1±16.5 41.2±20.3 0.001
Data are presented as mean ± standard deviation or as number (%). GMPS = gated myocardial 
perfusion single photon emission computed tomography; HBW = histogram bandwidth; LVEDV = left 
ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular 
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P<0.01
P<0.01
Figure 2. Patients with response to cardiac resynchronization therapy (CRT) showed significantly 
more left ventricular (LV) diastolic dyssynchrony on gated myocardial perfusion single photon 
emission computed tomography (SPECT) (GMPS) as compared to patients without response to 
CRT. Both diastolic histogram bandwidth (HBW) (205.3±64.0˚ vs. 126.9±70.5˚, p<0.01) and diastolic 
phase standard deviation (SD) (62.1±16.5˚ vs. 41.2±20.3˚, p<0.01) were significantly higher in 
responders to CRT (white bars) than in non-responders to CRT (black bars).
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Prediction of Response to CRT
The value of baseline clinical and imaging variables for prediction of CRT response was 
evaluated (Table 3). Univariate logistic regression analyses showed that systolic HBW 
(OR=1.02 95% CI 1.01-1.03, p<0.01), systolic phase SD (OR=1.08, 95% CI 1.03-1.13, 
p<0.01), diastolic HBW (OR=1.02, 95% CI 1.01-1.03, p<0.01) and diastolic phase SD 
(OR=1.07, 95% CI 1.02-1.11, p<0.01) were significantly associated with CRT response.
To avoid multi-collinearity among several variables, different multivariate models were 
constructed to determine independent predictors for CRT response, as shown in Table 4. As 
myocardial scar, electrical dyssynchrony (QRS duration) and age were regarded as important 
parameters in patients referred for CRT, they were also included in the multivariate model.
A
B
Figure 3. Phase analysis on gated myocardial perfusion single photon emission computed 
tomography (SPECT) (GMPS) was used for assessment of left ventricular (LV) diastolic 
dyssynchrony in patients referred for cardiac resynchronization therapy (CRT). Diastolic histogram 
bandwidth (HBW) and diastolic phase standard deviation (SD) were used as markers of LV diastolic 
dyssynchrony.
A. Example of a responder to CRT who showed extensive LV diastolic dyssynchrony as reflected 
by a wide histogram and a heterogenously color-coded diastolic phase polar map. Phase analysis 
on GMPS showed a diastolic HBW and diastolic phase SD of 313.0˚ and 91.6˚, respectively. After 6 
months of CRT, the patient showed a marked improvement in LV ejection fraction (LVEF) (23% vs. 
42%).
B. Example of a non-responder to CRT who showed no LV diastolic dyssynchrony on GMPS. Phase 
analysis showed a narrow histogram and homogenously color-coded diastolic phase polar map. 
In this patient, the diastolic HBW and diastolic phase SD were on average 64.0˚ and 28.9˚. No 
improvement in LVEF was observed after 6 months of CRT (32% vs. 30%).
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Multivariate analyses demonstrated that systolic HBW and systolic phase SD were inde-
pendent predictors for CRT response. In addition, diastolic HBW and diastolic phase SD as 
well as myocardial scar were independent predictors for response to CRT.
As shown in Figure 4, ROC curve analyses showed that diastolic HBW (AUC 0.79) and 
diastolic phase SD (AUC 0.80) could be used for prediction of response to CRT. The optimal 
cutoff value of diastolic HBW for prediction of CRT response was 157.5˚, yielding a sensitiv-
ity of 81% and a specificity of 79%. For diastolic phase SD, the optimal point was defined 
at 47.0˚ with a sensitivity of 86% and a specificity of 71%.





Age (yrs) 0.97 (0.91-1.04) 0.4
Male gender 1.04 (0.26-4.09) 1.0
Ischemic cardiomyopathy 0.78 (0.22-2.79) 0.7
Clinical evaluation
     Quality-of-life score 1.00 (0.96-1.05) 0.9
     6-minute walk test (m) 1.01 (1.00-1.01) 0.1
     QRS duration (ms) 1.01 (0.98-1.03) 0.5
Real-time 3D echocardiography
     LVEDV (mL) 1.00 (0.99-1.01) 1.0
     LVESV (mL) 0.99 (0.99-1.01) 0.9
     LVEF (%) 1.01 (0.90-1.12) 0.9
GMPS variables
     Myocardial scar (%) 0.97 (0.93-1.01) 0.2
     LV systolic dyssynchrony
     HBW (˚) 1.02 (1.01-1.03) <0.01*
     Phase SD (˚) 1.08 (1.03-1.13) <0.01*
     LV diastolic dyssynchrony
     HBW (˚) 1.02 (1.01-1.03) <0.01*
     Phase SD (˚) 1.07 (1.02-1.11) <0.01*
* Significant association with CRT response at a level of p<0.05 in univariate analysis.
CI = confidence interval; GMPS = gated myocardial perfusion single photon emission computed 
tomography; HBW = histogram bandwidth; LVEDV = left ventricular end-diastolic volume; LVEF = 
left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; OR = odds ratio; SD = 
standard deviation.
Chapter 10 : LV diastolic dyssynchrony on GMPS predicts response to CRT
197






Myocardial scar (%) 0.88 (0.80-0.96) <0.01*
Systolic HBW (˚) 1.04 (1.02-1.06) <0.01*
QRS duration (ms) 1.02 (0.98-1.06) 0.4
Age (yrs) 0.97 (0.88-1.08) 0.6
Model II
Myocardial scar (%) 0.87 (0.79-0.96) <0.01*
Systolic phase SD (˚) 1.18 (1.07-1.30) <0.01*
QRS duration (ms) 1.02 (0.98-1.07) 0.3
Age (yrs) 0.99 (0.89-1.10) 0.8
Model III
Myocardial scar (%) 0.87 (0.79-0.95) <0.01*
Diastolic HBW (˚) 1.04 (1.02-1.07) <0.01*
QRS duration (ms) 1.02 (0.98-1.06) 0.3
Age (yrs) 1.00 (0.90-1.11) 1.0
Model IV
Myocardial scar (%) 0.87 (0.80-0.95) <0.01*
Diastolic phase SD (˚) 1.16 (1.06-1.26) <0.01*
QRS duration (ms) 1.03 (0.99-1.08) 0.2
Age (yrs) 1.00 (0.90-1.11) 1.0
* Significant association with CRT response at a level of p<0.05 in multivariate analysis. CI = 
confidence interval; HBW = histogram bandwidth; OR = odds ratio; SD = standard deviation. The 
increment for systolic HBW, systolic phase SD, diastolic HBW and diastolic phase SD was 1˚.





























Figure 4. Receiver-operating characteristic (ROC) curve analyses showed that diastolic histogram 
bandwidth (HBW) (AUC 0.79) and diastolic phase standard deviation (SD) (AUC 0.80) can be used 
for prediction of response to cardiac resynchronization therapy (CRT). The optimal cutoff value for 
diastolic HBW (panel A) was defined at 157.5˚ with a sensitivity of 81% and a specificity of 79%. 




The current study showed that LV systolic dyssynchrony, LV diastolic dyssynchrony and 
myocardial scar are related to response to CRT. More specifically, the study demonstrated 
that both diastolic HBW and diastolic phase SD (markers of LV diastolic dyssynchrony) as 
assessed with phase analyses on GMPS can be used for identification of potential respond-
ers to CRT.
Resynchronization of the LV contraction pattern by synchronized pacing of both ven-
tricles (CRT) has resulted in substantial improvements in clinical symptoms, LV volumes 
and LV systolic function of patients with symptomatic HF and intra-ventricular conduction 
delay.1, 2 Beyond these beneficial effects, patients with CRT exhibit considerably lower 
mortality and morbidity rates when compared to patients with conventional HF medication 
alone.23, 24 However, on a patient level, it has been shown that around 30 to 40% of patients 
who fulfill current inclusion criteria for CRT do not show response to CRT.5-7 Accordingly, 
a large number of studies have focused on the identification of potential determinants of 
CRT response.25 Factors likely to influence CRT response include mechanical dyssynchrony, 
ischemic heart disease, LV lead position and CRT device programming. Among these fac-
tors, pre-existent mechanical dyssynchrony of the LV contraction pattern (LV systolic dys-
synchrony) has been identified as one of the important determinants of response to CRT.5, 6
In addition, it has been suggested that a dyssynchronous relaxation pattern of the LV (LV 
diastolic dyssynchrony) may also play a role in patients receiving CRT.8-10 Although most of 
the clinical studies have used echocardiographic techniques for assessment of LV diastolic 
dyssynchrony, echocardiography may show some intra- and interobserver variability as it 
requires special expertise and dedicated image and post-processing protocols.10, 11, 26
GMPS with phase analysis may overcome these limitations as it provides robust indices 
of mechanical dyssynchrony using an automatic approach with limited manual interference, 
which can be applied on conventional GMPS images.14, 15
The Influence of LV Diastolic Dyssynchrony as Assessed with GMPS on 
CRT Response
Although previous observations have indicated that GMPS can be used for prediction of CRT 
response, these studies have only focused on the assessment of pre-existent LV systolic dys-
synchrony with phase analysis, rather than LV diastolic dyssynchrony.16 The current evalua-
tion has shown that LV diastolic dyssynchrony on GMPS can also be used for identification 
of responders to CRT; patients with extensive LV diastolic dyssynchrony were more likely to 
respond to CRT as compared to patients without significant LV diastolic dyssynchrony. LV 
diastolic dyssynchrony may play an important role in CRT patients as resynchronization of 
the LV contraction pattern may also result in a resynchronization of the diastolic relaxation 
pattern of the LV. For this reason, CRT may (partially) correct abnormalities in LV diastolic 
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filling that have been associated with LV diastolic dyssynchrony.8, 27, 28 As diastolic dys-
synchrony of the LV has been linked to a reduced LV diastolic filling time and filling rate8, 27, 
28, a reduction of LV diastolic dyssynchrony by CRT may exert positive effects on LV diastolic 
filling, and as a consequence, may improve the hemodynamics of the heart. Furthermore, 
patients with LV diastolic dyssynchrony may benefit from CRT as resynchronization of the 
LV contraction and filling pattern could result in an improvement of diastolic interventricular 
interaction, particularly in patients with elevated LV filling pressures.8, 29
The current study findings are of interest as previous studies have shown that LV diastolic 
dyssynchrony represents a common pathophysiologic condition in patients fulfilling the 
criteria for CRT.10-13 In these patients, LV diastolic dyssynchrony is at least as common as 
LV systolic dyssynchrony with a prevalence of more than 50%.10-13 Moreover, it has been 
shown that LV diastolic dyssynchrony can be present without co-existence of LV systolic 
dyssynchrony in a substantial number of patients.10
Accordingly, the assessment of LV diastolic dyssynchrony may provide useful information 
to predict CRT response in a large number of HF patients. The present evaluation demon-
strated that both diastolic HBW and diastolic phase SD can be used to predict CRT response. 
Even though diastolic HBW and diastolic phase SD were both independent predictors of 
response to CRT, the optimal cutoff values of diastolic HBW and diastolic phase SD to 
predict CRT response showed suboptimal sensitivity and specificity values; diastolic HBW 
showed an optimal cutoff value of 157.5˚ with a sensitivity of 81% and a specificity of 79%, 
whereas diastolic phase SD showed an optimal cutoff value of 47.0˚ with a sensitivity of 
86% and a specificity of 71%. This may be related to the fact that other issues may have 
influenced the likelihood of response to CRT, including the presence of LV systolic dys-
synchrony as well as myocardial scar tissue.
The Influence of LV Systolic Dyssynchrony and Myocardial Scar as 
Assessed with GMPS on CRT Response
A large number of studies have currently indicated that the presence of pre-existent LV 
systolic dyssynchrony affects the likelihood of response to CRT.5, 6 Henneman et al.16 have 
evaluated the predictive value of LV systolic dyssynchrony as assessed with phase analysis 
on GMPS in 42 patients with advanced HF. In these patients, both systolic HBW and phase 
SD were significantly higher in patients with CRT response than in patients without CRT 
response. Moreover, both markers of LV systolic dyssynchrony were predictive for CRT 
response, as reflected by an AUC of 0.78 and 0.81 for systolic HBW and systolic phase SD, 
respectively. The current study has shown that LV systolic dyssynchrony plays an important 
role in patients with CRT as both systolic HBW and systolic phase SD were independent 
predictors for response to CRT. Patients with extensive LV systolic dyssynchrony were more 
likely to respond to CRT when compared to patients with no LV systolic dyssynchrony at 
baseline.
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Furthermore, the presence and location of (transmural) scarred myocardium may have 
influenced the possibility of CRT response in the current patient population. Previous 
observations have shown that patients with extensive myocardial scar tissue are less likely 
to respond to CRT than patients with no myocardial scar tissue.7, 30 Ypenburg et al.7 have 
evaluated whether myocardial infarction as assessed with myocardial perfusion scintigra-
phy was an important determinant for outcome after 6 months of CRT in 51 patients with 
ischemic cardiomyopathy. Patients with a low total scar score were more likely to respond 
to CRT as compared to patients with a high total scar score (p<0.05). Similarly, the present 
study has demonstrated that myocardial scar is an important determinant for prediction 
of CRT response. Non-responders to CRT showed a considerable higher myocardial scar 
burden as compared to responders to CRT.
Accordingly, GMPS with phase analysis permits assessment of LV systolic and diastolic 
dyssynchrony along with information on the presence, location and extent of myocardial 
infarct tissue. A comprehensive evaluation of CRT patients based upon assessment of LV 
systolic and diastolic dyssynchrony as well as myocardial scar tissue would improve the 
identification of potential responders to CRT. One of the major advantages of phase analysis 
on GMPS is the fact that it permits an integrated assessment of mechanical dyssynchrony 
and myocardial perfusion using a single SPECT study.
Conclusion
LV systolic dyssynchrony, LV diastolic dyssynchrony and myocardial scar tissue as assessed 
with GMPS are important determinants of response to CRT. Diastolic HBW and diastolic 
phase SD are markers of LV diastolic dyssynchrony which can be used for prediction of CRT 
response.




 (1)  Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, III, Freedman RA, Gettes LS, Gillinov AM, 
Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka 
MJ, Stevenson LW, Sweeney MO, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Buller CE, 
Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner 
FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA/
HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 
developed in collaboration with the American Association for Thoracic Surgery and Society of 
Thoracic Surgeons. Circulation 2008;117(21):e350-e408.
 (2)  Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, 
Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused 
update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of 
Heart Failure in Adults: a report of the American College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guidelines: developed in collaboration with the Interna-
tional Society for Heart and Lung Transplantation. Circulation 2009;119(14):e391-e479.
 (3)  Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets 
D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an 
implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350(21):2140-
2150.
 (4)  Bax JJ, Ansalone G, Breithardt OA, Derumeaux G, Leclercq C, Schalij MJ, Sogaard P, St John SM, 
Nihoyannopoulos P. Echocardiographic evaluation of cardiac resynchronization therapy: ready 
for routine clinical use? A critical appraisal. J Am Coll Cardiol 2004;44(1):1-9.
 (5)  Yu CM, Fung JW, Zhang Q, Chan CK, Chan YS, Lin H, Kum LC, Kong SL, Zhang Y, Sanderson 
JE. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the 
prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac 
resynchronization therapy. Circulation 2004;110(1):66-73.
 (6)  Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, Garrigue S, Gorcsan J, III, Hayes DL, Kass 
DA, Knuuti J, Leclercq C, Linde C, Mark DB, Monaghan MJ, Nihoyannopoulos P, Schalij MJ, 
Stellbrink C, Yu CM. Cardiac resynchronization therapy: Part 1--issues before device implantation. 
J Am Coll Cardiol 2005;46(12):2153-2167.
 (7)  Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, Stokkel MP, van 
der Wall EE, Bax JJ. Impact of viability and scar tissue on response to cardiac resynchronization 
therapy in ischaemic heart failure patients. Eur Heart J 2007;28(1):33-41.
 (8)  Morris-Thurgood JA, Turner MS, Nightingale AK, Masani N, Mumford C, Frenneaux MP. Pacing in 
heart failure: improved ventricular interaction in diastole rather than systolic re-synchronization. 
Europace 2000;2(4):271-275.
 (9)  Waggoner AD, Rovner A, de las FL, Faddis MN, Gleva MJ, Sawhney N, vila-Roman VG. Clinical 
outcomes after cardiac resynchronization therapy: importance of left ventricular diastolic function 
and origin of heart failure. J Am Soc Echocardiogr 2006;19(3):307-313.
 (10)  Shanks M, Bertini M, Delgado V, Ng ACT, Nucifora G, Van Bommel RJ, Borleffs CJW, Holman 
ER, Van de Veire NRL, Schalij MJ, Bax JJ. Effect of biventricular pacing on diastolic dyssynchrony. 
Journal of american college of cardiology 2010;56(19):1567-1575.
 (11)  Schuster I, Habib G, Jego C, Thuny F, Avierinos JF, Derumeaux G, Beck L, Medail C, Franceschi 
F, Renard S, Ferracci A, Lefevre J, Luccioni R, Deharo JC, Djiane P. Diastolic asynchrony is more 
frequent than systolic asynchrony in dilated cardiomyopathy and is less improved by cardiac 
resynchronization therapy. Journal of american college of cardiology 2005;46(12):2250-2257.
Chapter 10 : LV diastolic dyssynchrony on GMPS predicts response to CRT
203
 (12)  Wang J, Kurrelmeyer KM, Torre-Amione G, Nagueh SF. Systolic and diastolic dyssynchrony 
in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol 
2007;49(1):88-96.
 (13)  Yu CM, Zhang Q, Yip GW, Lee PW, Kum LC, Lam YY, Fung JW. Diastolic and systolic asynchrony 
in patients with diastolic heart failure: a common but ignored condition. J Am Coll Cardiol 
2007;49(1):97-105.
 (14)  Trimble MA, Velazquez EJ, Adams GL, Honeycutt EF, Pagnanelli RA, Barnhart HX, Chen J, Iskan-
drian AE, Garcia EV, Borges-Neto S. Repeatability and reproducibility of phase analysis of gated 
single-photon emission computed tomography myocardial perfusion imaging used to quantify 
cardiac dyssynchrony. Nucl Med Commun 2008;29(4):374-381.
 (15)  Lin X, Xu H, Zhao X, Folks RD, Garcia EV, Soman P, Chen J. Repeatability of left ventricular 
dyssynchrony and function parameters in serial gated myocardial perfusion SPECT studies. J Nucl 
Cardiol 2010;17(5):811-816.
 (16)  Henneman MM, Chen J, Dibbets-Schneider P, Stokkel MP, Bleeker GB, Ypenburg C, van der Wall 
EE, Schalij MJ, Garcia EV, Bax JJ. Can LV dyssynchrony as assessed with phase analysis on gated 
myocardial perfusion SPECT predict response to CRT? J Nucl Med 2007;48(7):1104-1111.
 (17)  Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as 
a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71(12):1106-1107.
 (18)  Bax JJ, Bleeker GB, Marwick TH, Molhoek SG, Boersma E, Steendijk P, van der Wall EE, Schalij 
MJ. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization 
therapy. J Am Coll Cardiol 2004;44(9):1834-1840.
 (19)  Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. 
Effect of object size. J Comput Assist Tomogr 1979;3(3):299-308.
 (20)  Galt JR, Garcia EV, Robbins WL. Effects of myocardial wall thickness on SPECT quantification. 
IEEE Trans Med Imaging 1990;9(2):144-150.
 (21)  Marsan NA, Bleeker GB, Ypenburg C, Van Bommel RJ, Ghio S, Van de Veire NR, Delgado V, 
Holman ER, van der Wall EE, Schalij MJ, Bax JJ. Real-time three-dimensional echocardiography 
as a novel approach to assess left ventricular and left atrium reverse remodeling and to predict 
response to cardiac resynchronization therapy. Heart Rhythm 2008;5(9):1257-1264.
 (22)  Van Bommel RJ, Mollema SA, Borleffs CJ, Bertini M, Ypenburg C, Marsan NA, Delgado V, van 
der Wall EE, Schalij MJ, Bax JJ. Impaired renal function is associated with echocardiographic 
nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 
2011;57(5):549-555.
 (23)  Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for 
ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in 
Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPAN-
ION Clinical Investigators. J Card Fail 2000;6(3):276-285.
 (24)  Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The 
effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 
2005;352(15):1539-1549.
 (25)  Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA, Leon AR, 
Oshinski JN. Agreement is poor among current criteria used to define response to cardiac resyn-
chronization therapy. Circulation 2010;121(18):1985-1991.
 (26)  Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, 
Leclercq C, Bax JJ, Yu CM, Gorcsan J, III, St John SM, De Sutter J, Murillo J. Results of the Predictors 
of Response to CRT (PROSPECT) trial. Circulation 2008;117(20):2608-2616.
 (27)  Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of left ventricular systolic and dia-
stolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 
2003;89(1):54-60.
204
 (28)  Burgess MI, Fang ZY, Marwick TH. Role of diastolic dyssynchrony in the delayed relaxation pat-
tern of left ventricular filling. J Am Soc Echocardiogr 2007;20(1):63-69.
 (29)  Atherton JJ, Moore TD, Lele SS, Thomson HL, Galbraith AJ, Belenkie I, Tyberg JV, Frenneaux MP. 
Diastolic ventricular interaction in chronic heart failure. Lancet 1997;349(9067):1720-1724.
 (30)  Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic 
response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 
2007;153(1):105-112.
 (31)  Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, Saba SF, Gorcsan J, III. Impact of 
scar burden by single-photon emission computed tomography myocardial perfusion imaging on 




123-I MIBG for Risk Stratification 






for Risk Stratification in Heart 
Failure Patients
A report on behalf of the European 
Council of Nuclear Cardiology (ECNC)
Mark M. Boogers, MD1, 2, Frank M. Bengel, MD3, Juhani Knuuti4, MD, 
PhD, Jeroen J. Bax, MD, PhD1; Leiden, and Utrecht, the Netherlands; 
Baltimore, USA; Turku, Finland
1Department of Cardiology, Leiden University Medical Center, 
Leiden, the Netherlands; 2The Interuniversity Cardiology Institute of 
the Netherlands, Utrecht, the Netherlands; 3Department of Nuclear 
Medicine, Johns Hopkins University, Baltimore, USA; 4Turku PET 
Centre, Turku University, Turku, Finland.
210
Chapter 11 : Cardiac 123-I MIBG for risk stratification in heart failure patients
211
Introduction
Chronic heart failure is an important health care problem in the developed world as inci-
dence and prevalence numbers have increased rapidly over the last decades. Recently, the 
American Heart Association Statistics and Stroke Statistics committee reported that chronic 
heart failure affects 5.3 million patients in the USA, with approximately 660,000 newly 
diagnosed patients each year.1 In western Europe, approximately 4 million patients have 
been diagnosed with chronic heart failure.2
Moreover, in the USA, one million hospital admissions for (decompensated) heart failure 
have been reported annually, resulting in an exponential increase in direct and indirect 
cost involved with chronic heart failure.1 Even though significant progress in prevention, 
diagnostic and therapeutic strategies for chronic heart failure has been made, mortality rate 
still exceeds 50%.
Coronary artery disease was found to be the main cause of heart failure in nearly 70% 
of patients, and despite rapid developing treatment options for ischemic and non-ischemic 
heart failure, long-term prognosis remains poor.3-6 In 7,599 patients with NYHA class II-IV 
heart failure, originating from the CHARM study, cardiovascular outcome was studied 
over a mean follow-up of 3 years. In patients with a LV ejection fraction <33%, all-cause 
and cardiac mortality were 34% and 28%, respectively.6 Even higher mortality rates were 
reported by Levy et al.4 in the Framingham-based study population; cardiac mortality rate 
was more than 50%, over a mean follow-up of 5 years. These high mortality rates along with 
an increasing number of hospitalizations due to (decompensated) heart failure emphasize 
the need for better risk stratification.
Heart failure represents a complex clinical syndrome resulting from a reduced cardiac 
pump function. Progressive deterioration in cardiac function is based upon several interact-
ing pathophysiologic mechanisms, in which particularly the neurohormonal system (con-
sisting of the adrenergic nervous system and renin-angiotensin-aldosteron system) plays an 
important role in chronic heart failure. Initially, neurohormonal feedback mechanisms tend 
to compensate hemodynamic consequences of cardiac dysfunction via positive inotropic 
and chronotropic effects. However, in a chronic state these neurohormonal effects are detri-
mental and may cause cardiac hypertrophy and fibrosis, eventually resulting in remodeling. 
Moreover, desensitization and downregulation of myocardial beta-adrenoceptors, and 
alterations of postsynaptic signaling lead to further decline in cardiac function.7
In addition, a dysfunctional cardiac autonomic nervous system may also be related to the 
development of ventricular arrhythmias.8-11 In this respect, exact mechanisms have to be 
elucidated and it has been suggested that regions with impaired innervation may be viable 
and hypersensitive to catecholamines, resulting in increased automaticity and enhanced 
triggering.8, 12, 13 In particular, the borderzone of myocardial scar tissue may be predisposed 
to develop reentrant circuits because these regions are viable but may have damaged 
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sympathetic nerves.14-18 The viable peri-infarct region can be (partially) denervated because 
sympathetic nerve fibers are more vulnerable to ischemia as compared to cardiomyocytes.19
Consequently, important clinical and prognostic information in heart failure patients 
can be provided by assessment of cardiac sympathetic innervation and function. Single 
photon emission computed tomography (SPECT) and positron emission tomography (PET) 
are presently the only 2 imaging modalities to allow assessment of myocardial sympathetic 
nerve activation and innervation by visualization of uptake and storage of radiolabeled 
neurotransmitters into presynaptic nerve endings. Both imaging techniques can be used to 
assess global and regional myocardial sympathetic nerve innervation.
Presently, several PET tracers have been used to visualize sympathetic neurotransmission, 
including carbon-11 hydroxyephedrine (HED), C-11 epinephrine and F-18 fluorodopamine. 
At present, HED is the most frequently used PET tracer and allows absolute quantification 
of tracer uptake into sympathetic nerve terminals. One of the major advantages of HED is 
its capability to detect regional abnormalities in myocardial sympathetic innervation. Hart-
mann and colleagues20 have performed an important study which demonstrated regional 
heterogeneity of impaired cardiac sympathetic innervation in 29 patients with idiopathic 
dilated cardiomyopathy as compared to patients with normal cardiac function. In heart 
failure patients, PET with HED has also been used to evaluate the prognostic value of 
sympathetic nerve innervation. In an elegant study, Pietila et al.21 have demonstrated that 
global reduced HED accumulation was an independent predictor of adverse outcome in 46 
patients with NYHA class II-III heart failure.
Cardiac 123-I MIBG Scintigraphy
Most studies on cardiac sympathetic innervation have been performed with 123-iodine 
metaiodobenzylguanidine (MIBG) scintigraphy. The labeling of MIBG with 123-iodine 
permits visualization of myocardial sympathetic neuronal uptake. MIBG is a false neu-
rotransmitter, an analog of norepinephrine, which uses similar uptake mechanisms in the 
presynaptic nerve terminals as norepinephrine. The tracer is primarily transported into 
the presynaptic nerve terminal by sodium- and ATP-dependent transporters, referred to 
as uptake-1. In the nerve terminal, no degradation of MIBG takes places resulting in an 
accumulation of MIBG with high signal intensity. These signals are used for planar and 
tomographic (SPECT) imaging. Early planar imaging and SPECT are performed at 10-20 min 
after MIBG administration, whereas delayed planar imaging and SPECT are performed 3-4 
h after tracer injection. From planar images, global cardiac MIBG uptake can be assessed 
visually or semi-quantitatively using early and late heart-to-mediastinum (H/M) ratio (Fig-
ure 1). To calculate H/M ratio, regions of interest are manually drawn over the heart and 
upper mediastinum and the mean of myocardial counts per pixel is divided by the mean of 
mediastinal counts per pixel. Another planar-based parameter is the cardiac washout rate 
which indicates the rate by which MIBG is released from the myocardium between early 
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and delayed imaging. To calculate cardiac washout rate, late H/M ratio is subtracted from 
the early H/M ratio and divided by the early H/M ratio.
These planar-based parameters have been studied extensively in heart failure patients.22-28 
In particular, the prognostic value of global MIBG uptake has been studied by Merlet and 
colleagues.22, 23, 25 Initially, these authors22 have studied 90 patients with moderate-to-
severe heart failure, who underwent MIBG scintigraphy, chest X-ray, echocardiography 
and radionuclide angiography. After follow-up of 27 months, cardiac death and cardiac 
transplantations were reported in 22 and 10 patients, respectively. H/M ratio on delayed 
images was found to be the best independent predictor for cardiovascular death. Of note, 
patients with cardiac transplants were discarded from the survival analysis, whereas the 
second prognostic study performed by Merlet et al.25 included patients who underwent 
cardiac transplantation. In this study, 112 patients with NYHA class II-IV heart failure and 
LV ejection fraction <40% (measured with radionuclide angiography), underwent MIBG 
scintigraphy, right-sided invasive angiography, and routine clinical care (echocardiography, 
chest X-ray and peak exercise testing). After a mean follow-up of 27±20 months, cardiac 
death was noted in 25 patients, and cardiac transplantation was performed in 19. As illus-
trated in Figure 2, late H/M ratio was significantly lower in patients with major cardiac 
events as compared to patients without major cardiac events. Furthermore, the authors 
Figure 1. Planar MIBG imaging provides semi-quantitative parameters for assessment of global 
cardiac sympathetic innervation. Regions of interests are manually drawn within the heart and 
upper mediastinum. To calculate the heart-to-mediastinum ratio, the mean of cardiac counts per 
pixel is divided by the mean of counts per pixel within upper mediastinum.
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have demonstrated that the only independent predictors for adverse outcome were reduced 
myocardial MIBG uptake on delayed planar images and depressed LV ejection fraction.
Besides the prognostic value of global MIBG uptake on delayed images, several studies 
have reported on cardiac washout rate as a potential predictor for adverse cardiovascular 
outcome.29-32 In 59 patients with NYHA class II-IV and dilated cardiomyopathy, the predic-
tive value of MIBG parameters was studied by Momose and coworkers29; among all planar 
MIBG parameters cardiac washout rate was the most powerful predictor of cardiac death, 
over a mean follow-up of 25±13 months. For cardiac washout rate, a threshold level of 
52% showed optimal predictive value for cardiac death. In addition, similar results were 
demonstrated by Yamada et al.31 in 65 heart failure patients. Over a mean follow-up of 
34±19 months, cardiac washout rate was the only independent predictor for cardiac events. 
Furthermore, patients with cardiac events showed significant higher myocardial washout 
rate in comparison to patients without cardiac events, as illustrated in Figure 3. However, 
importantly, different threshold levels for cardiac washout rate were used in these two 
studies. Yamada et al.31 used a cutoff value of 27% for myocardial washout rate, whereas 
Momose and coworkers29 used a threshold level of 52%.
Presently, no consensus exists on the optimal cutoff values for early and late H/M ratios, 
cardiac washout rate, or the defect score on SPECT for prediction of outcome. Agostini et 
al.33 have performed in this respect an important retrospective study on 290 heart failure 
patients from 6 centers across Europe. According to the study protocol, planar and SPECT 
examinations were re-analyzed in a core laboratory by 3 independent observers who were 
Figure 2. Differences in late heart-to-mediastinum (H/M) ratio among heart failure patients with and 
without major cardiac events (cardiac death or cardiac transplantation), data based on reference 
25. Patients with major cardiac events showed significantly lower H/M ratio on delayed images as 
compared to patients without major cardiac events (134±14% vs. 105±15% or 110±9%, p<0.05 (‡, 
*).
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blinded to all other data. Over a follow-up of 2 year, major cardiac events were noted, 
including cardiac death, cardiac transplantation, potential lethal ventricular arrhythmias or 
appropriate ICD therapy. The authors showed that patients with a major cardiac event had 
significant lower H/M ratio on delayed images as compared to patients without a major 
cardiac event within the 2-year follow-up period. Moreover, for late H/M ratio, the optimal 
threshold to predict cardiac events was defined at 1.75, and yielded a sensitivity of 84% 
and specificity of 60%.
The available studies have focused on an index MIBG study and its relation to cardiac 
outcome. However, several studies used imaging before and after heart failure therapy and 
demonstrated improved MIBG uptake after optimization of heart failure medication; cur-
rently, limited information is available on the predictive value of serial MIBG studies.34-37 
Recently, Kasama et al.38 have reported on the predictive value of serial MIBG imaging in 
208 heart failure patients with a LV ejection fraction <45%. According to the study design, 
MIBG scintigraphy was performed at baseline and at 6 months follow-up. During a mean 
follow-up of 5±2 months, cardiac death was reported in 56 patients. The authors have 
reported that a 6-month change in washout rate >5%, was an independent predictor for 
all-cause cardiac death and sudden cardiac death.
Figure 3. Difference in myocardial washout rate between heart failure patients with adverse 
cardiac outcome (cardiac death or hospitalization) and heart failure patients without adverse cardiac 
outcome (data based on reference 31). Patients with adverse cardiac outcome demonstrated 
significant higher myocardial washout rate as compared to patients without adverse cardiac 
outcome (44.0±14.7% vs. 25.6±12.8%, p<0.05).
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Prediction of Ventricular Arrhythmia
Although most prognostic studies used all-cause mortality, cardiac mortality (progressive 
heart failure), or cardiac transplantation as endpoints, some studies suggested that MIBG 
imaging can also be used for prediction of ventricular arrhythmias and sudden cardiac 
death.39-41 At present, it is known that parasympathetic stimulation of the ventricles exerts 
anti-fibrillatory effects on the myocardium, whereas sympathetic activation of the ventricles 
appears to have a pro-arrhythmogenic effect on the myocardium. In patients with heart 
failure, the increased sympathetic tone along with a decreased parasympathetic activa-
tion can cause ventricular arrhythmias by enhancing cardiomyocyte pacemaker activity 
and reentrant excitation.39-41 Moreover, the presence of sympathetic denervated regions 
alongside regions with preserved sympathetic innervation can lead to an inhomogeneous 
neuronal release of norepinephrine, which subsequently, can cause marked alterations in 
action potential duration and configuration of the cardiomyocytes. Therefore, the electri-
cal signaling of the heart becomes non-uniform (electrophysiologic heterogeneity) which 
contributes to its vulnerability for development of ventricular arrhythmias.
Arora et al.39 have evaluated the role of MIBG imaging in 17 patients with an implantable 
cardioverter-defibrillator (ICD). In total, 10 patients received appropriate ICD discharges 
(reflecting potential lethal ventricular arrhythmias or sudden cardiac death) and these 
patients showed significant lower global (early) and regional (early and late) MIBG uptake 
as compared to patients who did not receive appropriate ICD discharges. Furthermore, 
comparable results were reported by Nagahara and colleagues41 who evaluated whether 
MIBG scintigraphy was useful for prediction of appropriate ICD therapy in 54 patients, after 
a mean follow-up of 15 months. Ten patients who received appropriate ICD therapy showed 
significantly lower late MIBG uptake as compared to patients who did not receive appropri-
ate ICD therapy. Moreover, H/M ratio on delayed images was found to be an independent 
predictor for appropriate ICD therapy.
MIBG studies have reported on planar imaging as a potential tool for risk stratification 
in heart failure patients. Although some innervation studies have employed regional MIBG 
uptake as a prognostic marker, the role of SPECT for prognostification of heart failure patients 
is unclear.42-44 In particular, the role of regional sympathetic denervated myocardium in 
the genesis of spontaneous ventricular arrhythmias has to be further elucidated.14-18 Bax et 
al.45 have studied whether abnormalities in sympathetic innervation on MIBG SPECT could 
predict inducibility of ventricular arrhythmias on electrophysiological testing in 50 patients 
with coronary artery disease and LV ejection fraction ≤40%. The MIBG SPECT defect score 
was significantly larger in the 30 patients with a positive electrophysiologic test as compared 
to patients without inducible ventricular arrhythmias, as illustrated in Figure 4.
In conclusion, the available studies have shown that cardiac innervation imaging holds 
great potential for risk stratification of heart failure patients. Recent studies suggest that 
particularly MIBG imaging may play a major role in identifying patients with LV dysfunction 
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at elevated risk of heart failure death or arrhythmic death. The results of these initial studies 
are promising, and more studies will help to determine the precise role of innervation imag-
ing in risk stratification of heart failure patients.
Figure 4. Defect score on late single photon emission computed tomography (SPECT) in patients 
with positive and negative electrophysiologic (EP) test (data based on reference 45). Patients 
with inducible ventricular tachyarrhythmias during EP testing showed significantly higher defect 
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Abstract
Objectives To evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging 
predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator 
(ICD) therapy (primary endpoint) and the composite of appropriate ICD therapy or cardiac 
death (secondary endpoint).
Background Although cardiac sympathetic denervation is associated with ventricular 
arrhythmias, limited data are available on the predictive value of sympathetic nerve imaging 
with 123-I MIBG on the occurrence of arrhythmias.
Methods Before ICD implantation, patients underwent 123-I MIBG and myocardial perfu-
sion imaging. Early and late 123-I MIBG (planar and SPECT) imaging was performed to 
assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate and 123-I 
MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to 
assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During 
follow-up, appropriate ICD therapy and cardiac death were documented.
Results One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. 
During a mean follow-up of 23±15 months, appropriate ICD therapy (primary endpoint) was 
documented in 24 (21%) patients and appropriate ICD therapy or cardiac death (secondary 
endpoint) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an independent 
predictor for both endpoints. Patients with a large late 123-I MIBG SPECT defect (summed 
score >26) showed significantly more appropriate ICD therapy (52% vs. 5%, p<0.01) and 
appropriate ICD therapy or cardiac death (57% vs. 10%, p<0.01) than patients with a small 
defect (summed score ≤26) at 3-year follow-up.
Conclusions Cardiac sympathetic denervation predicts ventricular arrhythmias causing 
appropriate ICD therapy as well as the composite of appropriate ICD therapy or cardiac 
death.
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Introduction
Sudden cardiac death (SCD) represents a leading cause of death in the developed world 
with an estimated annual incidence of 300,000 to 350,000 patients in the United States.1 
Implantable cardioverter-defibrillator (ICD) treatment is well established in patients at high 
risk for arrhythmic death. Initially, ICD treatment was indicated in survivors of sustained ven-
tricular tachycardia or ventricular fibrillation and more recently, in a population at high risk, 
regardless of prior ventricular tachyarrhythmias.2, 3 Based on large randomized trials, current 
guidelines recommend ICD treatment based solely on a poor left ventricular (LV) systolic 
function with or without nonsustained ventricular tachycardia as a class I indication.4
Post-hoc analysis of the second Multicenter Automated Defibrillator Implantation Trial 
(MADIT II) population showed that only 35% of patients received appropriate ICD therapy 
after 3-year follow-up.5 Additionally, the majority of arrhythmic deaths occurs in a population 
without ICD indication.6 Although the benefits of ICD treatment have been demonstrated, 
the question has been raised whether improvements in patient selection can be made.
Dysfunction of the autonomic nervous system (which can be assessed with 123-iodine 
metaiodobenzylguanidine (123-I MIBG) imaging) is thought to play an important role in the 
development of ventricular tachyarrhythmias.7, 8 Observational studies have demonstrated 
that cardiac denervation (as evidenced by reduced 123-I MIBG uptake) is associated with 
the occurrence of ventricular tachyarrhythmias.9, 10 Moreover, it was recently shown that 
inducibility of ventricular tachyarrhythmias was related to regional cardiac sympathetic 
denervation as assessed with 123-I MIBG imaging.10
At present, limited data are available on the role of 123-I MIBG imaging for prediction 
of ventricular arrhythmias. Moreover, the value of 123-I MIBG imaging in identification of 
patients who may benefit from ICD treatment is unclear. Accordingly, this study evaluated 
the role of cardiac sympathetic nerve imaging with 123-I MIBG for the prediction of ven-
tricular arrhythmias causing appropriate ICD therapy (primary endpoint) and the composite 
of appropriate ICD therapy or cardiac death (secondary endpoint).
Methods
Patient Population and Protocol
The patient population consisted of consecutive advanced heart failure patients undergoing 
cardiac 123-I MIBG imaging for heart failure risk stratification. The patients were clinically 
referred for ICD implantation based on poor LV function with or without nonsustained 
ventricular tachycardia (primary prevention) or prior sustained ventricular tachycardia or 
ventricular fibrillation (secondary prevention).4
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Prior to ICD implantation, patients underwent 123-I MIBG imaging and gated myocardial 
perfusion single photon emission computed tomography (SPECT) with 99m-technetium 
tetrofosmin (99mTc-tetrofosmin). 123-I MIBG imaging was clinically performed to assess 
cardiac sympathetic innervation for risk stratification of heart failure patients.11 Stress-rest 
myocardial perfusion imaging was performed to assess myocardial infarction (location and 
extent) and perfusion abnormalities (ischemia). All patients received optimal pharmacologic 
and revascularization therapy prior to ICD implantation. Patient’s medication was continued 
during cardiac imaging.
During follow-up, ventricular arrhythmia with subsequent ICD therapy (appropriate ICD 
therapy) and cardiac mortality were documented. The occurrence of primary endpoints 
(appropriate ICD therapy) and secondary endpoints (the composite of appropriate ICD ther-
apy or cardiac death) was assessed for all patients. Subsequently, the value of 123-I MIBG 
and myocardial perfusion imaging variables in the prediction of endpoints was studied.
123-I MIBG Imaging
Patients were pretreated with 120 mg sodium iodide to block uptake of free iodine-123 by 
the thyroid gland. Sodium iodide was given orally one hour before intravenous administra-
tion of 185 MBq 123-I MIBG (AdreView, General Electric Healthcare, United Kingdom). 
123-I MIBG planar imaging and SPECT were performed in supine position. A 10-minute 
planar image was acquired from an anterior thoracic view (256 x 256 matrix) 10-15 minutes 
after tracer administration.
Thereafter, a SPECT study (step and shoot mode, 90 projections, imaging time 30 minutes) 
was performed using a dual-head camera system (GCA-7200, Toshiba Corp., Tokyo, Japan) 
equipped with low-energy, parallel-hole high-resolution collimators. A 128 x 128 matrix 
was used for SPECT studies and a 20% energy peak was centered around the 159-keV 
energy peak of 123-I MIBG. Planar imaging and SPECT were repeated after 3 to 4 hours of 
tracer administration.
Heart-to-mediastinum (H/M) ratio was calculated from planar imaging using regions of 
interest, placed over the entire heart and upper mediastinum.10
123-I MIBG SPECT studies were processed with filtered back-projection and reconstructed 
into standard long- and short-axis, perpendicular to the heart axis.12 Three late SPECT stud-
ies were uninterpretable and excluded from evaluation of late 123-I MIBG SPECT.
From planar images, the H/M ratio was computed by dividing the mean counts per pixel 
within the myocardium by the mean counts per pixel within the mediastinum. H/M ratio 
was computed for early and late planar imaging. Cardiac washout rate was calculated using 
the following formula: [(early H/M ratio) – (delayed H/M ratio)] / (early H/M ratio) x 100. No 
background correction was performed in this study.
From SPECT images, the 123-I MIBG SPECT defect score was calculated by assessment 
of patient’s segmental 123-I MIBG tracer uptake score using the 17-segment model.12 Each 
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myocardial segment was scored according to the following tracer uptake scale: 0 = normal 
tracer uptake, 1 = mildly reduced tracer uptake, 2 = moderately reduced tracer uptake, 
3 = severely reduced tracer uptake, 4 = no tracer uptake. Subsequently, the 123-I MIBG 
SPECT defect score was calculated by summation of segmental tracer uptake scores. The 
123-I MIBG SPECT defect score was calculated for early and delayed SPECT. Data analysis 
was performed by 2 blinded and independent observers. Both readers scored all study seg-
ments and disagreements were resolved by consensus. There was no association between 
the myocardial perfusion and 123-I MIBG SPECT images as the different SPECT images were 
evaluated in separate sessions.
Reproducibility of the scoring system was evaluated by assessment of intra- and interob-
server variability. To assess intraobserver variability myocardial segments were scored twice 
by the same observer in a subset of 30 randomly selected patients. To assess interobserver 
variability, the second SPECT reader independently graded the myocardial segments from 
the same subset of patients.
Gated Myocardial Perfusion SPECT
Stress-rest gated myocardial perfusion SPECT with 99mTc-tetrofosmin (500 MBq, MYOVIEW, 
General Electric Healthcare, United Kingdom) was performed as previously described.13 
Myocardial perfusion images were analyzed by 2 observers who were blinded to 123-I 
MIBG images. The myocardium was divided into 17 segments and patient’s segmental perfu-
sion score was assessed using a similar tracer uptake scale as used for 123-I MIBG images.12 
The rest perfusion defect score was calculated by summation of segmental perfusion scores 
on resting myocardial perfusion imaging. Stress perfusion defect score was calculated by 
summation of segmental perfusion scores on stress myocardial perfusion imaging. Accord-
ingly, both rest and stress perfusion defect scores could range from 0 to 68 (17 x 4) points. 
Subsequently, the summed perfusion difference score (indicating the extent of reversible 
myocardial perfusion defects) was calculated by subtracting the rest perfusion defect score 
from the stress perfusion defect score. Finally, the 123-I MIBG/perfusion mismatch score was 
calculated by subtracting the rest perfusion defect score from the late 123-I MIBG SPECT 
defect score.
ICD Implantation
ICDs were implanted transvenously and without thoracotomy. Testing of sensing and pacing 
thresholds and defibrillation threshold testing was performed during implantation. In case 
of patient eligibility for cardiac resynchronization therapy (CRT), a combined CRT-D device 
was implanted.14
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Clinical Follow-up and Endpoints
Clinical follow-up was performed by evaluation of device interrogation printouts and patient 
medical record data every 3 to 6 months.
The primary endpoint was defined as the occurrence of appropriate ICD therapy. 
Appropriate ICD therapy was defined as anti-tachycardia pacing (ATP) or shock triggered 
by ventricular tachycardia or ventricular fibrillation. ICD discharges were evaluated at the 
outpatient pacemaker clinic using ICD stored electrocardiographic data by 2 experienced 
electrophysiologists, blinded to other study data.
The secondary endpoint was a combined endpoint consisting of appropriate ICD therapy 
or cardiac death. Cardiac mortality included death caused by progressive heart failure or 
acute myocardial infarction.
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation, and categorical data are 
expressed in numbers and percentages. Intra- and interobserver agreements were evalu-
ated by calculating the intraclass correlation coefficients (ICC). Excellent agreement was 
defined as an intraclass correlation coefficient of >0.8. Cox proportional hazards regression 
analysis was performed to evaluate which variables were associated with the primary or 
secondary endpoint. At first, univariable analysis of baseline characteristics was performed 
to determine significant predictors for both endpoints. All variables that were significantly 
associated with the primary or secondary endpoint at the p<0.15 level were included in a 
multivariable analysis. When early and late 123-I MIBG imaging variables showed strong 
interrelation (Pearson’s correlation coefficient >0.8), early 123-I MIBG imaging variables 
were excluded from multivariable analysis. Only late 123-I MIBG imaging variables were 
included in the multivariable analysis as they are the most commonly used 123-I MIBG 
imaging parameters.11 For each variable, a hazard ratio (HR) with a 95% confidence interval 
(CI) was calculated.
Cumulative event rates were assessed using the method of Kaplan-Meier and log rank test. 
Additionally, late 123-I MIBG SPECT defect score was subdivided using the prospectively 
selected median value as a cutoff. The median value was selected to ensure that the number 
of patients was equally distributed across the two groups. Additionally, receiver-operating-
characteristic (ROC) curve analysis was performed to determine the optimal cutoff point 
of 123-I MIBG SPECT defect score for prediction of appropriate ICD therapy. The optimal 
cutoff point was defined as the highest sum of sensitivity and specificity. All analyses were 
two-sided and a p-value <0.05 was considered statistically significant. Statistical analyses 
were performed with SPSS software package, version 15.0 (SPSS Inc., Chicago, Illinois, 
USA).




A total of 116 patients (80 men, mean age 65±9 yrs) were enrolled. Baseline characteristics 
of all patients are summarized in Table 1. One-hundred three (89%) patients received an 
ICD as primary prevention and 13 (11%) patients as secondary prevention for SCD. Eighty-
six (74%) patients were diagnosed with ischemic cardiomyopathy and 30 (26%) patients 
with nonischemic cardiomyopathy. The mean New York Heart Association (NYHA) func-
tional class was 2.9±0.6 and the mean LV ejection fraction (LVEF) was 28±8%. A combined 
CRT-D device was implanted in 101 patients. Medication consisted of beta-blockers (71% of 
patients), amiodarone (19% of patients), angiotensin converting enzyme - inhibitors (ACE-I) 
or angiotensin II (AT II) antagonists (85% of patients) and diuretics (88% of patients).
Table 1. Baseline characteristics of the study population (n=116)
Characteristics Values
Age (yrs) 65±9
Male gender 80 (69)
CRT-D 101 (87)
ICD indication
Primary prevention 103 (89)
Secondary prevention 13 (11)
Ischemic cardiomyopathy 86 (74)











ACE-I / AT II antagonist 98 (85)
Oral anticoagulant 76 (66)
Statin 79 (68)
Diuretic 102 (88)
Data are presented as mean ± standard deviation or as number (%).
ACE-I = angiotensin converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery 
disease; CRT-D = cardiac resynchronization therapy - defibrillator; ICD = implantable cardioverter-
defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
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123-I MIBG and Myocardial Perfusion Imaging
Baseline variables of 123-I MIBG and myocardial perfusion imaging are shown in Table 2. 
Mean values of early and late H/M ratio were 1.58±0.18 and 1.47±0.18. Accordingly, the 
mean value of cardiac washout rate was 6.80±6.37. Furthermore, the early 123-I MIBG 
SPECT defect score had a mean value of 21.6±10.1 and the late 123-I MIBG SPECT defect 
score had a mean value of 26.8±10.0.
The mean rest perfusion defect score was 16.8±10.3, whereas the mean stress perfusion 
defect score was 18.3±10.6. Accordingly, the mean summed perfusion difference score was 
1.4±2.8.
The mean 123-I MIBG/perfusion mismatch score was 9.9±12.3, indicating larger 123-I 
MIBG defects as compared to perfusion defects (26.8±10.0 vs. 16.8±10.3, p<0.01).
An excellent reproducibility was observed for early (ICC 0.98, 95% CI 0.94-0.99) and 
late (ICC 0.98, 95% CI 0.95-0.99) 123-I MIBG SPECT defect score. Furthermore, both SPECT 
readers showed an excellent agreement for early (ICC 0.97, 95% CI 0.95-0.99) and late (ICC 
0.98, 95% CI 0.96-0.99) 123-I MIBG SPECT defect score.
Figure 1 shows an example of normal resting myocardial perfusion with a defect on late 
123-I MIBG SPECT in a patient who received appropriate ICD therapy after 18 months of 
follow-up.
Table 2. Baseline variables of 123-I MIBG and myocardial perfusion imaging
123-I MIBG imaging
Early planar H/M ratio 1.58±0.18  
Late planar H/M ratio 1.47±0.18
Cardiac washout rate (%) 6.80±6.37
Early 123-I MIBG SPECT defect score 21.6±10.1
Late 123-I MIBG SPECT defect score 26.8±10.0
Myocardial perfusion imaging
Rest perfusion defect score 16.8±10.3
Stress perfusion defect score 18.3±10.6
Summed perfusion difference score 1.4±2.8
123-I MIBG/perfusion mismatch score 9.9±12.3
Data are presented as mean ± standard deviation. H/M ratio = heart-to-mediastinum ratio; 123-
I MIBG = 123-iodine metaiodobenzylguanidine; SPECT = single photon emission computed 
tomography.
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Primary Endpoint: Appropriate ICD Therapy
During 23±15 months follow-up, 86 episodes of ventricular tachycardia or ventricular fibril-
lation were terminated by appropriate ICD therapy in 24 (21%) patients. Appropriate ICD 
therapy consisted of 44 episodes of ATP in 16 (14%) patients and 42 ICD shocks in 15 (13%) 
patients.
Univariable analyses demonstrated that ICD indication (secondary vs. primary preven-
tion), ischemic cardiomyopathy, early 123-I MIBG SPECT defect score, late 123-I MIBG 
SPECT defect score, summed perfusion difference score, and the 123-I MIBG/perfusion 
mismatch score were significantly associated with appropriate ICD therapy (Table 3). The 
early 123-I MIBG SPECT defect score was excluded for multivariable analysis as it showed 
strong interrelation (r=0.82) with the late 123-I MIBG SPECT defect score.
Subsequently, multivariable analysis demonstrated that ICD indication (secondary vs. pri-
mary prevention) (HR 3.85, 95% CI 1.43-10.37, p<0.01) and late 123-I MIBG SPECT defect 
score (HR 1.13, 95% CI 1.05-1.21, p<0.01) were independent predictors for appropriate 
ICD therapy.
Figure 1 Example of resting myocardial perfusion (panel A) and late 123-I MIBG (panel B) imaging 
in an ICD patient. In this patient, showing normal myocardial perfusion and abnormal 123-I MIBG 
imaging, an appropriate ICD therapy (ATP) was documented after 18 months of follow-up.
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Characteristics HR (95% CI) p-value HR (95% CI) p-value
Age (yrs) 1.02 (0.98-1.08)     0.3
Male gender 1.52 (0.57-4.06)     0.4
CRT-D 1.15 (0.34-3.86) 0.8
ICD indication 4.55 (1.95-10.65)   <0.01*     3.85 (1.43-10.37) <0.01**
Ischemic cardiomyopathy 3.16 (0.94-10.60)  0.06* 2.10 (0.58-7.64) 0.3
NYHA functional class 1.10 (0.54-2.24) 0.8
LVEF (%) 1.02 (0.97-1.07) 0.5
Cardiovascular risk factors
Diabetes 0.60 (0.14-2.54) 0.5
Hypertension 1.13 (0.48-2.65) 0.8
Hypercholesterolemia 1.08 (0.43-2.73) 0.9
Smoking 1.39 (0.61-3.19) 0.4
Positive family history of CAD 0.87 (0.36-2.09) 0.7
Medication use
Beta-blockade 1.03 (0.43-2.47) 1.0
Amiodarone 1.64 (0.65-4.12) 0.3
ACE-I / AT II antagonist 1.23 (0.37-4.14) 0.7
Oral anticoagulant 0.61 (0.27-1.37)     0.2
Statin 1.45 (0.57-3.65 0.4
Diuretic 1.13 (0.27-4.8) 0.9
123-I MIBG imaging
Early H/M ratio 0.35 (0.04-3.30) 0.4
Late H/M ratio 0.27 (0.03-2.32) 0.2
Cardiac washout rate (%) 1.02 (0.95-1.09) 0.6
Early 123-I MIBG SPECT defect score 1.07 (1.03-1.12)       <0.01*
Late 123-I MIBG SPECT defect score 1.14 (1.08-1.20)       <0.01* 1.13 (1.05-1.21) <0.01**
Myocardial perfusion imaging 
Rest perfusion defect score 1.02 (0.98-1.06) 0.4
Stress perfusion defect score 1.03 (0.99-1.07) 0.2
Summed perfusion difference score 1.09 (0.98-1.22) 0.12* 0.93 (0.83-1.05) 0.3
123-I MIBG/perfusion mismatch score 1.06 (1.02-1.09) <0.01* 1.01 (0.97-1.06) 0.5
* Significant association with appropriate ICD therapy at a level of p<0.15 in univariate analysis. 
**Significant association with appropriate ICD therapy in multivariate analysis. ACE-I = angiotensin 
converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; CRT-D = cardiac 
resynchronization therapy - defibrillator; H/M ratio = heart-to-mediastinum ratio; 123-I MIBG = 
123-iodine metaiodobenzylguanidine; LVEF = left ventricular ejection fraction; NYHA = New York 
Heart Association; SPECT = single photon emission computed tomography.
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Risk Stratification for Appropriate ICD Therapy
Patients were stratified according to the prospectively selected median value of the 123-I 
MIBG SPECT defect score (summed score of 26) into patients with large (summed score >26) 
or small (summed score ≤26) late 123-I MIBG SPECT defect. Twenty-two (40%) patients 
with a large late 123-I MIBG SPECT defect (summed score >26) versus 2 (3%) patients with a 
small late 123-I MIBG SPECT defect (summed score ≤26) received appropriate ICD therapy 
(p<0.01).
The cumulative event rate at 3-year follow-up for appropriate ICD therapy was 52% 
(95% CI 36-68%) for patients with a large late 123-I MIBG SPECT defect versus 5% (95% 
CI 0-11%) for patients with a small late 123-I MIBG SPECT defect (Figure 2). Appropriate 
ICD therapy was significantly more often documented in patients with a large late 123-I 
MIBG SPECT defect when compared to patients with a small late 123-I MIBG SPECT defect 
during a mean follow-up of 23±15 months (log rank test, p<0.01). Moreover, the risk for 
appropriate ICD therapy was 13 times higher in patients with a large late 123-I MIBG SPECT 
defect as compared to patients with a small defect (HR 12.81, 95% CI 3.01-54.50, p<0.01).
ROC curve analysis showed an excellent predictive value of late 123-I MIBG SPECT 
defect score (AUC 0.87). The optimal cutoff value of 123-I MIBG SPECT defect score was 
defined at 31, which yielded a sensitivity of 75% and a specificity of 82% for prediction 
of appropriate ICD therapy. Patients with large 123-I MIBG SPECT defect (>31) showed 
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Figure 2. Kaplan-Meier curve showing the difference in appropriate ICD therapy (primary endpoint) 
between patients with a large (summed score >26) and small (summed score ≤26) late 123-I MIBG 
SPECT defect.
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significantly more appropriate ICD therapy as compared to patients with small late 123-I 
MIBG SPECT defect (≤31) at 3-year follow-up (9% vs. 66%, p<0.01).
Secondary Endpoint: Appropriate ICD Therapy or Cardiac Mortality
Appropriate ICD therapy or cardiac mortality was documented in 32 (28%) patients. In total, 
24 (21%) patients received appropriate ICD therapy and 8 (7%) patients died of progres-
sive heart failure without previous appropriate ICD therapy. In total, cardiac death was 
documented in 13 (11%) patients, including 5 (4%) patients who received appropriate ICD 
therapy before cardiac death.
Univariable analysis demonstrated that ICD indication (secondary vs. primary preven-
tion), ischemic cardiomyopathy, delayed H/M ratio, early 123-I MIBG SPECT defect score, 
late 123-I MIBG SPECT defect score and 123-I MIBG/perfusion mismatch score were 
significant predictors for the secondary endpoint. Since early and late 123-I MIBG SPECT 
defect score were strongly interrelated (r=0.82), early 123-I MIBG SPECT defect score was 
excluded for multivariable analysis.
Late 123-I MIBG SPECT defect score (HR 1.12, 95% CI 1.05-1.19, p<0.01) was the only 
independent predictor in multivariable analysis.
Risk Stratification for Appropriate ICD Therapy or Cardiac Mortality
Appropriate ICD therapy or cardiac mortality was documented in 28 (51%) patients with a 
large late 123-I MIBG SPECT defect (summed score >26) and in 4 (7%) patients with a small 
late 123-I MIBG SPECT defect (summed score ≤26) (p<0.01).
The cumulative event rate at 3-year follow-up for appropriate ICD therapy or cardiac 
mortality was 57% (95% CI 43-72%) for patients with a large late 123-I MIBG SPECT defect 
as compared to 10% (95% CI 0-20%) for patients with a small defect. Appropriate ICD 
therapy or cardiac death was significantly more documented in patients with a large late 
123-I MIBG SPECT defect as compared to patients with a small defect during a mean follow-
up of 23±15 months (log rank test, p<0.01). Moreover, the risk for appropriate ICD therapy 
or cardiac death was 8 times higher in patients with a large late 123-I MIBG SPECT defect 
than patients with a small defect (HR 8.29, 95% CI 2.91-23.63, p<0.01).
Discussion
The main findings of the study can be summarized as follows. Late 123-I MIBG SPECT defect 
score was an independent predictor for ventricular arrhythmias causing appropriate ICD 
therapy (primary endpoint) as well as the composite of appropriate ICD therapy or cardiac 
death (secondary endpoint). In addition, cumulative event rates for appropriate ICD therapy 
(52% vs. 5%, p<0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p<0.01) 
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were significantly higher in patients with a large late 123-I MIBG SPECT defect (summed 
score >26) as compared to patients with a small late 123-I MIBG SPECT defect (summed 
score ≤26) at 3-year follow-up. Importantly, only 2 (3%) patients with a small late 123-I 
MIBG SPECT defect received appropriate ICD therapy during follow-up.
Sudden Cardiac Death and Substrate Imaging
ICD therapy has become a cornerstone treatment in patients at high risk for sudden arrhyth-
mic death.4 Although the benefits of ICD treatment have been demonstrated, the question 
has been raised whether patient selection according to the current guidelines is adequate, 
as it is still unclear which patients will benefit from ICD treatment.2, 3, 5 Post-hoc analysis 
of the second Multicenter Automated Defibrillator Implantation Trial (MADIT II) population 
demonstrated that 35% of patients received appropriate ICD therapy after 3-year follow-up.5 
Moreover, the majority of arrhythmic deaths occurs in patients without ICD indication.6
Accordingly, attention has shifted towards improved risk stratification of patients cur-
rently indicated for ICD therapy. Recently, the AHA/ACC/HRS scientific statement on the 
noninvasive risk stratification in patients at risk for sudden arrhythmic death was published, 
indicating that the optimal method for risk stratification is unclear.15 Although an LVEF of 
<40% is most commonly used for stratification of patients at risk for ventricular arrhythmias, 
it does not allow accurate discrimination of patients with or without sudden arrhythmic 
death.15 Moreover, sudden arrhythmic death is often occurred in patients with an LVEF of 
>40%.6, 15
Since the majority of patients with documented arrhythmic death is diagnosed with 
structural heart disease, predominantly coronary artery disease (CAD), risk stratification 
should focus on further identification of the underlying substrate for arrhythmic death.15, 16 
Although the exact mechanisms of ventricular arrhythmias have been a matter of debate, 
it has been recognized that scar tissue and myocardial ischemia may serve as important 
substrates for ventricular arrhythmias. In acute myocardial infarction, ischemia may serve 
as a substrate for ventricular arrhythmias by inducing electrical instability.17 In chronic 
myocardial infarction, areas of slow conduction are present that facilitate the development 
of reentrant tachycardia.17
Different imaging techniques (predominantly myocardial perfusion imaging) have been 
used to provide information on the underlying substrate. Borger van der Burg et al.18 have 
evaluated the occurrence of ventricular arrhythmia and cardiac death in relation to isch-
emia, viability and scar tissue in 156 survivors of sudden arrhythmic death. Extent of scar 
tissue and reduced LV function (LVEF ≤30%) were significantly associated with occurrence 
of ventricular arrhythmias and cardiac death in univariable and multivariable analysis. In 
the present study, ischemia (summed perfusion difference score) was significantly associ-
ated with appropriate ICD therapy in univariable analysis. However, myocardial infarction 
(resting perfusion defect score) and ischemia were not significantly associated with both 
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endpoints in multivariable analysis. One of the potential explanations for these findings is 
the fact that the current study included patients with nonischemic cardiomyopathy, whereas 
in the study performed by Borger van der Burg et al.18 all patients were diagnosed with 
significant CAD. In the present study, a small amount of myocardial ischemia was observed 
which can be explained by the fact that these patients received optimal pharmacologic and 
revascularization therapy prior to ICD implantation.
The autonomic nervous system may also play an important role in the pathogenesis of 
ventricular arrhythmias.7, 8 Observational studies have associated the occurrence of ven-
tricular arrhythmias with abnormalities in cardiac sympathetic innervation.9, 10 Although 
the pathophysiologic mechanisms are unclear, it has been suggested that denervated but 
viable myocardium may be hypersensitive to circulating catecholamines. As compared to 
regions with normal cardiac innervation, denervated myocardium may respond differently 
to sympathetic activation with increased automaticity and enhanced triggering.7 In particu-
lar, the borderzone of infarct tissue may be predisposed to develop reentrant circuits as these 
regions are viable but may have damaged sympathetic nerves. Viable myocardium may 
already exhibit areas of denervation (innervation/perfusion mismatch), as sympathetic nerve 
fibers are more susceptible to myocardial ischemia than cardiac tissue.19, 20
Recently, the innervation/perfusion mismatch score was assessed in 50 patients with 
LV systolic dysfunction referred for electrophysiologic testing.10 The innervation/perfusion 
mismatch score was not significantly associated with inducibility of tachyarrhythmias in uni-
variable and multivariable analysis.10 Although the current study showed that 123-I MIBG/
perfusion mismatch score was associated with the occurrence of ventricular arrhythmias in 
univariable analysis, no significant association was found in multivariable analysis. The lack 
of prognostic value of 123-I MIBG/perfusion mismatch score may be related to the relatively 
small extent of 123-I MIBG/perfusion mismatch observed in the patient population.
Risk Stratification in Heart Failure Patients with 123-I MIBG Imaging
Several studies using 123-I MIBG imaging have demonstrated that abnormalities in global 
cardiac innervation were predictive for overall cardiac mortality in heart failure patients.21, 
22 Merlet et al.22 have shown that impaired cardiac sympathetic innervation, as assessed 
with planar 123-I MIBG imaging, was associated to adverse cardiac outcomes in 112 
patients with heart failure and a poor LV function. Over a mean follow-up of 27±20 months, 
the only independent predictors for mortality were low 123-I MIBG uptake (p<0.01) and LV 
function (p=0.02). Recently, Agostini et al.11 have confirmed the predictive value of cardiac 
123-I MIBG imaging in 290 patients with moderate-to-severe heart failure. Most important, 
the study has shown that patients with normal 123-I MIBG uptake had a significantly higher 
2-year event-free survival as compared to patients with reduced 123-I MIBG uptake (95% 
vs. 62%, p<0.01).
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123-I MIBG Imaging to Predict Ventricular Arrhythmia
Abnormalities in the autonomic nervous system have been related to the occurrence of ven-
tricular arrhythmias.9, 10 Arora et al.23 have performed a pilot study that evaluated cardiac 
sympathetic innervation in 17 patients with ICD treatment. ICDs were implanted because 
of sustained ventricular tachycardia or ventricular fibrillation. Patients with a documented 
ICD discharge showed significantly more global (early H/M ratio) and regional sympathetic 
denervation (early and late 123-I MIBG defect score) than patients without an ICD dis-
charge. In addition, Nagahara et al.24 have evaluated in a small study population whether 
abnormalities in cardiac sympathetic innervation were related to appropriate ICD therapy 
or lethal cardiac events. During a mean follow-up of 15 months, global cardiac sympathetic 
innervation (assessed with delayed H/M ratio) was independently associated with appropri-
ate ICD therapy.
Tamaki et al.25 have shown that myocardial washout rate was significantly associated 
with the occurrence of sudden arrhythmic death in 106 heart failure patients. In the current 
study however, myocardial washout rate was not predictive for appropriate ICD therapy. 
One of the explanations for these different findings may be the fact that myocardial washout 
rate was significantly lower in the current population when compared to the study by Tamaki 
et al.25 Although both studies enrolled individuals with heart failure and severely reduced 
LV systolic function, patient’s medication use was different. The number of patients receiving 
ACE-inhibitors (or AT II antagonists) was higher in the current study (85%) when compared 
to the study by Tamaki et al. (71%).25 Moreover, patients received beta-blockade therapy 
during 123-I MIBG SPECT in this study, whereas Tamaki et al.25 have excluded patients who 
had been receiving beta-blocking agents. It has been demonstrated that the use of ACE-
inhibitors or beta-blockers is associated with beneficial modulation of cardiac sympathetic 
activity.26, 27 Accordingly, changes in pharmacologic regime may lead to differences in 
myocardial washout of 123-I MIBG.
The relation between cardiac sympathetic innervation and inducibility of ventricular 
arrhythmias during electrophysiologic testing was recently evaluated in 50 patients with 
previous myocardial infarction and reduced LV systolic function.10 Although no significant 
association between global cardiac denervation and inducible ventricular arrhythmias 
was found, regional cardiac denervation was significantly higher in patients with positive 
electrophysiologic tests than patients with negative electrophysiologic tests. In addition, 
Mitrani et al.9 have evaluated whether patients with documented ventricular arrhythmias 
showed abnormal sympathetic innervation. Patients with ventricular tachycardia showed 
significantly more regional sympathetic denervation as compared to patients without ven-
tricular tachycardia. Likewise, this study has demonstrated that regional cardiac sympathetic 
denervation derived from late 123-I MIBG SPECT was significantly associated with ventricu-
lar arrhythmias causing appropriate ICD therapy. Moreover, late 123-I MIBG SPECT defect 
score was an independent predictor for appropriate ICD therapy. Importantly, the risk for 
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appropriate ICD therapy was 13 times higher in patients with a large late 123-I MIBG SPECT 
defect than patients with a small defect.
Limitations
Although the current study has clearly demonstrated that cardiac sympathetic denervation 
on late 123-I MIBG SPECT was predictive for both study endpoints, some limitations need 
to be considered. In this study, a heterogeneous patient population was enrolled, including 
patients with ischemic and nonischemic cardiomyopathy. Additional studies are needed 
to establish the specific role of 123-I MIBG imaging in these subpopulations. In addition, 
innervation and perfusion scans were scored visually, whereas an automatic quantitative 
approach would be preferred. Finally, 123-I MIBG SPECT in patients with severe LV dys-
function can be limited by reduced myocardial tracer uptake, hampering the acquisition 
of tomographic images of the heart. These limitations have been compensated by a long 
acquisition time and the use of a dual-head SPECT camera equipped with low-energy, 
parallel-hole high-resolution collimators.
Conclusions
Cardiac sympathetic denervation on late 123-I MIBG imaging predicts ventricular arrhythmia 
causing appropriate ICD therapy (primary endpoint) as well as the composite of appropriate 
ICD therapy or cardiac death (secondary endpoint). Cardiac sympathetic denervation as 
assessed with delayed 123-I MIBG SPECT may improve risk stratification for arrhythmic 
death in patients who have an indication for ICD treatment.
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Abstract
Background: Contrast-enhanced magnetic resonance imaging (MRI) allows assessment 
of total infarct size and infarct border zone, which can be used as markers of vulnerable 
myocardium for ventricular arrhythmias. Combined 123-iodine metaiodobenzylguanidine 
(123-I MIBG) and myocardial perfusion scintigraphy may also be used for infarct tissue 
characterization. However, at present, contrast-enhanced MRI and 123-I MIBG/perfusion 
scintigraphy have not been compared for characterization of infarct tissue. Accordingly, this 
descriptive study evaluated the relation between contrast-enhanced MRI and 123-I MIBG/
perfusion scintigraphy for assessment of infarct size and infarct border zone.
Methods: Ischemic heart failure patients who underwent contrast-enhanced MRI and 123-I 
MIBG/myocardial perfusion scintigraphy were included. Contrast-enhanced MRI and myo-
cardial perfusion scintigraphy were compared for assessment of infarct size. Infarct tissue 
was defined as myocardium with signal intensity (SI) ≥50% of the maximum SI on contrast-
enhanced MRI. The total perfusion defect score was used to assess infarct size on myocardial 
perfusion scintigraphy. Additionally, contrast-enhanced MRI was compared to 123-I MIBG/
perfusion scintigraphy for assessment of infarct border zone. On contrast-enhanced MRI, a 
significant infarct border zone (myocardium with ≥35% SI <50% of the maximum SI) was 
defined as an infarct border zone of >16.7 grams. On 123-I MIBG/perfusion scintigraphy, the 
total 123-I MIBG SPECT defect score and the innervation/perfusion mismatch score (infarct 
border zone) were used to assess vulnerable myocardium for ventricular arrhythmias.
Results: Forty patients (29 men, mean age 66±10 yrs) with ischemic heart failure were 
included. Contrast-enhanced MRI and myocardial perfusion scintigraphy showed good 
correlations for infarct size (r=0.72, p<0.01). In addition, patients with a significant infarct 
border zone on contrast-enhanced MRI showed a significantly higher total 123-I MIBG 
SPECT defect score (48.2±12.5% vs. 32.1±9.5%, p<0.05) and innervation/perfusion mis-
match score (13.9±11.0% vs. 6.8±6.0%, p<0.05) than patients without a significant infarct 
border zone.
Conclusions: Contrast-enhanced MRI and myocardial perfusion scintigraphy showed good 
correlations for infarct size. Importantly, patients with a significant infarct border zone on 
contrast-enhanced MRI showed significantly larger areas of infarct border zone on 123-I 
MIBG/perfusion scintigraphy.
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Introduction
Assessment of myocardial infarct tissue has shown to play an important role to risk stratify 
patients for adverse cardiac events.1, 2 Infarct tissue may show considerable spatial hetero-
geneity due to the presence of necrotic areas that are intermingled with bundles of viable 
cardiomyocytes.3, 4 These regions of infarct tissue heterogeneity are primarily present in the 
periphery of the infarcted myocardium, which is commonly referred to as the infarct border 
zone or peri-infarct region. Previous studies have postulated that peri-infarct regions may 
serve as an important substrate for the development of potential life-threatening ventricular 
arrhythmias through the presence of reentrant circuits originating from slow-conduction 
pathways.4-7
With its high spatial resolution and signal-to-image noise ratio, contrast-enhanced 
magnetic resonance imaging (MRI) allows an accurate delineation of myocardial infarct 
tissue.3-6, 8 More specifically, contrast-enhanced MRI enables the discrimination between 
myocardial infarct core and peri-infarct regions using marked differences in contrast-media 
hyperenhancement.3-6, 8 Accordingly, contrast-enhanced MRI permits the assessment of 
vulnerable myocardium at risk for ventricular arrhythmias by assessment of infarct border 
zone.4-6
In addition, nuclear imaging can be used for evaluation of myocardial infarct tissue.9 
Myocardial perfusion scintigraphy can be used for assessment of infarct size, whereas 
cardiac 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging permits assessment of 
myocardial sympathetic denervation.9-11 It has been shown that viable myocardium may 
already exhibit areas of sympathetic denervation, as sympathetic nerve fibers are more prone 
to the detrimental effects of myocardial ischemia than cardiomyocytes.10, 12 Thus, regions 
with deprived sympathetic innervation may reflect the total extent of injured myocardium, 
rather than the myocardial perfusion defect alone.
At present, regions with cardiac sympathetic denervation as assessed with 123-I MIBG 
imaging have been marked as myocardium at risk for ventricular arrhythmias.11, 13, 14 Areas 
of sympathetic denervation may show an enhanced triggering and automaticity when com-
pared to adjacent regions with preserved sympathetic innervation.14
Furthermore, it has been shown that the mismatch between cardiac sympathetic innerva-
tion and myocardial perfusion, which is referred to as the innervation/perfusion mismatch 
or infarct border zone, may be used as a marker of pro-arrhythmogenic myocardium.15-17
Contrast-enhanced MRI and 123-I MIBG/perfusion scintigraphy have currently not been 
compared for characterization of infarct tissue. More specifically, the relation between 
contrast-enhanced MRI and 123-I MIBG/perfusion scintigraphy for assessment of infarct 
border zone as a marker of vulnerable myocardium for ventricular arrhythmias has not 
been evaluated. Accordingly, this descriptive study aimed to explore the relation between 
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contrast-enhanced MRI and 123-I MIBG/perfusion scintigraphy for assessment of infarct size 
and infarct border zone, as markers for vulnerable myocardium for ventricular arrhythmias.
Materials and Methods
Patient Population and Protocol
The patient population consisted of patients with ischemic heart failure who were clinically 
referred for cardiac MRI, myocardial perfusion single photon emission computed tomogra-
phy (SPECT) and cardiac 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging for 
risk stratification of heart failure. Patient data were prospectively collected in the depart-
mental Cardiology Information System (EPD-Vision®, Leiden University Medical Center, 
Leiden, the Netherlands) and retrospectively analyzed. All patients were treated according 
to the MISSION! - Heart Failure care track operational at the LUMC.18 Patients with unstable 
angina or acute coronary syndromes were excluded from study analysis.
Ischemic etiology was based on the presence of previous (1) myocardial infarction, (2) 
percutaneous coronary intervention, (3) coronary artery bypass grafting or (4) evidence 
of coronary artery disease (CAD) on previous diagnostic tests. Risk factors for CAD were 
derived from patient medical record data.
First, contrast-enhanced MRI and myocardial perfusion scintigraphy were compared 
for the assessment of myocardial infarct size. On contrast-enhanced MRI, infarct size was 
assessed with signal intensity (SI) analyses on short-axis images, in which infarct tissue was 
defined as myocardium with SI ≥50% of the maximum SI. On myocardial perfusion scintig-
raphy, the total perfusion defect score was used to assess myocardial infarct size (Table 1).
Consecutively, contrast-enhanced MRI and nuclear imaging were compared for 
assessment of infarct border zone (Table 1). Contrast-enhanced MRI was used to assess 
infarct border zone which was used as a marker of vulnerable myocardium for ventricular 
arrhythmias (pro-arrhythmogenic myocardium).4-6 As previously reported, a cutoff value of 
16.7 grams of infarct border zone allows identification of patients at risk for potential lethal 
ventricular arrhythmias.6 Accordingly, patients with >16.7 grams of infarct border zone were 
considered to have a significant infarct border zone on contrast-enhanced MRI.
In addition, both total 123-I MIBG SPECT defect score as derived from late 123-I MIBG 
SPECT and the mismatch between cardiac sympathetic innervation and myocardial per-
fusion (the innervation/perfusion mismatch) were used to identify the infarct border zone 
(Table 1).
Thereafter, the total 123-I MIBG SPECT defect score and the innervation/perfusion mis-
match score (infarct border zone) were evaluated in patients with (>16.7 grams) and without 
(≤16.7 grams) a significant infarct border zone on contrast-enhanced MRI.




Contrast-enhanced images were acquired with a 1.5-T Gyroscan ACS-NT/Intera MRI scanner 
(Philips Medical Systems, Best, the Netherlands) equipped with powertrack 6000 gradients 
in combination with a 5-element cardiac synergy coil. Using vector electrocardiographic 
(ECG) gating, cardiac images were acquired in patients in supine position during breath 
holds of approximately 15 seconds. Using 10-12 imaging levels (one slice per breath hold), 
the entire heart was imaged from apex to cardiac base19 in short-axis view with the use of 
a balanced turbo-field echo sequence with parallel imaging (SENSE, acceleration factor 2). 
Subsequently, contrast-enhanced imaging was performed 15 minutes after bolus infusion of 
0.15 mmol/kg of gadolinium diethylenetriamine penta-acetic (Magnevist, Schering/Berlin, 
Germany) using an inversion-recovery 3D turbo-field echo sequence with parallel imaging 
(SENSE, acceleration factor 2). The entire heart was imaged in short-axis view during one 
breath-hold with 20-24 imaging levels. The number of imaging levels was dependent on 
the size of the heart. The inversion time was assessed by real-time plan scan to null normal 
myocardial signal. The cardiac images were send to a remote off-line workstation with 
dedicated in-house developed MASS research software (Mass V2008-EXP, LKEB, Leiden, the 
Netherlands).20
At first, contrast-enhanced short-axis images were evaluated by an independent observer 
to assess infarct size as well as infarct border zone, as shown in Figure 1. For this purpose, 
endocardial and epicardial contours were manually outlined on contrast-enhanced short-
axis images. After the contour detection, the region with maximal SI within the scarred 
myocardium was defined on short-axis images. Myocardial infarct tissue was defined as 
myocardium with SI ≥50% of the maximum SI, whereas the infarct border zone was defined 
as myocardium with ≥35% SI <50% of the maximum SI. The full-width at half maximum 
(FWHM) criterion was used to define myocardial infarct tissue.21, 22 As previously reported, 
Table 1. Baseline imaging variables of the patient population (n=40)
Baseline variables Definition
Myocardial infarct Size
Contrast-enhanced MRI (%) Myocardium with SI ≥50% of maximum SI
Myocardial perfusion imaging (%) Total perfusion defect score
Myocardium at risk for ventricular arrhythmias
Contrast-enhanced MRI (%) Myocardium with ≥35% SI <50% of maximum SI
123-I MIBG imaging (%) Total 123-I MIBG SPECT defect score
123-I MIBG/perfusion imaging (%) Innervation/perfusion mismatch score
Data are presented as percentages (%). 123-I MIBG = 123-iodine metaiodobenzylguanidine; MRI 
= magnetic resonance imaging; SI = signal intensity; SPECT = single photon emission computed 
tomography.
248
the threshold for infarct border zone was based on the ratio of 2:3 for threshold SI of infarct 
border zone versus infarct core.5, 6 Myocardial infarct size and infarct border zone were 
expressed in percentages of the myocardium.
Patients with >16.7 grams of infarct border zone were classified as patients with a 
significant infarct border zone, whereas patients with ≤16.7 grams of infarct border zone 
were classified as patients without a significant infarct border zone.6 As previously reported, 
a cutoff of 16.7 grams of infarct border zone allows identification of patients at risk for 
potential lethal ventricular arrhythmias.6
Sympathetic Nerve Imaging with 123-I MIBG
Acquisition and Analysis
One hour prior to intravenous administration of 185 MBq 123-I MIBG (AdreView, General 
Electric Healthcare, United Kingdom), patients were pretreated with 120 mg sodium iodide 
to block the thyroid uptake of free iodine-123. In all patients, 123-I MIBG SPECT was per-
formed on a dual-head camera system (GCA-7200, Toshiba Corp., Tokyo, Japan) equipped 
with low-energy, parallel-hole high-resolution collimators. SPECT images were acquired 
using a step and shoot mode (90 projections, imaging time 30 minutes). A 128 x 128 matrix 
was used for SPECT studies and the energy window was symmetrically centered to 20% of 
the 159-keV energy peak of 123-I MIBG. SPECT was repeated 3-4 hours after intravenous 
injection of 123-I MIBG. After the SPECT studies were processed with iterative reconstruc-
tion, they were reconstructed into short-, vertical and horizontal long-axis according to the 
standard recommendations.23
A B C
Figure 1. Contrast-enhanced magnetic resonance imaging (MRI) was used for assessment of 
infarct tissue heterogeneity, which consisted of myocardial infarct tissue and infarct border zone. 
The infarct border zone was used as a marker of myocardium at risk for ventricular arrhythmias 
(pro-arrhythmogenic myocardium).5, 6 At first, contrast-enhanced short-axis images were used 
to evaluate the presence of myocardial infarct tissue (panel A, white arrows). Consecutively, 
endocardial (red) and epicardial (green) contours were manually outlined on short-axis images 
(panel B). With the use of the maximum signal intensity (SI) within the infarcted myocardium, the 
infarct tissue (red area) and the infarct border zone (yellow area) were assessed (panel C). Infarct 
tissue was defined as myocardium with SI ≥50% of the maximum SI, whereas the infarct border 
zone (area at risk) was defined as myocardium with ≥35% SI <50% of the maximum SI.
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The late 123-I MIBG SPECT images were used to calculate the total 123-I MIBG SPECT 
defect score by two independent observers. Using the 17-segment model23, each myocar-
dial segment was scored using the following tracer uptake scale: 0 = normal tracer uptake, 1 
= mildly reduced tracer uptake, 2 = moderately reduced tracer uptake, 3 = severely reduced 
tracer uptake, 4 = no tracer uptake. The total 123-I MIBG SPECT defect score was calculated 
by the summation of each segmental uptake score. Accordingly, the total 123-I MIBG defect 
score could range from 0 to 68 (0-100%). As previously reported11, a low intra-observer (ICC 
0.98, 95% CI 0.95-0.99) as well as a low inter-observer (ICC 0.98, 95% CI 0.96-0.99) vari-
ability was demonstrated for late 123-I MIBG SPECT defect score.11 The total 123-I MIBG 
SPECT defect score (%) was used as a measure of vulnerable myocardium for ventricular 
arrhythmias, as shown in Table 1.
Gated Myocardial Perfusion SPECT
Acquisition and Analysis
Resting ECG-gated myocardial perfusion SPECT with 99mTc-tetrofosmin (500 MBq, injected 
at rest) was performed using a triple-head SPECT camera system (GCA 9300/HG; Toshiba 
Corp., Tokyo, Japan) equipped with high-resolution, low-energy collimators. A 20% window 
was centered around the 140-keV energy peak of 99mTc-tetrofosmin. Ninety projections 
were acquired according to the step and shoot method (35 s/projection, 64 x 64 matrix, 
total imaging time 23 minutes) over a 360-degree circular orbit. ECG gating was applied 
on the cardiac cycle with 16 frames per cardiac cycle using a tolerance window of 50%. 
After the pre-filtration was performed using a Butterworth filter, images were reconstructed 
into long- and short-axis projections perpendicular to the heart axis using a filtered back 
projecting algorithm. No attenuation correction was used.23
Thereafter, resting myocardial SPECT images were evaluated by two independent observ-
ers who were unaware of the 123-I MIBG and contrast-enhanced MRI data. Based on the 
17-segment model23, each myocardial segment was scored using the similar tracer uptake 
scale as applied for 123-I MIBG SPECT images. Subsequently, patient’s segmental scores 
were summed, yielding a total perfusion defect score per patient, which could range from 0 
to 68 (0-100%). As shown in Table 1, the total perfusion defect score was used as a measure 
of myocardial infarct size.
Finally, the innervation/perfusion mismatch score (infarct border zone) was assessed by 
subtracting the total perfusion defect score from total 123-I MIBG SPECT defect score.11 The 
innervation/perfusion mismatch score was used as a measure of vulnerable myocardium 
for ventricular arrhythmias (Table 1). The innervation/perfusion mismatch score could vary 
between 0 and 68 (0-100%). Figure 2 provides an example of a patient with a considerable 
innervation/perfusion mismatch, in which the sympathetic nerve defect as assessed with late 
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123-I MIBG SPECT (panel B) was significantly larger than the myocardial perfusion defect 
(panel A).
Statistical Analysis
Continuous variables were expressed as mean ± SD, and categorical data as numbers or 
percentages. Kolmogorov-Smirnov tests were used to evaluate the distribution of the data. 
When non-normally distributed, data were presented as medians and 25th and 75th per-
centiles. Contrast-enhanced MRI and myocardial perfusion scintigraphy were compared 
for assessment of infarct size using Pearson’s linear regression analyses and paired t tests. 
Paired t tests were used to compare contrast-enhanced MRI with 123-I MIBG imaging and 
myocardial perfusion scintigraphy for assessment of infarct border zone.
Furthermore, patients were stratified according to the prospectively selected cutoff value 
of 16.7 grams of infarct border zone on contrast-enhanced MRI into patients with (>16.7 
grams) and without (≤16.7 grams) significant infarct border zone. As previously reported, 
a cutoff value of 16.7 grams of infarct border zone allows identification of patients at risk 
for potential lethal ventricular arrhythmias.6 Student’s t tests were used to evaluate the total 
123-I MIBG SPECT defect score and the innervation/perfusion mismatch score in patients 
with (>16.7 grams) and without (≤16.7 grams) a significant infarct border zone on contrast-
enhanced MRI. All p-values were two-sided and a p-value <0.05 was considered to indicate 
statistical significance. Statistical analyses were performed with the use of dedicated soft-
ware (SPSS version 16.0, SPSS inc., Chicago, Illinois, USA).
A B
Infarct Region Denervated Myocardium
Figure 2. Nuclear imaging techniques were used for assessment of myocardial infarct size as well 
as myocardium at risk for ventricular arrhythmias.
A. Myocardial scar tissue was assessed with 99mTc-tetrofosmin resting myocardial perfusion single 
photon emission computed tomography (SPECT). The total perfusion defect score on myocardial 
perfusion scintigraphy was used as a marker of myocardial infarct size.
B. The total 123-iodine metaiodobenzylguanidine (123-I MIBG) SPECT defect score as derived 
from late 123-I MIBG SPECT as well as the innervation/perfusion mismatch score (the difference 
between resting perfusion imaging and late 123-I MIBG SPECT) were used as markers of 
myocardium at risk for ventricular arrhythmias.




A total of 40 patients (29 men, mean age 66±10 yrs) with ischemic heart failure were 
enrolled. Baseline characteristics of the patient population are summarized in Table 2. 
The mean New York Heart Association (NYHA) functional class was 2.6±0.7. Medication 
consisted of diuretics (78% of patients), angiotensin converting enzyme - inhibitors (ACE-I) 
or angiotensin II (AT II) antagonists (88% of patients) or beta-blockers (68% of patients). 
Contrast-enhanced MRI and 123-I MIBG imaging were performed within a mean period of 
8.1±47.3 days. No acute coronary events or change in medication was documented between 
both examinations. Contrast-enhanced MRI showed a mean LV mass of 149.7±55.1 grams.
Table 2. Baseline characteristics of the study population (n=40)
Characteristics Values
Age (yrs) 66±10
Male gender 29 (73)
LVEF (%) 27±10
NYHA functional class 2.6±0.7
Previous MI 27 (68)
Previous PCI 17 (43)





Family history of CAD 14 (35)








Data are presented as mean ± standard deviation or as number (%).
ACE-I = angiotensin converting enzyme - inhibitor; AT = angiotensin; CABG = coronary artery bypass 
graft surgery; CAD = coronary artery disease; LVEF = left ventricular ejection fraction; MI = myocardial 
infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention.
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Assessment of Myocardial Infarct Size
The infarct size on myocardial perfusion scintigraphy was significantly larger as compared to 
the infarct size on contrast-enhanced MRI; the mean infarct size as assessed with myocardial 
perfusion scintigraphy and contrast-enhanced MRI were 30.6±12.6% and 16.9±11.8%, 
respectively (p<0.05). Contrast-enhanced MRI and myocardial perfusion scintigraphy were 
well-correlated for assessment of infarct size (r=0.72, n=40, p<0.01), as shown in Figure 3.
Assessment of Infarct Border Zone
Contrast-enhanced MRI showed a mean infarct border zone of 16.1±7.3%. The mean total 
123-I MIBG SPECT defect score was 41.4±13.8%, whereas the mean innervation/perfusion 
mismatch score (infarct border zone) was 10.9±9.8%. The total 123-I MIBG SPECT defect 
score (p<0.05) and the innervation/perfusion mismatch score (infarct border zone) (p<0.05) 
were significantly different when compared to the infarct border zone on contrast-enhanced 
MRI. Additionally, patients were stratified according to the prospectively selected value of 
16.7 grams of infarct border zone (as derived from contrast-enhanced MRI) into patients 
with (>16.7 grams) and without (≤16.7 grams) significant infarct border zone.6 In total, 23 
(58%) patients showed a significant infarct border zone on contrast-enhanced MRI, whereas 
17 (42%) patients showed no significant infarct border zone on contrast-enhanced MRI.
As shown in Figure 4, patients with a significant infarct border zone on contrast-enhanced 
MRI (>16.7 grams) showed a significantly larger total 123-I MIBG SPECT defect score as 











































y = 0.7691x + 17.571
r = 0.72, p<0.01
Figure 3. Contrast-enhanced magnetic resonance imaging (MRI) and myocardial perfusion 
scintigraphy were compared for the assessment of myocardial infarct size. Contrast-enhanced 
MRI and myocardial perfusion scintigraphy were well-correlated for the assessment of infarct size 
(r=0.72, p<0.01).
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Figure 4. The infarct border zone (myocardium at risk for ventricular arrhythmias) can be assessed 
with contrast-enhanced magnetic resonance imaging (MRI). As previously reported, a cutoff of 16.7 
grams of infarct border zone allows identification of patients at risk for life-threatening ventricular 
arrhythmias.6 Patients with a significant infarct border zone on contrast-enhanced MRI (infarct 
border zone >16.7 grams) showed a significantly larger total 123-iodine metaiodobenzylguanidine 
(123-I MIBG) single photon emission computed tomography (SPECT) defect as compared to 
patients without a significant infarct border zone on contrast-enhanced MRI (infarct border zone 
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Figure 5. Contrast-enhanced magnetic resonance imaging (MRI) permits assessment of infarct 
border zone, which was used as a marker of myocardium at risk for ventricular arrhythmias. A 
cutoff value of 16.7 grams of infarct border zone was used to define a significant infarct border 
zone.6 Patients with a significant infarct border zone on contrast-enhanced MRI (infarct border 
zone >16.7 grams) showed a significantly larger innervation/perfusion mismatch as assessed with 
123-iodine metaiodobenzylguanidine (123-I MIBG) imaging and myocardial perfusion scintigraphy 
as compared to patients without a significant infarct border zone on contrast-enhanced MRI (infarct 
border zone ≤16.7 grams) (13.9±11.0% vs. 6.8±6.0%, p<0.05).
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compared to patients without a significant infarct border zone on contrast-enhanced MRI 
(48.2±12.5% vs. 32.1±9.5%, p<0.05). Similarly, the innervation/perfusion mismatch (infarct 
border zone) was significantly larger in patients with an infarct border zone of >16.7 grams 
than in patients with an infarct border zone of ≤16.7 grams on contrast-enhanced MRI 
(13.9±11.0% vs. 6.8±6.0%, p<0.05) (Figure 5).
Discussion
The current study showed that infarct size as assessed with contrast-enhanced MRI was 
significantly correlated to infarct size on myocardial perfusion scintigraphy. Importantly, 
this descriptive study is the first showing that patients with a significant infarct border zone 
on contrast-enhanced MRI showed a significantly larger innervation/perfusion mismatch 
(infarct border zone) on 123-I MIBG/perfusion scintigraphy when compared to patients 
without a significant infarct border zone on contrast-enhanced MRI.
Infarct tissue may exhibit substantial heterogeneity as necrotic myocardium can be pres-
ent along with different stages of healed myocardial infarction.3, 4 Myocardial necrosis is 
primarily located in the middle of the infarct region, while bundles of viable cardiomyocytes 
bordered by dense fibrosis (referred to as tissue heterogeneity) can be found in the periphery 
of the infarct region, the so-called peri-infarct zone or border zone.4-6 Thus far, cardiac 
MRI and 123-I MIBG/perfusion scintigraphy have not been related for infarct tissue char-
acterization, nor have these imaging techniques been compared for assessment of infarct 
border zone, which can be used as a marker of vulnerable myocardium for ventricular 
arrhythmias.4, 6
Myocardial Infarct Size
Myocardial infarct tissue can be assessed with several non-invasive imaging techniques, 
including contrast-enhanced MRI, echocardiography as well as nuclear imaging. Among 
these techniques, contrast-enhanced MRI is considered the standard of reference for 
evaluation of infarct tissue as it allows an accurate delineation of infarct area and border 
zone using marked differences in contrast-media hyperenhancement within the infarcted 
myocardium.3-6, 8
Beyond contrast-enhanced MRI, nuclear imaging is another reliable imaging technique 
for assessment of myocardial infarct tissue.9 Moreover, nuclear imaging techniques, such as 
myocardial perfusion scintigraphy have been used frequently for evaluation of myocardial 
infarct tissue in clinical practice. Previous studies have shown that myocardial perfusion 
scintigraphy was significantly correlated to contrast-enhanced MRI for assessment of infarct 
size.3, 24, 25 In 12 post-infarct patients, Lima et al.3 have demonstrated good correlations 
between contrast-enhanced MRI and myocardial perfusion imaging for myocardial infarct 
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size (r=0.92, p<0.01). More recently, Ibrahim et al.25 have shown that infarct size as assessed 
with contrast-enhanced MRI was well-correlated with infarct size as derived from myocardial 
perfusion SPECT (r=0.86, p<0.05). Moreover, infarct size was significantly overestimated by 
myocardial perfusion SPECT (7% of the LV, p<0.03) at 42 minutes post-injection using a 
constant inversion time of 300 ms. Similarly, the current study has shown that myocardial 
infarct size on contrast-enhanced MRI was significantly correlated to infarct size as assessed 
with myocardial perfusion scintigraphy. Moreover, both studies showed an overestimation 
of infarct size on myocardial perfusion SPECT as compared to contrast-enhanced MRI. This 
finding may be related to differences in spatial resolution between both techniques; myocar-
dial perfusion SPECT has a markedly lower spatial resolution than contrast-enhanced MRI, 
which may have introduced partial volume effects with an overestimation of infarct size. In 
addition, both techniques used a different approach for quantification of infarct size. In the 
current study, the infarct size on contrast-enhanced MRI was defined as myocardium with SI 
≥50% of the maximum SI (expressed as a percentage of the total myocardium), whereas the 
infarct size on myocardial perfusion SPECT was assessed using the semi-quantitative resting 
perfusion defect score (expressed as a percentage of the total perfusion defect).
Infarct Border Zone
Beyond the assessment of infarct size, contrast-enhanced MRI allows evaluation of infarct 
tissue heterogeneity by demarcation of infarct core and border zone.4-6 The infarct border 
zone is considered an important infarct region as it may serve as substrate for development 
of ventricular arrhythmias; patients with a large infarct border zone showed an increased 
susceptibility for ventricular arrhythmias as compared to patients with small infarct border 
zone.4, 6
Nuclear imaging may also be used for evaluation of arrhythmogenic myocardium by 
assessment of total denervated myocardium and the innervation/perfusion mismatch, which 
is referred to as the infarct border zone.11, 13, 14 Previous studies have indicated that regions 
with deprived cardiac sympathetic innervation as assessed with 123-I MIBG imaging may 
play an important role in ventricular arrhythmogenesis as they show an enhanced triggering 
and automaticity when compared to adjacent regions with relatively intact sympathetic 
innervation of the myocardium.14 In addition, the mismatch between cardiac sympathetic 
innervation and myocardial perfusion (innervation/perfusion mismatch) can be used as 
a marker for pro-arrhythmogenic myocardium as it reflects the infarct border zone.15-17 
Regions with cardiac sympathetic denervation but preserved myocardial viability can be 
present as neural tissue exhibits an increased susceptibility to hypoxia as compared to 
cardiomyocytes.10 Simoes et al.16 have shown that the innervation/perfusion mismatch as 
assessed with 123-I MIBG imaging and 201-thallium perfusion scintigraphy was significantly 
correlated to prolonged ventricular repolarization and delayed depolarization in 67 patients 
with ischemic heart disease. Based upon these initial studies, it has been suggested that 
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nuclear imaging with 123-I MIBG/perfusion scintigraphy can be used to identify patients at 
risk for arrhythmic events.
The current descriptive study has shown that patients with a significant infarct border 
zone on contrast-enhanced MRI exhibited a significantly higher total 123-I MIBG SPECT 
defect score and innervation/perfusion mismatch score (infarct border zone) as compared 
to patients without a significant infarct border zone on contrast-enhanced MRI. This is an 
important finding as it indicates that 123-I MIBG/perfusion scintigraphy permits identifica-
tion of patients with a significant infarct border zone, and for this reason may help to identify 
patients at risk for adverse arrhythmic events. Eventually, the assessment of arrhythmogenic 
substrate (infarct border zone) may be used for identification of patients indicated for 
implantable cardioverter-defibrillator (ICD) therapy.
Although contrast-enhanced MRI and 123-I MIBG/perfusion scintigraphy allowed identi-
fication of vulnerable myocardium for ventricular arrhythmia by assessment of infarct border 
zone, both techniques showed differences in the size of the infarct border zone. This may be 
related to the superior spatial resolution of contrast-enhanced MRI when compared to the 
nuclear imaging techniques. In addition, the differences between both imaging techniques 
for assessment of infarct border zone may be related to the fact that the infarct border 
zone on contrast-enhanced MRI can be calculated using several approaches. At present, 
additional studies are needed that determine the optimal criterion for assessment of infarct 
border zone.
Although the study showed that 123-I MIBG/perfusion scintigraphy can be used to assess 
infarct border zone, some limitations need to be acknowledged. First, the study findings are 
based on a relatively small patient population consisting of 40 patients with ischemic heart 
failure, whereas a larger patient population would have been preferred for comparison of 
both techniques. Moreover, the prognostic value of infarct size and infarct border zone has 
not been evaluated as the current study was only designed to describe the relation between 
contrast-enhanced MRI and 123-I MIBG/perfusion scintigraphy for assessment of infarct size 
and infarct border zone.
Conclusion
Contrast-enhanced MRI and myocardial perfusion scintigraphy were significantly correlated 
for infarct size. Importantly, patients with a significant infarct border zone on contrast-
enhanced MRI showed a significantly larger innervation/perfusion mismatch (infarct border 
zone) on 123-I MIBG/perfusion scintigraphy.
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Cardiovascular Disease 
Cardiovascular disease remains one of the leading health care issues these days, even 
though considerable advances in diagnosis, therapeutic options and prognostification of 
patients with cardiovascular disease have been made in the last couple of decades.1-3
Novel insights into cardiac imaging and post-processing techniques can be used to 
further improve currently applied diagnostic, therapeutic and prognostic algorithms for 
patients with cardiovascular disease.
The general introduction of the thesis (chapter 1) describes novel insights into cardiac 
imaging for evaluation of patients with cardiovascular disease, predominantly in the setting 
of coronary artery disease (CAD) and chronic heart failure.
The aim of the thesis was to evaluate the role of novel insights into cardiac imaging 
for diagnosis (Part I), treatment (Part II) and risk stratification (Part III) of patients with 
cardiovascular disease.
Part I: Dedicated Automated Quantitative Computed Tomography in 
Patients with Coronary Artery Disease
Chapter 2 provides an overview of the currently available approaches for cardiac computed 
tomography (CT) to quantify coronary atherosclerosis. In addition, it reviews the potential 
value of quantitative cardiac CT to guide percutaneous coronary intervention procedures.
The study described in chapter 3 was designed to demonstrate the feasibility of a novel 
dedicated algorithm for automated quantification of stenosis severity on cardiac CT in a direct 
comparison to quantitative coronary angiography (QCA). In 100 patients (53 men, 59.8±8.0 
yrs), cardiac CT and QCA showed good correlations for percentage diameter stenosis on a 
vessel-basis (n=282, r=0.83, p<0.01) and a patient-basis (n=93, r=0.86, p<0.01). Further-
more, a good agreement was observed between cardiac CT and QCA for semi-quantitative 
assessment of diameter stenosis (accuracy of 95%). Moreover, quantitative CT showed a 
significantly higher positive predictive value (100% vs. 78%, p<0.05) and higher diagnostic 
accuracy (95% vs. 87%, p=0.08) for assessment of ≥50% diameter stenosis when compared 
to visual analysis. In summary, quantitative CT was well-correlated to QCA for assessment 
of stenosis severity. Importantly, the study showed an improved diagnostic accuracy and 
positive predictive value of quantitative CT when compared to visual analysis of CT images.
Chapter 4 describes the feasibility of automated coronary plaque quantification on 
cardiac CT using dedicated software with a novel 3D coregistration algorithm of CT and 
intravascular ultrasound (IVUS). A total of 51 patients (40 men, 58±11 yrs, 103 coronary 
arteries) with 146 lesions were evaluated. Quantitative CT and IVUS showed good correla-
tion for minimal lumen area (MLA) (n=146, r=0.75, p<0.001). Both quantitative techniques 
were well-correlated for lumen area stenosis (n=146, r=0.79, p<0.001) and plaque burden 
(n=146, r=0.70, p<0.001) at the level of the MLA. Finally, mean plaque burden (n=146, 
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r=0.64, p<0.001) and remodeling index (n=146, r=0.56, p<0.001) showed significant 
correlations between QCT and IVUS. In conclusion, automated quantification of coronary 
plaque using CT with a dedicated quantitative software and a novel 3D registration algo-
rithm is feasible.
In chapter 5, the value of cardiac CT for assessment of diastolic function in comparison 
with 2D echocardiography using tissue Doppler imaging (TDI) is evaluated. A total of 70 
patients (46 men, mean age 55±11 yrs) who had undergone both cardiac CT and 2D echo-
cardiography with TDI were included. Cardiac CT and 2D echocardiography were well-
correlated for early transmitral peak velocity (E) (r=0.73, p<0.01), E/A (r=0.87, p<0.01), peak 
mitral septal tissue velocity (Ea) (r=0.82, p<0.01) and E/Ea (r=0.81, p<0.01). Furthermore, a 
good agreement was observed between cardiac CT and 2D echocardiography with TDI for 
assessment of diastolic function (agreement of 79%). Accordingly, cardiac CT can be used 
to provide information on LV diastolic dysfunction in addition to coronary atherosclerosis.
Part II: Myocardial Perfusion SPECT for Selection of Heart Failure Patients 
Referred for Cardiac Resynchronization Therapy
The potentials of nuclear imaging with gated myocardial perfusion single photon emission 
computed tomography (SPECT) (GMPS) in heart failure patients referred for cardiac resyn-
chronization therapy (CRT) are evaluated in chapter 6. The review concluded that GMPS 
with phase analysis allows detailed assessment of myocardial ischemia, infarct tissue and 
viability along with left ventricular (LV) mechanical dyssynchrony using a single SPECT data 
set. A comprehensive evaluation of heart failure patients referred for CRT with the use of 
GMPS and phase analysis can improve the selection of patients who will benefit from CRT.
In chapter 7, the QGS algorithm for phase analysis on GMPS is validated in a direct 
comparison with echocardiography using TDI for assessment of LV systolic dyssynchrony. 
Additionally, the prediction of response to CRT using GMPS with phase analysis is evaluated 
in chapter 7. In 40 heart failure patients (32 men, mean age 63±8 yrs), phase analysis 
on GMPS was significantly correlated with TDI for assessment of LV systolic dyssynchrony 
(histogram bandwidth (HBW) (r=0.69, p<0.01) and phase standard deviation (SD) (r=0.65, 
p<0.01). Moreover, phase analysis on GMPS allowed prediction of CRT response, in which 
the optimal cutoff value for HBW was defined at 72.5°, yielding a sensitivity of 83% and a 
specificity of 81%. The area under the curve for HBW was 0.83. The optimal cutoff value for 
phase SD was set at 19.6°, which yielded a sensitivity of 83% and a specificity of 81%. The 
area under the curve for phase SD was 0.85.
Chapter 8 evaluates the relation between the site of latest mechanical activation on 
GMPS, LV lead position and response to CRT. A total of 90 heart failure patients (72% men, 
mean age 67±10 yrs) were included, of which 52 (58%) patients showed a concordant 
LV lead position and 38 (42%) patients showed a discordant LV lead position. GMPS and 
2D speckle tracking radial strain analysis agreed well for assessment of the site of latest 
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mechanical activation (total agreement of 86%, k value=0.79). Furthermore, the study has 
demonstrated that response to CRT was significantly more often documented in patients 
with concordant LV lead position as compared to patients with discordant LV lead position 
(79% vs. 26%, p<0.01). Moreover, patients with concordant LV lead position showed signifi-
cant improvement in LV volumes and LV systolic function (p<0.05) at 6 months follow-up, 
whereas patients with discordant LV lead position showed no significant improvement in LV 
volumes and LV systolic function. In conclusion, GMPS with phase analysis can be used to 
assess the site of latest mechanical activation. Importantly, a concordant LV lead position 
was associated with significant improvement in LV volumes and LV systolic function.
The study in chapter 9 has evaluated the feasibility of phase analysis on GMPS for assess-
ment of LV diastolic dyssynchrony in comparison with TDI. In 150 heart failure patients (114 
men, mean age 66.0±10.4 yrs), diastolic HBW (r=0.75, p<0.01) and diastolic phase SD 
(r=0.81, p<0.01) showed good correlations with LV diastolic dyssynchrony on TDI. In addi-
tion, patients with LV diastolic dyssynchrony on TDI (>55 ms) showed significantly larger 
diastolic phase SD (68.1±13.4˚ vs. 40.7±14.0˚, p<0.01) and diastolic HBW (230.6±54.3˚ 
vs. 129.0±55.6˚, p<0.01) as compared to patients without LV diastolic dyssynchrony on 
TDI (≤55 ms). Accordingly, phase analysis on GMPS allows assessment of LV diastolic dys-
synchrony.
Finally, chapter 10 describes whether LV diastolic dyssynchrony on GMPS allows predic-
tion of response to CRT. A total of 50 moderate-to-severe heart failure patients (36 men, 
mean age 66.5±9.9 yrs) with depressed LV systolic function (LV ejection fraction (LVEF) 
≤35%) were included. Thirty-four (68%) patients showed response to CRT, while 16 (32%) 
patients were non-responders. CRT responders showed a significant improvement in New 
York Heart Association (NYHA) functional class, quality-of-life score, 6-minute walk dis-
tance, LV volumes and LVEF at 6 months follow-up (p<0.05). Multivariate analyses showed 
that LV diastolic dyssynchrony along with LV systolic dyssynchrony and myocardial scar 
were independent predictors of CRT response (p<0.05).
Part III: Cardiac Sympathetic Nerve Scintigraphy with 123-I 
Metaiodobenzylguanidine for Risk Stratification of Patients with 
Cardiovascular Disease
The role of cardiac sympathetic nerve imaging with 123-iodine metaiodobenzylguanidine 
(123-I MIBG) scintigraphy for risk stratification of patients with cardiovascular disease 
is described in chapter 11. The review concludes that cardiac innervation imaging with 
123-I MIBG holds great potential for risk stratification and prognostification of heart failure 
patients. Cardiac 123-I MIBG imaging can be used to identify patients with heart failure at 
risk for (cardiac) death, worsening heart failure as well as ventricular arrhythmias or sudden 
cardiac death.
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The potentials of 123-I MIBG scintigraphy for prediction of ventricular arrhythmias are 
evaluated in chapter 12. In total, 116 heart failure patients (80 men, mean age 65±9 yrs) 
referred for implantable cardioverter-defibrillator (ICD) therapy were included. During a 
mean follow-up of 23±15 months, appropriate ICD therapy was documented in 24 (21%) 
patients and appropriate ICD therapy or cardiac death in 32 (28%) patients. The study 
showed that late 123-I MIBG SPECT defect score was an independent predictor for appropri-
ate ICD therapy and the combined endpoint of appropriate ICD therapy or cardiac death. 
More specifically, patients with a large late 123-I MIBG SPECT defect (summed score >26) 
showed significantly more appropriate ICD therapy (52% vs. 5%, p<0.01) and appropriate 
ICD therapy or cardiac death (57% vs. 10%, p<0.01) when compared to patients with a 
small late 123-I MIBG SPECT defect (summed score ≤26) at 3-year follow-up. Thus, cardiac 
sympathetic denervation allowed prediction of ventricular arrhythmias causing appropriate 
ICD therapy.
Chapter 13 describes the relation between contrast-enhanced magnetic resonance imag-
ing (MRI) and 123-I MIBG/perfusion scintigraphy for assessment of myocardial infarct size 
and infarct border zone, referred to as myocardium at risk for ventricular arrhythmias. In 40 
patients with ischemic heart failure (29 men, mean age 66±10 yrs), contrast-enhanced MRI 
and myocardial perfusion scintigraphy showed good correlations for infarct size (r=0.72, 
p<0.01). Moreover, the 123-I MIBG SPECT defect score (48.2±12.5% vs. 32.1±9.5%, p<0.05) 
and innervation/perfusion mismatch score (13.9±11.0% vs. 6.8±6.0%, p<0.05), which were 
used as markers of myocardium at risk for ventricular arrhythmias, were significantly larger 
in patients with an infarct border zone on contrast-enhanced MRI (≤16.7 grams of infarct 
border zone) than in patients without an (≤16.7 grams of infarct border zone) infarct border 
zone on contrast-enhanced MRI. In conclusion, the study has demonstrated that contrast-
enhanced MRI and 123-I MIBG/perfusion scintigraphy correlated for assessment of infarct 
size and infarct border zone, which are commonly referred to as myocardium at risk for 
ventricular arrhythmias.
Conclusions and Future Perspectives
The purpose of the thesis was to explore the role of novel insights into cardiac imaging for 
diagnosis (Part I), treatment (Part II) and risk stratification (Part III) of patients with cardiovas-
cular disease. Rapid developments in cardiac imaging techniques have already contributed 
significantly in the evaluation of patients with a broad spectrum of cardiovascular disease, 
predominantly in the setting of coronary artery disease and chronic heart failure.4-7
New insights in cardiac imaging and post-processing technologies can further refine 
currently applied diagnostic, therapeutic and prognostic algorithms for patients with 
cardiovascular disease. Moreover, further developments in cardiac imaging can help to 
generate a patient-tailored health care system, which in turn should result in an improved 
cost-effectiveness as patients are more appropriately selected for diagnostic procedures and 
 : Summary, Conclusions and Future Perspectives 
267
therapeutic interventions, such as (percutaneous) coronary intervention procedures and 
dedicated cardiac device therapies.
At first, the value of automated quantitative CT for evaluation of coronary atherosclerosis 
has been demonstrated in this thesis. As the feasibility of quantitative CT has been shown in 
several studies presented in this thesis, new developments in quantitative software should 
further improve its diagnostic accuracy for quantification of coronary plaque, particularly 
for coronary lesions with severe calcifications. Additionally, refinements in quantitative 
algorithms for cardiac CT may help to solve difficulties regarding quantification of in-stent 
stenosis and bifurcation lesions. Consecutively, the value of quantitative CT to guide coro-
nary intervention procedures as well as to monitor progression of coronary atherosclerosis 
(e.g. once pharmacologic treatment has been started) can be prospectively validated in 
future studies. Moreover, further improvements in quantitative CT algorithms should reduce 
the amount of post-processing time required for evaluation of CAD.
Secondly, the thesis has shown that GMPS with phase analysis provides important infor-
mation in heart failure patients referred for CRT. GMPS with phase analysis allows integrated 
assessment of myocardial infarction, viability and ischemia along with LV mechanical 
dyssynchrony and site of latest mechanical activation, which altogether play an important 
role in response to CRT. Accordingly, phase analysis on GMPS provides information that 
can be used to improve the currently applied algorithm for selection of patients who will 
benefit from CRT. As the value of GMPS with phase analysis has been demonstrated in 
patients referred for CRT, additional studies are needed that prospectively validate selection 
algorithms including GMPS with phase analysis for identification of responders to CRT. 
Ultimately, one should demonstrate the improved cost-effectiveness of these comprehensive 
algorithms for selection of heart failure patients for CRT.
Finally, the thesis has demonstrated that cardiac 123-I MIBG scintigraphy can be used for 
selection of patients prone for ventricular arrhythmias or sudden cardiac death. Although 
the benefits of cardiac 123-I MIBG scintigraphy have been demonstrated in patients at risk 
for ventricular arrhythmias, the incremental value of cardiac 123-I MIBG scintigraphy in 
relation to other non-invasive risk markers for ventricular arrhythmias or sudden cardiac 
death should be addressed more thoroughly in future studies. Implementation of cardiac 
123-I MIBG scintigraphy in currently applied risk models for ventricular arrhythmias 
would provide important information on the incremental value of 123-I MIBG imaging 
over already existing risk markers for ventricular arrhythmias or sudden cardiac death. In 
addition, the role of cardiac 123-I MIBG scintigraphy for prediction of clinical outcome in 
patients with unstable clinical conditions, such as acute coronary syndromes, needs to be 
further elucidated. Currently, cardiac 123-I MIBG imaging has only been used in patients 
with prior myocardial infarction or acute coronary syndrome for assessment of sympathetic 
denervation patterns.8-10 In this subset of patients, regions with deprived sympathetic inner-
vation may be present which reach beyond the peripheral border of myocardial necrosis, 
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indicating the presence of viable but denervation myocardium.8-10 Accordingly, beyond the 
setting of chronic heart failure, cardiac 123-I MIBG scintigraphy may provide incremental 
information to risk stratify patients with ischemic heart disease.
Samenvatting, Conclusies en 
Toekomstperspectief
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Hart- en vaatziekten zijn één van de belangrijkste problemen voor de volksgezondheid, 
ondanks vele ontwikkelingen die in de afgelopen decennia hebben plaatsgevonden op het 
gebied van diagnostiek, therapie en risicostratificatie van patiënten met hart- en vaatziek-
ten.1-3
Nieuwe ontwikkelingen op het gebied van cardiale beeldvorming en post-processing 
kunnen gebruikt worden om de huidige diagnostische, therapeutische en prognostische 
algoritmen voor patiënten met hart- en vaatziekten te verbeteren.
De algemene inleiding van het proefschrift (hoofdstuk 1) beschrijft nieuwe inzichten 
in cardiale beeldvormingstechnieken die kunnen worden toegepast voor de evaluatie van 
patiënten met hart- en vaatziekten, in het bijzonder voor patiënten met coronairlijden (ader-
verkalking van de kransslagaderen) en chronisch hartfalen.
De doelstelling van dit proefschrift was om nieuwe ontwikkelingen op het gebied van 
cardiale beeldvorming voor diagnostiek (Deel I), therapie (Deel II) en risicostratificatie (Deel 
III) van patiënten met hart- en vaatziekten te evalueren.
Deel I: Automatische Computed Tomografie in Patiënten met 
Coronairlijden
Hoofdstuk 2 beschrijft een overzicht van de huidige methoden voor het kwantificeren van 
coronairlijden met cardiale computed tomografie (CT). Voorts beschrijft hoofdstuk 2 de rol 
die kwantitatieve CT kan spelen bij percutane coronaire interventies.
De studie beschreven in hoofdstuk 3 is destijds opgezet om de toepasbaarheid te demon-
streren van een specifiek algoritme voor automatische kwantificatie van coronairstenose op 
cardiale CT in een directe vergelijking met kwantitatieve coronair angiografie (quantitative 
coronary angiography, QCA). In 100 patiënten (53 mannen 59.8±8.0 jaar), lieten cardiale 
CT en QCA een goede correlatie zien voor percentage diameter stenose bij analyse naar 
de culprit lesie per coronair (n=282, r=0.83, p<0.01) of per patiënt (n=93, r=0.86, p<0.01). 
Tevens, werd er een goede agreement gevonden tussen cardiale CT en QCA voor semi-
kwantitatieve analyse naar diameter stenose (diagnostische nauwkeurigheid van 95%). 
Bovendien liet kwantitatieve CT een significante hogere positief voorspellende waarde 
(100% vs. 78%, p<0.05) en diagnostische nauwkeurigheid (95% vs. 87%, p=0.08) zien voor 
≥50% diameter stenose in vergelijking met visuele CT analyse. Samenvattend, kwantitatieve 
CT liet een goede correlatie zien met QCA voor het evalueren van coronairstenose. In aan-
vulling, liet de studie een verbetering zien in de diagnostische nauwkeurigheid en positief 
voorspellende waarde van kwantitatieve CT ten opzichte van visuele CT.
In hoofdstuk 4 wordt de uitvoerbaarheid van automatische kwantificatie van coronair-
lijden met behulp van cardiale CT en speciale software met een nieuw 3D coregistratie 
CT algoritme voor CT en intravascular ultrasound (IVUS) beschreven. Een cohort van 51 
patiënten (40 mannen, 58±11 jaar, 103 coronairen) met 146 coronair lesies werd geëva-
lueerd. Kwantitatieve CT en IVUS lieten een goede correlatie zien voor minimal lumen 
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area (MLA) (n=146, r=0.75, p<0.001). Beide kwantitatieve technieken lieten eveneens een 
goede correlatie zien voor lumen area stenose (n=146, r=0.79, p<0.001) en plaque burden 
(n=146, r=0.70, p<0.001) op het niveau van de MLA. Tenslotte, de mean plaque burden 
(n=146, r=0.64, p<0.001) en remodeling index (n=146, r=0.56, p<0.001) lieten significante 
correlaties zien tussen kwantitatieve CT en IVUS. Samenvattend liet de studie zien dat 
automatische kwantificatie van coronairlijden op cardiale CT mogelijk is met behulp van 
nieuwe kwantificatie software met een 3D registratie algoritme.
De waarde van cardiale CT voor het bepalen van de diastolische hartfunctie in verge-
lijking met 2D echocardiografie met tissue Doppler imaging (TDI) werd in hoofdstuk 5 
geëvalueerd. Een cohort van 70 patiënten (46 mannen, 55±11 jaar), welke cardiale CT en 
2D echocardiografie met TDI hadden ondergaan, werd geïncludeerd. Cardiale CT en 2D 
echocardiografie lieten een goede correlatie zien voor early transmitral peak velocity (E) 
(r=0.73, p<0.01), E/A (r=0.87, p<0.01), peak mitral septum velocity (Ea) (r=0.82, p<0.01) 
en E/Ea (r=0.81, p<0.01). In aanvulling lieten beide technieken een goede agreement zien 
voor het vaststellen van diastolische disfunctie (agreement van 79%). Op basis van deze 
onderzoeksresultaten werd geconcludeerd dat cardiale CT kan worden gebruikt voor de 
evaluatie van diastolische hartfunctie.
Deel II: Myocard Perfusie Scintigrafie voor de Selectie van Hartfalen 
Patiënten Verwezen voor Cardiale Resynchronizatie Therapie
The rol van nucleaire beeldvorming met gated myocard perfusie scintigrafie (myocardial 
perfusion single photon emission computed tomography (SPECT), GMPS) in patiënten met 
hartfalen, die verwezen werden voor cardiale resynchronizatie therapie (CRT) is geëvalueerd 
in hoofdstuk 6. De review concludeerde dat GMPS met fase analyse gebruikt kan worden 
voor het evalueren van cardiale ischemie, infarcering, viabiliteit van het myocard alsmede 
linker kamer (LV) mechanische dyssynchronie. Tenslotte kan een complete en uitgebreide 
evaluatie van patiënten met hartfalen met GMPS en fase analyse de selectie van patiënten 
voor CRT verbeteren.
In hoofdstuk 7 werd het QGS algoritme voor fase analyse van GMPS gevalideerd voor 
LV mechanische dyssynchronie in een directe vergelijking met echocardiografie met TDI. In 
hoofdstuk 7 werd eveneens onderzocht of GMPS met fase analyse kon worden gebruikt om 
response op CRT te voorspellen. In 40 patiënten met hartfalen (32 mannen, 63±8 jaar), liet 
GMPS met fase analyse significante correlaties zien met TDI voor LV systolische dyssynchro-
nie (histogram bandbreedte (HBW) (r=0.69, p<0.01) en fase standaard deviatie (SD) (r=0.65, 
p<0.01). Bovendien liet de studie zien dat GMPS met fase analyse kan worden gebruikt om 
CRT response te voorspellen, waarbij de optimale cutoff waarde voor HBW 72.5° was met 
een sensitiviteit van 83% en een specificiteit van 81%. De area under the curve (AUC) voor 
HBW was 0.83. De optimale cutoff waarde voor fase SD was 19.6° met een sensitiviteit van 
83% en een specificiteit van 81%. De AUC voor fase SD was 0.85.
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In Hoofdstuk 8 wordt de relatie tussen het myocard met laatste mechanische activatie 
(met behulp van GMPS met fase analyse), LV lead positie en response op CRT geëvalueerd. 
Een groep van 90 patiënten met hartfalen (72% mannen, 67±10 jaar) werd geïncludeerd. 
Van deze groep patiënten waren er 52 (58%) met een concordante LV lead positie en 38 
(42%) met een discordante LV lead positie. GMPS en 2D speckle tracking radial strain ana-
lyse lieten een goede agreement zien voor het bepalen van het myocard met laatste mecha-
nische activatie (agreement van 86%, k=0.79). Daarnaast liet de studie zien dat response op 
CRT significant vaker werd geobserveerd in patiënten met een concordante LV lead positie 
in vergelijking met patiënten met een discordante LV lead positie (79% vs. 26%, p<0.01). 
Bovendien lieten patiënten met een concordante LV lead positie significante verbeteringen 
zien in LV volumina en LV systolische functie (p<0.05) na 6 maanden follow-up, terwijl 
patiënten met een discordante LV lead positie geen significante verbetering lieten zien in 
LV volumina en LV systolische functie. Concluderend liet deze studie zien dat GMPS met 
fase analyse kan worden gebruikt om het laatste geactiveerde myocard vast te stellen. Dit 
is belangrijk aangezien een concordante LV lead positie geassocieerd was met significante 
reverse remodeling evenals een verbetering van de LV systolische functie.
De studie in hoofdstuk 9 onderzocht de toepasbaarheid van GMPS met fase analyse 
voor het evalueren van LV diastolische dyssynchronie in vergelijking met TDI. In 150 
patiënten met hartfalen (114 mannen, 66.0±10.4 jaar), lieten diastolisch HBW (r=0.75, 
p<0.01) en diastolisch fase SD (r=0.81, p<0.01) goede correlaties zien met LV diastolische 
dyssynchronie op TDI. Tevens lieten patiënten met LV diastolische dyssynchronie op TDI 
(>55 ms) significant grotere diastolische fase SD (68.1±13.4˚ vs. 40.7±14.0˚, p<0.01) en 
HBW (230.6±54.3˚ vs. 129.0±55.6˚, p<0.01) zien in vergelijking met patiënten zonder LV 
diastolische dyssynchronie op TDI (≤55 ms). Deze studie liet zien dat fase analyse op GMPS 
gebruikt kan worden voor het evalueren van LV diastolische dyssynchronie.
In hoofdstuk 10 wordt de voorspellende waarde van LV diastolisch dyssynchronie op 
GMPS voor response op CRT beschreven. Vijftig patiënten met matig tot ernstig hartfalen 
(36 mannen, 66.5±9.9 jaar) met verminderde LV systolische functie (LV ejectie fractie (LVEF) 
≤35%) werden geïncludeerd. In totaal lieten 34 (68%) patiënten response op CRT (respon-
ders) zien, terwijl 16 (32%) patiënten geen response lieten zien op CRT (non-responders). 
Response werd gedefinieerd als ≥15% reductie in LV eind-systolisch volume na 6 maanden 
follow-up. CRT responders lieten een significante verbetering zien in New York Heart Asso-
ciation (NYHA) functionele klasse, kwaliteit van leven, 6-minuten looptest, LV volumina en 
LVEF na 6 maanden follow-up (p<0.05). Multivariate analyse liet zien dat LV diastolische 
dyssynchronie, LV systolische dyssynchronie en myocard infarct onafhankelijke voorspellers 
waren voor response op CRT (p<0.05).
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Deel III: Cardiale Sympathische Scintigrafie met 123-I 
Metaiodobenzylguanidine voor Risicostratificatie van Patiënten met Hart- 
en Vaatziekten
De rol van cardiale sympathische beeldvorming met 123-iodine metaiodobenzylguanidine 
(123-I MIBG) scintigrafie voor risicostratificatie van patiënten met hart- en vaatziekten is 
beschreven in hoofdstuk 11. De review concludeert dat cardiale innervatie beeldvorming 
met 123-I MIBG kan worden gebruikt voor risicostratificatie van patiënten met hartfalen. 
Cardiale 123-I MIBG scintigrafie kan worden gebruikt voor het identificeren van patiënten 
met hartfalen die een verhoogd risico hebben op (cardiale) dood, progressief hartfalen en 
ventriculaire aritmiëen of plotse hartdood.
De rol van cardiale 123-I MIBG scintigrafie in het voorspellen van ventriculaire aritmi-
een wordt geëvalueerd in hoofdstuk 12. Er werden 116 hartfalen patiënten (80 mannen, 
65±9 jaar), die werden verwezen voor implantable cardioverter-defibrillator (ICD) therapie 
geëvalueerd. Tijdens een gemiddelde follow-up duur van 23±15 maanden, werd terechte 
ICD therapie in 24 (21%) patiënten geobjectiveerd en terechte ICD therapie of cardiale 
dood in 32 (28%) patiënten. De studie liet zien dat 123-I MIBG SPECT defect score op late 
123-I MIBG scintigrafie een onafhankelijke voorspeller was voor het optreden van terechte 
ICD therapie evenals het gecombineerde eindpunt terechte ICD therapie of cardiale dood. 
In het bijzonder lieten patiënten met een groot 123-I MIBG SPECT defect (summed score 
van >26) significant vaker terechte ICD therapie (52% vs. 5%, p<0.01) en terechte ICD 
therapie of cardiale dood (57% vs. 10%, p<0.01) zien, dan patiënten met een klein 123-I 
MIBG SPECT defect (summed score ≤26) op 3-jaar follow-up. Samenvattend liet de studie 
zien dat cardiale sympathische denervatie belangrijke informatie geeft voor het voorspellen 
van ventriculaire aritmiëen resulterend in ICD therapie.
Hoofdstuk 13 evalueert de relatie tussen contrast-enhanced magnetic resonance imaging 
(MRI) and 123-I MIBG/perfusie scintigrafie in het kwantificeren van infarct grootte en infarct 
border zone, gebruikt als surrogaat voor myocard met een verhoogd risico op het ontstaan 
van ventriculaire aritmiëen. In 40 patiënten met hartfalen (29 mannen, 66±10 jaar), lie-
ten contrast-enhanced MRI en myocard perfusie scintigrafie, een goede relatie zien voor 
infarct grootte (r=0.72, p<0.01). Bovendien, liet de studie zien dat de 123-I MIBG SPECT 
defect score (48.2±12.5% vs. 32.1±9.5%, p<0.05) en de innervatie/perfusie mismatch 
score (13.9.±11.0% vs. 6.8±6.0%), markers voor myocard met een verhoogd risico op 
ventriculaire aritmiëen, significant groter waren in patiënten met een infarct border zone op 
contrast-enhanced MRI in vergelijking met patiënten zonder infarct border zone op contrast-
enhanced MRI. Concluderend, liet de studie zien dat 123-I MIBG/perfusie scintigrafie kon 
worden gebruikt voor het evalueren van infarct grootte en infarct border zone.
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Conclusies en Toekomstperspectief
Het doel van dit proefschrift was om nieuwe ontwikkelingen op het gebied van cardiale 
beeldvorming te evalueren voor diagnostiek (Deel I), therapie (Deel II) en risicostratifica-
tie (Deel III) van patiënten met hart- en vaatziekten. Nieuwe ontwikkelingen in cardiale 
beeldvormingstechnieken hebben tot op heden significant bijgedragen aan de evaluatie 
van patiënten met hart- en vaatziekten, in het bijzonder in patiënten met coronairlijden en 
chronisch hartfalen.4-7
Nieuwe inzichten in cardiale beeldvorming en post-processing technologie kunnen de 
huidige diagnostische, therapeutische en prognostische algoritmen voor patiënten met hart- 
en vaatziekten verder verbeteren. Voortschrijdend inzicht in cardiale beeldvorming kan 
bovendien worden gebruikt om de kosten-effectiviteit van de huidige gezondheidszorg ver-
der te optimaliseren door patiënten beter te selecteren voor diagnostische en therapeutische 
interventies, zoals (percutane) coronaire interventies of cardiale pacemaker of ICD therapie.
Ten eerste werd in dit proefschrift de waarde van automatische kwantitatieve CT voor 
de evaluatie van coronairlijden beschreven. Aangezien de beschreven studies de toepas-
baarheid van kwantitatieve CT voor het evalueren van coronairlijden hebben laten zien, 
kunnen toekomstige studies zich gaan richten op het verbeteren van de nauwkeurigheid 
van kwantitatieve CT in het evalueren van ernstige verkalkte coronair lesies alsmede de 
in-stent stenoses of bifurcatie lesies. Door verbeterde kwantitatieve CT, kan cardiale CT 
mogelijkerwijs een grotere rol gaan spelen bij het voorbereiden van percutane coronaire 
interventies alsmede in het monitoren van progressie van coronairlijden (bijvoorbeeld na 
starten medicamenteuze therapie). Bovendien kunnen ontwikkelingen in kwantitatieve CT 
algoritmen mogelijkerwijs de tijd, welke nodig is voor de post-processing van cardiale CT, 
verkorten.
Ten tweede laten de studies in dit proefschrift zien dat GMPS met fase analyse kan worden 
gebruikt ter analyse van patienten met hartfalen die verwezen worden voor CRT. GMPS met 
fase analyse biedt de mogelijkheid om (1) myocard infarct, (2) viabiliteit van het myocard, 
(3) ischemie, (4) LV mechanische dyssynchronie en (5) myocard met de laatste mechanische 
activatie te evalueren in een enkel SPECT onderzoek. Met behulp van deze informatie kan 
een goede inschatting worden gemaakt welke patienten respons op CRT laten zien en kan 
derhalve de selectie van patiënten voor CRT worden geoptimaliseerd.
Alhoewel de waarde van GMPS met fase analyse in patiënten met hartfalen verwezen 
voor CRT is beschreven in diverse studies, zijn additionele onderzoeken geïndiceerd die 
de selectie algoritmen met GMPS en fase analyse prospectief gaan valideren. Vervolgens 
moeten studies de kosten-effectiviteit van dergelijke selectie algoritmen voor hartfalen 
patiënten gaan aantonen.
Tenslotte laat dit proefschrift zien dat cardiale 123-I MIBG scintigrafie kan worden 
gebruikt voor de selectie van patiënten met een verhoogd risico op ventriculaire aritmiëen 
of plotse hartdood. Ondanks het feit dat de prognostische waarde van cardiale 123-I MIBG 
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scintigrafie voor het optreden van ventriculaire aritmiëen of plotse hartdood is aangetoond, 
is de waarde van 123-I MIBG scintigrafie in relatie tot andere niet-invasieve risicomarkers 
voor plotse hartdood onvoldoende onderzocht. Daarnaast zijn er additionele studies nodig 
die de prognostische waarde van cardiale 123-I MIBG scintigrafie in patiënten met insta-
biele klinische condities (acuut coronair syndroom) gaan evalueren. Tot op heden is cardiale 
123-I MIBG scintigrafie enkel gebruikt voor het evalueren van sympathische denervatie 
patronen in patiënten met status na myocardinfarct of acuut coronair syndroom.8-10 De prog-
nostische waarde van 123-I MIBG scintigrafie in patienten met acuut coronair syndroom is 
onvoldoende onderzocht. In deze patiënten, kunnen gebieden met sympathische denervatie 
zich uitstrekken tot voorbij het geïnfarceerde myocard (de innervatie/perfusie mismatch of 
infarct border zone).8-10 Dientengevolge, kan cardiale 123-I MIBG scintigrafie additionele 
informatie geven voor risicostratificatie in patiënten met ischemische hartziekten.
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